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 1 
Summary 
 
Hepatitis C is a major cause of chronic liver disease with over 120 million infected people 
worldwide. Untreated chronic hepatitis C (CHC) infection leads in 20-50% to liver cirrhosis 
culminating in cirrhosis-related complications and hepatocellular carcinoma eventually 
leading to death. For the last decade a combination therapy of pegylated Interferon-alpha 
(pegIFN-α) and Ribavirin was the standard of care resulting in sustained virologic response 
(SVR) rates of approximately 50%. The antiviral effect of this naturally occurring cytokine is 
not achieved through a direct targeting of the virus but instead by creation of an antiviral state 
in infected host-cells and triggering of the host’s immune system through induction of 
hundreds of interferon stimulated genes (ISGs). Interestingly, some patients with CHC who 
show a strong induction of ISGs in the liver even before treatment do not respond to 
administered pegIFN-α and do not clear the virus. The lack of response is most likely due to 
refractoriness of the IFN signaling. The reason for this preactivation of the IFN system in the 
liver in a subset of patients and the following non-response remains unclear. 
It is the aim of this thesis to improve the understanding of host-virus interactions in hepatitis 
C infection with regard to the preactivation of the IFN system and its consequential failure to 
IFN-α based treatment regimens. The thesis consists of three different parts: 
 
First, the host-response in the liver of patients in the acute phase of hepatitis C (AHC) 
infection, i.e. the first six months after transmission, was investigated. To elucidate molecular 
mechanisms involved in non-response, we wanted to exploit the fact that in AHC SVR rates 
to therapy with pegIFN-α are substantially better than in CHC (>90% versus 50%). Six liver 
biopsies of AHC patients were analyzed for ISG expression and IFN signaling by 
transcriptome, protein and immunohistochemical analyses and compared to a set of patients 
with CHC as well as control liver samples. Additionally, IFN-α and -γ specific gene sets were 
defined in primary human hepatocytes. While both AHC and CHC non-responders (CHC-
NR) showed a strong induction of ISGs, enrichment analysis revealed that in CHC-NR 
mainly IFN-α stimulated genes were induced, in contrast to IFN-γ stimulated gene expression 
in AHC. IFN-γ was increased in AHC and correlated with the amount of infiltrating CD8+ T 
cells that by immunostaining were found to be co-localized with activated hepatocytes. 
Analysis of negative regulators of IFN signaling in the IFN-α stimulated gene set revealed 
exclusively in CHC-NR an upregulation of USP18, a key molecule in establishing 
refractoriness to IFN-α signaling. These results provide an explanation for the preserved 
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response to pegIFN-α in AHC and highlight USP18 as a potential therapeutical target to 
improve treatment in CHC patients with a pre-activated IFN system. 
 
Second, a possible connection between genetic variants near the IL28B gene and ISG 
induction in livers of CHC patients was assessed. Four independent genome-wide association 
studies have revealed a highly significant association of single nucleotide polymorphisms 
(SNPs) near the IL28B gene with the outcome of therapy with pegIFN-α and ribavirin in 
CHC. We hypothesized that these genetic variants near the IL28B gene, which encodes for 
IFN-λ3, might be responsible for the preactivation of the IFN system in certain patients. 109 
patients with CHC were genotyped for IL28B SNPs and the hepatic ISG expression was 
quantified. Interestingly, despite an association of the IL28B genotype with the expression of 
ISGs, stratification revealed that ISG expression is associated with response independent of 
its IL28B genotype making a direct link rather unlikely. A multivariate analysis using a 
random forest classifier analysis defined ISG expression, by the means of a 4-gene-classifier, 
as the strongest treatment predictor. 
 
Third, the pharmacodynamics of pegIFN-α in the livers of patients with CHC was explored. 
Due to higher efficacy, pegIFN-α has replaced conventional IFN-α as standard of care. It is 
generally assumed that the improved pharmacokinetic properties of the former with a longer 
half-life leads to better effectiveness through a continuous induction of ISGs. However, basic 
studies in vitro and in mouse models suggest a long-lasting refractoriness of the IFN-α 
signaling that is not responsive to further stimulation. We therefore addressed this issue 
directly in CHC patients receiving treatment. To avoid non-response only patients with a non-
preactivated IFN system were included. Each patient received a paired biopsy before and at a 
certain time point after the first injection with pegIFN-α. After transcriptome analyses, 
clusters of genes with distinctive temporal patterns were generated. The upregulation in the 
early ISG clusters was only transient and no prolonged upregulation or a second wave of 
induction could be noticed. Additionally, a direct comparison of the two commercially 
available pegIFNα, pegIFNα-2a versus -2b at 144h showed no significant difference in the 
amount or extension of upregulated ISGs, despite the longer serum half-life of pegIFNα-2a. 
This study indicates that the superior efficacy of pegIFN-α compared to conventional IFN-α 
cannot be explained by persistent signaling and ISG induction. 
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Abbreviations 
 
 
 
 
AHC acute hepatitis C 
ALT alanine-aminotransferase 
AUC area under the curve 
cEVR complete early virologic response 
CHC chronic hepatitis C 
DAA direct-acting antivirals 
DNA deoxyribonucleic acid 
EGFR epidermal growth factor receptor 
ELISA enzyme-linked immunosorbent 
assay 
EoTR end of treatment response 
ERR error rate 
ES  enrichment score 
EVR early virologic response 
GAS gamma-activation sequence 
GSEA gene set enrichment analysis 
GWAS genome-wide association study 
h hour 
HBV hepatitis B virus 
HCC hepatocellular carcinoma 
HCV hepatitis C virus 
HCVcc cell-culture-derived hepatitis C virus 
HIV human immunodeficiency virus 
IFNAR Interferon alpha receptor 
IFN-α Interferon alpha 
IFN-γ Interferon gamma 
IFN-λ Interferon lambda 
IL28B Interleukin 28B 
IP-10 Interferon-γ inducible protein 10 
IRF Interferon regulatory factor 
IRES internal ribosome entry site 
ISG Interferon stimulated gene 
ISGF3 IFN-stimulated gene factor 3 
ISRE IFN-stimulated response element 
Jak Janus kinase 
kb kilobases 
LDL low density lipoprotein 
MAVS mitochondrial antiviral signaling 
protein 
Mio million 
mRNA messenger RNA 
miRNA microRNA 
NCR non-coding region 
NLR NOD-like receptor 
NR non-responder 
NS non-structural 
ORF open reading frame 
PAMP pathogen-associated molecular 
pattern 
PBMC peripheral blood mononuclear 
cell 
PCR polymerase chain reaction 
pDC plasmacytoid dendritic cell 
PEG polyethylene glycol 
pegIFN-α pegylated Interferon alpha 
PKR protein kinase R  
PNR primary non-response 
PP2A protein phosphatase 2A 
PRMT1 protein arginine 
methyltransferase 1 
PRR pattern recognition receptor 
pSTAT1 phosphorylated STAT1 
R responder 
RdRp RNA-dependent RNA 
polymerase 
REL relapse 
RFFS random forest feature score 
RNA ribonucleic acid 
ROC receiver operating characteristic 
RVR rapid virologic response 
SNP single nucleotide polymorphism 
SOC standard of care 
SOCS suppressor of cytokine signaling 
STAT signal transducer and activator of 
transcription 
SVR sustained virologic response 
TLR toll-like receptor 
TRIF TIR-domain-containing adapter-
inducing interferon-β 
USP18 Ubiquitin-specific peptidase 18 
VL viral load 
VLDL very low density lipoprotein 
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1. Introduction 
 
1.1 Hepatitis C virus 
 
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease with development 
of liver cirrhosis and hepatocellular carcinoma (HCC). It is estimated that worldwide more 
than 120 million are infected with HCV with approximately 3-4 million new cases every 
year1. 
HCV was first isolated in 1989 by screening an expression library with serum from a patient 
with non-A, non-B hepatitis2. However, the low viral abundance in serum and liver tissue of 
patients, the lack of successful culture of HCV in vitro, and the limitation of infections 
occurring in  humans and chimpanzees only made it very difficult to study its lifecycle, to 
identify and characterize viral products, and moreover to develop specific antiviral agents. 
Continuous efforts over the last 23 years led to great progress in the study of structure and 
replication of HCV by establishing in vitro models such as cellular expression systems3, a 
subgenomic replicon system4,5, and in 2005, 16 years after its discovery, for the first time a 
complete infectious cell-culture system (HCVcc)6,7, producing HCV that was again infectious 
in chimpanzees, thus finally fulfilling Koch’s postulates8. Additionally, a main objective has 
been to generate a mouse model fully supporting HCV infection for many years. First, 
different models with immunodeficient mice carrying chimeric livers with human hepatocytes 
were created9,10, and recently a model with adenovirus-mediated delivery of essential 
receptors for HCV allowed to study HCV entry in further detail11. However, efforts to create a 
transgenic mouse model in immunocompetent mice that fully supports HCV entry as well as 
replication are still ongoing. 
Nevertheless, all these models have been leading to big advances in the understanding of the 
viral structure and its lifecycle. 
 
 
1.1.1 Genome and classification 
 
HCV is a positive-strand RNA virus and is classified as Hepacivirus within the Flaviviridae 
family. The HCV genome has a size of 9.6 kilobases and is very heterogenous and prone to 
mutations due to a high replicative activity and the lack of proof-reading ability of the viral 
RNA-dependent RNA polymerase (RdRp). 
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HCV is classified into 7 major genotpyes (1-7) that differ up to 35% in their nucleotide 
sequence, and within subtypes that differ by 25%12. These genotypes have important 
implications for therapy, since treatment response to Interferon-based treatment regimens 
differs significantly according to HCV genotype, and new direct-acting antivirals (DAA) do 
not efficiently target viral proteins from every genotype. 
HCV has a positive-strand RNA genome composed of a 5’-non-coding region (NCR) 
containing an internal ribosome entry site (IRES), an open reading frame (ORF) with 3 
structural and 6 non-structural proteins, and a 3’-NCR. In the 5’-NCR binding sites for a liver 
specific microRNA (miRNA) miR-122 have been discovered13. Binding of miR-122 to the 
HCV 5’-NCR enhanced viral replication - a finding that provided a first example of a virus 
exploiting cellular miRNA13. The single ORF encodes a polyprotein precursor with a size of 
approximately 3300 amino acids that is posttranslationally processed by cellular and viral 
proteases into 3 structural proteins (core, envelope proteins E1 and E2), the p7 polypeptide 
and 6 non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) (reviewed in 14 and 
15) (Figure 1.1).  
 
 
 
Figure 1.1. Genetic organization and polyprotein processing of HCV 14.
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1.1.2 Structure and lifecycle 
 
So far the HCV virions have not been definitely visualized, but based on filtration and 
electron microscopy studies the virions have a size of about 40-70 nm in diameter7, and have 
been shown to be tightly associated with lipoproteins16. It is believed that multiple copies of 
core form a nucleocapsid containing the genomic RNA, and that the envelope glycoproteins 
E1 and E2 are anchored to a surrounding cell-derived double-layer lipid membrane14.  
Entry. Viral entry is the best studied phase of the lifecycle so far. HCV has a narrow host 
range, infecting humans and chimpanzees only. Hepatocytes are the main cells targeted by 
HCV but it has been reported that B lymphocytes, dendritic cells and also endothelial cells 
can be infected17. The first membrane-receptor described to bind HCV was CD8118, followed 
by the LDL receptor19, scavenger receptor class B type I (SR-BI)20, Claudin-121 and 
Occludin22. More recently, epidermal growth factor receptor (EGFR)23 and Niemann-Pick 
C1–like 1 cholesterol absorption receptor (NPC1L1)24 have been identified as entry receptors, 
for both of which already pharmacological inhibitors exist. In an orchestrated process HCV 
virions sequentially bind to these receptors and then get internalized most likely by clathrin-
mediated endocytosis25. 
Translation, Replication. The exact mechanisms regulating translation, replication and 
packaging of the viral genome remain to be elucidated. The 5’-NCR of the viral genome 
contains a highly conserved IRES that is essential for translation of the RNA. The polyprotein 
is posttranslationally cleaved by cellular enzymes and the viral protease NS3 with NS4A as a 
cofactor. NS3 has a range of catalytic sites containing a serine-type protease, RNA helicase 
and NTPase activity that are indispensable for polyprotein processing, RNA replication and 
possibly virion assembly (reviewed in 26). The NS3-4A protease has therefore emerged as a 
main target of DAAs with newly approved drugs, Telaprevir and Boceprevir, now in clinical 
practice, and another wide range of protease inhibitors in clinical development27.  
NS4B, a highly hydrophobic protein, is then involved in creating an assembly of lipid vesicles 
in a membraneous matrix, designated as membraneous web which most likely functions as a 
scaffold for the assembly of the replication machinery28. 
The positive-strand RNA is copied by the NS5B RdRp into a negative-strand intermediate 
forming a double-strand replicative form, which serves as template for the production of new 
positive-strand genomes. The structure of NS5B has been comprehensively characterized29,30 
and NS5B inhibitors are currently tested in advanced phases of clinical development31. 
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Assembly. Both, NS2 and the polypeptide p7 have been shown to be necessary for virion 
morphogenesis and release32. p7 forms oligomer complexes and has been shown to have a 
cation channel activity33. The full-length protein of NS2 including its protease domain but not 
its enzymatic activity is required for the production of infectious virus34. Several reports state 
that the formation of infectious particles and their release depends on members of the LDL 
and VLDL pathway, and that they require apolipoprotein E and other proteins35,36,37 (Figure 
1.2). 
 
 
 
Figure 1.2. Lifecycle of HCV. (a) Viral entry; (b) cytoplasmic release and uncoating; (c) 
IRES-mediated translation and polyprotein processing; (d) RNA replication; (e) packaging 
and assembly; (f) virion maturation and release14. 
 
 
1.1.3 Natural history of hepatitis C virus infection 
 
The discovery of HCV and the consequential emergence of serological and virological assays 
made it possible to understand the evolution of hepatitis C infection.  
Transmission. Before HCV was detectable in human blood, transmission in blood-transfusion 
settings was the most common cause of infection (called initially non-A, non-B hepatitis) in 
industrialized countries38. Currently, intravenous drug use, unprotected sex with multiple 
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partners and viral exposure during medical procedures or in piercing and tattoo studios are the 
most common risk factors for infection39. 
Spontaneous clearance. Acute hepatitis C is defined as the period of the first 6 months after 
transmission with HCV. Unlike with other viral hepatitis infections, clinical symptoms at the 
acute onset of disease are usually mild and unspecific, such as fatigue, abdominal pain, or 
dyspepsia, while jaundice is reported in only 30%39. Thus, acutely infected patients rarely go 
to see a doctor and are therefore under-reported. This impedes of course the proper analysis of 
spontaneous clearance or progression of HCV infection. However, epidemiologic studies in 
well-defined patient cohorts that got infected by blood transfusion before the onset of HCV 
testing revealed that in about 75-85% of the cases the virus persisted and progressed to 
chronic infection38,40. Similar results were obtained in other settings of infection41. 
Interestingly, the rate of viral persistence seems to be significantly lower in children and 
young women (55-60%)42,43.  
Spontaneous clearance in the chronic phase of infection, i.e. later than 6 months after 
transmission, is extremely rare and negligible.  
Fibrosis progression. Once a chronic infection is established in the liver, continuous 
inflammation generally leads to hepatic fibrogenesis and ultimately cirrhosis and HCC. With 
the prospect of lacking effective treatment options, many clinical studies had been performed 
to assess natural fibrosis progression. However, the risk to progress to cirrhosis varied 
considerably between different studies from 7% - 55%41,44. This variability most probably 
derives from biases obtained by different methodological approaches (prospective vs. 
retrospective), different patient collectives (liver clinic patients vs. community-based cohorts) 
and the difficulty to exactly assess the time point of infection due to the often clinically silent 
onset of disease. A recent meta-analysis including data from 111 clinical studies computed a 
mean prevalence of cirrhosis after 20 years of infection in 16% of patients45. Three main 
conclusions can be drawn from all these reports: first, there are huge inter-individual 
differences regarding the rate of progression depending on both host and viral factors44; 
second, the progression rate seems to remain linear over time45; and third, environmental 
factors like alcohol intake or HBV/HIV co-infection etc. can dramatically increase 
progression rate46,44. 
Importantly, once the causal agent of the liver disease, in this case HCV, is removed before 
cirrhosis has developed, liver fibrosis regresses almost completely again47. 
End-stage liver disease. Once cirrhosis is established the risk of impaired liver function as 
well as the development of HCC increases tremendously. In patients with HCV-induced 
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cirrhosis the 5-year cumulative incidence of HCC is very high with 17-31%48 and HCV-
related cirrhosis with its associated complications like variceal bleeding, spontaneous 
bacterial peritonitis, hepatic encephalopathy etc. increases overall mortality with a factor of 
three49. While in industrialized countries the incidence of newly acquired HCV infections is 
declining, the disease burden due to the slow fibrosis progression is still ascending, 
highlighting the urgent need for effective antiviral treatment regimens.  
 
 
1.1.4 Interferon-based therapy of hepatitis C virus 
 
Even before HCV was successfully isolated, first clinical trials with recombinant human IFN-
α have been conducted50 and for over 25 years IFN-α has remained the backbone of anti-HCV 
therapies. IFN-α has no direct interaction with HCV but rather indirect antiviral and 
immunomodulatory effects. Through the Jak-STAT pathway IFN-α induces interferon 
stimulated genes (ISGs) that lead to a non-virus-specific cellular antiviral state51. This rather 
special mode of action clearly distinguishes IFN-α from other conventional antiviral drugs.  
 
Evolution of Interferon-therapy. In the late eighties, three times weekly subcutaneous 
injections of recombinant IFN-α (3 Mio units) for 48 weeks established itself as initial 
standard of care (SOC) therapy achieving overall a sustained virologic response (SVR, i.e. 
undetectable viral load 6 months after end of treatment) in 15-20%52. In 1998, a first 
randomized clinical trial testing a dual therapy with IFN-α2b and oral administration of the 
broad-spectrum antiviral ribavirin increased SVR rates considerably to 35-43% and replaced 
monotherapy53. 3 years later, pegylated IFN-α (pegIFN-α, IFN-α tethered with a polyethylene 
glycol (PEG)) with a much longer serum half-life was introduced. Injections could be reduced 
to once weekly and combination therapy with ribavirin led to higher overall SVR rates of 
approximately 55%54. 
PegIFN-α-2a vs. pegIFN-α-2b. Two different pegIFN-α are available which vary 
considerably in their pharmacologic properties. IFN-α-2b is covalently linked to a linear 
12kDa PEG, while pegIFN-α-2a has a 40kDa PEG moiety, comprising two 20kDa chains 
linked to form a branched chain55. These molecular differences have a considerable effect on 
the pharmacokinetics and –dynamics of these drugs. The PEG bond with IFN-α-2b is unstable 
and undergoes hydrolysis, which leads to a quick release of IFN-α-2b that then circulates the 
body. Basically, pegIFN-α-2b is a pro-drug, and only IFN-α-2b interacts with the IFN 
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receptor. In contrast, pegIFN-α-2a is not subject to hydrolysis and therefore the entire 
pegylated molecule circulates the body and interacts with the receptor55. It has been shown 
that the attachment of the large PEG reduces the affinity of pegIFN-α-2a to the IFN receptor 
leading to an antiviral activity in vitro of only 7% compared to conventional IFN-α55. 
However, the advantage of pegIFN-α-2a is its greater stability and reduced clearance leading 
to a much longer serum half-life. Unlike with pegIFN-α-2a, more than half of the patients 
receiving pegIFN-α-2b have low serum levels at day 5 after injection, and over 90% at day 
756.  
Nevertheless, in the majority of the 18 trials where in direct comparison the antiviral efficacy 
by SVR was measured, no significant differences in SVR rates were obtained (reviewed in 55). 
Thus, no recommendations exist to favor one drug over the other. 
Side effects. Almost all patients are subject to adverse events during treatment, which is a 
main reason of discontinuation. In general, 10% to 14% of patients have to stop therapy due 
to an adverse event57. Most common are influenza-like symptoms, such as fatigue, headache, 
fever and rigors in more than half of the patients. Psychiatric effects like depression, 
insomnia, irratibility are also very common (20% to 30%). IFN has a bone marrow-
suppressive effect that may lead to neutropenia, anemia and thrombocytopenia. Ribavirin 
additionally can lead to hemolytic anemia. Peg-IFN-α may lead to autoimmune disorders, 
such as autoimmune thyroiditis. Ribavirin has caused fetal death and abnormalities in 
toxicological animal studies and is therefore only allowed under strict contraception. 
Treatment indication. The fact that only about half of the patients profit permanently from 
treatment and that these considerable side effects together with substantial costs arise from 
this therapy, led to recommendations for rational treatment decision making, balancing 
benefits and costs. Guidelines have been developed and the recommended minimal 
requirements to consider treatment are positive serum HCV RNA and significant fibrosis in 
the liver as assessed by liver biopsy57. Evidently, each individual patient’s general and liver 
health, as well as social aspects have additionally to be taken into consideration. 
 
 
1.1.5 Treatment predictors  
 
Pre-treatment predictors. Considering the limited chance of SVR and the serious side effects 
accompanying IFN-α treatment, there has ever been the incentive to predict before treatment, 
which individual patient will profit from therapy. The most important predictor so far is the 
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viral genotype. SVR rates are much higher in patients infected with HCV genotype 2 or 3 
(about 80%), while in genotype 1 rates are at 45%57. An additional viral factor is the viral 
load in the serum; less than 800,000 IU/mL seems to give higher likelihood for SVR58. Host 
characteristics that are generally less strongly associated with a positive response include 
female gender, age younger than 40 years, nonblack race, lower body weight (<75 kg), the 
absence of insulin resistance, and the absence of bridging fibrosis or cirrhosis on liver 
biopsy58. Additionally, there has been growing evidence that activation of the endogenous 
IFN system in the liver and genetic variants near the IL28B gene are highly associated with 
treatment response, which will be discussed in more detail in chapter 1.3.3 and 1.3.4.
On-treatment predictors. The most powerful predictors are the viral kinetics on treatment. A 
negative viral load at week 4 of treatment, so called rapid virological response (RVR, see 
table 1.1 for further definitions), is the strongest predictor of treatment outcome58. Achieving 
RVR is associated with 86-100% SVR rates regardless of the viral genotype58. However, only 
a minority of patients reach an RVR, and the negative predictive value is not very good, since 
many patients without RVR still achieve SVR. The best reason to stop therapy due to limited 
chance of SVR is the viral kinetics at week 12 of therapy. Not achieving an early virologic 
response (EVR, more than 2log10 drop of viral load compared to baseline) is associated with 
0-3% of SVR58, and therefore was implied as a stopping rule57. Figure 1.3 depicts the 
different types of virological responses in pegIFN- α/ribavirin regimens. 
 
 
 
 
 
 
 
Figure 1.3. Virological responses to HCV 
therapy. (red) primary non-response 
(PNR); (green) partial non-response with 
no end of treatment response (no EoTR); 
(lilac) relapse (REL); (blue) sustained 
virologic response (SVR) 59. 
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Table 1.1. Definitions of viral responses during treatment with pegIFN-α/ribavirin. 
Rapid virological response (RVR) = undetect. VL at 4 weeks 
Complete early virologic response (cEVR) = undetect. VL at 12 weeks 
Early virologic response (EVR) = > 2 log10 decline in VL at 12 weeks 
End of treatment response (EoTR) = undetect. VL at end of treatment 
Sustained virologic response (SVR) = undetect. VL 24 weeks after end of treatment 
Primary non-response (PNR) = < 2 log10 decline in VL at 12 weeks 
Partial non-response = > 2 log10 decline in VL at 12 weeks but still detectable at 24 weeks 
Viral breakthrough = undetect. VL at any time and still on treatment re-detection of VL 
Relapse (REL) = re-detection of VL after end of treatment response 
Abbreviations: undetect., undetectable; VL, viral load 
 
 
1.1.6 Direct-acting antivirals  
 
In 2011, Boceprevir and Telaprevir, two NS3-4A protease inhibitors, were approved as 
therapeutics for patients infected with genotype 1. Monotherapy with these drugs has been 
shown to be very effective but quickly inducing viral resistance and leading to viral 
breakthrough60. Thus, so far IFN-α is still needed as the backbone of HCV therapy. Phase 3 
randomized controlled trials of triple combination therapy showed improved SVR rates in 
treatment naïve genotype 1 patients compared to dual therapy from 40% to 68% for 
Boceprevir, and from 44% to 75% for Telaprevir, respectively61,62 (Figure 1.4). Therefore, 
triple therapy in combination with pegIFN-α and ribavirin is now regarded as SOC for this 
group of patients63. Despite the big improvement of SVR rates in this difficult-to-treat patient 
group, the success comes at the cost of additional side effects, like severe anemia, rash or 
dysgeusia and pruritus61,62, and strongly increased expenses. These two protease inhibitors 
though reflect a first promising tip of the iceberg of DAAs that are in development and let us 
look optimistically into the future of HCV treatment. 
 
Nevertheless, promising DAAs for patients with genotype 2, 3 or 4 that did not respond to the 
combination therapy of pegIFN-α and ribavirin will not be available in the near future. 
Additionally, pegIFN-α is still essential in combination therapy. Therefore it is clinically 
absolutely relevant to identify patients that will respond to IFN-α, and on the other side to 
understand why certain patients show no response to IFN-α.  
13 
                           
Figure 1.4. Evolution of treatment responses. Triple combination therapy with proteinase 
inhibitors is only available for patients infected with Genotype 1. PI, proteinase inhibitor. 
 
 
1.2 Interferon signaling 
 
In HCV infection the endogenous IFN system is not only activated during acute infection, but 
in some patients also during the chronic phase, which hasn’t been described for any other 
chronic viral infection. Considering that exogenous IFN is also used as a therapeutic agent in 
this disease and many patients just do not respond to it, further underlines the need for better 
comprehension of these mechanisms. The basis for a thorough understanding of the host-virus 
interactions in HCV infection and its implications on treatment response is a detailed 
knowledge of Interferon signaling on the molecular level. In this chapter the different 
members of the IFN family, the pathways important for the sensing of HCV, the signal 
transduction through the Jak-STAT pathway and induction of ISGs, and last the negative 
regulation of IFN signaling will be outlined. 
 
 
1.2.1 The Interferon family and its receptors 
 
IFNs, first discovered by Isaacs and Lindenmann in 195764, belong to the class II cytokines 
and have important antiviral properties, are potent cell growth regulators, but also have 
immunomodulatory effects65. The IFNs have been grouped into three different classes: type I 
IFNs comprise of 13 IFN-α subtypes, IFN-β, IFN-ε, IFN-κ and IFN-ω; type II consists only of 
IFN-γ; and the most recent discovered type III IFNs include 3 IFN-λ (-1, -2 and -3) (Figure 
1.5)66.  
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Figure 1.5. Different types of IFN and their receptors. (from Heim MH, IFN Signaling in the 
Liver, EASL monothematic conference, 2010). 
 
Type I IFN. Type I IFNs bind to the IFN-α receptor (IFNAR), which consists of two chains 
(IFNAR1 and IFNAR2). It is assumed that type I IFN upon viral exposure are ubiquitously 
induced in basically any cell type, and these IFN are absolutely essential to fight viruses. 
IFNAR knockout mice are highly susceptible to viral infections and the outcome is fatal even 
at exposure of very low viral titers67. 
Type II IFN. IFN-γ engages the IFN-γR1 (IFNGR1) and IFN-γR2 (IFNGR2) chains to 
assemble its functional receptor complex66. It behaves quite different compared to type I IFN. 
IFN-γ is only produced by certain immune cells, including natural killer (NK) cells, CD4+ T 
helper cells and CD8+ cytotoxic T cells65. Accordingly, its function is more 
immunomodulatory by stimulating cell-mediated immune responses in an adaptive immunity 
setting68. Consequently, IFN-γ has complementary tasks compared to type I IFNs, and they 
work synergistically to fight viral infections67. 
Type III IFN. The IFN-λ family has only recently been discovered69,70. The IFN-λ1, -2 and -3 
(also named IL29, IL28A, IL28B) bind to the IFN-λ receptor chain (IL28RA) that leads to the 
recruitment of the IL-10 receptor 2 chain (IL10RB). IFN-λ induces a similar set of ISGs like 
IFN-α, though with slower kinetics and a weaker induction71. While type III IFNs, similar to 
type I IFNs, seem to be inducible in any cell type, the expression of the IL28RA is mostly 
limited to epithelial cells, especially from the lung and gastrointestinal tract72. Consequently, 
thorough viral infection studies in mice lacking IFNAR and/or IL28RA revealed that IFN-λ 
plays an important role in fighting pneumotropic and gut-infecting viruses72,73. However, in 
the liver there is an apparent discrepancy between mice and human in regard to IL28RA 
expression. Human hepatocytes express IL28RA and are responsible to IFN-λ, which mouse 
hepatocytes clearly lack72,74. 
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Function-wise type I and III IFN are more closely related than type II IFN, and the current 
knowledge suggests that type III IFN have evolutionarily evolved as an additional - and in 
some cases essential - support to type I IFN in fighting viral infections especially in locations 
frequently exposed to viruses, like the lung and gastrointestinal tract. 
 
 
1.2.2 Viral sensory pathways in the context of HCV infection  
 
The prerequisite for an effective IFN signaling is the proper sensing of viral pathogens. 
Pattern recognition receptors (PRRs) recognize pathogen-associated molecular patterns 
(PAMPs) in the extracellular environment as well as intracellularly. Four different classes of 
PRR families have been identified: the transmembrane toll-like receptors (TLR) and C-type 
lectin receptors, as well as the cytoplasmic retinoic acid-inducible gene (RIG)-I-like receptors 
and NOD-like receptors (NLRs)75.  
 
RIG-I. In the context of HCV evidence has been collected that sensing of intracellular HCV 
RNA occurs by RIG-I, a cytoplasmic RNA helicase, which recognizes a polyuridine motif in 
the 3’NCR of the virus, but also viral 5’ triphosphate motifs76,77. Ubiquitination of RIG-I by 
TRIM25 is then needed to interact with mitochondrial antiviral signaling protein (MAVS, 
also known as CARDIF, VISA, IPS-1) to activate the signaling cascade78. RIG-I then 
interacts with MAVS, an adaptor protein connected to the mitochondrial membrane, by its 
CARD domain75. MAVS is able through binding to TRAF3 and TRAF6 to induce the IFN 
regulatory factor 3 (IRF3) and the NF-κB transcription activators that localize to the nucleus, 
bind to the IFN-β promoter, recruit co-factors and the RNA polymerase II to induce 
transcription. 
TLR3. TL3, a membrane-bound receptor mainly located in the endosome, seems to sense 
HCV independent of RIG-I79,80. This receptor has first been described as a sensor of double 
stranded RNA and requires dimerization of TLR3 and phosporylation of a tyrosine residue to 
recruit the adaptor protein TIR-domain-containing adapter-inducing IFN-β (TRIF)81. The 
further downstream signaling pathway is common to the RIG-I signaling pathway 
downstream of MAVS (Figure 1.6)75. 
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Figure 1.6. Scheme of HCV sensing mechanisms. Depicted are simplifications of the RIG-I 
pathway, which senses cytoplasmic HCV RNA, and signals through MAVS, and the TLR3 
pathway signaling through TRIF. Both transduce the signal through TRAFs and eventually 
induce NF-κB and IRF3/7 that enhance transcription of IFN-β. 
 
TLR7. One article focused on the role of TLR7 in plasmacytoid dendritic cells (pDCs) in 
HCV sensing82. pDCs are the most powerful type I IFN producing cells in the blood with the 
ability to release 200-1000 fold more cytokines than other cells83. TLR7 is only expressed in 
professional antigen expressing cells, localized in the endosome and recognizes single 
stranded RNA84. They show that cultured pDCs only upon direct contact with HCV-infected 
hepatocytes produce IFN through a TLR7-dependent pathway82. 
 
 
1.2.3 Jak-STAT pathway 
 
As already mentioned, all IFN signal through the Jak-STAT pathway. This pathway consists, 
as its names reveals, of Janus kinases (Jaks) and signal transducers and activators of 
transcription (STATs). The canonical Jak-STAT pathway has been extensively studied and is 
well understood (reviewed in 85,86,87). In mammals there are 4 Jak proteins (Jak1-3 and Tyk2) 
and 7 STAT genes (STAT1-4, STAT5A, STAT5B and STAT6) allowing for cell- and ligand-
specificity, and to process diverse responses to extracellular signaling proteins. The signaling 
pathway is therefore not only used by IFN but by many other cytokines and growth 
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hormones. However, here it will be focused only on the signaling induced by the different 
IFN types, highlighting their similarities and their differences.  
All IFNs have in common that binding to their receptors (e.g. IFNAR, IFNGR, IL28RA) 
induces an oligomerization of the two receptor chains, which leads to conformational changes 
of the associated Jak proteins, such that the Jaks can phosphorylate a tyrosine residue of each 
receptor chain. This phosphorylation creates a strong interaction site for the Src-homology 2 
(SH2) domain of the STATs, that get recruited one to each receptor chain, then get 
phosphorylated on a tyrosine residue by the respective Jak protein, which allows the STATs 
to form stable dimers. They then translocate rapidly to the nucleus, where they bind to 
sequence motifs in the promoters of their respective target genes and enhance transcription of 
so called interferon stimulated genes (ISGs) (Figure 1.7). 
Type I IFN bind to IFNAR1 and IFNAR2 that are associated with Tyk2 and Jak1, 
respectively. The receptor phosphorylation leads then to recruitment of each a STAT1 and a 
STAT2 molecule, the former getting phosphorylated on tyrosine 701 and the latter on tyrosine 
689, leading to a strong heterodimer formation. After translocation to the nucleus the STAT1-
STAT2 heterodimer interacts with IRF9 to build the IFN-stimulated gene factor 3 (ISGF3) 
that then binds to IFN-stimulated response elements (ISRE) in the promoters of classical 
ISGs. Again, signaling in response to type III IFN seems to follow a very similar pattern to 
that in response to type I IFN and also leads to ISGF3 formation that binds to ISRE88. On the 
other hand, type II IFN signaling is again different. IFNGR1 and IFNGR2 are associated with 
Jak1 and Jak2. Upon binding of the IFN-γ dimer to the receptor and the resulting receptor 
dimerization, Jak2 gets activated and first trans-phosphorylates Jak1, before both Jaks 
phosphorylate the receptor chains. Two STAT1 molecules get recruited that are 
phoshporylated at tyrosine 701 and form STAT1-STAT1 homodimers. They then translocate 
to the nucleus and bind to the gamma-activating sequence (GAS) elements that are distinct 
from ISRE. 
It has to be noted, that these pathways are not exclusive and there is interplay between the 
canonical pathways. IFN-α is also able to partly induce STAT1 and STAT3 homo- and 
heterodimers, which then bind to GAS elements (Figure 1.7). What conditions apply to induce 
this cross-talk and to what extent this happens in vivo under physiological circumstances is 
not known. 
 
Treatment of cells with IFN upregulates the expression of several hundred genes (ISGs), 
which specify the antiviral state. Transcriptome analysis of human peripheral blood 
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mononuclear cells (PBMCs) and human liver after treatment with pegIFN-α revealed that the 
ISG-sets induced is overlapping but also distinct, indicating a cell-type specific induction of 
ISGs89. Some of the ISGs, especially the ones encoding enzymes, have been studied 
thoroughly, e.g. protein kinase R (PKR), oligoadenylate synthetases (OAS), and Mx. In 
general different combinations of ISGs seem to be effective in different viruses, rather than 
one single ISG84.  
Recently, a very comprehensive overexpression screen has been performed to evaluate over 
380 ISGs for their capability to inhibit the replication of several viruses, including HCV90. 
Among the strongest inhibitors of HCV replication were MDA5, RIG-I, IRF1 and IRF790. 
Additionally, translational inhibition came out to be a general and potent mechanism to inhibit 
viral replication. Interestingly, several ISGs also enhanced the replication of some viruses, 
bringing forward another layer of complexity in virus-host interactions90. 
 
 
                                 
 
Figure 1.7. Scheme of the proteins involved in the canonical Jak-STAT pathway of type I and 
II IFN (adapted from Heim MH, IFN Signaling in the Liver, EASL monothematic conference, 
2010). 
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1.2.4 Negative regulation of the Jak-STAT pathway 
 
The activation of the Jak-STAT pathway is tightly controlled by several negative regulators 
that interfere at different steps of the pathway (Figure 1.8).  
SOCS. A classical negative feedback loop in Jak-STAT signaling is the STAT-induced 
transcription of suppressor of cytokine signaling (SOCS) proteins. SOCS family members 
have a SH2 domain that can bind to phosphotyrosine residues of the cytokine receptor or the 
Jaks and the catalytic activity of the Jak proteins, or compete with STAT binding sites, or 
target bound signaling proteins for proteosomal degradation91. The exact mechanism remains 
to be elucidated.  
PIAS. Another family of negative regulators that were discovered is called protein inhibitors 
of activated STATs (PIAS). PIAS acts in the nucleus by specifically binding to 
phosphorylated STATs and inhibiting their association with the DNA92.  
SHP. SH2 containing phosphatases (SHP) are ubiquitously expressed unspecific 
phosphatases that can attenuate cytokine signal transduction by dephosphorylating signaling 
intermediates such as JAK and its receptor91. 
USP18. More recently, ubiquitin-specific peptidase 18 (USP18), a classical ISG, has been 
identified as a novel negative regulator in Type I IFN signaling93. USP18 was first described 
to cleave ubiquitin-like modifier ISG15 from target proteins94, but it has been demonstrated 
that it also blocks the Jak-STAT pathway, and this independently of its peptidase activity93. 
USP18 seems to bind specifically to the IFNAR2 receptor subunit and inhibits the activity of 
JAK1 by blocking the interaction between JAK1 and IFNAR2. Functionally, silencing of 
USP18 in cells infected with HCVcc potentiated the negative effect of IFN-α on the 
replication of HCVcc95. 
           
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. Schematic overview of 
negative regulators at the different levels 
of the Jak-STAT pathway. 
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1.2.5 Refractoriness to IFN signaling 
 
It has been discovered many years ago that cultured cells treated with IFN-α become 
refractory within hours and remain unresponsive up to 3 days96. Refractoriness has also been 
demonstrated in livers of mice with continuous exposure to IFN-α97. A comprehensive study 
with different genetic mouse models revealed that while upregulation of SOCS proteins is 
responsible for an immediate negative regulation of the Jak-STAT pathway it cannot explain 
long-term refractoriness97. However, USP18 knockout mice remained responsive to further 
IFN-α stimulation suggesting a key function of USP18 in maintaining the cells refractory97. 
New evidence has been gathered in vitro and in vivo that this phenomenon of refractoriness is 
restricted to IFN-α signaling and does not affect IFN-β or IFN-λ signaling98,74. 
 
However, whether refractoriness to IFN-α signaling also occurs in the human liver has not 
been investigated so far, although this understanding would be important to improve IFN-α 
therapy regimens. pegIFN-α has replaced IFN-α because of its higher efficacy with more 
patients reaching SVR. It is commonly believed that the superior half-life of pegIFN-α with 
constant high serum levels is the reason for a better effectiveness by providing uninterrupted 
antiviral activity through continuous stimulation of the IFN signaling pathways99. Clearly, the 
evidence from cell culture and mouse models speaks against this hypothesis and 
pharmacodynamics studies in the human liver are needed if we want to understand the 
efficacy of pegIFN-α and its underlying molecular mechanisms.  
 
 
1.3 Virus-host interactions 
 
As indicated previously, proper small animal models to study HCV infection are still missing. 
So far the investigation of viral infection and the host’s immune response has been limited to 
chimpanzees and human patients. Cell culture experiments in this context have clearly their 
limitations but have been helpful in discovering direct interactions of viral proteins with the 
host’s intracellular defense mechanisms. This chapter will thus cover the gathered knowledge 
of the interference of HCV with the antiviral response, the dynamics of the host’s immune 
response to HCV, the phenomenon of a pre-activated IFN system in CHC, and the relevance 
of IL28B genetic variations in HCV infection. 
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1.3.1 Molecular interactions of HCV with the host’s immune response 
 
It remains astounding, how HCV with its small genome, encoding for only 10 different 
proteins, is able to survive the immune response in most of the acutely infected persons and 
establish a lifelong persistent infection. One can only speculate which of the strategies 
discovered in different virus infections are predominantly useful for HCV to win the battle 
against the host’s immune system, but one property that especially holds true for HCV with 
ever growing evidence is the ability to interfere directly with the molecular pathways 
involved in the IFN signaling pathways. 
Viral sensing. As mentioned previously, the main sensing pathways responsible for HCV 
detection are the RIG-I pathway through adaptor protein MAVS and the TLR3 signaling via 
TRIF. Even before the discovery of the RIG-I pathway it has been shown that the NS3/4A 
protease is able to diminish the induction of IFN-β by an interaction upstream of IRF3100. It 
was only later revealed with the discovery of MAVS that this adaptor protein is the target 
cleaved by NS3/4A resulting in abrogated IFN-β induction in vitro101,102,103. Similarly, it has 
been shown that also TRIF gets cleaved in vitro by NS3/4A (Figure 1.9)79,104. 
 
 
 
 
Figure 1.9. NS3/4A of HCV cleaves MAVS and TRIF, and thus prevents the induction of IFN. 
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Jak-STAT pathway. Overexpression of HCV core protein seems to interfere with IFN-
signaling downstream of IFNAR, suggested by direct interaction with STAT1 leading to 
reduced STAT1 phosphorylation105,106 (Figure 1.10). These findings are contrary to what has 
been shown when the whole HCV polyprotein is expressed in cells or in mouse liver, where 
STAT1 phosphorylation and nuclear translocation are not impaired but the binding of STATs 
to the DNA is abrogated107,108. This mechanism has been thoroughly investigated, introducing 
a model that the ubiquitously expressed protein phosphatase 2A (PP2A) is upregulated in 
infected hepatocytes probably due to an endoplasmatic reticulum stress response109,110. PP2A 
directly inhibitis the protein arginine methyltransferse 1 (PRMT1), which leads to a 
hypomethylation of STAT1, and promotes the association with the negative regulator 
PIAS1111 (Figure 1.10) - a mechanism which has also been demonstrated in human liver 
biopsies109,112. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. Interference of HCV with the 
Jak-STAT pathway.
 
 
IFN effector mechanisms. There has also been evidence that HCV proteins interact with 
IFN-induced effector proteins. Most prominent is dsRNA-activated protein kinase R (PKR), 
which seems to be bound and antagonized by NS5A113,114. PKR regulates cellular translation 
through dsRNA-stimulated autophosphorylation and subsequent phosphorylation of the 
translation initiation factor eIF2α, and it has been demonstrated that PKR inhibits the 
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replication of HCV in vitro115. Quite on the contrary is the following proposed model that 
HCV actually phosphorylates PKR which leads to an arrest of ISG translation, therefore 
favouring HCV replication116. However, all this data is derived from cell culture models and 
has not yet been confirmed in the liver of infected patients.  
 
 
1.3.2 Host response to acute HCV infection 
 
The study of the acute phase of HCV in human is hindered by rare clinical detection since 
most infections occur with unspecific symptoms or even asymptomatically. However, studies 
were conducted with subjects after needle stick injuries, which showed a very rapid increase 
of HCV viral load to maximal levels within the first 2 to 4 weeks117. Serial liver biopsies and 
blood sampling in artificially infected chimpanzees showed accordingly a very fast rise in 
viral load in the first 2 weeks followed by a slower rise for another couple of weeks and a 
concomitant induction of the innate immune system with upregulation of ISGs118,119, 120. HCV 
RNA levels only began to decrease with a significant rise of ALT (alanine-aminotransferase) 
– a marker of hepatocyte death - that coincided with infiltration of T cells in the liver, which 
happened approximately 8 to 12 weeks after infection118,119. The outcome then varied leading 
to either chronic infection with a lower steady level of viral load or to spontaneous clearance. 
Analyses of immunological determinants of spontaneous clearance in chimpanzees as well as 
humans revealed that only those subjects with a strong and multispecific T cell response were 
able to eradicate the virus117,119. It has to be noted, that all chimpanzees showed a strong 
hepatic ISG upregulation which however was not associated with any disease outcome118. The 
strong ISG upregulation would also argue against a very important role of MAVS cleavage by 
NS3/4A at the beginning of infection. However, MAVS cleavage in chimpanzees has not 
been studied (and neither in acutely infected humans) and it might be that NS3/4A is just not 
effective in cleaving chimpanzee MAVS. Interestingly, the only IFN that was measurable on 
the mRNA level during the whole phase of acute infection was IFN-γ which coincided with 
the T cell response and the rise in ALT119,118,120. The IFN responsible for the early induction 
of ISGs so far has not been identified. 
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1.3.3 Host response in chronic HCV infection 
 
All studies performing transcriptome analyses from liver biopsy specimens obtained from 
patients with CHC uniformly observed an induction of the endogenous IFN system with a 
transcriptional upregulation of ISGs in a subpopulation of the patients121,89,122. More 
strikingly, this preactivation of the IFN system at baseline was very strongly associated with 
non-response to treatment with pegIFN-α and ribavirin, irrespective of the viral genotype the 
patient was infected with89, while patients with a non-preactivated IFN system with ISG 
expression levels comparable to non-infected livers reached SVR. The phenomenon of an 
endogenously activated IFN system is restricted to the liver and does not occur for example in 
PBMCs89. While in humans only a part of the patients showed preactivation, all chimpanzees 
reaching CHC showed an induction of ISGs and consequently did not respond to therapy 
making the chimpanzee a suboptimal model to study this phenomenon123,124. An analysis of 
expression profiles in paired liver biopsies of 16 patients before and 4h after a single dose of 
pegIFN-α revealed that responder patients showed a strong induction of ISGs at 4h, while 
non-responder patients were not able to further increase transcription of ISGs89. Very 
interesting was the fact that the expression levels of >93% of the induced ISGs in the 
responder patients after 4h were not higher than the baseline expression levels in the non-
responders, but obviously they were not able to clear the virus spontaneously. The reasons for 
non-response without a decrease in viral load in these patients also remain unclear, most 
likely this is due to a refractory state of the IFN system. 
Explanations, why certain patients with CHC induce their IFN system and others do not, are 
also not truly found so far. A study with a comprehensive analysis of MAVS cleavage and 
ISG expression in liver biopsies showed a negative correlation between the amount of cleaved 
MAVS and ISG expression levels, meaning basically, the more successful HCV is in 
inhibiting antiviral defense the more susceptible it gets to treatment125. However, the 
correlation is not very strong and cannot wholly explain the activation of the endogeneous 
IFN system. Clearly, further factors that contribute to preactivation have to be identified. 
 
 
1.3.4 Genetic variations near the IL28B gene 
 
In 2009 four independent genome-wide association studies (GWAS) identified different 
single nucleotide polymorphisms (SNPs) near the IL28B gene to be highly associated with 
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treatment outcome to pegIFN-α and ribavirin126,127,128,129. These findings had a tremendous 
impact in the field. Not only was it the first genetic host marker to be linked to treatment 
response, but it also could explain to a big part the racial differences in response rates126. Due 
to different analysis platforms and different study populations different marker SNPs were 
identified to be most significant (Table 1.2). Homozygous carriers of the respective major 
(good-response) allele had a 2-fold higher chance to achieve SVR than carriers of the minor 
(bad-response) allele, and the effect of the minor allele seemed to be dominant, since 
heterozygous carriers had response rates similar to homozygous minor allele carriers. 
Interestingly, not only treatment response but also spontaneous clearance was associated with 
the IL28B genotype with an odds ratio between 2.3 and 3.1129,130.  
 
Table 1.2 Strongest SNPs identified in 4 genome-wide association studies. 
GWAS Region SNP (P value) 
Ge et al., 126 North America rs12979860 (1.21 x 10-28) 
Tanaka et al., 127 Japan rs8099917 (3.11 x 10-15) 
Suppiah et al., 128 Australia, Northern Europe rs8099917 (9.25 x 10-9) 
Rauch et al., 129 Switzerland rs8099917 (5.47 x 10-8) 
 
However, the causal variant has so far not been identified. GWAS merely narrow down an 
area where the functional variant may be localized. But neither direct sequencing of the 
region nor recombinant mapping were able to identify a causal variant due to the high linkage 
disequilibrium in the IL28B region126,129. The two strongest SNPs are localized 3 and 8 
kilobases (kb) upstream of the IL28B gene, hinting at a possible influence in gene expression. 
First results of gene expression analyzed in PBMCs of these patients were contradictory. Two 
groups found lower IL28A/B gene expression, while the third group didn’t find any 
differences126,127,128. These results were obtained in only a minor part of the study population 
though, and due to the high sequence similarity expression of IL28B and IL28A was not 
differentiated. Since the causal variant has not been identified, it is impossible to delineate 
how the polymorphisms influence treatment response and spontaneous clearance, whether it is 
through functional changes of the cytokine or differences in expression. However, since 
IL28B encodes for an IFN, IL28B polymorphisms would be a likely contributing factor to 
explain the preactivation of the IFN system in this subgroup of CHC patients, who through 
mechanisms that remain to be elucidated fail to therapy. 
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2. Aims of the PhD-thesis 
 
The lack of proper in vivo models for HCV infection (besides chimpanzees) and the 
longstanding expertise of the Hepatology Laboratory to obtain valuable patient liver biopsy 
specimens for research purposes made it an obvious choice to study directly HCV-infected 
liver biopses for a better understanding of HCV-host interactions. Three main questions in the 
context of virus-host interactions and treatment response upon IFN-α in HCV infection were 
addressed: 
 
1. In acute HCV infection more than 90% of the patients achieve an SVR with pegIFN-α 
monotherapy, while in CHC with a combination therapy of pegIFN-α/ribavirin SVR rates are 
in the range of only 50%. Reasons for this discrepancy are unknown. While the host reaction 
in the liver of CHC patients has been studied and an association of ISG induction and non-
response to treatment has been established, none of this has so far been analyzed in the liver 
of patients with AHC. We therefore wanted to assess the host reaction upon AHC infection 
and to elucidate molecular mechanisms that might explain the discrepancies in response to 
IFN. 
 
2. Genetic variants near the IL28B gene were the first genetic host factor discovered to be 
highly associated with treatment response. The fact that IL28B encodes for IFN-λ3, which is 
able to induce ISGs, which overexpressed has been shown to be strongly associated with non-
response to treatment led us to the hypothesis that these genetic variants might be the driver of 
ISG induction in non-responder patients through upregulation of IFN- λ3. The aim was to 
address this hypothesis in a collection of CHC liver biopsies and also to assess all existing 
pre-treatment predictors to create a classifier that could be useful for prediction of treatment 
response in a clinical setting. 
 
3. pegIFN-α is an essential therapeutic in HCV treatment regimens. It has replaced IFN-α due 
to higher efficacy, and it has been postulated that the reason is the superior half-life of 
pegIFN-α that leads to a strong and continuous induction of ISGs. However, in vitro and 
mouse studies suggest refractoriness to continuous IFN-α application. Thus, it was the aim to 
study for the first time the pharmacodynamics of pegIFN-α in the human liver. 
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3. Material and Methods 
 
The materials and methods of the results of section 4.1 and 4.2 are described in the respective 
parts of the incorporated articles: Dill M.T. et al., Interferon gamma stimulated gene 
expression and lack of USP18 induction in the liver of patients with acute hepatitis C 
(submitted), and Dill M.T. et al., Interferon-Induced Gene Expression Is a Stronger Predictor 
of Treatment Response than IL28B Genotype in Patients with Hepatitis C, Gastroenterology. 
2011 Mar;140(3):1021-1031. 
 
The following material and methods refer to the results in section 4.3: 
 
Patients. From November 2005 to April 2010, patients with CHC that were referred to the 
Hepatology Outpatient Clinic of the University Hospital Basel and gave written informed 
consent to use part of the diagnostic biopsy (B-1) for research purposes and were planned to 
receive treatment, were screened for hepatic ISG expression. Only patients with low ISG 
expression were asked to participate in the study which included a second paired biopsy (B-2) 
at a given time point in the first week after the first injection with pegIFN-α. 3 patients were 
included for the following time points: 16h, 48h, 96h, and 144h, and additionally data of 6 
patients from a previous study biopsied at 4h (no. 1, 2, 6, 7, 8, 9) were included in the 
analysis89. The data reported in that previous paper have been deposited in the Gene 
Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE11190). 
All patients received 1.5 µg/kg body weight pegIFN-α-2b (Essex Chemie, Switzerland). 
Weight-adjusted ribavirin treatment was initiated only after the second biopsy to avoid 
confounding effects. An additional 3 patients that were treated with pegIFN-α-2a (Roche, 
Switzerland) were included for the 144h time point. Blood for serum analysis was also taken. 
All patients gave written informed consent to the study, which was approved by the Ethics 
Committee of Basel. Serum HCV RNA was quantified using the COBAS AmpliPrep/COBAS 
Taqman HCV-Test and the Cobas Amplicor Monitor from Roche Molecular Systems. 
 
Measurement of serum IFN-α. 
Serum was collected before the first injection with pegIFN-α and at the time of the second 
biopsy. Serum levels of IFN-α-2b and peg-IFN-α-2a was measured with an enzyme-linked 
immunosorbent assay (ELISA) kit (Verikine #41100, PBL Interferonsource, Piscataway, NJ). 
Standard curves were prepared separately for peg-IFN-α-2a and -2b by a serial dilution 
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starting from 12.5 pg/ml in the sample diluent. The serum samples were diluted 10 times in 
sample diluent. Samples with concentration below 12.5 pg/ml were considered below the 
lower limit of detection. 
 
RNA extraction and microarray hybridization. Total RNA was extracted from human liver 
tissue using Qiazol reagent and RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
instruction. Gene expression was assessed by microarray analysis using Affymetrix Human 
Genome U133 Plus 2.0 arrays (3’ IVT array). 1 µg of total RNA from each sample was 
reverse transcribed using Genechip 3’IVT Express Kit (Affymetrix) according to the 
manufacturer’s instructions. The Hybridization and Wash Kit (Affymetrix) was used to 
hybridize the samples. 
 
Statistical analysis. Microarray analysis was performed with Bioconductor packages of R 
statistical environment131. Data were preprocessed using standard RMA algorithm. Batch 
effects observed between the human liver samples processed and hybridized at different times 
were corrected using the ComBat algorithm132. Probe sets with very low expression intensities 
(below 80 in the highest-expressing sample) as well as the control probe sets were excluded 
from the subsequent analyses. For the gene cluster analysis genes with fold change between 
B1 and B2 >2 up- or downregulated in 2/3 of the patients of the respective time point were 
included and normalized prior to the analysis. An infinite Gaussian mixture model with a 
Dirichlet process prior was used133. This non-parametric model suggests a growing number of 
Gaussians to describe the gene expressions. The model is fully probabilistic in nature, which 
means that on output samples from a distribution over partitions are given. By the special 
choice of a Dirichlet process prior, the number of clusters need not to be fixed in advance, but 
is inferred from the data. The results were tested for robustness by moderately changing the 
hyperparameters that control the Dirichlet process. 
Additional statistical analyses were carried out using GraphPad Prism software version 4.0. 
 
IL28B SNP genotyping. Genotyping for the rs12979860 SNP was performed with TaqMan 
SNP genotyping assays (Applied Biosystems Inc, Foster City, CA). TaqMan probes and 
primers were designed and synthesized by Applied Biosystems: forward 5’-TGTACT- 
GAACCAGGGAGCTC-3’, reverse 5’-GCGCGGAGTGCAAT- TCAAC-3’; Vic probe 5’-
TGGTTCGCGCCTTC-3’, Fam probe 5’-CTGGTTCACGCCTTC-3’. Automated allele 
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calling was performed using SDS software from Applied Biosystems. Positive and negative 
controls were used in each genotyping assay. 
 
Western blot. Whole cell extracts were obtained by homogenizing a 5mm cylinder of the liver 
biopsy lysis buffer (50mmol/L Tris pH8, 280mmol/L NaCl, 0.5% NP40, 0.2mmol/L EDTA, 
2mmol/L EGTA, 10% glycerol, 100mol/L NaVO4, 1mmol/L PMSF, and protease inhibitors), 
incubating for 30 minutes on ice with regular vortexing, and centrifugation at 14,000g for 15 
minutes. 10µg of total protein from human liver lysates was loaded for SDS/PAGE and 
transferred onto a nitrocellulose membrane (Schleicher & Schuell, Switzerland). The 
membranes were blocked in 3% BSA/milk (1:1) for 1h, washed with Tris-buffered saline 
Tween-20 (TBST), and then incubated with primary antibodies specific to tyrosine-
phosphorylated STAT1 (PY701-STAT1; # 9171; Cell Signalling), STAT1 (C-terminus; 
610186; BD Transduction Laboratories, BD Biosciences), USP18 (#4813; Cell Signalling) all 
1:1000, and β -Actin (A5441; Sigma) 1:2000 in Tris-buffered saline Tween-20 (TBST) 
overnight at 4°C. After 3 washes with TBST, membranes were incubated with fluorescent 
secondary goat anti-mouse (IRDye 680) or anti-rabbit (IRDye 800) antibodies (both LI-COR 
Biosciences) for 1h at room temperature. Blots were scanned by Odyssey Infrared Imaging 
System (LI-COR). Quantification of the bands was done with ImageJ software. 
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4. Results 
 
4.1 Interferon gamma stimulated gene expression and lack of USP18 
induction in the liver of patients with acute hepatitis C 
 
Dill M.T., Makowska Z., Duong F.H.T., Merkofer F., Filipowicz M., Baumert T.F., Tornillo 
L., Terracciano L., Heim M.H., Interferon gamma stimulated gene expression and lack of 
USP18 induction in the liver of patients with acute hepatitis C. (submitted manuscript) 
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Abstract 
 
BACKGROUND & AIMS: Therapy of chronic hepatitis C (CHC) with pegylated interferon-
α (pegIFN-α) and ribavirin achieves a sustained virological response (SVR) in approximately 
half of the patients. Non-response to treatment is associated with constitutively increased 
expression of IFN stimulated genes (ISGs) in the liver already before therapy. In acute 
hepatitis C (AHC), therapy is much more effective, with SVR rates > 90%. The aims of this 
study were to elucidate mechanisms responsible for the different treatment response rates 
between CHC and AHC.  
METHODS: We analyzed IFN signaling and ISG expression in liver biopsies of patients with 
AHC, CHC and controls by microarray, immunohistochemical and protein analysis. By 
stimulating primary human hepatocytes with IFN-α or IFN-γ reference gene sets were created 
for gene set enrichment analysis. 
RESULTS: Hundreds of genes, many of them IFN-γ stimulated genes, were differentially 
regulated in AHC compared to controls. There was only a limited overlap with the set of 
mostly IFN-α responsive genes dysregulated in patients with CHC. Expression analysis of 
negative regulators of IFN-α signaling showed no differences of SOCS1 or SOCS3 
expression between AHC and CHC. However, USP18, another important negative regulator 
of IFN-α signaling, was strongly induced in CHC non-responders, but not in AHC.  
CONCLUSIONS: The results provide an explanation for the preserved response to pegIFN-α 
in AHC despite strong ISG induction and identify USP18 as a therapeutic target for 
improving IFN-α responsiveness in CHC. 
 
Key words: Hepatitis C virus; Jak-STAT signaling; host-virus interaction 
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Introduction 
 
Chronic infection with hepatitis C virus (HCV) is a major cause of liver disease worldwide 1. 
For the last decade, a combination of pegylated interferon α (pegIFN-α) with ribavirin was the 
standard therapy for chronic hepatitis C (CHC). This treatment achieves an overall sustained 
virological response (SVR) in ~55% of patients 2. Recently, two HCV protease inhibitors 
used in conjunction with pegIFN-α and ribavirin have been approved for the treatment of 
CHC, and triple combination therapies will most likely be the standard of care for a majority 
of patients in developed countries 3. However, non-response to pegIFN-α remains an 
important problem in the setting of triple therapy, because it significantly increases the rate of 
viral breakthrough during therapy caused by the emergence of HCV variants resistant to 
protease inhibitors 4, 5. It has been well documented that non-response to pegIFN-α is 
associated with persistent induction of IFN stimulated genes (ISGs) in the liver 6-8. The very 
same set of hundreds of ISGs is induced by therapeutically applied pegIFN-α in patients 
without pretreatment activation of ISGs who have a good response to treatment 7. 
Paradoxically, activation of the endogenous IFN system not only is ineffective in clearing the 
infection, but also impedes response to pegIFN-α therapy, possibly because of refractoriness 
of the IFN-α signal transduction pathway. We have previously shown that IFN-α signaling in 
the mouse liver becomes unresponsive within hours after the injection of IFN-α and have 
identified USP18 as a key mediator of refractoriness 9. 
 
Contrary to patients with CHC, most patients with acute hepatitis C (AHC) respond very well 
to monotherapy with (peg)IFN-α 10, 11. The reasons for the discrepant response to pegIFN-α 
are unknown. Given the association of intrahepatic ISG expression and non-response to 
pegIFN-α in CHC, an obvious explanation for the good response to therapy in AHC could be 
a lack of ISG induction in AHC. The intrahepatic immune response has not been studied in 
patients with AHC, but serial liver biopsies in chimpanzees obtained during the first 6-8 
months after infection with HCV have revealed a strong induction of ISGs 12-14. In the present 
study, we analyzed inflammatory infiltrates, the activation of IFN signal transduction 
pathways and gene expression profiles in liver biopsies of 6 patients with AHC.
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Materials and Methods 
 
Patients. 
All patients were recruited in the Hepatology Outpatient Clinic of the University Hospital 
Basel, Switzerland. From October 2007 to December 2010, 6 patients with AHC (between 0-
6 months after the HCV transmission) gave written informed consent to participate in this 
study and donated a liver biopsy specimen for research purposes. The study was approved by 
the Ethics Committee of Basel. 
Liver biopsies from 16 patients with CHC and 4 normal liver tissue samples were used for 
comparative analysis. These samples have been obtained during a previous study that has 
been published 7. The data reported in that paper have been deposited in the Gene Expression 
Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE11190). Additional 
16 liver biopsies of patients with CHC were used for immunohistochemical analyses. All 
patients with CHC were treated with pegIFN-α and ribavirin, the standard of care during the 
study period. Patients with a sustained virological response defined as undetectable HCV-
RNA 6 months after the end of treatment were classified as responders (R), all others as non-
responders (NR). Serum HCV RNA was quantified using the COBAS AmpliPrep/COBAS 
Taqman HCV-Test and the Cobas Amplicor Monitor from Roche Molecular Systems. AHC 
patients were closely monitored for transaminases and HCV-PCR and if there was no decline 
of the viral load below the limit of detection within a month after the first visit, they were 
treated with 1.5µg/kg body weight pegIFN-α-2b (PegIntron, Essex Chemie, Switzerland) 
monotherapy for 24 weeks, unless indicated otherwise (Table 4.1.1). 
 
Isolation and treatment of primary human hepatocytes. 
PHH were isolated from liver resections obtained from non-infected patients at described 
previously 15. Freshly isolated PHH were seeded on 6-well-plates precoated with collagen 
(BD Biosciences) and maintained in culture in William's E medium (Sigma) supplemented 
with 1% Glutamax (Gibco), 1% insulin transferrin selenium (Gibco), 10-7 M dexamethasone 
(Sigma), 0.15% BSA (Sigma), and 10% FBS (PAN Biotec). PHH were treated with 
1000U/mL of human IFN-α (Roferon, Roche) or human IFN-γ (BioLegend) for 6h and 24h. 
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RNA extraction and microarray hybridization. 
Total RNA was extracted from human liver tissue and PHH using Qiazol reagent and RNeasy 
Mini Kit (Qiagen) according to the manufacturer’s instruction. Gene expression was assessed 
by microarray analysis using Affymetrix Human Genome U133 Plus 2.0 arrays (3’ IVT array) 
for human liver specimens and Affymetrix Human Gene 1.0 ST arrays (whole-transcript 
array) for PHH. For the 3’ IVT arrays, 1 µg of total RNA from each sample was reverse 
transcribed using Genechip 3’IVT Express Kit (Affymetrix) according to the manufacturer’s 
instructions. For the whole-transcript arrays, 500 ng of total RNA was reverse transcribed and 
biotinylated with the whole-transcript Expression Kit (Ambion) and whole-transcript 
Terminal Labeling Kit (Affymetrix) according to the manufacturer’s instructions. The 
Hybridization and Wash Kit (Affymetrix) was used to hybridize all samples. All original 
array data are being deposited at the National Center for Biotechnology Information Gene 
Expression Omnibus database. 
 
Statistical analysis. 
Microarray analysis was performed with Bioconductor packages of R statistical environment 
16. Data were preprocessed using standard RMA algorithm. Batch effects observed between 
the human liver samples processed and hybridized at different times were corrected using the 
ComBat algorithm 17. Probe sets with very low expression intensities (below 80 in the 
highest-expressing sample) as well as the control probe sets were excluded from the 
subsequent analyses. Genome-wide hierarchical clustering of the human liver samples was 
carried out using Ward’s linkage method, with 1 – Pearson correlation as a distance metric. 
Differential gene expression for AHC, CHC-R and CHC-NR versus control samples was 
assessed using limma package 18, with fold change cutoff of 2 and false discovery rate (FDR) 
cutoff of 0.05. To calculate the FDR, moderated t-statistics were first generated using the 
empirical Bayes method, as implemented in the limma package, and the obtained p-values 
were corrected for multiple testing using Benjamini and Hochberg adjustment 19. Enrichment 
of Gene Ontology Biological Process terms was performed using the list of genes 
significantly upregulated in AHC patients with respect to CTRL patients. Significance 
estimation of the enrichment analysis was carried out using a hypergeometric test as 
implemented in g:Profiler software. Terms with p-values below 10-6 were clustered into 
distinct groups based on the GO hierarchy. The enrichment scores were calculated for each 
cluster (–log10 of the geometric mean of the p-values for all categories in a cluster). 
Area-proportional Venn diagrams were created with the help of BioVenn software 20. 
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Two gene sets for Gene Set Enrichment Analysis (GSEA) 21 were obtained as follows 
(Supplementary Figure 4.1.3A): (i) 2 initial probe set lists were derived from the PHH 
expression dataset based on upregulation in IFN-α or IFN-γ treated samples compared to 
untreated samples (fold change between the means of treated and untreated samples above 2 
at least at one timepoint); (ii) within the 2 lists we selected probe sets for which at least at one 
time point there was more than a 2-fold difference between the means of α- and γ-IFN-treated 
samples, with the p-value from a Welch t-test between the corresponding samples below 0.05. 
These two lists were then annotated with gene symbols and their enrichment was assessed in 
AHC versus CHC-NR samples with javaGSEA software version 2.07 (Broad Institute), using 
signal-to-noise ratio as a ranking metric. On the GSEA plot, the x axis represents a list of all 
genes on the array rank-ordered according to their decreasing correlation with AHC 
phenotype (red: genes overexpressed in AHC, blue: genes overexpressed in CHC-NR). Black 
ticks along the x axis show positions of  genes which are part of the tested gene set. The y axis 
unit is the enrichment score defined as a running-sum statistic calculated walking down the 
ranked gene list. The running-sum increases when a gene in the ordered list is present in the 
gene set in question and decreases when it is absent. The increment of the enrichment score 
depends on the value of the ranking metric. 
Enrichment of KEGG pathways and Gene Ontology Biological Process terms in lists of genes 
significantly altered between AHC and CHC-NR was assessed using DAVID software 
version 6.7. To facilitate the interpretation, terms with p-values (modified Fisher exact test) 
below 0.05 were grouped based on the overlapping gene membership. The enrichment score 
is equal to –log10 of the geometric mean of the p-values for all categories in a cluster. 
Statistical analyses of real-time RT-PCR and immunohistochemical data were carried out 
using GraphPad Prism software version 4.0. 
 
IL28B genotyping. 
Extraction of DNA and genotyping for the single nucleotide polymporphism rs12979860 near 
the IL28B gene was performed as described previously 22. 
 
Real-time RT-PCR. 
RNA was reverse transcribed by Moloney murine leukemia virus reverse transcriptase 
(Promega Biosciences, Wallisellen, Switzerland) in the presence of random primers 
(Promega) and deoxynucleoside triphosphates. The reaction mixture was incubated for 5 min 
at 70°C and then for 1 h at 37°C. The reaction was stopped by heating at 95°C for 5 min. For 
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the measurement of IFNα and IFNβ genes containing only one exon, the same amount of 
RNA was also mock reverse transcribed to control for genomic DNA contamination. SYBR-
realtime-PCR was performed using SYBR green (Applied Biosystems, Foster City, CA). The 
intron-spanning primers are listed in Supplementary Table VII. IFNα primers were designed 
to detect all 13 IFNα genes. All reactions were run in duplicate with an ABI 7500 Real-Time 
PCR System (Applied Biosystems). mRNA expression levels of the transcripts were 
normalized to GAPDH using the ∆Ct method. 
 
Western Blot.  
Whole cell extracts and blotting of human liver samples were performed as described 7. The 
membranes were incubated with primary antibodies (listed in Supplementary Table VIII) in 
Tris-buffered saline Tween-20 (TBST) overnight at 4°C. After 3 washes with TBST, 
membranes were incubated with fluorescent secondary goat anti-mouse (IRDye 680) or anti-
rabbit (IRDye 800) antibodies (both LI-COR Biosciences) for 1h at room temperature. Blots 
were scanned by Odyssey Infrared Imaging System (LI-COR). For MAVS the membrane was 
incubated with HRP-conjugated goat anti-mouse antibody (Pierce) and developed on Biomax 
MR films (Kodak). 
 
Immunohistochemistry. 
4 µm-thick serial sections were cut from formalin-fixed, paraffin-embedded liver biopsy 
specimens, rehydrated, pretreated for 20 minutes in ER2 solution, incubated with the 
respective primary antibody and counterstained with haematoxilin. Standard indirect 
immunoperoxidase procedures were used for immunohistochemistry (ABC-Elite, Vectra 
Laboratories). The staining procedure was performed with an automated stainer (Bond, 
Vision BioSystems, UK). The primary antibodies are listed in Supplementary Table VIII. 
For the co-localization analysis each section was photographed at 50x magnification with a 
11.7 megapixel Axio Zeiss camera (picture size: 3900 x 3000 pixels) choosing the same area 
of the biopsy. 5 random high power fields (HPF, 279 x 252 pixels) were chosen within the 
parenchyma of the biopsy of the first section (Supplementary Figure 4.1.4). Then identical 
HPFs of the other sections were defined, all HPFs enlarged digitally and the amount of 
positive hepatocytes or immune cells were counted by two independent observers (MTD, FM) 
(Supplementary Table VI). To ensure the quality of the count on the digitally enlarged HPFs 
the corresponding HPFs were also counted by microscopic assessment. For the digital 
processing Adobe Photoshop and Illustrator version 5 were used. 
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Results 
 
Host-virus interactions during acute hepatitis C induce a distinct pattern of gene 
expression in the liver. 
Six patients with HCV monoinfection underwent a liver biopsy 2-5 months after HCV 
transmission, i.e. during the acute phase of HCV infection (Table 4.1.1). Gene expression in 
these liver biopsies was analyzed with Affymetrix U133 Plus 2.0 arrays and compared to 4 
samples from patients without liver disease (controls) and 16 samples from patients with CHC 
recruited in a previous study 7. We found between 203 and 492 genes (average 312) 
upregulated and 239 to 374 genes (average 294) downregulated more than 2-fold in the liver 
of patients with AHC compared to the healthy controls (Figure 4.1.1A). The extent of up- or 
downregulation was not associated with response to treatment, spontaneous clearance, 
estimated time from infection to biopsy, serum viral load or IL28B genotype (data not 
shown). Transcriptome profiles of AHC liver samples were highly homogenous: between 50 
and 80% of genes altered in a particular patient were also changed in at least two other AHC 
patients (Figure 4.1.1A). Genes upregulated in AHC patients compared to healthy liver 
included chemokines and their receptors, ISGs, and genes involved in cellular immune 
responses (Figure 4.1.1B and Supplementary Table I). Many of the downregulated genes are 
involved in intermediate metabolism and lipid homeostasis (Supplementary Table II). 
 
A comparable number of genes were dysregulated in the group of CHC patients who were 
non-responders to pegIFN-α (CHC-NR), but intersecting the sets of differentially regulated 
genes showed only a limited overlap between CHC and AHC patients, with 147 genes 
upregulated and 138 genes downregulated specifically in AHC (Figure 4.1.1B). Genome-wide 
unsupervised clustering of the healthy liver, CHC and AHC samples (Supplementary Figure 
4.1.1) showed that AHC samples form a well-defined, separate cluster, further demonstrating 
the specific molecular signature of this group of patients. 
 
 
Activation of Jak-STAT signaling and ISG induction in AHC. 
As outlined above, functional annotation of the genes dysregulated in AHC identified several 
classical ISGs (Supplementary Table I). To investigate more rigorously to what extent ISGs 
were induced in AHC, we made use of a list of bona fide hepatic ISGs. This list was compiled 
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in a previous study where we obtained paired biopsies before and 4 hours after the first 
injection of pegIFN-α in 10 selected patients with CHC, who didn’t show induction of ISGs 
before treatment and responded well to pegIFN-α 7. It contains 167 genes (242 probe sets) 
significantly (paired t test, P < 0.05) changed >2-fold by pegIFN-α (157 upregulated, 10 
downregulated). Of the 167, 125 were detected above the minimal expression cutoff in our 
dataset. Unexpectedly, only 30 of these 125 IFN-α-regulated genes were regulated > 2-fold in 
AHC. This low number of induced ISGs could be explained by a relatively weak activation of 
IFN signaling pathways in AHC. However, when we analyzed phoshorylation and nuclear 
translocation of STAT1 in the AHC samples, we found a strong activation of this central 
mediator of the IFN signaling pathway (Figure 4.1.2A-C). Alternatively, the absence of a 
broad induction of pegIFN-α induced genes in AHC could be explained by the activation of 
STAT1 by IFN-γ, another strong inducer of STAT1 phosphorylation 23 that has been 
implicated in the immune response during AHC in chimpanzees and human 24, 25. We 
therefore measured the mRNA expression levels of IFN-γ, and found them indeed 
significantly upregulated in AHC biopsies compared to CHC (Figure 4.1.2D). IFN-γ induced 
signaling typically leads to pSTAT1 homodimers, while type I IFN signaling phosphorylates 
STAT1 and STAT2 that create heterodimers. We therefore hypothesized that in AHC we 
should observe exclusively STAT1 phosphorylation while CHC-NR should also show STAT2 
phospohorylation signals. However, while AHC indeed only showed pSTAT1 we were not 
able to detect a pSTAT2 signal in the CHC-NR, which was only weakly detectable in liver 
biopsy samples from responder patients after 4h exposure to pegIFN-α (Figure 4.1.2E). But 
despite similar pSTAT1 levels in AHC and those liver samples under pegIFN-α treatment, 
pSTAT2 was limited to the latter. We therefore conclude that in AHC, STAT1 activation is 
caused by IFN-γ and not by IFN-α/β. 
 
 
IFN-γ-specific gene signature is enriched in the AHC gene expression profiles, while 
IFN-α-induced transcription patterns characterize CHC-NR patients. 
To further study the pattern of ISG induction in AHC and CHC-NR we generated IFN-α and 
IFN-γ-induced gene lists and compared them to the ISG expression in the biopsies. Because 
ISG expression differs considerably between different cells and tissues, we did not use 
published ISG lists obtained in non-hepatic cells, but stimulated primary human hepatocytes 
(PHH) from 2 donors with 1000 IU/ml of human α- and γ-IFN for 6 and 24 hours and 
performed microarray analysis (Figure 4.1.3A). There were 256 genes upregulated more than 
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2-fold in the PHH from both donors after IFN-α stimulation, with the majority of the genes 
induced already after 6 hours of treatment. IFN-γ induced a comparable number of genes 
(288), but with different kinetics. The majority of the IFN-γ induced genes were detected after 
24 hours of treatment. Treatment of PHH with IFN-α led to a very broad gene 
downregulation: transcript levels of 850 genes were reduced more than 2-fold in PHH from 
both donors. Interestingly, the observed suppression was very transient and only 15 genes 
were found downregulated after 24 hours of IFN-α exposure. Gene downregulation after IFN-
γ treatment involved 123 genes, with a slightly larger number of genes found suppressed after 
24 hours of treatment (77) compared to 6 hours (60) and a limited overlap between the two 
time points (14). 
 
Comparison of the gene sets induced by IFN-α or IFN-γ identified 149 common genes, but 
also similar number of genes specifically induced by either IFN-α or IFN-γ (Figure 4.1.3A 
and Supplementary Tables III and IV). This allowed us to generate two gene lists 
representative of IFN-α or IFN-γ stimulated genes (see Materials and Methods section and 
Supplementary Figure 4.1.2). These gene sets were then used to assess the enrichment of 
specific IFN-α and IFN-γ signatures in liver biopsies of AHC and CHC-NR patients using the 
gene set enrichment analysis (GSEA) algorithm 21 (Figure 4.1.3B and Supplementary Table 
V). We observed a significant enrichment of IFN-γ-regulated genes in AHC compared to 
CHC-NR (ES=0.52, p-value=0.04). On the other hand, the genes upregulated in PHH by IFN-
α were enriched in CHC-NR samples (ES=-0.83, p-value<0.001). Selecting IFI27 and IFIT1 
as IFN-α specific ISGs as well as GBP5 and HLA-DMB for IFN-γ specificity we were able to 
confirm the data obtained from the microarrays in the PHH and the liver biopsies by 
quantitative RT-PCR (Supplementary Figure 4.1.4). These results disclose a predominant role 
of IFN-γ in driving the ISG transcription in the acute phase of HCV infection, whereas ISG 
expression in pre-activated patients in the chronic phase shows a type I IFN-specific pattern. 
 
 
CD8+ T cells co-localize with pSTAT1 positive hepatocytes in AHC. 
To investigate the source of IFN production in the infected liver, serial sections from AHC 
and CHC liver biopsy specimens were stained for phosphorylated STAT1 (pSTAT1) and 
markers for T cells (CD3, CD8), for B cells (CD20), for NK cells (CD56) and for 
plasmacytoid dendritic cells (CD123) (Supplementary Figure 3 and Supplementary Table VI). 
In general, the liver parenchyma of AHC showed more inflammatory infiltrates than CHC 
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and most of these cells were positive for CD3 (Figure 4.1.4B). Co-localization analysis 
revealed that in AHC areas with high amounts of pSTAT1 positive hepatic nuclei were 
associated with high numbers of CD3+ and CD8+ cells, but not with CD20+, CD56+ or 
CD123+ cells (Figure 4.1.4A). We did not observe a co-localization of any of these cell types 
with pSTAT1-positive hepatocytes in CHC-NR samples (Figure 4.1.4A). There was a 
statistically significant correlation of STAT1 phosphorylation with the amount of CD3+ cells 
(Spearman r = 0.70, P < 0.0001) and CD8+ cells in AHC (Spearman r = 0.69, P < 0.0001, 
Figure 4.1.4C). Additionally, we detected a positive correlation of CD8+ cells and IFN-γ 
mRNA levels in AHC that due to the low sample size slightly missed statistical significance 
(Figure 4.1.4D). Enrichment analysis of Gene Ontology terms and KEGG pathways revealed 
a significant overrepresentation of categories related to T-cell activation in the AHC 
compared to CHC-NR patients (Supplementary Figure 4.1.2B). Taken together, these data 
provide evidence that infiltrates of CD8+ T cells in the liver of patients with AHC are 
responsible for IFN-γ production and induction of the Jak-STAT signaling pathway. 
 
 
USP18 expression correlates with treatment response to pegIFN-α. 
Non-response to treatment with pegIFN-α and ribavirin in CHC is associated with a general 
upregulation of ISGs in the liver, but the molecular mechanism linking ISG induction to IFN 
non-response remains unknown 6-8. In the present study, we found a similar extent of ISG 
upregulation in AHC samples, but most of the patients either cleared HCV spontaneously or 
responded to therapy (Figure 4.1.1 and Table 4.1.I). We therefore hypothesized that the IFN-α 
driven ISG set in CHC included specific genes that are not upregulated by IFN-γ in AHC. 
Because negative feed-back inhibition of Jak-STAT signaling pathways could underlie 
treatment non-response 9, 26, we analyzed the expression of pathway inhibitors in AHC and 
CHC liver biopsy samples. SOCS1 and SOCS3, two IFN-induced negative regulators of IFN 
signaling, showed no difference between AHC and CHC (data not shown). However, USP18, 
a more recently discovered negative regulator that is instrumental for the refractory state of 
IFN signaling in the mouse liver 9, 27, was significantly upregulated in CHC-NR patients 
compared to CHC-R and AHC (Figure 4.1.5A). To investigate if the differential induction of 
USP18 in CHC-NR versus AHC results from its preferential activation by IFN-α, we 
analyzed USP18 induction in PHH stimulated by either IFN subtype. Indeed, USP18 was 
almost exclusively induced by IFN-α (Figure 4.1.5B). This preferential induction of USP18 in 
CHC-NR was also apparent on the protein level (Figure 4.1.5C-D). 
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Discussion 
 
The study of the acute phase of HCV in human is hampered by the fact that most infections 
are asymptomatic. Spontaneous clearance occurs in about 20-30% of patients 28. Studies of 
subjects after needle stick injuries revealed a very rapid increase of HCV viral load to 
maximal levels within the first 2-4 weeks 25. Viral replication is then slowed down, most 
likely by an innate immune response involving the induction of ISGs in the liver 14, 24. HCV 
specific T cells are detectable 5-9 weeks after infection, accompanied by a rise in alanine 
aminotransferase (ALT) levels and a decline of the serum viral load 25. Liver biopsy studies in 
chimpanzees documented the presence of HCV-specific CD8+ T cells and an increase in 
intrahepatic IFN-γ mRNA during this period of viral decline 14, 24. In the present study, we 
analyzed human liver biopsies obtained 2-5 months after HCV infection, i.e. during the early 
phase of the adaptive immune response. In accordance with the chimpanzee studies, we found 
CD8+ T- cell infiltrates, increased intrahepatic IFN-γ mRNA expression, and ALT elevation. 
Importantly, T cell infiltrates were co-localized with hepatocytes positive for nuclear pSTAT1 
immunostaining, providing evidence that the predominant mediator of STAT1 activation is 
IFN-γ that is secreted by infiltrating T cells which are in close contact to stimulated 
hepatocytes. The microarray analysis of ISG expression revealed a strong enrichment of IFN-
γ specific ISGs in AHC liver biopsy samples, further confirming that the predominant IFN in 
this phase of HCV infection is IFN-γ and not IFN-α. These results do not support the 
hypothesis that liver infiltrating HCV-specific T cells are stunned, with impaired IFN-γ 
production, and are therefore not capable to clear the infection 25, 29, 30. Our results are more 
consistent with a model where recruitment of T cells, IFN-γ secretion by T cells and IFN-
signaling in hepatocytes is intact, but the induction of hundreds of ISGs is little effective, 
either because of a block of translation of ISG mRNAs 31 or because of interference of viral 
proteins with antiviral effector systems. 
 
Upregulation of ISGs during the chronic phase of HCV infection is also ineffective in 
clearing the virus, and even strongly associated with non-response to therapy with pegIFN-α 
and ribavirin 6-8. We have shown previously that in liver biopsies of CHC patients with 
persistently induced ISG expression, nuclear pSTAT1 staining is detectable in 40-80% of 
hepatocytes already in pre-treatment samples, and that this number does not increase in 
biopsies obtained 4 hours after the injection of pegIFN-α 7. In such pre-activated livers, 
STAT1 phosphorylation seems to be refractory to further IFN-α stimulation. These findings 
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can explain why about half of the patients with CHC do not respond to treatment with 
pegIFN-α and ribavirin. On the other side, patients with AHC have an excellent, over 90% 
response rate to treatment with pegIFN-α, even when given as monotherapy. Before our 
present study, an attractive hypothesis to explain the efficacy of pegIFN-α in AHC postulated 
the lack of ISG induction in AHC. The seminal findings that the HCV protease NS3/4A can 
cleave an inactivate TRIF and MAVS, two important components of cellular pathways 
involved in viral sensing and IFN-β induction, provided a molecular mechanism to explain 
the lack of induction of the endogenous hepatic IFN system 32, 33. However, we could not 
detect cleaved MAVS in any of the 6 AHC biopsy samples (Supplementary Figure 4.1.5). 
Furthermore, microarray analysis studies of liver biopsies from chimpanzees during the acute 
phase of HCV infection revealed a strong induction of ISGs 12, 13, 34. These findings do not 
support the hypothesis that efficient MAVS cleavage is a central viral escape mechanism by 
preventing the induction of the IFN system. Our present study in human liver biopsies 
confirms these findings by showing a strong activation of STAT1 and ISG induction during 
AHC. However, whereas biopsies were obtained during the entire course of AHC in the 
chimpanzee studies, we obtained the biopsies in the “late” phase of AHC. Therefore, we 
cannot exclude that TRIF and/or MAVS cleavage are important viral escape mechanisms in 
the very first weeks after infection in humans. 
 
In a previous study in mice we have identified USP18 as a key mediator of IFN-α 
refractoriness 9. Here we show that USP18 is upregulated in CHC-NR but not in AHC 
patients. Comparison of responders versus non-responders to pegIFN-α in a combined 
analysis including AHC, CHC-R and CHC-NR showed that USP18 induction is associated 
with non-response to pegIFN-α. Its preferential induction by IFN-α can explain the low 
expression levels in patients with AHC, where ISG induction is predominantly IFN-γ driven. 
Because USP18 is an important mediator of refractoriness to IFN-α signaling, the apparent 
lack of its induction in AHC might explain the markedly improved response rate to pegIFN-α 
treatments in these patients compared to patients with CHC. 
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Figure 4.1.1. 
Acute hepatitis C patients show a distinct pattern of gene expression in the liver. 
(A) Number of genes 2-fold up- or downregulated in each AHC patient compared to the mean 
gene expression in healthy liver samples (n = 4). Different shades show the extent of overlap 
between patients as indicated. 
(B) Enrichment of Gene Ontology Biological Process terms among genes upregulated in AHC 
patients with respect to CTRL patients. Terms with p-values below 10-6 were clustered based 
on the GO hierarchy. The barplot shows the enrichment score for each term. The numbers to 
the left from the term name show the number of genes which represent a given Gene Ontology 
term in AHC patients. 
(C) Venn diagram of genes identified as up- or downregulated in AHC (n = 6), CHC-NR (n = 
6) or CHC-R patients (n =10) compared to healthy liver. A gene was considered differentially 
regulated in a group if the fold change of expression values between the mean of the group 
and the mean of healthy liver samples was > 2 and the corresponding FDR < 0.05. 
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Figure 4.1.2. 
Acute hepatitis C induces a distinct set of ISGs. 
(A) STAT1 phosphorylation and STAT1 protein expression by Western Blot analysis using 
whole cell extracts of liver samples from AHC (lane 1-6, no. according to Table I), healthy 
liver (lane 7), CHC-R (lane 8-9) and CHC-NR (lane 10-11). 
(B) Representative pictures of immunohistochemistry for pSTAT1 showing strong nuclear 
staining in AHC and moderate staining in CHC-NR, while CHC-R is not positively stained.  
(C) Quantification of pSTAT1 nuclear staining in hepatocytes per high power field (HPF) in 
AHC, healthy liver (Ctrl) and CHC-R and -NR. There were significant differences of the mean 
amount of positive hepatocytes between the four groups (p-value obtained by one-way 
ANOVA). 
(D) Measurement of hepatic expression of IFN-γ mRNA in AHC and CHC by quantitative 
PCR normalized to GAPDH. Each dot represesents one sample. P-value was obtained with 
Student’s t-test. 
(E) STAT1 and STAT2 phosphorylation and whole protein expression by Western Blot 
analysis using whole cell extracts of Huh7 cells untreated (lane 1) or treated for 30 min. with 
1000 U/ml IFN-α (2); or of liver samples of AHC patients 2 and 3 (3-4), of 2 CHC-NR 
patients (5-6) and of 3 responder patients biopsied 4h after subcutaneous pegIFN-α injection 
(7-9) indicating a weak but distinguishable pSTAT2 band in the latter. 
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Figure 4.1.3. 
IFN-γ-specific gene signature is enriched in the AHC gene expression profiles, while IFN-α-
induced transcription patterns characterize CHC-NR patients. 
(A) Venn diagrams of genes differentially expressed in primary human hepatocytes (PHH) 
upon IFN-α or IFN-γ treatment. A gene was considered differentially expressed if in PHH 
from both donors up- or downregulated more than 2-fold with respect to untreated samples. 
Diagrams in gray boxes show temporal patterns of IFN-induced gene expression in PHH, 
with genes differentially regulated at 6 and at 24 hours. In the middle the overlap between the 
sets of genes differentially regulated by IFN-α (green) and IFN-γ (orange) at any of the two 
time points is shown. 
(B) Genes were rank-ordered based on differential expression between the AHC and CHC-
NR patients and the overrepresentation of the experimentally defined IFN-α and IFN-γ-
specific gene sets at the top and bottom of the list was assessed by GSEA algorithm. Below 
the GSEA plots are heatmaps of the genes which contribute to the enrichment score of the 
gene set tested. 
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Figure 4.1.4.  
In AHC pSTAT1 positive hepatocytes co-localize with CD8+ T cells. 
(A) Number of mean CD3+ cells per high power field (HPF) of the liver parenchyma. Each 
dot represents the mean number per patient. P-value was obtained by Student’s t-test. 
(B)Representative pictures of serial sections from liver biopsies analyzed 
immunohistochemically for pSTAT1 and markers for T cells (CD3), cytotoxic T cells (CD8), B 
cells (CD20), NK cells (CD56) and plasmacytoid dendritic cells (CD123). For each section 
within the sample the same detail is shown. In AHC pSTAT1+ hepatocytes co-localized with 
immune cells positive for CD3 and CD8. 
(C) Correlation analysis of the number of CD3+ cells and CD8+ cells / HPF with the number 
of nuclear pSTAT1 signals in hepatocytes / HPF (n=30). The values represent the number of 
positive cells counted in 5 random HPF in the parenchyma of each biopsy in AHC patients, 
which are shown in Supplementary Figure 3 and listed in Supplementary Table VI. Each dot 
represents one HPF. Association was assessed by Spearman correlation analysis. 
(D) Correlation analysis of the mean number of CD8+ cells with the IFNγ mRNA amount in 
AHC (Pearson correlation). 
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Figure 4.1.5. 
USP18 expression in AHC and CHC liver biopsies. 
(A) Hepatic expression of USP18 mRNA measured by quantitative PCR and normalized to 
GAPDH. Each dot represents one sample. The line indicates the median. P-values were 
obtained by Mann-Whitney tests. 
(B) Expression of USP18 mRNA as measured by Human Gene 1.0 ST arrays in PHH treated 
with α- and γ-IFN for 6 hours, and untreated PHH (Ctrl). Mean+SD is shown. 
(C) USP18 protein expression by Western Blot analysis using whole cell extracts of liver 
samples from AHC (lane 1-6, no. according to Table I), healthy liver (lane 7), CHC-R (lane 
8-9) and CHC-NR (lane 10-11). 
(D) Representative pictures of immunohistochemistry for USP18 in healthy liver (Ctrl), AHC 
and CHC-NR, showing a strong cytoplasmic and patchy staining in CHC-NR (magnification 
400x). 
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Tables 
 
Table 4.1.1: Patient characteristics 
 
Patient 
no. Age Gender 
HCV 
Genotype 
Viral load 
at Bx, (log 
IU/mL) 
ALT at 
Bx, (U/L) 
IL28B 
rs12979860 
Week 4 
Response Response HIV ∆T Inf-Bx 
1 31 M 3 <12 60 CC - SC - 3 months 
2 17 F 1 <12 421 CT - SC - 3 months 
3 16 F 1 3.53 86 CT RVR SVR
a - 4 months 
4 30 M 4 2.49 125 CT RVR SVR - 2 months 
5 44 M 3 5.98 571 CC - Interrupted - 2-5 months 
6 56 M 3 4.15 155 TT RVR EoTR
b - 3-4 months 
           
Abbreviations: Bx, biopsy; EoTR, end of treatment response; Inf, infection; 
RVR, rapid virological response (below limit of detection at week 4); SC, spontaneous clearance; SVR, sustained virologic response 
a Treatment withPegIFN-α-2a for 12 weeks b Treatment with PegIFN-α-2b & Ribavirin  
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Supplementary Material 
 
Supplementary Figure 4.1.1. 
Genome-wide unsupervised hierarchical clustering groups all AHC patients in a distinct 
cluster, separate from the CHC or control samples. The heatmap shows the expression 
patterns of 1003 probe sets identified as up- or downregulated in at least one of AHC, CHC-
NR or CHC-R compared to the healthy liver.  
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Supplementary Figure 4.1.2. 
(A) Scheme representation of the generation of gene sets for GSEA.  
A gene was included if the difference between the means of IFN-α and IFN-γ-treated PHH 
was larger than 2-fold and the p-value from a Welch t-test of the corresponding samples 
lower than 0.05. The example in the scheme shows expression values for USP18 after 6 hours 
of IFN-α or IFN-γ treatment. 
(B) Gene Ontology Biological Process terms and KEGG collection pathways were tested for 
overrepresentation in lists of genes significantly altered between AHC and CHC-NR patients. 
Enriched categories were then clustered in order to bring together closely related terms. The 
heatmap shows expression patterns of all differentially expressed genes which belong to one 
of the enriched categories. 
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Supplementary Figure 4.1.3. 
Collection of all liver biopsy serial sections from AHC patients no. 1-6 (red number), 
immunohistochemically stained for pSTAT1 and markers for T cells (CD3), cytotoxic T cells 
(CD8), B cells (CD20), NK cells (CD56) and plasmacytoid dendritic cells (CD123). The 5 
boxes per slide indicate the high power fields in the liver parenchyma that were randomly 
chosen for the co-localization analysis. 
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Supplementary Figure 4.1.4. 
Confirmation of microarray data by quantitative RT-PCR. 
(A) Quantification of IFN-α specific ISGs (IFI27 and IFIT1) and IFN-γ specific ISGs (GBP5 
and HLA-DMB) by quantitative RT-PCR in IFN-α or IFN-γ treated PHH confirmed specific 
induction as previously assessed by the microarray analysis (time point 24h). 
(B) Quantitative RT-PCR confirmed upregulation of IFN-α ISGs (IFI27 and IFIT1)  in CHC-
NR and upregulation of IFN-γ ISGs (GBP5 and HLA-DMB) in AHC. (p-values by Mann-
Whitney test) 
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Supplementary Figure 4.1.5. 
Analysis of MAVS cleavage by Western blot. Arrowheads indicate full-length (FL) and 
cleaved (CL) MAVS. Lysates from Huh-7.5 cells harboring a subgenomic HCV replicon 
(Repl, lane 1) and healthy liver (Ctrl, lane 8) served as controls for cleaved and full-length 
MAVS. Lysates from AHC patients 1-6 (according to Table I) are displayed on lanes 2-7. 
 
 
For supplementary tables please refer to the appendix A of this thesis (p. 102). 
 
Supplementary Table 1.  
Fold changes of the upregulated genes in functional categories (fold change of at least 2 
between the means of AHC and healthy liver samples with the corresponding FDR 
(Benjamini-Hochberg correction) below 0.05). 
Supplementary Table 2.  
Fold changes of the downregulated genes in functional categories (fold change of at least 2 
between the means of AHC and healthy liver samples with the corresponding FDR 
(Benjamini-Hochberg correction) below 0.05).  
Supplementary Table 3.  
Fold changes of the upregulated genes in IFN-treated PHH. The table shows genes that in 
PHH from both donors were at least 2-fold upregulated between untreated and IFN-treated 
PHH samples. 
Supplementary Table 4.  
Fold changes of the downregulated genes in IFN-treated PHH. The table shows genes that in 
PHH from both donors were at least 2-fold downregulated between untreated and IFN-
treated PHH samples. 
Supplementary Table 5.  
PHH-derived gene sets used for GSEA. The table shows genes that are preferentially induced 
by IFN-α or IFN-γ in PHH (at least at one time point the fold difference of expressions 
induced by the two cytokines is higher than 2, with the corresponding p-value below 0.05). 
Supplementary Table 6. 
Amount of cells positively stained for pSTAT1, CD3, CD8, CD20, CD56 and CD123 per high 
power field (HPF) in AHC. Shown are the numbers for each of the 5 HPF in each AHC 
patient. Below of each patient the mean is shown. Note that for patient no. 2 due to limitations 
of the biopsy section for CD8 not the same HPFs could be assessed (numbers in italics) and 
are therefore not directly comparable to the other HPFs. 
Supplementary Table 7 and 8. 
Primer sequences used for real-time RT-PCR analysis and primary antibodies used for 
immunohistochemistry. 
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4.2 The effect of genetic variations near the IL28B gene in the liver of 
patients with hepatitis C 
 
4.2.1 Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment 
Response than IL28B Genotype in Patients with Hepatitis C 
 
Dill M.T., Duong F.H.T., Vogt J.E., Bibert S., Bochud P.Y., Terracciano L., 
Papassotiropoulos A., Roth V., Heim M.H., Interferon-Induced Gene Expression Is a Stronger 
Predictor of Treatment Response than IL28B Genotype in Patients with Hepatitis C, 
Gastroenterology. 2011 Mar;140(3):1021-1031. 
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BACKGROUND & AIMS: The host immune response
during the chronic phase of hepatitis C virus infection
varies among individuals; some patients have a no inter-
feron (IFN) response in the liver, whereas others have full
activation of IFN-stimulated genes (ISGs). Preactivation
of this endogenous IFN system is associated with nonre-
sponse to pegylated IFN- (pegIFN-) and ribavirin. Ge-
nome-wide association studies have associated allelic
variants near the IL28B (IFN3) gene with treatment
response. We investigated whether IL28B genotype deter-
mines the constitutive expression of ISGs in the liver and
compared the abilities of ISG levels and IL28B genotype
to predict treatment outcome. METHODS: We geno-
typed 109 patients with chronic hepatitis C for IL28B
allelic variants and quantified the hepatic expression of
ISGs and of IL28B. Decision tree ensembles, in the form
of a random forest classifier, were used to calculate the
relative predictive power of these different variables in a
multivariate analysis. RESULTS: The minor IL28B allele
was significantly associated with increased expression of
ISG. However, stratification of the patients according to
treatment response revealed increased ISG expression in
nonresponders, irrespective of IL28B genotype. Multivar-
iate analysis of ISG expression, IL28B genotype, and sev-
eral other factors associated with response to therapy
identified ISG expression as the best predictor of treat-
ment response. CONCLUSIONS: IL28B genotype and
hepatic expression of ISGs are independent predic-
tors of response to treatment with pegIFN- and
ribavirin in patients with chronic hepatitis C. The
most accurate prediction of response was obtained
with a 4-gene classifier comprising IFI27, ISG15,
RSAD2, and HTATIP2.
Keywords: Hepatitis C Virus; Jak-STAT Signaling; Host-
Virus Interaction; Innate Immunity.
Chronic infection with hepatitis C virus (HCV) is amajor cause of liver disease worldwide.1 The current
standard therapy of chronic hepatitis C (CHC) achieves
an overall sustained virologic response (SVR) in 55% of
patients.1 The treatment requires up to 72 weeks of
weekly subcutaneous injection of pegylated interferon
(pegIFN)- combined with twice-daily intake of ribavirin
tablets. Pretreatment predictors of response are useful for
advising patients. SVR rates are higher in patients in-
fected with HCV genotype non-1 (mostly genotypes 2
and 3) and in those with a viral load of less than 600,000
IU/mL.1 Other less consistently reported baseline charac-
teristics associated with a favorable response include fe-
male gender, age younger than 40 years, nonblack race,
lower body weight (75 kg), the absence of insulin resis-
tance, and the absence of bridging fibrosis or cirrhosis on
liver biopsy.1 Infection with HCV can activate the endog-
enous IFN system in the liver. However, despite a strong
induction of hundreds of IFN-stimulated genes (ISGs) in
the liver, the activation of the endogenous IFN system in
CHC is ineffective in clearing the infection and even
impedes the response to therapy, most likely by inducing
a refractory state of the IFN signaling pathway.2–5 The
causal factors and the mechanism underlying this preac-
tivation of the IFN system in some patients with CHC are
not well understood. We have shown that the cleavage of
mitochondrial antiviral signaling protein by HCV
NS3-4A protease correlates with a reduced activation of
the endogenous IFN system.6 Recently, several groups
reported a strong association between allelic variants of
the IL28B gene encoding IFN3 and response to treat-
ment. Failure to respond to treatment was associated
with the minor alleles of rs12979860 (T),7 rs8099917
(G),8–10 and rs12980275 (G).10 The association was sig-
nificant in HCV genotypes 1 and 4 but not in HCV
genotypes 2 and 3.8 Moreover, the IL28B genotype was
also associated with the rate of spontaneous clearance of
HCV infection.8,11 The functional mechanism underlying
the association of IL28B polymorphisms with response to
Abbreviations used in this paper: AUC, area under the curve; CHC,
chronic hepatitis C; ERR, error rate; GAPDH, glyceraldehyde-3-phos-
phate dehydrogenase; ISG, interferon-stimulated gene; PBMC, periph-
eral blood mononuclear cell; pegIFN, pegylated interferon; RFFS, ran-
dom forest feature score; ROC, receiver operating characteristic; RVR,
rapid virologic response; SNP, single nucleotide polymorphism; SVR,
sustained virologic response.
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treatment is unknown, but 2 groups observed a lower
expression of IFN3 in peripheral blood mononuclear
cells (PBMCs) in individuals carrying the minor
rs8099917 IL28B allele that is associated with nonre-
sponse to treatment.9,10 We hypothesized that allelic vari-
ants in IL28B might be responsible for the difference of
endogenous IFN activation and studied the association
between IL28B polymorphisms and hepatic ISG expres-
sion as well as the predictive power of the different
factors. Here we show that IL28B genotype and hepatic
ISG expression are independent predictors of treatment
response in CHC. There is no direct link between altered
IFN3 expression and preactivation of the endogenous
IFN system in the liver. Importantly, hepatic ISG expres-
sion is by far the better predictor of treatment response
than IL28B genotype.
Materials and Methods
Liver Biopsies and Patient Data
Liver biopsy specimens from white patients with
CHC (n  109) were obtained during routine diagnostic
workup at the University Hospital Basel. Grading and
staging of CHC was according to METAVIR classifica-
tion. A specimen was frozen for research purposes if more
than sufficient material was obtained for histopathologic
examination and the patient gave his or her written
informed consent in accordance with the Ethics Com-
mittee of Basel. Serum HCV RNA was quantified using
the Cobas AmpliPrep/COBAS TaqMan HCV Test and the
Cobas Amplicor Monitor from Roche Molecular Systems
(Basel, Switzerland). Patients were treated with pegIFN-
2a or 2b in combination with ribavirin according to
current guidelines.1 Definitions of response to treatment
are as follows: SVR, HCV RNA level 12 IU/mL 6
months after end of treatment; relapse, HCV RNA level
12 IU/mL at the end of treatment but 12 IU/mL 6
months after the end of treatment; nonresponse, HCV
RNA level 12 IU/mL at the end of treatment; rapid
virologic response (RVR), HCV RNA level 12 IU/mL
after 4 weeks of treatment. Patient characteristics are
shown in Table 1 and Supplementary Table 1.
Measurement of Messenger RNA Levels in
the Liver
Total RNA was extracted from human liver tissue
using TRIzol reagent (Invitrogen, Basel, Switzerland) ac-
cording to the manufacturer’s instructions. RNA sam-
ples were then treated with deoxyribonuclease and
purified on columns (Nucleospin kit; Machery-Nagel,
Oensingen, Switzerland) according to the manufacturer’s
instructions. RNA was stored at75°C. RNA was reverse
transcribed by Moloney murine leukemia virus reverse
transcriptase (Promega Biosciences, Wallisellen, Switzer-
land) in the presence of random primers (Promega) and
deoxynucleoside triphosphate. The samples were incu-
bated for 5 minutes at 70°C and then for 1 hour at 37°C.
The reaction was stopped by heating at 95°C for 5 min-
utes. SYBR real-time polymerase chain reaction was per-
formed using the SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA). Intron-spanning primers
for GAPDH, IFI44L, RSAD2, ISG15, IFI27, OAS3, LAMP3,
LGALS3BP, HTATIP2, IL29, IL28RA, and IL10RB were de-
signed. To differentiate the very homologous IL28A and
IL28B genes, primers were designed accordingly so that
the last nucleotide of the 3= end of each primer bound to
a nucleotide differing in each gene. Primer sequences are
displayed in Supplementary Table 2.
All reactions were performed in duplicate on an ABI
7500 Fast Real-Time PCR System (Applied Biosystems).
For IL28A and IL28B, the polymerase chain reaction
product was run on an agarose gel to exclude unspecific
amplification from genomic DNA (data not shown). Mes-
senger RNA (mRNA) expression levels of the transcripts
were normalized to glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) using the Ct method. Supplementary
Table 3 contains the complete result set.
Extraction of Genomic DNA
Genomic DNA was isolated from human liver
tissue with TRIzol reagent (Invitrogen) and DNeasy
Blood & Tissue Kit (Qiagen) according to the manufac-
turer’s instructions.
Table 1. Patient Characteristics
SVR Relapse Nonresponse Total
Patients, n 33 9 31 109
Age (y), mean  SDa 40.9  10.2 45.9  6.8 49.6  8.6 45.9  9.4
Sex, n
Female 14 3 10 39
Male 19 6 21 70
HCV RNA (IU/mL), mean  SEb 3.1  0.9  106 4.5  2.0  106 3.9  1.2  106 3.9  0.8  106
Genotypes 1/2/3/4, n 7/4/16/6 5/1/3/0 24/2/2/3 63/7/27/12
METAVIR stages F0–1/F2/F3/F4, n 5/13/7/8 0/3/2/4 1/11/7/12 16/41/21/31
METAVIR grades A1/A2/A3, n 6/19/8 3/5/1 5/14/12 30/49/30
aRange, 20–69 years.
bRange, 4.4  102 to 6.9  107.
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Genotyping of IL28B Single Nucleotide
Polymorphisms
Genotyping for rs8099917 and rs12979860 single
nucleotide polymorphisms (SNPs) was with TaqMan SNP
genotyping assays (Applied Biosystems Inc, Foster City, CA).
TaqMan probes and primers were designed and synthesized
by Applied Biosystems: rs12979860, forward 5=-TGTACT-
GAACCAGGGAGCTC-3=, reverse 5=-GCGCGGAGTGCAAT-
TCAAC-3=; Vic probe 5=-TGGTTCGCGCCTTC-3=, Fam probe
5=-CTGGTTCACGCCTTC-3=; rs8099917, ABI reference
C_11710096_10. Automated allele calling was performed
using SDS software from Applied Biosystems. Positive and
negative controls were used in each genotyping assay.
Statistical Analyses
All gene expression data were log10 transformed for
analysis. After confirmation of normal distribution (Shapi-
ro–Wilk), the data were analyzed with Student t test using
GraphPad Prism V4 (GraphPad Software, San Diego, CA).
The association of the SNPs with SVR was assessed with a
logistic regression model, where the IL28B genotypes were
encoded for an additive model based on the minor alleles.
For building a suitable design matrix, these factors were
represented internally by contrasting each level with the
baseline level “0.” Significance estimates for the remaining
nonbaseline levels were computed in the standard way, that
is, as 2-tailed P values corresponding to the z-ratio based on
a normal reference distribution.
Decision Trees and Random Forest Classifier
A decision tree is a tree-structured classifier. The tree
is iteratively built by selecting variables according to their
relevance for discriminating between the classes, where rel-
evance is measured in terms of information gain.12
The random forest classifier generalizes this concept by
building an ensemble of decision trees. For each object to be
classified (in our case each patient), a tree in the ensemble
votes for membership in one of the classes, and finally a
patient is assigned to the class with the most votes. During
the training phase, the patients are randomly divided into a
training set (“bag”) and a test set (“out-of-bag”) using resa-
mpling techniques. The average error on the “out-of-bag”
sets serves as an estimate for the predictive error (ERR) on
new patients. The random forest feature score (RFFS) is a
measure of the predictive power of the variables for sepa-
rating the classes. Because this measure is a “true” out-of-
bag estimate, negative importance scores can occur, indicat-
ing overfitting phenomena, that is, weaker predictive
performance despite an augmented set of variables used for
learning the decision trees.
The large datasets from the previously reported ge-
nome-wide association studies were taken from Supple-
mentary Table 2 in Suppiah et al9 and extrapolated from
Figure 1 (European-Americans) from Ge et al.7 These
data were run through the random forest classifier, and
area under the curve (AUC), and ERR estimates were
calculated as described previously.
Results
Minor Alleles of the IL28B Gene Are
Associated With Decreased Hepatic IL28B
Expression
We genotyped 109 patients with CHC who under-
went a liver biopsy. The clinical characteristics of the
patients are shown in Table 1, and the full dataset is
available in Supplementary Table 1. Among 73 patients
assessable for response to pegIFN- and ribavirin treat-
ment, 33 had an SVR, 9 had a relapse, and 31 were
nonresponders. The allele frequencies in this group of
109 white patients and also in the subgroup of the 73
treated patients were comparable to the previously re-
ported frequencies, and the association of the IL28B ge-
notypes with SVR was statistically significant (Figure 1A
and Supplementary Table 1).7–10 We extracted RNA from
all liver biopsy specimens and quantified the expression
of IL28A (IFN2), IL28B (IFN3), IL29 (IFN1), IL28
receptor  (IL28R, encoded by IL28RA), and IL-10 re-
ceptor  (IL10R) (the 2 chains of the heterodimeric class
II cytokine receptor that binds all IFNs) by quantitative
polymerase chain reaction. Homozygosity for the minor
rs12979860 allele was significantly associated with de-
creased IL28B expression (Figure 1B). The minor
rs8099917 allele was also associated with decreased IL28B
expression, but the differences did not reach statistical
significance (Figure 1B). There was no association of
IL28B allele variants with the other members of the IFN
family or with the IFN receptor chains (Supplementary
Figure 1).
ISG Expression and Response to Treatment
We next quantified the expression of the classifier
genes IFI44L, RSAD2, ISG15, IFI27, LAMP3, OAS3,
LGALS3BP, and HTATIP2 in the liver biopsy specimens of
all 109 patients. These genes belong to the group of 29
genes previously identified as best predictors of response
to treatment in a supervised classifier analysis of microar-
ray data from liver biopsy specimens.2 The first 6 genes of
this subgroup are ISGs.2 In accordance with previous
reports,2–5 ISG expression was significantly higher in
nonresponders and patients who experienced a relapse
compared with patients with an SVR (Figure 2A). The
expression of IL28A, IL28B, IL29, IL28RA, and IL10RB did
not differ between patients with and without SVR (Fig-
ure 2B).
IL28B Polymorphisms and Activation of the
Hepatic IFN System Are Independent
Predictors of Response to Treatment
The minor IL28B variants could be associated with
poor treatment outcome because they induce the consti-
tutive expression of ISGs in the liver during HCV infec-
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tion. Compatibly with such a causal link, we found a
statistically significant association between IL28B allele
variants and the expression levels of the 6 ISGs (Figure
3A and Supplementary Figure 2A). As expected, the mi-
nor allele (poor response allele) was associated with an
increased expression of ISGs.
To rigorously test the link between IL28B allelic vari-
ants and ISG expression, we compared ISG expression
levels of SVR versus non-SVR patients within the differ-
ent IL28B genotype groups. If the IL28B genotype would
determine the expression level of ISGs in the liver, one
would expect that both responders and nonresponders
within the group of patients with the rs12979860 CC
genotype have low ISG expression levels and that the
patients with the rs12979860 CT or TT genotype have
high expression levels irrespective of their treatment re-
sponse. However, stratification of the samples according
to treatment response revealed that ISG expression dif-
fered significantly between response groups within a
given IL28B genotype group (Figure 3B and C and Sup-
plementary Figures 2, 3, 4, 5B and C). In contrast, pa-
tients with an SVR had comparable ISG expression levels
irrespective of their IL28B genotype. We conclude that
the apparent correlation between IL28B genotype and
ISG expression found in the nonstratified analysis (Fig-
ure 3A) is due to the unequal distribution of patients;
there are few nonresponders in the rs12979860 CC group
(3 of 19) but many in the rs12979860 CT group (33
of 47).
A significant correlation between IL28B genotypes and
response to treatment has been reported for patients with
HCV genotype 1 and 4 infections but not for HCV ge-
notypes 2 and 3.8 To exclude a potential confounding
effect, we also analyzed our data after exclusion of HCV
genotype 2 and 3 samples (Figure 4). Again, nonre-
sponders had significantly higher ISG expression levels
irrespective of the IL28B genotypes (Figure 4B and C and
Supplementary Figures 3 and 5). We conclude that the
IL28B genotype does not determine ISG expression.
Rather, both ISG expression and IL28B genotype are
associated with response to treatment but largely inde-
pendent from each other.
Multivariate Analysis of Factors Associated
With Final Treatment Response Identifies
Hepatic Gene Expression of a Set of 4 Genes
as Best Predictor
We used decision tree ensembles in the form of a
random forest classifier12 to quantify the relative predic-
tive power of the IL28B allele variants; the hepatic expres-
sion of IFI44L, RSAD2, ISG15, IFI27, LAMP3, OAS3,
LGALS3BP, and HTATIP2; the HCV genotype; viral load;
sex; age; inflammatory grade; and fibrosis stage for pre-
diction of response to treatment. As a result of this
multivariate analysis, the predictive power of a variable
for separating the 2 classes (eg, patients with an SVR vs
patients without an SVR) is expressed as the RFFS. In the
entire dataset including 73 patients, we identified the
hepatic expression of IFI27 (RFFS, 2.65), ISG15 (RFFS,
2.01), and RSAD2 (RFFS, 1.75) and the HCV genotype
(RFFS, 1.77) as the strongest predictors (Figure 5A). The
rs12979860 SNP followed at position 5. After exclusion
of patients with HCV genotypes 2/3, the strongest pre-
dictors in this group of 45 patients with genotypes 1/4
Figure 1. Association of IL28B SNPs with SVR and hepatic IL28B
mRNA expression. (A) Percentage of SVR in different IL28B genotypes
for the SNPs rs12979860 and rs8099917. The minor allele frequencies
(MAF) for each SNP are indicated. Association of the major allele with
SVR was assessed by a logistic regression model and is statistically
significant for each SNP. (B) The minor IL28B allele correlates with lower
expression of IL28B mRNA in the liver of patients with CHC. IL28B
mRNA was determined by quantitative reverse-transcription polymer-
ase chain reaction and normalized relative to GAPDH mRNA. Shown
are the mean values (SEM) after log transformation. The P values were
obtained with Student t test. The IL28B genotypes for the rs12979860
and the rs8099917 SNPs and the number of patients in each group are
shown below the plots.
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infection were IFI27 (RFFS, 2.87), LGALS3BP (RFFS,
2.53), ISG15 (RFFS, 2.31), RSAD2 (RFFS, 1.68), and IFI44L
(RFFS, 1.49) (Figure 5B). The rs12979860 SNP followed
at position 6.
We then calculated receiver operating characteristic
(ROC) curves for the individual predictors. The HCV
genotype had an AUC of 0.75 with an ERR of 0.27 (data
not shown). In patients with HCV genotypes 1 and 4, the
IL28B SNP variants rs12979860 and rs8099917 had
AUCs/ERRs of 0.76/0.16 and 0.58/0.31, respectively (Fig-
ure 5C). These rather low values are not due to our small
sample size, because we obtained similar values when
using the published larger datasets for rs12979860 (0.69/
0.32)7 and rs8099917 (0.57/0.40).9 When combining the
2 SNPs into one classifier, the AUC was 0.73 with an ERR
of 0.16 (Figure 5D). By iteratively testing the predictive
power of variable sets composed of the individual genes,
we identified a set of 4 genes as having the best test
performance: a random forest classifier using IFI27,
ISG15, RSAD2, and HTATIP2 had an AUC of 0.90 with an
ERR of 0.12 (Figure 5E). The same 4 gene classifiers
performed even slightly better in the HCV genotypes 1
and 4 subgroup (AUC, 0.92; ERR, 0.09) (Figure 5E). The
performance was decreased by adding the information
from the rs12979860 SNP (AUC, 0.90; ERR, 0.13) (Figure
5F). The weaker performance indicates that conditioned
on the 4 genes IFI27, ISG15, RSAD2, and HTATIP2, the
IL28B genotype carries no further discriminative infor-
mation and only increases the model complexity, leading
to overfitting phenomena.
Figure 2. The expression of 8 classifier genes
differs significantly between SVR, nonresponse,
and relapse. Aligned dot plot of hepatic gene
expression in patients with CHC stratified ac-
cording to response to treatment (SVR, n  33;
relapse [REL], n 9; nonresponse [NR], n 31).
Relative hepatic mRNA was assessed with quan-
titative polymerase chain reaction for (A) the 8
classifier genes (IFI44L, RSAD2, ISG15, IFI27,
LAMP3, OAS3, LGALS3BP, and HTATIP2) and
(B) genes from the IL28 cytokine family (IL28A,
IL28B, IL29) and the IL28 receptor chains
(IL28RA, IL10RB). Values are shown after log
transformation and normalization to GAPDH.
Each dot represents one sample. Mean  SEM
are shown. P values were obtained with Student
t test.
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Multivariate Analysis of Factors Associated
With Initial Treatment Response Identifies
Hepatic Gene Expression of a Set of 5 Genes
as Best Predictor
The prediction of the initial response to IFN-
could become important for future therapies with HCV
protease or polymerase inhibitors, because patients with
a preactivated endogenous IFN system would be exposed
to direct antivirals without an effective protection against
resistance development provided by coadministration of
pegIFN-/ribavirin. We therefore calculated a random
forest classifier for predicting RVR, that is, a viral load
12 IU/mL after 4 weeks of treatment. In patients with
HCV genotype 1 or 4, we identified the hepatic expression
of ISG15, RSAD2, IFI27, LAMP3, and IFI44L as the stron-
gest predictors (Figure 6A). ROC curves for the individual
predictors showed an AUC of 0.6 with an ERR of 0.12 for
the rs12979860 SNP (Figure 6B). The 5-gene classifier
with ISG15, RSAD2, IFI27, LAMP3, and HTATIP2 had an
excellent performance with an AUC of 0.94 and an ERR
of 0.04 (Figure 6C). The performance was not improved
by adding the information from the rs12979860 SNP
(AUC, 0.94; ERR, 0.06) (Figure 6D).
Discussion
The highly significant association of IL28B allelic
variants with treatment outcome in CHC discovered re-
cently by several research groups7–10 opened up the per-
spective of developing IL28B genotyping as a pretreat-
ment predictor of treatment response for individual
patients. However, based on our ROC calculations with
genotype data for IL28B SNPs rs12979860 and
rs8099917, we conclude that the predictive power of such
a test is insufficient for counseling individual patients
with CHC. On the other hand, quantification of a set of
Figure 3. Hepatic ISG expression according to
IL28B genotypes (SNP  rs12979860). (A) Ex-
pression of 4 ISGs (IFI44L, RSAD2, ISG15, IFI27)
in the liver according to the IL28B genotype
(rs12979860) in 109 patients with CHC. (B) He-
patic expression of 4 ISGs (IFI44L, RSAD2,
ISG15, IFI27) in 19 patients with the rs12979860
CC genotype, stratified according to treatment
response (SVR vs non-SVR). (C) Hepatic expres-
sion of 4 ISGs (IFI44L, RSAD2, ISG15, IFI27) in
47 patients with the rs12979860 CT genotype,
stratified according to treatment response (SVR
vs non-SVR). Shown are mean values (SEM)
after log transformation. P values were obtained
with Student t test. The number of patients in
each group is shown below the plots.
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4 genes in pretreatment liver biopsy specimens allows
prediction of treatment response to the current standard
of care with pegIFN- and ribavirin with an error rate of
less than 15%. This classifier using IFI27, ISG15, RSAD2,
and HTATIP2 showed excellent test performance with an
AUC of 0.90. Adding the IL28B genotype information to
the 4-gene classifier did not improve the test perfor-
mance.
For quantification of gene expression, a small piece of
the liver biopsy specimen obtained during the workup of
patients with CHC is stored at 4°C in buffer that stabi-
lizes and protects cellular RNA. The samples can be
shipped at ambient temperature to the laboratory. Ex-
traction of RNA and quantification of classifier gene
expression can be done within 1 day. Using standard
expression values obtained from patients with known
treatment response, the test allows us to predict the
individual likelihood of a patient to have a response to
therapy. In current clinical practice, liver biopsies are
omitted in many patients, limiting the potential practi-
cability of our test. PBMCs would be easier to obtain
than liver biopsy material. Unfortunately, IFN- induced
quite distinct sets of genes in PBMCs versus liver,2,13 and
gene expression levels in PBMCs could not reliably clas-
sify patients into response groups in a supervised classi-
fier analysis.2 Quantitative serum protein analysis is also
not a promising alternative to liver biopsy analysis, be-
cause none of the 4 classifier gene products identified in
the present analysis and none of the 29 predictor genes
identified in our previous analysis2 is secreted from hepa-
tocytes.
The causal factors and the mechanisms underlying the
induction of ISGs in the liver of patients with CHC are
not well understood. A genetic predisposition that regu-
lates the host reaction to HCV infection could explain the
observed interindividual differences in ISG induction. In
this context, the IL28B genotype is a very attractive can-
didate for such a genetic factor, all the more because the
Figure 4. Hepatic ISG expression according to
IL28B genotypes (SNP  rs12979860) in pa-
tients infected with HCV genotype 1 or 4. (A)
Expression of 4 ISGs (IFI44L, RSAD2, ISG15,
IFI27) in the liver according to the IL28B geno-
type (rs12979860) in 75 patients with CHC in-
fected with HCV genotype 1 or 4. (B) Hepatic
expression of 4 ISGs (IFI44L, RSAD2, ISG15,
IFI27) in 10 patients with rs12979860 CC geno-
type, stratified according to treatment response
(SVR vs non-SVR). (C) Hepatic expression of 4
ISGs (IFI44L, RSAD2, ISG15, IFI27) in 32 patients
with rs12979860 CT genotype, stratified according
to treatment response (SVR vs non-SVR). Shown
are mean values (SEM) after log transformation.P
values were obtained with Student t test. The num-
ber of patients in each group is shown below the
plots.
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IL28B gene product, IFN3, activates the same signal
transduction pathways as type I IFNs and induces the
same set of target genes.14–18 Indeed, a recent study re-
ported a strong association of hepatic ISG expression
with IL28B genotype.19 In this model, an increased ex-
pression of IL28B/IFN3 in patients with the minor allele
would result in higher ISG expression in the liver, which
then would lead to nonresponse to pegIFN- and riba-
virin. However, our data do not support a direct link
between IL28B genotype and hepatic ISG induction. First,
the expression of IL28B/IFN3 in the liver is decreased
rather than increased in patients with the minor allele
(Figure 1B). This finding is consistent with previous re-
ports showing a lower expression of IL28B/IFN3 in PB-
MCs from individuals with the minor allele.9,10 Second,
the strong association of higher ISG expression in the
liver with the minor IL28B allele disappears after strati-
fication for treatment response (Figures 3 and 4). If the
IL28B genotype would determine ISG expression, we
should have observed higher expression levels in re-
sponder patients with the minor allele compared with
responders homozygous for the major allele, and the
same genotype-dependent differences would also be pres-
ent within the group of nonresponders. However, re-
Figure 5. Hepatic expression of IFI27, ISG15, RSAD2, and HTATIP2 is a better predictor of treatment response than IL28B allelic variants. (A)
Importance plot of all variables in the entire 73 patient dataset (including all HCV genotypes). (B) Importance plot of all variables in the 45 treated
patients with HCV genotypes 1 and 4. The RFFS is a measure of the predictive power of the variables for separating the classes. The importance of
the variables is computed by permuting the values of a variable m in the out-of-bag case and putting these cases down the decision tree. The number
of votes for the correct class in the permuted out-of-bag set is subtracted from the number of votes for the correct class in the untouched
out-of-bag-set and averaged over all trees in the forest. This gives the importance score for variable m. Note that the importance score is computed
on the out-of-bag set; hence, overfitting can occur. Negative importance scores imply that such overfitting phenomena indeed occur for some
variables. (C) ROC curve for prediction of treatment response using the rs12979860 SNP (AUC, 0.76; ERR, 0.16) or the rs8099917 SNP (AUC, 0.58;
ERR, 0.31) in patients with HCV genotype 1 or 4. (D) ROC curve with the combination of the rs12979860 and rs8099917 SNPs in patients with HCV
genotypes 1 and 4 (AUC, 0.73; ERR, 0.16). (E) ROC curve for prediction of treatment response with a combination of IFI27, ISG15, RSAD2, and
HTATIP2 in the entire 73 patient dataset (AUC, 0.90; ERR, 0.12) or in the patients infected with HCV genotype 1 or 4 (AUC, 0.92; ERR, 0.09). (F) ROC
curve using the combination of IFI27, ISG15, RSAD2, HTATIP2, and the rs12979860 SNP in patients with HCV genotypes 1 and 4 (AUC, 0.90; ERR,
0.13). Adding the IL28B genotype information to the 4-gene classifier impairs the performance of the classifier because of an increase in the
complexity of the model without additional information gain (overfitting phenomenon).
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sponders had lower ISG expression levels than nonre-
sponders irrespective of the genotype (Figures 3 and 4).
We therefore conclude that IFN-induced gene expression
in the liver and IL28B allelic variants are not causally
linked but rather are independent predictors of response
to therapy in CHC.
The association of IL28B allelic variants with response
to pegIFN-/ribavirin treatment has been discovered in
large cohorts of HCV genotype 1–infected patients.7–10 In
patients with HCV genotype 2 or 3 infections, the re-
sponse rates were also higher in rs8099917 TT patients
compared to rs8099917 TG or GG (86% vs 80% SVR), but
the difference did not reach statistical significance.8 The
same tendency without statistical significance was found
in patients coinfected with HCV genotype 3 and human
immunodeficiency virus (86% vs 81% SVR).20 Genotype
4–infected patients behave more like genotype 1–infected
patients and show large differences in SVR rates accord-
ing to the IL28B genotype.8,20 We believe that the absence
of significant associations between SVR and IL28B geno-
type in genotype 2/3–infected patients is not caused by
fundamental biological differences of the host-virus in-
teractions. Rather, the published studies of patients with
HCV genotype 2/3 were probably underpowered to detect
associations between SVR rates and IL28B genotype be-
cause of the very high SVR rates found in HCV genotype
2/3–infected patients in general. We have included all
HCV genotypes in our present analysis, because we have
shown previously that pretreatment hepatic ISG expres-
sion levels and HCV genotype are independent predictors
of response to treatment2 and because we do not expect
that the HCV genotype has an influence on the expres-
sion level of IL28B mRNA. Nevertheless, we have also
analyzed the association between ISG expression and
IL28B genotype separately for the patients infected with
HCV genotype 1 and 4. As shown in Figure 4, ISG
expression level analysis stratified according to treatment
response showed significantly higher ISG expression in
non-SVR patients independent of IL28B genotype even in
this smaller group of patients infected with HCV geno-
type 1 and 4.
The discovery of the IL28B polymorphism has gener-
ated a strong interest in its potential usefulness for the
pretreatment counseling of patients with CHC. Genotyp-
ing is a rather simple and straightforward procedure and
does not require a liver biopsy, making it an attractive
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Figure 6. Prediction of RVR in patients infected with HCV genotype 1
or 4. (A) Importance blot of all variables in the 50 patients infected with
HCV genotype 1 or 4 and with RVR data available. (B) ROC curve with
the rs12979860 SNP for prediction of RVR (AUC, 0.60; ERR, 0.12). (C)
ROC curve using a combination of IFI27, ISG15, RSAD2, HTATIP2, and
LAMP3 as a 5-gene classifier to predict RVR (AUC, 0.94; ERR, 0.04). (D)
ROC curve with the combination of IFI27, ISG15, RSAD2, HTATIP2,
LAMP3, and the rs12979860 SNP to predict RVR (AUC, 0.94; ERR,
0.06).
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alternative to hepatic ISG testing. However, there are
some intrinsic limitations to genotyping. At present,
IL28B genotyping is restricted to HCV genotype 1 infec-
tions. Also, genotyping has a high error rate in predicting
SVR, because at least 1 in 5 patients with the favorable
rs8099917 TT or rs12979860 CC genotype will not have
an SVR. Likewise, genotyping has a high error rate in
predicting nonresponse, because approximately 2 in 5
patients with rs8099917 TG/GG or rs12979860 CT/TT
genotypes will still have an SVR. Genotyping can assign
an individual patient to one of 2 (or maximal 3) groups
with distinct mean SVR rates. On the other hand, hepatic
ISG expression measurements can generate continuous
probability values, allowing us to assign a distinct likeli-
hood of SVR to an individual patient. Such classifiers
using a limited number of ISGs seem to be more accurate
for prediction of treatment response, independent from
HCV genotypes. For patients with a liver biopsy specimen
obtained during the routine diagnostic workup, tests
that quantify the expression of a limited number of ISGs
in the liver could become important for individualized
patient counseling. Furthermore, pretreatment assess-
ment of hepatic ISG induction could become an impor-
tant tool for patient management in the upcoming era of
directly acting antiviral therapy in CHC. Current experi-
ence with HCV protease and polymerase inhibitors has
shown their strong antiviral activity but also the capacity
of HCV to develop drug resistance within the first weeks
of therapy. To some degree, the selection of drug-resis-
tant strains can be prevented by the coadministration of
pegIFN- and ribavirin. However, combination therapy
most likely will not effectively protect patients who do
not respond to pegIFN- at all (IFN-null responders)
because of a highly preactivated endogenous IFN system
in the liver.
In conclusion, IL28B genotype and hepatic ISG expres-
sion are both associated with response to treatment with
pegIFN-/ribavirin but not causally linked. The associa-
tion of ISG expression with treatment outcome is dom-
inant over the IL28B genotype, because patients with high
pretreatment ISG expression do not respond to treat-
ment despite a favorable IL28B genotype, whereas low
ISG expression is strongly linked to SVR even in patients
with an unfavorable IL28B genotype. In our analysis, the
most accurate prediction of response was obtained with a
4-gene classifier comprising IFI27, ISG15, RSAD2, and
HTATIP2.
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4.2.2 IL28B genotype affects the susceptibility to IFN-α in the liver of patients 
with hepatitis C but not in non-infected primary human hepatocytes  
 
Stronger induction of a subset of ISGs in CC carriers upon pegIFN-α-2b injection in 
vivo. 
So far the mechanism by which the effect of the IL28B polymporphisms on treatment 
response is achieved could not be identified by direct sequencing and association studies, and 
functional studies are direly needed. The lack of a defined functional mutation limits the use 
of possible genetic constructs and restricts the research so far to human samples. We had a 
look at the transcriptome data from a previous study where paired liver biopsies were 
obtained from patients with CHC before treatment and 4h after the first injection with 
pegIFN-α-2b89. 10 patients who had shown low pretreatment ISG transcript levels in the liver 
and had responded well with over 3 log10 drop of viral load within 4 weeks were selected for 
further analysis, and IL28B genotype (rs12979860) was determined. 7 patients carried the 
favorable CC genotype, and 3 were CT carriers. Of a total of 157 upregulated ISGs an amount 
of 26 genes, of which 3 representative genes are depicted in Figure 4.2.1, were significantly 
higher induced in CC than CT carriers at 4h after pegIFN-α-2b injection (t test, P < 0.005). 
We hypothesized that these 26 genes represents a subset of differently regulated ISGs which 
is affected by IL28B genetic variants rendering them more susceptible to IFN-α stimulation. 
However, we cannot exclude due to the relative small sample size that these 26 genes are 
false positives, despite the application of a stringent P value of < 0.005.  
 
ISG induction after IFN-α or IFN-λ treatment in primary human hepatocytes is not 
affected by IL28B genotype. 
Thus, we next wanted to explore, whether this effect was reproducible in a cell culture model 
of primary human hepatocytes (PHH), which would give us the means to properly study 
possible underlying mechanisms. PHH were genotyped for IL28B, and treated with IFN-α or 
IFN-λ for 4h. However, neither by IFN-α nor by IFN-λ any difference in fold induction 
between PHH with CC and CT alleles was observed looking at BATF2, IFIT3 and RSAD2 
(Figure 4.2.2), rendering this an unsuitable model to study the effect we observed in vivo. 
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Figure 4.2.1. Three exemplary genes differentially induced in IL28B CC and CT carriers. 10 
rapid responder patients of Sarasin-Filipowicz et al. 89, were genotyped for IL28B 
rs12979860 SNP. Stratification of paired transcriptome data according to IL28B genotype 
revealed a stronger induction of 26 ISGs in CC than CT carriers. Shown is fold induction 
between pre-treatment biopsy and the paired biopsy 4h after pegIFN-α-2b injection. Student’s 
t test, P < 0.005. 
 
 
 
 
Figure 4.2.2. Gene induction in PHH carrying different IL28B genotypes. PHH were 
genotyped for IL28B and treated with IFN-α (1000 U/ml) or IFN-λ (100ng/ml) for 4h. Shown 
is the fold induction compared to untreated PHH of the same donor. Student’s t test. P value 
<0.05 was considered significant.  
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4.3 Despite persistent high serum levels, peg-IFNα only transiently induces 
ISGs in the liver of patients with chronic hepatitis C 
 
 
Transient induction of the Jak-STAT pathway in the liver upon administration of peg-IFN-
α-2b. 
To study the long-term pharmacodynamics of pegIFN-α-2b in the liver of patients with CHC 12 
subjects were included to undergo a second paired biopsy (B2) at one of the following time 
points within a week after the first subcutaneous injection of pegIFN-α-2b: 16h, 48h, 96, or 144h 
(Figure 4.3.1A). Additional data from 6 responder patients derived from an earlier study in the 
Hepatology Laboratory were included for a 4h time point89. Patients were only asked to 
participate after decision for treatment has been already taken and gene expression analysis in 
the diagnostic liver biopsy (B1) by real-time RT-PCR revealed low ISG expression with a high 
chance to accomplish good response to pegIFN-α. Indeed, all included patients achieved cEVR 
and 94% SVR upon treatment with pegIFN-α-2b and ribavirin irrespective of viral or Il28B 
genotype, fibrosis stage or any other factor known to be associated with response (Table 4.3.1).  
For most of the patients serum was available to test for IFN-α-2b levels at the time of the second 
biopsy. Serum levels measured by ELISA were very similar to those described in previous 
studies56,134, with a peak at the 16h time point around 1000 pg/ml following a decline to 200 
pg/ml, but without reaching pre-treatment levels even at 144h (Figure 4.3.1B). In contrast, 
despite continuous elevated serum IFN-α levels, phosphorylation of STAT1 (pSTAT1) reflecting 
induction of the Jak-STAT pathway in the liver was mainly induced in the first 16h and was not 
prolonged (Figure 4.3.1C-D). 
 
 
Formation of temporally distinct clusters of interferon regulated genes. 
We next analyzed gene expression in the B1 and B2 liver samples with Affymetrix U133 Plus 
2.0 arrays. A considerable amount of genes were up- or downregulated with a fold change > 2.0 
between B2 and B1 in 2/3 of the patients at each time point with a maximum at 16h (Figure 
4.3.2A). Interestingly, these results differ from what has been observed in healthy chimpanzees, 
where maximum induction has been seen at 4h and most genes had again basal expression levels 
at 24h135. Since clearly not all genes were already upregulated immediately at 4h, we wanted to 
further dissect possible different transcriptional patterns. Rather than focusing on single genes 
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we chose a global clustering approach. The data was normalized in order to avoid that the 
difference in fold induction amplitude of the genes affects the clustering which was merely 
focused on temporal distribution. Using a Dirichlet process we were able to let the clustering 
algorithm define the amount of clusters from the data itself in an unbiased way. The algorithm 
produced four robust clusters of upregulated genes, which we termed early (number of genes: 
144), intermediate (31), late (299), and very late ISG cluster (20); and two downregulated gene 
clusters with 143 and 98 genes, respectively (Figure 4.3.2B-C). We observed that the majority of 
genes were maximally upregulated at 4h and 16h and didn’t show prolonged nor any second 
wave of induction. It has been shown that the IFN signaling cascade gets refractory to 
continuous IFNα exposure in vitro and in vivo96,97, and that the main negative regulator 
responsible for this refractoriness in the mouse liver has been identified to not be SOCS1 or 
SOCS3, two important negative regulators, but USP1897. Consistently, mRNA levels of SOCS1 
and SOCS3 were only upregulated initially or weakly induced, while USP18 showed elevated 
mRNA levels throughout the observation period, and also continuous higher protein expression 
than at baseline (Figure 4.3.2D-E). 
 
PegIFN-α-2a does not induce the IFN signaling differently than PegIFN-α-2b at 144h, 
despite continuous high serum levels. 
The different design of pegIFN-α-2b and pegIFN-α-2a leads to very distinct pharmacokinetic 
properties. While the single chain PEG moiety of pegIFN-α-2b is subject to hydrolysis, which 
leads to a release of IFN-α-2b into the human body and faster elimination of the drug, pegIFN-α-
2a is not hydrolyzed, has a lower absorption rate and is much slower eliminated. 
Pharmacokinetic studies have shown that unlike pegIFN-α-2b with a serum level peak around 
24h and subsequent gradual decline, pegIFN-α-2a achieves maximum serum levels around 80h 
which sustain up to 168h56,134. Accordingly, in our three study patients treated with pegIFN-α-2a 
serum levels of 6800, 7200, and 20’000 pg/ml at 144h were comparable to those assessed in 
previous studies. We wanted to exploit this difference in pharmacokinetic behavior to gain more 
evidence that IFN signaling is indeed refractory regardless of the amount of pegIFN-α 
circulating the body. Indeed, even with high level of pegIFN-α-2a in the serum STAT1 
phosphorylation in the liver was not markedly increased at 144h (Figure 4.3.3A). 
We next tried to assess with several approaches whether pegIFN-α-2a leads to a different and 
stronger induction of ISGs at 144h than pegIFN-α-2b. The amount of genes expressed over 2 
fold in 2/3 of the patients in each group was similar (49 vs. 59), and genes with the highest 
absolute expression levels from each group or the biggest fold change compared to B1 didn’t 
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show significant differences than the usual inter-individual variabilities. We also assessed 
different genes from each representing cluster, to see whether some clusters might be specifically 
affected by continuous high exposure to pegIFN-α. However, again genes of all clusters behaved 
identically between the two groups. Taken together, this evidence suggests that in the human 
liver the gene induction is refractory to continuous IFN-α exposure and thus does not support the 
hypothesis that the superiority of pegIFN-α in antiviral therapy is due to longer serum half-life. 
 
 
 
 
 
 
Figure 4.3.1. Transient induction of the Jak-STAT pathway in the liver upon administration of 
peg-IFN-α-2b. (A) Study design. All patients had a diagnostic biopsy before therapy (B1). Paired 
second biopsies (B2) were taken at the indicated time points. Numbers of patients are indicated 
below the plot. (B) Serum concentration of pegIFN-α-2b measured by ELISA. Median is 
indicated. (C) Phosphorylated STAT1 (pSTAT1) and STAT1 protein expression by Western Blot 
analysis using whole cell extracts of liver samples from B1 and B2 of each patient. At TP 16h 
only liver material from patient 9 was left for protein analysis. (D) Graphical representation of 
the induction of pSTAT1 between B2 and B1. The intensity of the pSTAT1 bands on the Western 
blots has been assessed by ImageJ. The values of time point 4h have been taken from Sarasin-
Filipowicz et al.89. P-value obtained by Mann-Whitney test. Patient numbers as indicated in 
Table 1. 
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Figure 4.3.2. ISGs are induced in temporally distinct clusters. (A) Number of genes > 2-fold up- 
or downregulated at each time point in 2/3 of the patients. (B) Clustering analysis of the 
upregulated genes produced four robust clusters (1-4) that comprised of early, intermediate, 
late, and very late ISGs. Blue line indicates the median expression. The number of genes in each 
cluster is provided in the plot. (C) Two clusters of downregulated genes (5-6). (D) Bar plot of the 
fold change of mRNA expression between B1 and B2 of SOCS1, SOCS3 and USP18. Shown are 
mean with SEM. Black line indicates baseline. (E) USP18 protein expression by Western blot 
analysis using whole cell extracts of liver samples from B1 and B2. Patient numbers as indicated 
in Table 1. 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.3. PegIFN-α-2a does not induce the IFN signaling differently than pegIFN-α-2b at 
144h, despite continuous high serum levels. Phosphorylated STAT1 (pSTAT1) and STAT1 
protein expression by Western Blot analysis using whole cell extracts of liver samples from B1 
and B2 of each patient. Fold induction of the pSTAT1 bands is indicated. 
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Table 1: Patient characteristics          
    
Viral load, log 
IU/mL  Response       
Patient no. Age Sex 
HCV 
GT Baseline 4-week 12-week 4-week 12-week Follow-up METAVIR 
IL28B 
GT Time point Medication 
1 52 m 3 7.14 neg neg RVR cEVR SVR A2/F2 CC 4h 
2 37 m 3 4.9 neg neg RVR cEVR SVR A1/F2 CT 4h 
3 54 f 2 4.95 neg neg RVR cEVR SVR A3/F3 CT 4h 
4 57 m 3 5.25 2.15 neg RR cEVR Relapse A3/F4 CC 4h 
5 38 m 4 4.08 1.66 neg RR cEVR SVR A2/F2 CT 4h 
6 51 f 1 6.82 3.52 neg RR cEVR SVR A1/F2 CT 4h 
7 26 m 3 4.58 neg neg RVR cEVR SVR A1/F1 TT 16h 
8 42 f 3 5.49 neg neg RVR cEVR SVR A1/F2 CT 16h 
9 41 m 3 5.66 neg neg RVR cEVR SVR A1/F2 CT 16h 
10 30 m 3 7.07 neg neg RVR cEVR SVR A2/F2 CT 48h 
11 57 f 1 5.95 neg neg RVR cEVR SVR A2/F2 CC 48h 
12 37 m 3 6.72 1.28 neg RR cEVR SVR A3/F2 CT 48h 
13 62 m 4 7.16 neg neg RVR cEVR SVR A3/F4 CT 96h 
14 43 m 1 5.6 1.63 neg RR cEVR SVR A3/F2 CC 96h 
15 40 m 1 5.16 1.41 neg RR cEVR SVR A3/F4 CT 96h 
16 25 f 1 2.64 neg neg RVR cEVR SVR A2/F2 CC 144h 
17 70 m 2 6.86 1.84 neg RR cEVR SVR A2/F3 CT 144h 
18 34 m 3 5.56 neg neg RVR cEVR SVR A2/F2 CT 144h 
PegIFNα-
2b 
19 57 f 2 5.18 neg neg RVR cEVR SVR A2/F2 CC 144h 
20 57 m 1 6.54 4.59 3.33 Non-RR EVR interrupted A3/F4 CT 144h 
21 38 f 4 6.32 5.07 neg Non-RR cEVR SVR A3/F4 CC 144h 
PegIFNα-
2a 
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5. Discussion 
 
5.1 The host response in acute hepatitis C infection 
 
In this first study, human liver biopsies obtained 2-5 months after HCV infection, i.e. during 
the early phase of the adaptive immune response, were analyzed. In accordance with data 
obtained from experimentally infected chimpanzees that were then biopsied during acute 
infection118,119,120, we found CD8+ T- cell infiltrates, increased intrahepatic IFN-γ mRNA 
expression, and ALT elevation. Importantly, T cell infiltrates were co-localized with 
hepatocytes positive for nuclear pSTAT1 immunostaining, providing evidence that the 
predominant mediator of STAT1 activation in that phase of infection is IFN-γ that is secreted 
by infiltrating T cells which are in close contact to stimulated hepatocytes. The microarray 
analysis of ISG expression revealed a strong enrichment of IFN-γ specific ISGs in AHC liver 
biopsy samples, further confirming that the predominant IFN in this phase of HCV infection 
is IFN-γ and not IFN-α. These results do not support the hypothesis that liver infiltrating 
HCV-specific T cells are stunned, with impaired IFN-γ production, and are therefore not 
capable to clear the infection117,136. We were however not able to draw any conclusions on 
possible molecular factors that favour viral persistence or spontaneous clearance due to the 
small sample size and the ethical necessity to treat those patients while they were still in the 
acute phase of infection with greater chances of achieving SVR. 
 
It is puzzling that in this phase of infection the vast majority of typical IFN-α stimulated 
genes are not induced. Interference of HCV with the innate immune system could explain 
these findings. However, the Jak-STAT pathway doesn’t seem to be impaired as IFN-γ 
signaling is very effective with strong pSTAT1 signals and IFN-γ stimulated gene induction. 
We weren’t able to detect MAVS cleavage and thus impairment of the viral sensing 
mechanism in any of the AHC patients either. This is clearly in contrast to CHC, where 
MAVS cleavage has been identified in about half of the patients125. The lack of detection of 
cleaved MAVS in our AHC patients might be due the low viral load in these patients 
rendering MAVS cleavage below detection levels, or that MAVS cleavage is an important 
viral escape mechanism in the very first weeks after infection in humans which we fail to 
detect at our observation period.  
It would also be very interesting to find the time range after unsuccessful spontaneous 
clearance when preactivation of the IFN system is induced. So far we do not know whether 
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this actually happens early after persistence to chronic infection and or whether it occurs only 
later. This would allow us to better understand the mechanisms that are involved in the 
establishment of preactivation. This assessement is however limited by the fact that it is rather 
impossible to extrapolate the exact time of infection in most of the patients, as long as they 
were not diagnosed during acute infection.  
 
One aim of this study was to find possible molecular explanations for the difference in 
response rates to pegIFN-α in AHC (SVR >90%) and CHC (SVR 50%). The idea that AHC 
patients did not induce hepatic ISGs clearly proved to be wrong. However, since we were able 
to dissect these ISG expression profiles into IFN-γ driven in AHC or IFN-α driven in CHC-
NR, we could thoroughly examine possible differences. A candidate molecule that 
immediately attracted attention was USP18. In a previous study in mice USP18 has been 
identified as a key mediator of IFN-α refractoriness97. Similarly, an association between 
induction of USP18 and impaired IFN signaling has been seen in the livers of responder 
patients upon injection with pegIFN-α (Figure 4.3.2). Comparison of responders versus non-
responders to pegIFN-α in a combined analysis including AHC, CHC-R and CHC-NR 
showed that USP18 induction is associated with non-response to pegIFN-α (Figure 4.1.5). 
Therefore the apparent lack of USP18 induction in AHC might explain the improved response 
rate to pegIFN-α treatments in these patients compared to patients with CHC, and it could be 
worthwile to investigate USP18 as a potential therapeutical target to improve response to 
IFN-α. 
 
 
5.2 IL28B genetic variations and the host response in chronic hepatitis C 
infection 
 
The discovery of polymorphisms around the IL28B gene and its association with treatment 
response had a tremendous impact on hepatitis C research. For one the possibility to predict 
treatment response in the clinical setting was considered, and on the other hand the first 
genetic factor was uncovered that would allow new means to explore and better understand 
the interplay between the immune system and HCV infection. However, IL28B genotype has 
so far not been compared with other predictive factors, especially hepatic ISG induction. We 
therefore wanted to assess the power of different treatment predictors, and explore if IL28B 
genetic variants could explain the preactivation of the IFN system in some CHC patients. 
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First, by analyzing a large cohort of CHC patients we have shown that a 4-gene classifier 
measuring hepatic mRNA expression levels had much better predictive power than IL28B 
genotyping. IL28B genotyping is just one variable that gives only three distinct outputs while 
measurement of ISG expression levels allows for continuous variable measurements. A 
combination of ISGs thus creates continuous probability values that can much better define 
the likelihood for treatment response in an individual patient than IL28B genotyping. It can 
also be speculated, that hepatic ISG expression is a more immediate phenotype more 
accurately representing the actual situation in the liver before treatment that dictates response 
to pegIFN-α.  
The arrival of two protease inhibitors Boceprevir and Telaprevir to the therapy of CHC 
patients infected with genotype 1 HCV infection adds further complexity. Phase 1 studies 
have clearly shown that monotherapy is not applicable and only leads to selection of resistant 
virus strains97. Therefore triple combination with pegIFN-α and ribavirin is the treatment of 
choice. However, about 30% of the patients still do not respond to this treatment and from our 
current knowledge it has to be hypothesized that the majority of these non-responders would 
be probably preactivated with high ISG levels and thus do not respond to pegIFN-α, rendering 
the addition of a protease inhibitor useless. Prediction of non-response in the era of triple 
therapy could therefore be very useful to avoid the rising of resistant strains, and it should be 
tested if high expression of hepatic ISGs indeed predicts non-response in this setting. 
The drawback of hepatic ISG expression measurement is the requirement of a liver biopsy, 
which is invasive and has a small risk of complications. While a diagnostic liver biopsy is still 
included in the American Association of the Study of Liver Diseases (AASLD) guidelines57, 
biopsies are often omitted in current clinical practice. An appropriate alternative with more 
easy to obtain material would be very promising. I just discussed that IL28B genotyping to 
our opinion is not suitable, and analysis of ISG expression in PBMCs revealed that it does not 
represent the situation of IFN activation in the liver89,135.  Recently, measurement of IFN-γ 
inducible protein 10 (IP-10), a chemokine secreted to the blood, came forward as a potential 
predictor of non-response that was able to improve the predictive power of IL28B 
genotyping137–139. However, whether this is superior or at least equal to our four gene 
classifier or hepatic ISG levels in general has not been investigated. In our study a 
combination of IL28B genotype with ISG expression did not improve our classifier, and we 
didn’t have blood samples to test for IP-10 levels, and thus compare its predictive power. 
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In our study we have seen that hepatic ISG induction representing the activation of the 
endogenous IFN system is associated with genetic polymorphisms near the IL28B gene. 
However, this association is lost when the patients are stratified to treatment response, which 
led us to the conclusion that it is very unlikely that IL28B genetic variants are the only and 
direct cause of preactivation of the endogenous hepatic IFN system. Whether this is really the 
cause is still under debate since our conclusions diverge from two other studies140,141. 
However, three more recently published articles again drew similar conclusions that IL28B 
genotype and ISG expression are rather independent factors associated with treatment 
response142,143,144. To clearly settle this matter, a thorough understanding of the effect of the 
IL28B genotype would be necessary. 
One hypothesis is that the genetic variations lead to difference in expression, since no obvious 
variation in the coding sequence could be discovered. But analyses of IL28B mRNA levels 
led to very contradictory results in the field. The expression seems to be very low and the high 
sequence similarity between IL28A and IL28B makes it difficult to properly design assays to 
distinguish them. In two GWAS publications IL28 mRNA expression was measured in 
PBMCs indicating paradoxically lower expression in minor allele carriers, which are the ones 
showing higher hepatic ISG expression. We observed a similar trend in the liver (Section 
4.2.1, Figure 1), while others could not detect a significant difference141. Despite discrepant 
data none has so far described higher IL28B levels in minor allele carriers and this hypothesis 
thus can probably be abolished. How lower levels of IL28B might explain higher ISG 
induction remains a mystery. 
By looking at our data from 10 responder patients with paired liver biopsies, one before and 
one after 4h of pegIFN-α injection, we hoped to gain some insight of the effect of IL28B 
genetic variants on the response to pegIFN-α. Although the sample size was relatively low, 
there was a consistent and significant difference in induction of a subset of ISGs according to 
the IL28B genotype. It has to be stated that all these patients had low pretreatment ISG levels 
and virologically responded well to therapy, limiting the risk of any bias interfering with 
response to IFN. However, we were however not able to reproduce these findings in an in 
vitro model using PHH. It might very well be that HCV infection is necessary, or that a 
complex interaction of different cell types as in an infected liver is required to see that effect. 
PHH are not very easily infected with HCVcc and the replication rate is usually very low. 
Marukian et al. infected fetal liver cells with different IL28B genotypes with HCVcc and 
looked at HCV-induced ISG induction145. Similarly, they were not able to see an IL28B 
genotype driven difference in ISG expression. Another group has investigated the effect of 
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IL28 polymorphisms on the induction of ISGs in PBMCs upon treatment in CHC patients143. 
They saw a stronger induction of ISGs in patients with the favorable CC genotype, and thus 
concluded that the non-response associated T allele carriers had an aberrant baseline induction 
of the innate immune system. These interpretations should be considered with some caution 
since they did not control for hepatic ISG induction in these patients and it has been shown 
that PBMCs do not reflect the hepatic immune response in the case of HCV infection89,135. 
Thus, the effect of IL28B polymorphisms in HCV infection remains unclear, and more 
research is needed to uncover the underlying mechanisms. 
 
 
5.3 Refractoriness to pegIFN-α therapy 
 
In our study of the pharmacodynamics of pegIFN-α in the liver we were able to show that the 
IFN signaling is transient with peak pSTAT1 levels in the first 16 hours and also a peak 
induction of ISGs at 16h. The majority of genes thereafter decrease steadily back to baseline 
and do not show prolonged or a second wave of induction. This refractoriness was associated 
with a permanent increase in USP18 mRNA and protein levels, which has been shown to be a 
key mediator of refractoriness to IFN-α in the mouse liver97.  
 
A first analysis of uninfected chimpanzees which were treated with either human or 
chimpanzee IFN-α or human pegIFN-α and then serially liver biopsied at 4h, 8h and 24h 
revealed with all three treatments a rapid induction with a maximal response for most ISGs at 
4h, a decline at 8h and baseline levels at 24h135.  Those data are surprisingly different from 
our observations in humans where we clearly see a majority of ISGs maximally increased at 
16h (Section 4.3, figure 2). In this chimpanzee study the rapid downregulation has been 
interpreted with the IFNAR receptor and the Jak-STAT pathway getting desensitized. A more 
rapid induction of USP18 in the chimpanzees could be a possible explanation for this 
phenomenon.  However, USP18 as a key negative regulator has not yet been discovered at 
that time, and thus has not been looked at.  
 
We describe here for the first time different clusters of interferon regulated genes in the liver 
that differ in their temporal transcription pattern upon pegIFN-α treatment. We have identified 
4 clusters of upregulated genes (early, intermediate, late, and very late), as well as two 
downregulated gene clusters. It would be interesting to learn how these different transcription 
patterns arise. One obvious explanation would be a first induction of additional transcription 
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activators that in a second wave induce further ISGs. A biocomputional approach looking at 
main transcription factor binding sites in the promoter of the genes in the different clusters 
revealed however, that in each cluster, be it early or late ISGs, ISRE binding sites that are 
bound by the phosphorylated STATs were the absolutely dominant motifs (data not shown) 
rendering this possibility unlikely. Clearly further research has to be done to understand the 
orchestrated process of ISG induction over time.  
The canonical Jak-STAT pathway and the regulation of transcription upon IFN stimulation is 
very well understood on the molecular level. In our analysis we did also see over 200 genes 
transcriptionally downregulated more than 2-fold upon IFN-α stimulation. While repression 
of genes upon IFN-α treatment has already been described earlier135, it is not clear how this is 
actually achieved. One could think of induction of transcriptional repressors or epigenetic 
changes, and it would be worthwile to further elucidate these mechanisms for a more 
thorough understanding of IFN signaling. 
 
We could definitely observe that at late time points the liver is refractory to circulating IFN-α. 
Even constant high serum levels of pegIFN-α did not lead to a continuous upregulation of 
ISGs to remain a constant antiviral state. Therefore we still have no proof that the superiority 
of pegIFN-α is explained by permanent ISG induction until the next injection is received, but 
rather evidence for the opposite. We are aware that we do not have a treatment arm that 
received IFN-α injections instead of pegIFN-α to directly compare possible differences in 
pharmacodynamics, since it would be ethically not correct to provide a sub-standard of care 
treatment to those patients. Nevertheless, no differences in ISG induction between IFN-α and 
pegIFN-α application have been found in chimpanzees and our data clearly also indicate a 
transient induction albeit with slower kinetics than in the chimpanzees. It would be very 
interesting to investigate if the patients are again as responsive to a second injection of 
pegIFN-α after 7 days as they were to the first injection, but this would require 3 biopsies per 
patient and is thus not really realizable. 
Taken together, we provide first evidence for refractoriness to IFN-α in the human liver and 
our data might be a helpful resource for further research of IFN-signaling in the liver. 
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5.4 Outlook: Visualization of HCV 
 
One completely unresolved question remains why patients with a preactivated IFN system 
who show similar induction of ISGs like responder patients upon pegIFN-α treatment are not 
able to spontaneously clear the virus.  
One could imagine that the infected cells are repressed to induce ISGs by the means which 
HCV has to inhibit the Jak-STAT pathway, and therefore ISGs are expressed only in non-
infected hepatocytes, where they are ineffective. A model derived from in vitro data also 
postulates that HCV is effectively blocking translation by phosphorylating PKR, and thus also 
inhibits the translation of ISG mRNA116. 
The limitation that so far hampered the investigation and proof of these important concepts in 
vivo was the inability to reliably visualize HCV in liver biopsies. Several 
immunohistochemical protocols with different antibodies have not been reproducible. 
Another approach combining 2-photon microscopy with virus-specific, fluorescent, 
semiconductor probes has also not been reproduced so far146.  
 
Additionally, the source that is responsible for this ISG induction has also not been identified. 
We failed to measure hepatic IFN-α or IFN-β mRNA levels in CHC patients, as did earlier 
studies in chimpanzees123,147 and more recently also in humans148. IFN-λ levels again are also 
very low expressed and not different between responders and non-responders, and IFN-γ is 
induced in the late acute phase, but not in CHC. It remains puzzling that despite strong 
induction of ISGs the respective source is not measurable in liver biopsies, and it leads to the 
question, whether a so far unidentified IFN or cytokine might be responsible. An IFN that has 
slightly different properties compared to IFN-α making it unsuccessful to clear the virus 
effectively. 
 
New visualization techniques and more sensitive measuring techniques are therefore one of 
the most direly needed advances that would help to unravel the unresolved questions in the 
field of virus-host interactions in HCV infection. 
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5.5 Concluding remarks 
 
With the experimental approaches outlined in this thesis we were able to contribute to the 
understanding of host-virus interactions in acute and chronic hepatitis C. Analyzing liver 
biopsy samples, we were able to dissect the molecular differences between the host response 
in acute and chronic hepatitis C together with a possible explanation to the difference in 
treatment susceptibility, and we have shed some light on the connection of IL28B genetic 
variants and preactivation of the IFN system, additionally providing a test to predict treatment 
response that could be readily used in the clinical setting. Last, we describe for the first time 
the pharmacodynamics of pegIFN-α in the human liver gathering evidence that IFN-α 
signaling gets refractory, questioning a ten-year-old theory that the superior pharmacokinetics 
of pegIFN-α are responsible for the better efficacy in the treatment of CHC. 
Altogether these findings provide insights that help to better understand hepatitis C infection 
and IFN-signaling in the human liver, knowledge that should be eventually helpful to improve 
the care of patients suffering from this important liver disease.  
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Chemokines, receptors and related
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
32128_at CCL18 3.5 8.1 3.9 5.7 9.0 11.0 2.0 1.8 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)
210072_at CCL19 5.5 2.0 9.5 4.5 2.4 3.1 8.1 7.4 chemokine (C-C motif) ligand 19
216598_s_at CCL2 3.3 2.9 4.4 2.9 5.6 2.7 2.0 1.8 chemokine (C-C motif) ligand 2
205476_at CCL20 8.4 7.1 5.7 2.8 42.6 5.1 3.4 6.7 chemokine (C-C motif) ligand 20
204606_at CCL21 3.0 2.6 2.6 3.1 1.4 1.8 3.1 4.6 chemokine (C-C motif) ligand 21
204103_at CCL4 1.8 3.2 2.4 1.9 5.1 3.7 1.4 1.2 chemokine (C-C motif) ligand 4
1405_i_at CCL5 2.2 5.5 3.6 2.7 5.7 5.4 2.2 2.3 chemokine (C-C motif) ligand 5
214038_at CCL8 2.1 8.5 2.0 2.6 7.2 6.6 1.8 2.3 chemokine (C-C motif) ligand 8
206991_s_at CCR5 1.5 2.3 2.4 2.1 2.0 2.4 1.5 1.6 chemokine (C-C motif) receptor 5
204533_at CXCL10 9.7 13.1 20.4 11.3 23.3 31.3 11.5 19.8 chemokine (C-X-C motif) ligand 10
211122_s_at CXCL11 6.6 10.9 13.8 11.0 13.4 17.0 5.8 10.1 chemokine (C-X-C motif) ligand 11
203915_at CXCL9 3.6 7.2 18.3 10.8 21.4 19.8 8.6 4.0 chemokine (C-X-C motif) ligand 9
217028_at CXCR4 1.6 2.0 3.1 1.7 2.5 3.6 2.3 2.8 chemokine (C-X-C motif) receptor 4
206974_at CXCR6 1.4 3.2 2.6 2.7 2.6 3.0 1.3 1.3 chemokine (C-X-C motif) receptor 6
210354_at IFNG 1.7 4.7 3.5 3.2 4.2 3.8 1.2 0.9 interferon, gamma
222868_s_at IL18BP 2.4 3.3 2.1 2.1 2.9 2.4 1.3 1.3 interleukin 18 binding protein
205067_at IL1B 2.1 2.7 1.9 1.7 3.9 2.3 1.2 1.1 interleukin 1, beta
204116_at IL2RG 1.8 3.2 2.5 1.9 2.7 2.4 1.7 1.6 interleukin 2 receptor, gamma (severe combined immunodeficiency)
203828_s_at IL32 1.7 2.5 2.0 1.6 4.1 2.0 1.6 2.2 interleukin 32
202859_x_at IL8 3.4 3.1 3.9 1.5 15.7 4.0 2.2 2.2 interleukin 8
209035_at MDK 2.9 4.1 1.9 1.5 2.8 3.0 1.3 3.5 midkine (neurite growth-promoting factor 2)
206366_x_at XCL1 2.1 1.8 2.4 1.4 3.2 1.7 1.3 1.2 chemokine (C motif) ligand 1
ISGs
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
202269_x_at GBP1 4.1 5.9 4.2 4.9 4.5 4.6 1.9 2.0 guanylate binding protein 1, interferon-inducible, 67kDa
202748_at GBP2 2.3 3.0 2.3 2.3 2.3 1.7 1.3 1.3 guanylate binding protein 2, interferon-inducible
235574_at GBP4 2.1 3.5 2.7 2.6 2.2 2.8 1.3 1.5 guanylate binding protein 4
229625_at GBP5 1.9 3.3 2.1 3.2 2.2 2.0 1.2 1.0 guanylate binding protein 5
205483_s_at ISG15 2.2 3.3 1.5 1.5 2.0 4.5 2.1 15.4 ISG15 ubiquitin-like modifier
204698_at ISG20 4.0 5.6 2.7 2.4 3.3 4.5 2.2 5.7 interferon stimulated exonuclease gene 20kDa
205569_at LAMP3 6.1 5.0 11.3 6.4 4.7 15.7 4.8 29.2 lysosomal-associated membrane protein 3
204972_at OAS2 1.8 3.6 1.7 1.4 1.7 3.9 1.4 6.5 2'-5'-oligoadenylate synthetase 2, 69/71kDa
205660_at OASL 3.8 5.2 3.2 2.4 5.6 9.0 7.5 21.7 2'-5'-oligoadenylate synthetase-like
Cellular immune response
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
205831_at CD2 2.0 3.9 3.6 2.6 3.7 3.7 2.3 2.3 CD2 molecule
213539_at CD3D 1.8 3.4 3.1 2.6 3.1 3.3 2.1 2.1 CD3d molecule, delta (CD3-TCR complex)
34210_at CD52 1.6 3.3 2.2 1.6 3.3 2.7 2.0 1.9 CD52 molecule
205758_at CD8A 2.1 5.0 4.1 2.8 5.4 4.9 2.0 1.7 CD8a molecule
204440_at CD83 2.0 2.2 2.5 2.0 3.0 2.5 1.6 1.7 CD83 molecule
204118_at CD48 1.6 3.0 2.0 1.7 2.3 2.1 1.5 1.5 CD48 molecule
203416_at CD53 1.8 2.7 2.1 1.7 2.4 2.3 1.3 1.3 CD53 molecule
210895_s_at CD86 1.7 3.5 1.9 1.8 2.6 2.6 1.3 1.1 CD86 molecule
209835_x_at CD44 2.2 3.0 1.7 1.7 2.5 1.6 1.2 1.0 CD44 molecule (Indian blood group)
215925_s_at CD72 1.6 3.1 1.6 2.0 2.7 2.6 1.3 0.9 CD72 molecule
205159_at CSF2RB 2.1 3.4 1.7 2.0 2.5 2.2 1.5 1.4 colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)
231496_at FCAMR 7.3 5.4 4.0 3.4 10.6 4.7 4.5 3.4 Fc receptor, IgA, IgM, high affinity
1554899_s_at FCER1G 2.0 3.1 1.7 1.9 2.0 1.8 1.0 0.9 Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide
214511_x_at FCGR1B 3.0 5.3 2.3 3.1 3.1 2.3 0.9 0.9 Fc fragment of IgG, high affinity Ib, receptor (CD64)
203561_at FCGR2A 1.7 2.8 1.9 1.5 2.6 2.4 1.1 1.1 Fc fragment of IgG, low affinity IIa, receptor (CD32)
205488_at GZMA 1.4 3.4 2.4 2.2 2.7 2.7 1.3 1.2 granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)
206082_at HCP5 3.6 4.8 3.1 5.2 3.1 5.2 2.2 4.1 HLA complex P5
203932_at HLA-DMB 1.9 3.3 2.3 2.1 2.6 2.9 1.4 1.3 major histocompatibility complex, class II, DM beta
213537_at HLA-DPA1 3.8 7.5 1.8 4.8 4.6 5.5 1.8 1.6 major histocompatibility complex, class II, DP alpha 1
212998_x_at HLA-DQB1 1.5 4.3 3.0 1.8 2.2 4.0 1.4 1.1 major histocompatibility complex, class II, DQ beta 1
210982_s_at HLA-DRA 1.7 2.5 2.1 1.8 2.5 2.5 1.4 1.4 major histocompatibility complex, class II, DR alpha
204806_x_at HLA-F 1.8 2.4 2.0 2.6 1.6 2.9 1.5 2.7 major histocompatibility complex, class I, F
216491_x_at IGHM 7.1 3.0 3.2 11.1 4.8 2.6 5.2 4.7 immunoglobulin heavy constant mu
234884_x_at IGL@ 2.8 1.2 2.1 2.7 2.3 1.8 2.5 2.5 Immunoglobulin lambda locus
234764_x_at IGLV1-44 5.7 2.1 3.3 5.8 4.0 2.4 5.2 3.1 Immunoglobulin lambda variable 1-44
206420_at IGSF6 1.7 2.6 2.1 1.5 3.0 3.0 1.1 0.8 immunoglobulin superfamily, member 6
211339_s_at ITK 1.6 3.1 3.6 2.6 3.7 3.9 2.1 2.3 IL2-inducible T-cell kinase
214470_at KLRB1 1.3 3.6 1.8 2.6 2.2 2.2 1.1 1.0 killer cell lectin-like receptor subfamily B, member 1
1555691_a_at KLRK1 1.3 3.1 2.5 1.7 2.5 2.6 1.2 1.1 killer cell lectin-like receptor subfamily K, member 1
204890_s_at LCK 2.1 3.7 2.8 2.1 3.0 2.7 1.8 1.7 lymphocyte-specific protein tyrosine kinase
205269_at LCP2 1.7 2.9 1.8 1.8 2.3 2.2 1.4 1.4 lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa)
208949_s_at LGALS3 2.7 3.7 2.3 1.7 3.3 2.8 1.7 2.2 lectin, galactoside-binding, soluble, 3
210732_s_at LGALS8 2.8 3.5 2.2 2.1 2.2 1.9 1.3 1.0 lectin, galactoside-binding, soluble, 8
206881_s_at LILRA3 2.0 2.6 1.6 1.8 2.5 1.7 1.0 1.0 leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 3
203523_at LSP1 2.1 2.8 2.4 2.2 2.3 2.5 1.7 1.7 lymphocyte-specific protein 1
1555745_a_at LYZ 5.4 4.2 1.9 3.4 12.1 7.4 5.3 3.9 lysozyme (renal amyloidosis)
206247_at MICB 2.2 3.6 2.1 2.0 3.0 2.4 1.8 2.1 MHC class I polypeptide-related sequence B
214770_at MSR1 1.3 2.6 1.6 1.7 2.6 3.2 0.9 1.0 macrophage scavenger receptor 1
219788_at PILRA 1.6 3.0 1.8 1.5 3.0 2.7 1.1 1.1 paired immunoglobin-like type 2 receptor alpha
202963_at RFX5 1.7 2.5 1.7 1.9 2.1 2.4 1.6 2.0 regulatory factor X, 5 (influences HLA class II expression)
229723_at TAGAP 1.7 3.4 2.6 2.1 2.9 2.9 2.0 2.4 T-cell activation RhoGTPase activating protein
202307_s_at TAP1 2.3 3.1 1.9 2.5 2.3 2.4 1.4 1.9 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
225973_at TAP2 1.9 3.0 2.2 3.3 1.6 2.9 1.8 2.9 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)
1555565_s_at TAPBP 1.9 2.7 1.7 2.9 1.3 2.0 1.2 1.1 TAP binding protein (tapasin)
218746_at TAPBPL 2.6 2.4 1.7 2.8 2.2 1.9 1.3 1.5 TAP binding protein-like
209670_at TRAC 1.5 2.9 3.2 2.1 2.7 2.8 1.9 1.7 T cell receptor alpha constant
213193_x_at TRBC1 2.1 4.7 4.1 2.9 4.3 4.0 2.4 2.4 T cell receptor beta constant 1
Transcription factors
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
212420_at ELF1 2.3 3.3 2.2 2.6 1.9 2.5 1.5 1.6 E74-like factor 1 (ets domain transcription factor)
223287_s_at FOXP1 2.3 2.1 2.3 2.4 1.9 2.2 1.9 1.9 forkhead box P1
202431_s_at MYC 1.9 3.1 1.6 1.3 4.3 2.5 1.2 1.3 v-myc myelocytomatosis viral oncogene homolog (avian)
233446_at ONECUT2 2.9 1.7 3.0 2.9 2.5 1.9 1.4 1.5 one cut homeobox 2
209969_s_at STAT1 3.6 5.5 3.6 4.9 3.0 6.4 2.6 5.8 signal transducer and activator of transcription 1, 91kDa
Signal transduction
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
242961_x_at DDX58 2.0 3.4 1.7 1.7 1.5 2.4 1.2 2.1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58
207651_at GPR171 1.6 3.3 3.5 2.0 4.5 3.2 1.7 1.5 G protein-coupled receptor 171
210279_at GPR18 1.5 3.5 2.4 2.1 3.0 2.4 1.7 1.6 G protein-coupled receptor 18
209631_s_at GPR37 1.9 2.4 2.8 1.2 2.5 2.1 1.1 1.9 G protein-coupled receptor 37 (endothelin receptor type B-like)
1552611_a_at JAK1 2.1 2.2 2.4 3.3 1.7 2.3 1.5 1.3 Janus kinase 1
229560_at TLR8 2.2 3.2 2.4 2.0 3.2 2.5 1.3 1.2 toll-like receptor 8
Lipid homeostasis-related
Supplementary Table I. 
Fold changes of the upregulated genes in functional 
categories (fold change of at least 2 between the means of 
AHC and healthy liver samples with the corresponding FDR 
(Benjamini-Hochberg correction) below 0.05). 
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
221087_s_at APOL3 2.2 2.9 2.3 2.9 2.7 3.5 1.8 3.1 apolipoprotein L, 3
38241_at BTN3A3 1.7 2.3 2.4 2.8 1.6 2.7 1.4 1.9 butyrophilin, subfamily 3, member A3
220029_at ELOVL2 2.0 2.1 3.6 1.4 1.6 2.4 2.2 2.5 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2
202345_s_at FABP5 3.2 4.8 3.1 2.1 5.5 4.2 1.5 1.7 fatty acid binding protein 5 (psoriasis-associated)
209785_s_at PLA2G4C 1.8 2.4 2.4 2.4 2.0 2.9 1.5 1.8 phospholipase A2, group IVC (cytosolic, calcium-independent)
206214_at PLA2G7 2.4 5.5 3.1 1.8 6.5 5.2 1.1 1.2 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)
211708_s_at SCD 1.5 2.6 2.4 3.8 1.1 3.3 1.6 1.6 stearoyl-CoA desaturase (delta-9-desaturase)
220232_at SCD5 1.9 3.3 1.8 2.9 1.3 2.3 1.0 0.8 stearoyl-CoA desaturase 5
204881_s_at UGCG 3.0 2.5 2.2 1.3 3.0 1.6 1.5 1.7 UDP-glucose ceramide glucosyltransferase
Apoptosis-related
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
224461_s_at AIFM2 1.9 2.4 1.6 1.6 2.9 2.7 1.3 1.7 apoptosis-inducing factor, mitochondrion-associated, 2
211367_s_at CASP1 2.2 3.5 1.8 2.0 2.0 2.1 1.3 1.6 caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)
Ubiquitination, proteasome
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
204279_at PSMB9 2.8 3.5 2.8 3.5 2.7 3.2 1.6 2.4 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2)
222600_s_at UBA6 2.2 3.1 2.0 2.9 1.7 2.1 1.2 1.7 ubiquitin-like modifier activating enzyme 6
226035_at USP31 2.7 2.0 3.3 2.6 2.1 2.5 1.7 1.4 ubiquitin specific peptidase 31
Antiviral
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
204205_at APOBEC3G 1.8 3.6 2.2 1.8 2.7 3.1 1.9 2.3 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G
204502_at SAMHD1 1.7 3.3 1.7 1.6 2.0 2.3 1.2 1.3 SAM domain and HD domain 1
Metabolism
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
206561_s_at AKR1B10 8.4 25.4 2.0 5.8 23.7 6.9 2.2 4.8 aldo-keto reductase family 1, member B10 (aldose reductase)
209646_x_at ALDH1B1 2.0 2.3 2.3 2.7 1.9 2.7 1.4 1.7 aldehyde dehydrogenase 1 family, member B1
203922_s_at CYBB 2.1 3.7 1.8 1.6 2.7 1.9 1.1 0.9 cytochrome b-245, beta polypeptide
210272_at CYP2B7P1 3.3 2.0 5.2 4.4 2.9 4.3 2.4 3.5 cytochrome P450, family 2, subfamily B, polypeptide 7 pseudogene 1
224009_x_at DHRS9 2.2 3.6 3.6 2.9 4.4 5.2 1.3 1.4 dehydrogenase/reductase (SDR family) member 9
210029_at IDO1 2.0 3.5 3.1 3.8 2.9 2.9 2.0 1.7 indoleamine 2,3-dioxygenase 1
204059_s_at ME1 1.7 3.1 1.9 1.8 2.5 3.3 1.6 1.5 malic enzyme 1, NADP(+)-dependent, cytosolic
210154_at ME2 1.8 2.6 2.0 1.9 1.9 2.1 1.0 1.1 malic enzyme 2, NAD(+)-dependent, mitochondrial
201761_at MTHFD2 2.5 3.2 1.9 1.6 2.6 1.8 1.3 1.5 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase
223298_s_at NT5C3 2.0 2.9 1.5 1.6 2.0 2.7 1.2 2.5 5'-nucleotidase, cytosolic III
200628_s_at WARS 2.2 3.1 2.0 2.8 1.8 1.6 1.1 0.9 tryptophanyl-tRNA synthetase
Cell membrane, adhesion, extracellular matrix
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
214701_s_at FN1 2.0 1.8 4.4 2.7 2.0 2.0 1.4 1.0 fibronectin 1
207165_at HMMR 1.8 3.5 1.2 1.6 2.6 2.9 1.5 1.5 hyaluronan-mediated motility receptor (RHAMM)
219403_s_at HPSE 1.7 3.3 2.1 1.5 2.9 3.3 1.1 1.3 heparanase
219697_at HS3ST2 3.2 5.4 3.8 2.9 8.9 6.9 1.2 1.3 heparan sulfate (glucosamine) 3-O-sulfotransferase 2
202746_at ITM2A 2.4 3.8 2.1 1.8 5.7 3.2 2.1 2.5 integral membrane protein 2A
219574_at MARCH1 2.7 4.9 1.8 2.3 2.5 2.5 1.3 1.7 membrane-associated ring finger (C3HC4) 1
Cell cycle
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
210559_s_at CDC2 1.8 3.2 1.6 1.2 2.7 2.8 1.4 1.5 cell division cycle 2, G1 to S and G2 to M
208727_s_at CDC42 1.5 5.9 1.4 1.7 2.9 4.6 1.5 1.2 cell division cycle 42 (GTP binding protein, 25kDa)
224851_at CDK6 1.9 2.5 2.5 4.0 1.6 3.1 1.4 1.3 cyclin-dependent kinase 6
210416_s_at CHEK2 1.8 2.8 1.7 2.6 2.4 4.8 1.6 2.2 CHK2 checkpoint homolog (S. pombe)
Kinases/phosphatases and related
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
226702_at CMPK2 1.9 4.0 1.3 1.7 1.4 3.2 1.5 6.7 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
203302_at DCK 1.9 2.8 2.1 1.8 2.0 2.1 1.5 1.4 deoxycytidine kinase
201251_at PKM2 2.2 3.3 2.3 1.9 2.9 1.9 1.5 1.4 pyruvate kinase, muscle
212588_at PTPRC 1.7 2.9 2.7 1.8 2.5 2.6 1.5 1.5 protein tyrosine phosphatase, receptor type, C
204960_at PTPRCAP 1.4 2.6 1.9 1.8 2.7 2.4 1.4 1.6 protein tyrosine phosphatase, receptor type, C-associated protein
202693_s_at STK17A 1.5 3.1 2.0 1.4 2.8 2.2 1.5 1.7 serine/threonine kinase 17a
DNA damage-related
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
222850_s_at DNAJB14 2.6 2.8 2.3 2.7 2.9 2.8 1.4 1.4 DnaJ (Hsp40) homolog, subfamily B, member 14
1558080_s_at DNAJC3 2.6 4.5 1.6 4.0 2.4 2.3 1.4 1.5 DnaJ (Hsp40) homolog, subfamily C, member 3
218627_at DRAM1 1.7 2.4 1.6 1.9 2.4 2.2 1.3 1.2 DNA-damage regulated autophagy modulator 1
Other
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
221008_s_at AGXT2L1 1.5 1.8 1.8 3.0 2.0 3.3 1.9 3.0 alanine-glyoxylate aminotransferase 2-like 1
238439_at ANKRD22 4.3 6.5 2.3 5.7 3.2 1.8 1.0 0.6 ankyrin repeat domain 22
238332_at ANKRD29 1.6 1.8 2.4 2.1 1.7 2.7 1.8 2.9 ankyrin repeat domain 29
213503_x_at ANXA2 1.8 2.7 1.9 1.3 2.3 2.4 2.0 2.3 annexin A2
225285_at BCAT1 2.2 2.9 1.9 1.7 2.5 3.3 1.4 2.3 branched chain aminotransferase 1, cytosolic
205681_at BCL2A1 2.3 3.5 2.8 2.2 4.1 2.4 1.3 1.1 BCL2-related protein A1
210538_s_at BIRC3 3.0 2.9 3.6 2.5 6.8 2.9 1.8 1.9 baculoviral IAP repeat-containing 3
226054_at BRD4 2.3 1.8 2.1 3.0 1.9 2.5 1.8 1.8 bromodomain containing 4
205548_s_at BTG3 2.1 2.3 2.0 1.6 2.7 1.6 1.3 1.3 BTG family, member 3
201850_at CAPG 2.6 3.6 3.6 2.1 3.3 3.5 1.6 1.7 capping protein (actin filament), gelsolin-like
1552701_a_at CARD16 2.3 3.2 1.8 1.7 2.3 1.6 1.7 2.4 caspase recruitment domain family, member 16
228323_at CASC5 2.1 1.8 2.5 2.4 1.8 2.7 1.9 2.9 cancer susceptibility candidate 5
226425_at CLIP4 1.9 3.0 2.2 1.7 2.7 2.5 2.2 2.8 CAP-GLY domain containing linker protein family, member 4
209536_s_at EHD4 2.1 2.4 1.6 1.8 2.0 2.3 1.4 1.8 EH-domain containing 4
227609_at EPSTI1 2.4 4.7 1.9 2.0 2.0 3.6 1.4 5.7 epithelial stromal interaction 1 (breast)
217234_s_at EZR 2.4 2.8 2.0 2.7 2.0 1.8 1.3 1.3 ezrin
203305_at F13A1 3.7 3.1 1.9 2.1 2.2 1.2 2.3 2.2 coagulation factor XIII, A1 polypeptide
231769_at FBXO6 1.7 2.6 1.7 1.9 1.9 2.6 1.5 2.0 F-box protein 6
230422_at FPR3 1.7 3.4 2.5 1.7 3.0 3.2 1.3 1.5 formyl peptide receptor 3
205285_s_at FYB 1.3 3.2 1.4 2.0 2.4 2.5 1.2 1.1 FYN binding protein (FYB-120/130)
221521_s_at GINS2 2.1 2.3 1.6 2.1 2.5 3.1 2.0 1.9 GINS complex subunit 2 (Psf2 homolog)
35820_at GM2A 1.7 2.7 1.6 1.9 2.2 2.5 1.3 1.3 GM2 ganglioside activator
224863_at GNAQ 1.9 1.7 2.3 2.5 1.6 2.1 1.4 1.7 Guanine nucleotide binding protein (G protein), q polypeptide
201141_at GPNMB 2.3 4.0 4.6 2.1 5.2 5.5 1.3 1.2 glycoprotein (transmembrane) nmb
227614_at HKDC1 4.9 18.3 2.4 1.5 17.1 6.3 2.6 10.5 hexokinase domain containing 1
211597_s_at HOPX 2.3 3.4 2.1 1.3 3.9 2.1 1.6 1.7 HOP homeobox
200598_s_at HSP90B1 1.9 2.8 1.9 2.0 2.6 2.1 1.3 1.2 heat shock protein 90kDa beta (Grp94), member 1
211006_s_at KCNB1 1.4 2.0 2.0 4.8 4.1 3.7 1.1 0.9 potassium voltage-gated channel, Shab-related subfamily, member 1
244111_at KRT222 1.8 1.9 1.7 2.9 1.8 3.8 1.8 4.2 keratin 222
201151_s_at MBNL1 2.0 2.6 3.1 2.8 1.8 2.1 1.4 1.2 muscleblind-like (Drosophila)
202107_s_at MCM2 1.8 2.1 1.6 1.8 2.2 3.0 2.0 1.5 minichromosome maintenance complex component 2
216237_s_at MCM5 2.2 2.5 1.4 2.0 2.2 2.6 2.0 1.7 minichromosome maintenance complex component 5
201930_at MCM6 2.2 3.4 1.8 2.1 3.3 3.5 2.1 1.9 minichromosome maintenance complex component 6
225325_at MFSD6 2.2 3.1 1.7 1.8 2.2 1.9 1.5 1.8 major facilitator superfamily domain containing 6
224726_at MIB1 2.4 1.7 2.1 3.0 1.9 2.3 1.5 1.7 mindbomb homolog 1 (Drosophila)
218883_s_at MLF1IP 2.4 2.9 1.6 2.6 3.2 4.8 2.1 2.4 MLF1 interacting protein
204959_at MNDA 2.2 3.3 1.8 2.0 2.2 1.7 1.3 1.2 myeloid cell nuclear differentiation antigen
202149_at NEDD9 2.0 2.5 2.1 1.7 1.7 2.5 1.8 1.9 neural precursor cell expressed, developmentally down-regulated 9
218039_at NUSAP1 1.8 2.6 1.6 1.6 2.3 2.5 1.4 1.3 nucleolar and spindle associated protein 1
200906_s_at PALLD 3.1 2.6 1.3 1.8 3.0 1.2 1.3 1.5 palladin, cytoskeletal associated protein
207469_s_at PIR 2.5 2.8 1.7 1.8 2.9 2.1 1.3 1.3 pirin (iron-binding nuclear protein)
201927_s_at PKP4 2.5 2.1 2.0 2.9 2.0 1.8 1.6 1.8 plakophilin 4
221538_s_at PLXNA1 2.4 2.0 2.4 2.1 2.7 2.8 1.6 1.8 plexin A1
213241_at PLXNC1 1.7 2.6 2.4 1.6 2.7 2.4 1.6 1.8 plexin C1
208879_x_at PRPF6 3.3 3.0 2.3 3.3 1.9 2.0 1.6 1.5 PRP6 pre-mRNA processing factor 6 homolog (S. cerevisiae)
204897_at PTGER4 1.6 2.9 1.8 1.6 2.7 2.3 1.3 1.2 prostaglandin E receptor 4 (subtype EP4)
203554_x_at PTTG1 2.0 3.3 1.6 2.0 2.5 2.5 1.5 1.3 pituitary tumor-transforming 1
207419_s_at RAC2 1.8 3.0 2.0 2.6 1.7 2.2 1.4 1.4 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)
200607_s_at RAD21 2.8 3.1 2.6 3.2 2.5 2.6 1.7 1.5 RAD21 homolog (S. pombe)
221872_at RARRES1 1.9 3.4 2.1 2.1 5.3 4.3 1.7 1.5 retinoic acid receptor responder (tazarotene induced) 1
205590_at RASGRP1 1.6 2.6 2.8 2.2 2.8 2.3 1.9 2.1 RAS guanyl releasing protein 1 (calcium and DAG-regulated)
201890_at RRM2 3.6 4.4 1.6 2.7 4.0 3.7 1.6 2.3 ribonucleotide reductase M2
220330_s_at SAMSN1 1.7 3.6 1.8 2.0 3.0 2.8 1.2 1.1 SAM domain, SH3 domain and nuclear localization signals 1
202062_s_at SEL1L 1.9 2.4 2.1 2.6 2.6 2.8 1.3 1.0 sel-1 suppressor of lin-12-like (C. elegans)
209723_at SERPINB9 1.8 2.8 1.4 1.6 3.0 2.3 1.8 2.5 serpin peptidase inhibitor, clade B (ovalbumin), member 9
219159_s_at SLAMF7 3.5 6.5 3.6 3.8 5.0 3.4 2.2 1.3 SLAM family member 7
219386_s_at SLAMF8 3.1 5.1 5.6 3.7 5.7 6.2 2.0 2.2 SLAM family member 8
202800_at SLC1A3 1.6 2.4 2.0 1.5 2.7 2.6 0.9 1.0 solute carrier family 1 (glial high affinity glutamate transporter), member 3
212295_s_at SLC7A1 2.5 3.2 2.0 1.6 2.4 2.0 1.8 1.9 solute carrier family 7 (cationic amino acid transporter, y+ system), member 1
201996_s_at SPEN 2.9 2.5 2.0 4.4 1.6 2.4 1.4 1.7 spen homolog, transcriptional regulator (Drosophila)
209875_s_at SPP1 6.0 8.6 1.7 1.4 6.8 1.2 2.5 3.4 secreted phosphoprotein 1
1554690_a_at TACC1 2.2 2.4 1.7 2.7 1.6 2.1 1.3 1.3 transforming, acidic coiled-coil containing protein 1
201813_s_at TBC1D5 2.6 2.9 2.5 2.5 2.7 2.6 1.7 1.5 TBC1 domain family, member 5
208691_at TFRC 4.0 1.8 3.1 1.7 4.3 1.5 1.7 1.6 transferrin receptor (p90, CD71)
202643_s_at TNFAIP3 2.0 1.7 2.4 2.1 2.9 2.3 1.6 1.7 tumor necrosis factor, alpha-induced protein 3
219725_at TREM2 2.1 3.0 1.7 1.5 3.3 2.7 1.3 1.5 triggering receptor expressed on myeloid cells 2
1568592_at TRIM69 2.0 3.3 1.9 2.7 1.9 2.9 1.2 2.1 tripartite motif-containing 69
218245_at TSKU 2.2 1.8 2.8 2.0 2.6 2.8 1.3 1.4 tsukushin
202589_at TYMS 1.7 2.1 1.3 1.4 3.4 3.1 1.9 2.1 thymidylate synthetase
238657_at UBXN10 1.6 3.4 1.4 1.9 3.9 5.6 2.2 2.2 UBX domain protein 10
208998_at UCP2 2.2 2.9 1.7 2.1 2.5 2.6 1.3 1.1 uncoupling protein 2 (mitochondrial, proton carrier)
214382_at UNC93A 2.2 2.4 2.9 7.0 3.0 6.2 7.6 7.0 unc-93 homolog A (C. elegans)
222387_s_at VPS35 2.1 2.7 2.7 2.7 1.5 1.6 1.5 1.3 vacuolar protein sorting 35 homolog (S. cerevisiae)
204026_s_at ZWINT 1.8 3.0 1.3 1.9 3.2 3.7 1.7 1.8 ZW10 interactor
227918_s_at ZYG11B 2.7 2.6 2.1 5.1 1.5 3.0 1.3 1.1 zyg-11 homolog B (C. elegans)
_Unannotated
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
219099_at C12orf5 1.5 3.1 1.6 1.5 3.2 3.0 1.3 2.0 chromosome 12 open reading frame 5
225105_at C12orf75 2.4 3.0 1.8 1.6 3.0 1.2 1.6 2.2 chromosome 12 open reading frame 75
219757_s_at C14orf101 1.9 1.9 2.5 2.6 1.8 2.0 1.0 1.1 chromosome 14 open reading frame 101
223484_at C15orf48 3.2 6.9 3.5 2.6 5.1 4.7 2.3 2.2 chromosome 15 open reading frame 48
226456_at C16orf75 2.2 3.3 1.7 2.1 3.0 3.9 2.0 2.3 chromosome 16 open reading frame 75
235377_at C6orf142 3.1 5.3 3.0 3.8 3.5 3.4 0.7 0.8 chromosome 6 open reading frame 142
217967_s_at FAM129A 2.9 2.8 2.5 2.0 2.4 1.8 1.7 1.9 family with sequence similarity 129, member A
229391_s_at FAM26F 1.6 3.6 1.9 2.6 2.3 2.4 0.9 0.7 family with sequence similarity 26, member F
mean fold change versus controls
>10
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Metabolism
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
214829_at AASS 0.40 0.35 0.69 0.64 0.38 0.55 0.64 0.50 aminoadipate-semialdehyde synthase
203559_s_at ABP1 0.18 0.34 0.53 0.87 0.15 0.42 0.23 0.09 amiloride binding protein 1 (amine oxidase (copper-containing))
227962_at ACOX1 0.44 0.35 0.62 0.47 0.64 0.52 0.88 0.74 acyl-Coenzyme A oxidase 1, palmitoyl
231675_s_at ADH4 0.28 0.30 0.37 0.30 0.36 0.29 0.47 0.49 alcohol dehydrogenase 4 (class II), pi polypeptide
214423_x_at ALDOB 0.22 0.26 0.30 0.32 0.25 0.28 0.44 0.57 Aldolase B, fructose-bisphosphate
231662_at ARG1 0.17 0.30 0.30 0.23 0.29 0.38 0.49 0.53 Arginase, liver
201171_at ATP6V0E1 0.36 0.64 0.36 0.43 0.48 0.53 0.55 0.65 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1
232449_at BCO2 0.26 0.16 0.62 0.22 0.46 0.39 0.41 0.43 beta-carotene oxygenase 2
231591_at BHMT 0.26 0.37 0.67 0.41 0.35 0.60 0.62 0.68 Betaine-homocysteine methyltransferase
231672_at CES4 0.27 0.34 0.30 0.24 0.37 0.33 0.54 0.67 Carboxylesterase 4-like
206424_at CYP26A1 0.06 0.22 0.22 0.23 0.14 0.28 0.27 0.27 cytochrome P450, family 26, subfamily A, polypeptide 1
219903_s_at CYP2C8 0.29 0.34 0.50 0.33 0.35 0.45 0.59 0.66 cytochrome P450, family 2, subfamily C, polypeptide 8
214420_s_at CYP2C9 0.22 0.25 0.36 0.20 0.36 0.27 0.56 0.58 Cytochrome P450, family 2, subfamily C, polypeptide 9
222100_at CYP2E1 0.36 0.46 0.47 0.53 0.35 0.51 0.62 0.52 Cytochrome P450, family 2, subfamily E, polypeptide 1
1554931_at CYP4A11 0.52 0.22 0.70 0.62 0.19 0.30 0.59 0.56 cytochrome P450, family 4, subfamily A, polypeptide 11
213868_s_at DHRS7 0.34 0.36 0.38 0.44 0.30 0.40 0.56 0.81 Dehydrogenase/reductase (SDR family) member 7
235305_s_at ECHDC2 0.55 0.22 0.57 0.76 0.41 0.49 0.49 0.38 enoyl Coenzyme A hydratase domain containing 2
211934_x_at GANAB 0.30 0.37 0.33 0.18 0.75 0.36 0.99 0.93 glucosidase, alpha; neutral AB
231686_at GATM 0.28 0.29 0.23 0.21 0.21 0.17 0.46 0.54 Glycine amidinotransferase (L-arginine:glycine amidinotransferase)
210328_at GNMT 0.18 0.19 0.16 0.32 0.13 0.14 0.49 0.29 glycine N-methyltransferase
220801_s_at HAO2 0.57 0.34 0.69 0.86 0.27 0.36 0.70 0.73 hydroxyacid oxidase 2 (long chain)
204110_at HNMT 0.26 0.30 0.29 0.34 0.51 0.36 0.61 0.64 histamine N-methyltransferase
209703_x_at METTL7A 0.37 0.41 0.43 0.37 0.33 0.40 0.76 0.58 methyltransferase like 7A
219959_at MOCOS 0.46 0.35 0.57 0.76 0.16 0.62 0.79 0.99 molybdenum cofactor sulfurase
231559_at NNMT 0.25 0.39 0.17 0.23 0.21 0.17 0.30 0.26 Nicotinamide N-methyltransferase
203515_s_at PMVK 0.43 0.53 0.38 0.36 0.73 0.47 0.99 0.84 phosphomevalonate kinase
204476_s_at PC 0.38 0.45 0.26 0.18 0.73 0.26 0.69 0.56 pyruvate carboxylase
242662_at PCSK6 0.42 0.27 0.72 0.68 0.37 0.63 0.71 0.54 Proprotein convertase subtilisin/kexin type 6
237248_at PDE11A 0.35 0.28 0.82 0.49 0.54 0.51 0.61 0.80 phosphodiesterase 11A
1562321_at PDK4 0.16 0.15 0.46 0.36 0.15 0.39 0.45 0.35 pyruvate dehydrogenase kinase, isozyme 4
217383_at PGK1 0.42 0.41 0.27 0.36 0.42 0.24 0.46 0.61 Phosphoglycerate kinase 1
222049_s_at RBP4 0.31 0.38 0.40 0.29 0.35 0.38 0.53 0.59 Retinol binding protein 4, plasma
1566472_s_at RETSAT 0.41 0.60 0.40 0.31 0.74 0.56 0.82 0.79 retinol saturase (all-trans-retinol 13,14-reductase)
219934_s_at SULT1E1 0.42 0.25 0.74 0.76 0.19 0.35 0.74 0.42 sulfotransferase family 1E, estrogen-preferring, member 1
1555189_a_at TAT 0.19 0.34 0.27 0.35 0.25 0.71 0.40 0.35 tyrosine aminotransferase
231702_at TDO2 0.29 0.46 0.35 0.48 0.25 0.52 0.44 0.59 Tryptophan 2,3-dioxygenase
224043_s_at UPB1 0.28 0.26 0.36 0.22 0.41 0.30 1.01 0.77 ureidopropionase, beta
Immune response
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
201641_at BST2 0.31 0.45 0.29 0.18 0.99 0.51 0.79 2.04 bone marrow stromal cell antigen 2
1554459_s_at CFHR3 0.51 0.26 0.69 0.70 0.32 0.22 0.40 0.12 complement factor H-related 3
207874_s_at CFHR4 0.56 0.37 0.70 0.63 0.36 0.26 0.47 0.20 complement factor H-related 4
208088_s_at CFHR5 0.55 0.64 0.39 0.45 0.61 0.30 0.51 0.23 complement factor H-related 5
220305_at MAVS 0.50 0.53 0.50 0.35 0.77 0.42 0.78 0.64 mitochondrial antiviral signaling protein
Lipid-related genes
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
231359_at APOH 0.33 0.36 0.33 0.26 0.31 0.30 0.47 0.64 Apolipoprotein H (beta-2-glycoprotein I)
231693_at FABP1 0.33 0.52 0.27 0.24 0.45 0.40 0.58 0.67 Fatty acid binding protein 1, liver
207584_at LPA 0.54 0.33 0.59 0.57 0.32 0.35 0.42 0.15 lipoprotein, Lp(a)
220675_s_at PNPLA3 0.37 0.41 0.23 0.30 0.57 0.44 0.91 1.01 patatin-like phospholipase domain containing 3
Apoptosis
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
208478_s_at BAX 0.42 0.57 0.28 0.23 1.20 0.52 1.14 1.63 BCL2-associated X protein
Translation and ribosomes
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
213087_s_at EEF1D 0.23 0.34 0.20 0.25 0.25 0.25 0.46 0.44 eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein)
219138_at RPL14 0.36 0.42 0.39 0.39 0.55 0.44 0.58 0.58 ribosomal protein L14
212044_s_at RPL27A 0.47 0.44 0.46 0.56 0.31 0.38 0.66 0.76 Ribosomal protein L27a
213350_at RPS11 0.41 0.47 0.39 0.57 0.35 0.48 0.70 0.75 Ribosomal protein S11
230034_x_at MRPL41 0.46 0.51 0.42 0.59 0.42 0.42 0.69 0.81 mitochondrial ribosomal protein L41
223292_s_at MRPS15 0.29 0.42 0.25 0.21 0.37 0.26 0.49 0.52 mitochondrial ribosomal protein S15
Blood-related genes
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
231684_at ANGPTL3 0.22 0.35 0.47 0.35 0.47 0.49 0.52 0.56 Angiopoietin-like 3
209116_x_at HBB 0.32 0.52 0.36 0.40 0.27 0.22 0.36 0.27 hemoglobin, beta
240033_at PLG 0.60 0.32 0.84 0.56 0.43 0.40 0.54 0.44 plasminogen
1558603_at PLGLB2 0.32 0.39 0.42 0.37 0.29 0.34 0.40 0.34 plasminogen-like B2
RNA binding or processing
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
225191_at CIRBP 0.52 0.35 0.47 0.38 0.50 0.40 0.65 0.65 cold inducible RNA binding protein
231011_at LARP2 0.24 0.27 0.18 0.17 0.22 0.17 0.37 0.35 La ribonucleoprotein domain family, member 2
242837_at SFRS4 0.43 0.21 0.64 0.31 0.70 0.42 0.64 0.65 Splicing factor, arginine/serine-rich 4
212266_s_at SFRS5 0.45 0.45 0.52 0.32 0.64 0.40 0.84 0.85 splicing factor, arginine/serine-rich 5
226670_s_at PABPC1L 0.54 0.30 0.51 0.42 0.45 0.48 0.63 0.67 poly(A) binding protein, cytoplasmic 1-like
227244_s_at SSU72 0.26 0.34 0.22 0.31 0.22 0.23 0.46 0.78 SSU72 RNA polymerase II CTD phosphatase homolog (S. cerevisiae)
DNA binding
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
221646_s_at ZDHHC11 0.61 0.42 0.65 0.40 0.44 0.36 0.87 1.07 zinc finger, DHHC-type containing 11
224445_s_at ZFYVE21 0.49 0.60 0.45 0.31 0.73 0.48 0.90 0.84 zinc finger, FYVE domain containing 21
206373_at ZIC1 0.18 0.40 0.28 0.29 0.51 0.66 0.30 0.15 Zic family member 1 (odd-paired homolog, Drosophila)
1557953_at ZKSCAN1 0.58 0.39 0.56 0.51 0.53 0.43 0.78 0.90 zinc finger with KRAB and SCAN domains 1
239937_at ZNF207 0.29 0.16 0.36 0.15 0.47 0.25 0.64 0.61 Zinc finger protein 207
215012_at ZNF451 0.47 0.34 0.64 0.33 0.71 0.49 0.71 0.71 zinc finger protein 451
205594_at ZNF652 0.51 0.50 0.37 0.48 0.61 0.54 1.01 0.91 zinc finger protein 652
Protein phosphatases/kinases and related
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
218744_s_at PACSIN3 0.55 0.49 0.34 0.35 0.52 0.36 0.92 0.61 protein kinase C and casein kinase substrate in neurons 3
240187_at PPP1R3C 0.26 0.11 0.39 0.41 0.13 0.18 0.32 0.37 protein phosphatase 1, regulatory (inhibitor) subunit 3C
222351_at PPP2R1B 0.24 0.26 0.33 0.22 0.54 0.45 0.42 0.55 protein phosphatase 2 (formerly 2A), regulatory subunit A, beta isoform
200637_s_at PTPRF 0.44 0.48 0.34 0.29 0.75 0.34 0.84 0.61 protein tyrosine phosphatase, receptor type, F
209622_at STK16 0.35 0.44 0.38 0.21 0.67 0.40 0.76 0.71 serine/threonine kinase 16
Supplementary Table II. 
Fold changes of the downregulated genes in functional 
categories (fold change below 0.5 between the means of 
AHC and healthy liver samples with the corresponding FDR 
(Benjamini-Hochberg correction) below 0.05). 
Ubiquitination
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
236235_at ITCH 0.34 0.29 0.58 0.40 0.39 0.31 0.75 0.53 Itchy E3 ubiquitin protein ligase homolog (mouse)
225179_at UBE2K 0.41 0.44 0.38 0.32 0.53 0.36 0.85 0.83 ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast)
Ras oncogene-related
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
215506_s_at DIRAS3 0.45 0.28 0.49 0.71 0.23 0.24 0.57 0.52 DIRAS family, GTP-binding RAS-like 3
228161_at RAB32 0.38 0.59 0.45 0.36 0.65 0.67 0.61 0.69 RAB32, member RAS oncogene family
231075_x_at RAPH1 0.48 0.42 0.33 0.64 0.39 0.52 0.87 0.94 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1
213409_s_at RHEB 0.35 0.29 0.64 0.64 0.23 0.33 0.56 0.46 Ras homolog enriched in brain
SLC family
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
219915_s_at SLC16A10 0.52 0.26 0.47 0.78 0.24 0.28 0.67 0.39 solute carrier family 16, member 10 (aromatic amino acid transporter)
221661_at SLC22A7 0.45 0.32 0.35 0.40 0.42 0.30 0.51 0.57 solute carrier family 22 (organic anion transporter), member 7
209236_at SLC23A2 0.26 0.25 0.41 0.25 0.56 0.36 0.67 0.42 solute carrier family 23 (nucleobase transporters), member 2
218136_s_at SLC25A37 0.44 0.48 0.47 0.52 0.44 0.41 0.52 0.39 solute carrier family 25, member 37
205799_s_at SLC3A1 0.49 0.56 0.35 0.32 0.30 0.18 0.44 0.28 solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activator of cystine, dibasic and neutral amino acid transport), member 1
233123_at SLC40A1 0.49 0.36 0.76 0.33 0.61 0.44 0.63 0.66 Solute carrier family 40 (iron-regulated transporter), member 1
219820_at SLC6A16 0.44 0.29 0.44 0.37 0.28 0.24 0.67 0.58 solute carrier family 6, member 16
Other
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
205730_s_at ABLIM3 0.51 0.54 0.46 0.28 0.81 0.37 0.56 0.58 actin binding LIM protein family, member 3
211489_at ADRA1A 0.53 0.36 0.71 0.32 0.58 0.36 0.49 0.49 adrenergic, alpha-1A-, receptor
232810_at AIG1 0.30 0.20 0.47 0.32 0.35 0.32 0.57 0.48 androgen-induced 1
214425_at AMBP 0.37 0.45 0.36 0.42 0.29 0.35 0.53 0.64 Alpha-1-microglobulin/bikunin precursor
226663_at ANKRD10 0.29 0.14 0.44 0.18 0.46 0.23 0.60 0.59 ankyrin repeat domain 10
216563_at ANKRD12 0.50 0.32 0.32 0.59 0.55 0.57 0.66 0.76 Ankyrin repeat domain 12
203747_at AQP3 0.51 0.51 0.38 0.38 0.74 0.44 0.79 0.61 aquaporin 3 (Gill blood group)
209824_s_at ARNTL 0.33 0.38 0.77 0.28 0.61 0.42 0.48 0.57 aryl hydrocarbon receptor nuclear translocator-like
211852_s_at ATRN 0.44 0.38 0.55 0.27 0.88 0.49 0.96 0.80 attractin
215460_x_at BRD1 0.52 0.47 0.49 0.42 0.63 0.47 0.89 1.07 bromodomain containing 1
229163_at CAMK2N1 0.34 0.35 0.28 0.44 0.32 0.32 0.54 0.64 calcium/calmodulin-dependent protein kinase II inhibitor 1
214475_x_at CAPN3 0.45 0.31 0.56 0.60 0.39 0.52 0.45 0.36 calpain 3, (p94)
226736_at CHURC1 0.75 0.38 0.37 0.28 0.38 0.39 0.74 0.72 churchill domain containing 1
227953_at CMTM6 0.32 0.61 0.27 0.32 0.51 0.37 0.63 0.69 CKLF-like MARVEL transmembrane domain containing 6
206417_at CNGA1 0.65 0.34 0.63 0.35 0.61 0.38 0.68 0.63 cyclic nucleotide gated channel alpha 1
216389_s_at DCAF11 0.45 0.50 0.50 0.40 0.57 0.45 0.88 0.75 DDB1 and CUL4 associated factor 11
225549_at DDX6 0.39 0.29 0.51 0.27 0.76 0.45 0.94 1.03 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6
213645_at ENOSF1 0.57 0.38 0.46 0.64 0.38 0.42 0.78 0.71 enolase superfamily member 1
201216_at ERP29 0.38 0.46 0.38 0.25 0.68 0.42 0.91 0.91 endoplasmic reticulum protein 29
212697_at FAM134C 0.31 0.34 0.35 0.18 0.72 0.41 1.03 1.22 family with sequence similarity 134, member C
215600_x_at FBXW12 0.55 0.39 0.56 0.44 0.60 0.47 0.83 0.81 F-box and WD repeat domain containing 12
214417_s_at FETUB 0.28 0.35 0.49 0.28 0.44 0.48 0.63 0.80 Fetuin B
203391_at FKBP2 0.38 0.57 0.38 0.33 0.71 0.49 0.95 0.88 FK506 binding protein 2, 13kDa
200959_at FUS 0.38 0.40 0.30 0.17 0.71 0.33 1.13 1.18 fusion (involved in t(12;16) in malignant liposarcoma)
236548_at GIPC2 0.42 0.38 0.50 0.73 0.36 0.53 0.86 0.82 GIPC PDZ domain containing family, member 2
224997_x_at H19 0.71 0.43 0.71 0.40 0.30 0.25 0.71 1.05 H19, imprinted maternally expressed transcript (non-protein coding)
1557100_s_at HECTD1 0.33 0.29 0.47 0.26 0.51 0.33 0.59 0.50 HECT domain containing 1
219976_at HOOK1 0.58 0.53 0.41 0.48 0.60 0.41 0.67 0.78 hook homolog 1 (Drosophila)
227139_s_at HPS3 0.51 0.54 0.48 0.41 0.52 0.43 0.77 0.87 Hermansky-Pudlak syndrome 3
202718_at IGFBP2 0.25 0.16 0.22 0.03 0.51 0.13 1.12 1.28 insulin-like growth factor binding protein 2, 36kDa
203424_s_at IGFBP5 0.48 0.28 0.33 0.35 0.24 0.25 0.63 0.58 insulin-like growth factor binding protein 5
229125_at KANK4 0.55 0.48 0.48 0.72 0.38 0.28 0.64 0.43 KN motif and ankyrin repeat domains 4
210078_s_at KCNAB1 0.31 0.29 0.32 0.62 0.26 0.31 0.52 0.42 potassium voltage-gated channel, shaker-related subfamily, beta member 1
242931_at LONRF3 0.52 0.41 0.70 0.51 0.46 0.38 0.60 0.71 LON peptidase N-terminal domain and ring finger 3
231640_at LYRM5 0.35 0.38 0.31 0.42 0.32 0.30 0.57 0.64 LYR motif containing 5
232168_x_at MACF1 0.54 0.40 0.55 0.39 0.66 0.48 0.75 0.66 microtubule-actin crosslinking factor 1
212708_at MSL1 0.46 0.54 0.36 0.31 0.82 0.52 0.89 0.99 male-specific lethal 1 homolog (Drosophila)
217546_at MT1M 0.65 0.40 0.10 0.61 0.38 0.16 0.17 0.13 metallothionein 1M
214753_at N4BP2L2 0.38 0.24 0.66 0.26 0.45 0.34 0.57 0.70 NEDD4 binding protein 2-like 2
1558515_at NCRNA00182 0.28 0.19 0.47 0.18 0.54 0.37 0.61 0.63 non-protein coding RNA 182
206453_s_at NDRG2 0.26 0.26 0.26 0.11 0.46 0.22 1.17 1.10 NDRG family member 2
224566_at NEAT1 0.40 0.31 0.50 0.33 0.50 0.44 0.53 0.52 nuclear paraspeckle assembly transcript 1 (non-protein coding)
225355_at NEURL1B 0.48 0.54 0.39 0.37 0.69 0.43 1.18 1.44 neuralized homolog 1B (Drosophila)
232158_x_at NIPAL1 0.43 0.36 0.49 0.36 0.31 0.36 0.89 0.95 NIPA-like domain containing 1
207202_s_at NR1I2 0.46 0.47 0.58 0.54 0.38 0.61 0.67 0.80 nuclear receptor subfamily 1, group I, member 2
1570188_at NR1I3 0.30 0.16 0.39 0.39 0.27 0.33 0.49 0.40 nuclear receptor subfamily 1, group I, member 3
224582_s_at NUCKS1 0.38 0.32 0.41 0.24 0.41 0.23 1.07 0.88 nuclear casein kinase and cyclin-dependent kinase substrate 1
226643_s_at NUDCD2 0.28 0.30 0.39 0.38 0.25 0.43 0.58 0.65 NudC domain containing 2
205728_at ODZ1 0.54 0.25 0.79 0.64 0.41 0.50 0.65 0.52 odz, odd Oz/ten-m homolog 1(Drosophila)
228881_at PARL 0.24 0.36 0.33 0.30 0.38 0.39 0.58 0.65 presenilin associated, rhomboid-like
1567213_at PNN 0.43 0.38 0.56 0.33 0.42 0.39 0.54 0.66 pinin, desmosome associated protein
219392_x_at PRR11 0.46 0.42 0.56 0.38 0.56 0.51 0.81 0.78 proline rich 11
203354_s_at PSD3 0.28 0.38 0.41 0.31 0.52 0.75 1.03 1.05 pleckstrin and Sec7 domain containing 3
207330_at PZP 0.38 0.34 0.34 0.23 0.35 0.11 0.09 0.04 pregnancy-zone protein
210751_s_at RGN 0.52 0.52 0.50 0.47 0.46 0.46 1.05 1.32 regucalcin (senescence marker protein-30)
212482_at RMND5A 0.40 0.38 0.52 0.34 0.50 0.38 0.88 0.85 required for meiotic nuclear division 5 homolog A (S. cerevisiae)
228806_at RORC 0.60 0.43 0.52 0.59 0.33 0.35 0.73 0.77 RAR-related orphan receptor C
216962_at RPAIN 0.32 0.42 0.34 0.33 0.35 0.46 0.55 0.70 RPA interacting protein
206211_at SELE 0.47 0.43 0.13 0.19 0.55 0.08 0.14 0.05 selectin E
230707_at SORL1 0.49 0.21 0.58 0.67 0.29 0.36 0.57 0.43 sortilin-related receptor, L(DLR class) A repeats-containing
212468_at SPAG9 0.44 0.38 0.30 0.43 0.45 0.41 0.76 0.67 sperm associated antigen 9
208610_s_at SRRM2 0.62 0.40 0.28 0.77 0.40 0.47 0.53 0.52 serine/arginine repetitive matrix 2
214064_at TF 0.48 0.29 0.77 0.52 0.26 0.44 0.58 0.58 transferrin
221871_s_at TFG 0.39 0.42 0.56 0.49 0.43 0.51 0.70 0.70 TRK-fused gene
229302_at TMEM178 0.55 0.41 0.59 0.32 0.60 0.50 0.72 0.86 transmembrane protein 178
226083_at TMEM70 0.49 0.46 0.44 0.50 0.60 0.52 0.55 0.72 transmembrane protein 70
229574_at TRA2A 0.39 0.24 0.69 0.35 0.49 0.40 0.62 0.71 transformer 2 alpha homolog (Drosophila)
237350_at TTC36 0.59 0.39 0.60 0.60 0.43 0.41 0.73 0.47 tetratricopeptide repeat domain 36
208844_at VDAC3 0.38 0.41 0.39 0.28 0.42 0.34 0.54 0.73 voltage-dependent anion channel 3
205506_at VIL1 0.38 0.41 0.37 0.28 0.30 0.20 0.44 0.34 villin 1
242234_at XAF1 0.41 0.31 0.35 0.27 0.50 0.60 0.53 0.90 XIAP associated factor 1
213999_at YIPF4 0.46 0.52 0.38 0.60 0.36 0.46 0.67 0.76 Yip1 domain family, member 4
Unannotated
probe set ID Symbol pat1 pat2 pat3 pat4 pat5 pat6 CHC-R CH-NR Gene Name
231538_at C11orf1 0.40 0.60 0.36 0.75 0.37 0.53 0.71 0.82 Chromosome 11 open reading frame 1
227535_at C15orf24 0.31 0.48 0.24 0.25 0.35 0.35 0.61 0.96 Chromosome 15 open reading frame 24
216483_s_at C19orf10 0.43 0.62 0.35 0.25 1.07 0.46 1.21 1.14 chromosome 19 open reading frame 10
230213_at C19orf43 0.42 0.35 0.41 0.36 0.56 0.37 0.61 0.67 chromosome 19 open reading frame 43
230256_at C1orf104 0.26 0.20 0.16 0.17 0.31 0.24 0.44 0.39 Chromosome 1 open reading frame 104
223126_s_at C1orf21 0.41 0.39 0.48 0.60 0.35 0.49 0.87 0.80 chromosome 1 open reading frame 21
230424_at C5orf13 0.56 0.43 0.38 0.47 0.25 0.27 0.52 0.44 chromosome 5 open reading frame 13
213089_at LOC100272216 0.65 0.35 0.63 0.35 0.72 0.40 0.75 0.79 hypothetical LOC100272216
213810_s_at LOC100292682 0.41 0.37 0.37 0.32 0.44 0.32 0.58 0.83 hypothetical protein LOC100292682
231258_at LOC100293390 0.45 0.59 0.42 0.41 0.33 0.36 0.60 0.64 hypothetical protein LOC100293390
1560679_at LOC151438 0.49 0.28 0.65 0.81 0.28 0.53 0.82 0.83 hypothetical protein LOC151438
225762_x_at LOC284801 0.42 0.62 0.37 0.38 0.73 0.57 0.72 0.88 hypothetical protein LOC284801
237889_s_at LOC553137 0.14 0.10 0.23 0.10 0.23 0.14 0.30 0.23 Hypothetical LOC553137
239432_at FLJ31306 0.44 0.28 0.75 0.41 0.58 0.40 0.61 0.62 hypothetical LOC379025
238127_at FLJ41484 0.30 0.42 0.43 0.39 0.39 0.56 0.76 0.71 hypothetical LOC650669
mean fold change versus controls
>10
 5-10
 3-5
 2-3
 1.5-2
 0.7-1.5
 0.5-0.7
 0.3-0.5
 0.2-0.3
 0.1-0.2
 <0.1
 > 2-fold induced in both donors IFN-alpha, but not in IFN-gamma
probeSetID Symbol D1 D2 D1 D2 D1 D2 D1 D2 GeneName
8170704 ABCD1 2.5 2.5 1.7 2.4 1.1 1.3 1.4 1.3   ATP-binding cassette, sub-family D (ALD), member 1 (ABCD1), mRNA. 
7947462 ABTB2 2.2 2.1 1.5 1.5 1.3 1.1 1.2 1.2   ankyrin repeat and BTB (POZ) domain containing 2 (ABTB2), mRNA. 
8141648 ACHE 1.9 4.5 2.1 6.5 1.1 3.3 1.5 6.6   acetylcholinesterase (Yt blood group) (ACHE), transcript variant E4-E5, mRNA. 
7905233 ADAMTSL4 2.1 2.3 1.3 2.2 1.4 2.4 1.7 3.0   ADAMTS-like 4 (ADAMTSL4), transcript variant 1, mRNA. 
7900087 ADPRHL2 2.7 2.4 1.4 1.7 1.7 1.6 1.3 1.6   ADP-ribosylhydrolase like 2 (ADPRHL2), nuclear gene encoding mitochondrial protein, mRNA. 
8011599 ANKFY1 2.1 2.3 1.7 1.9 1.5 1.4 1.7 1.9   ankyrin repeat and FYVE domain containing 1 (ANKFY1), transcript variant 1, mRNA. 
8073062 APOBEC3B 5.5 4.3 1.8 2.0 1.5 1.3 1.2 1.1   apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B (APOBEC3B), mRNA. 
8180374 APOBEC3F 4.9 3.1 2.2 2.3 1.5 1.0 2.0 1.6   apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F (APOBEC3F), transcript variant 2, mRNA 
8016215 ARHGAP27 2.3 2.8 1.3 2.2 0.9 1.4 1.1 1.8   Rho GTPase activating protein 27 (ARHGAP27), transcript variant 1, mRNA. 
8142098 ATXN7L1 2.1 1.4 2.2 2.3 0.9 0.8 1.4 1.5   ataxin 7-like 1 (ATXN7L1), transcript variant 1, mRNA. 
8035304 BST2 2.3 2.1 3.2 3.8 1.1 1.1 1.8 2.7   bone marrow stromal cell antigen 2 (BST2), mRNA. 
7996403 C16orf70 2.2 2.2 1.3 1.7 0.9 1.1 1.4 1.5   chromosome 16 open reading frame 70 (C16orf70), mRNA. 
7899394 C1orf38 3.1 2.2 1.4 1.1 0.8 0.5 1.6 1.0   chromosome 1 open reading frame 38 (C1orf38), transcript variant 3, mRNA. 
7930577 CASP7 2.2 2.3 1.7 1.6 2.5 1.9 1.9 1.7   caspase 7, apoptosis-related cysteine peptidase (CASP7), transcript variant delta, mRNA. 
8126371 CCND3 2.3 2.6 1.6 2.3 1.2 1.2 1.6 2.0   cyclin D3 (CCND3), transcript variant 2, mRNA. 
8007188 CNP 3.4 3.6 2.0 2.3 1.3 1.1 1.8 2.1   2',3'-cyclic nucleotide 3' phosphodiesterase (CNP), mRNA. 
8086330 CSRNP1 2.9 2.3 1.7 1.9 1.7 1.9 1.1 1.9   cysteine-serine-rich nuclear protein 1 (CSRNP1), mRNA. 
7916616 CYP2J2 2.3 1.7 2.1 2.4 1.1 1.0 1.5 1.5   cytochrome P450, family 2, subfamily J, polypeptide 2 (CYP2J2), mRNA. 
8018922 CYTH1 2.1 2.3 1.7 1.9 1.1 1.3 1.3 1.4   cytohesin 1 (CYTH1), transcript variant 1, mRNA. 
8128843 DDO 3.2 2.6 3.1 2.9 1.2 1.1 1.8 1.7   D-aspartate oxidase (DDO), transcript variant 1, mRNA. 
7987772 EHD4 3.4 2.8 1.5 1.7 1.3 1.3 1.0 1.5   EH-domain containing 4 (EHD4), mRNA. 
8098439 EPCAM 2.0 30.9 1.0 24.8 1.8 28.9 0.5 17.5   epithelial cell adhesion molecule (EPCAM), mRNA. 
8127778 FAM46A 1.3 1.8 2.1 2.4 1.4 1.2 1.5 2.0   family with sequence similarity 46, member A (FAM46A), mRNA. 
7904361 FAM46C 3.8 2.6 1.1 1.2 1.6 1.7 1.7 1.9   family with sequence similarity 46, member C (FAM46C), mRNA. 
8152812 FAM84B 2.3 2.5 1.2 1.5 1.0 1.1 1.0 0.9   family with sequence similarity 84, member B (FAM84B), mRNA. 
8119198 FTSJD2 2.8 1.9 2.1 2.3 1.2 1.3 1.5 2.0   FtsJ methyltransferase domain containing 2 (FTSJD2), mRNA. 
8142687 GPR37 2.7 3.0 1.3 1.9 1.3 1.5 1.1 1.4   G protein-coupled receptor 37 (endothelin receptor type B-like) (GPR37), mRNA. 
7917472 GTF2B 2.5 2.5 1.3 1.4 1.8 1.8 1.4 1.9   general transcription factor IIB (GTF2B), mRNA. 
8072926 H1F0 1.2 1.0 2.2 2.5 1.0 1.2 1.8 1.9   H1 histone family, member 0 (H1F0), mRNA. 
8096361 HERC5 8.2 8.0 13.1 9.3 1.1 0.6 2.1 1.9   hect domain and RLD 5 (HERC5), mRNA. 
7919619 HIST2H2AA3 1.7 2.3 2.4 3.2 0.9 1.6 1.3 2.2   histone cluster 2, H2aa3 (HIST2H2AA3), mRNA. 
8026533 HSH2D 3.8 5.7 3.0 6.4 1.2 1.8 1.7 3.4   hematopoietic SH2 domain containing (HSH2D), mRNA. 
7914127 IFI6 2.2 1.8 3.0 3.0 1.5 0.5 1.9 2.0   interferon, alpha-inducible protein 6 (IFI6), transcript variant 1, mRNA. 
8132694 IGFBP1 2.4 2.5 0.9 1.5 1.8 1.8 1.1 1.3   insulin-like growth factor binding protein 1 (IGFBP1), mRNA. 
7913768 IL22RA1 3.5 3.9 1.8 5.0 0.7 1.8 1.5 2.2   interleukin 22 receptor, alpha 1 (IL22RA1), mRNA. 
7924058 IRF6 2.9 4.7 1.2 3.1 0.9 2.8 0.4 2.4   interferon regulatory factor 6 (IRF6), mRNA. 
7945462 IRF7 4.0 2.6 2.7 2.5 1.3 1.0 1.4 1.5   interferon regulatory factor 7 (IRF7), transcript variant d, mRNA. 
7936242 ITPRIP 2.9 3.3 1.6 2.0 1.8 1.7 1.7 1.6   inositol 1,4,5-triphosphate receptor interacting protein (ITPRIP), mRNA. 
7992685 KCTD5 2.2 2.4 1.2 1.7 1.5 2.1 0.9 1.6   potassium channel tetramerisation domain containing 5 (KCTD5), mRNA. 
8093230 KIAA0226 2.3 3.6 1.2 2.1 1.5 2.1 1.5 2.1   KIAA0226 (KIAA0226), transcript variant 1, mRNA. 
7926679 KIAA1217 2.8 3.0 1.3 1.7 1.9 2.0 1.7 1.8   KIAA1217 (KIAA1217), transcript variant 1, mRNA. 
8015133 KRT23 1.8 22.7 2.2 30.2 0.6 15.6 1.1 10.2   keratin 23 (histone deacetylase inducible) (KRT23), mRNA. 
7994237 LCMT1 2.3 2.9 1.1 1.5 1.2 1.5 1.2 2.2   leucine carboxyl methyltransferase 1 (LCMT1), transcript variant 1, mRNA. 
8018975 LGALS3BP 1.8 1.2 2.2 2.3 1.4 0.8 1.9 1.9   lectin, galactoside-binding, soluble, 3 binding protein (LGALS3BP), mRNA. 
8097773 MAB21L2 9.4 2.1 2.4 1.2 1.5 1.2 1.7 1.3   mab-21-like 2 (C. elegans) (MAB21L2), mRNA. 
8131091 MAFK 2.1 2.5 1.2 2.0 1.5 1.9 0.7 1.4   v-maf musculoaponeurotic fibrosarcoma oncogene homolog K (avian) (MAFK), mRNA. 
7926821 MASTL 2.3 3.1 2.4 3.1 1.1 1.1 1.4 1.5   microtubule associated serine/threonine kinase-like (MASTL), transcript variant 1, mRNA. 
8118116 MICB 2.2 3.3 1.3 2.0 1.4 2.3 1.8 2.7   MHC class I polypeptide-related sequence B (MICB), mRNA. 
7915861 MOBKL2C 3.3 2.8 1.6 1.6 2.0 1.8 2.0 1.8   MOB1, Mps One Binder kinase activator-like 2C (yeast) (MOBKL2C), transcript variant 1, mRNA. 
8151334 MSC 2.0 4.2 1.4 5.0 1.5 2.7 1.1 4.0   musculin (MSC), mRNA. 
8042503 MXD1 2.2 2.9 1.3 1.7 1.5 1.6 1.8 2.8   MAX dimerization protein 1 (MXD1), mRNA. 
8078729 MYD88 3.1 3.4 1.9 2.5 1.4 1.7 1.7 2.0   myeloid differentiation primary response gene (88) (MYD88), transcript variant 1, mRNA. 
8001317 N4BP1 2.1 2.2 2.2 2.3 1.4 1.7 1.7 2.1   NEDD4 binding protein 1 (N4BP1), mRNA. 
8031899 NA 2.4 2.5 1.5 2.1 1.3 1.5 1.4 1.6   similar to envelope protein, mRNA (cDNA clone MGC:16737 IMAGE:4129886), complete cds. 
8037913 NAPA 2.1 2.3 1.8 2.4 1.4 1.5 1.5 1.9   N-ethylmaleimide-sensitive factor attachment protein, alpha (NAPA), mRNA. 
8063955 OGFR 3.5 3.7 1.7 2.2 1.7 2.0 1.7 2.3   opioid growth factor receptor (OGFR), mRNA. 
8090018 PARP9 1.5 1.5 2.4 2.2 1.6 1.2 1.6 1.7   poly (ADP-ribose) polymerase family, member 9 (PARP9), transcript variant 1, mRNA. 
7899455 PHACTR4 2.4 2.8 1.7 2.1 1.4 1.7 1.5 1.9   phosphatase and actin regulator 4 (PHACTR4), transcript variant 1, mRNA. 
8038225 PLEKHA4 5.3 4.4 2.3 2.3 1.7 1.2 1.5 1.9   pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 4 (PLEKHA4), transcript variant 1, mRNA. 
8052331 PNPT1 1.7 2.8 3.8 4.6 1.1 1.3 0.9 1.6   polyribonucleotide nucleotidyltransferase 1 (PNPT1), mRNA. 
7941214 POLA2 2.8 2.0 1.3 1.4 1.0 1.0 1.1 0.9   polymerase (DNA directed), alpha 2 (70kD subunit) (POLA2), mRNA. 
8037794 PRKD2 5.0 4.8 2.2 2.8 1.4 1.4 1.2 1.5   protein kinase D2 (PRKD2), transcript variant 1, mRNA. 
8132031 PRR15 2.7 3.6 1.0 1.2 1.1 1.2 1.6 1.7   proline rich 15 (PRR15), mRNA. 
8090529 RAB43 2.4 2.0 1.0 1.2 1.3 1.2 1.6 1.7   RAB43, member RAS oncogene family (RAB43), mRNA. 
7941865 RAD9A 2.7 2.6 1.2 1.4 1.1 1.0 1.2 1.7   RAD9 homolog A (S. pombe) (RAD9A), mRNA. 
7927120 RET 6.8 3.9 3.4 3.9 1.5 1.0 1.7 1.6   ret proto-oncogene (RET), transcript variant 2, mRNA. 
8116622 RIPK1 2.7 2.2 1.6 1.7 1.7 2.0 1.9 2.7   receptor (TNFRSF)-interacting serine-threonine kinase 1 (RIPK1), mRNA. 
7920297 S100A14 2.6 3.7 1.1 1.8 1.5 3.2 1.2 2.1   S100 calcium binding protein A14 (S100A14), mRNA. 
8064418 SDCBP2 2.1 3.4 1.1 2.4 1.3 2.9 0.9 1.9   syndecan binding protein (syntenin) 2 (SDCBP2), transcript variant 1, mRNA. 
8123598 SERPINB1 2.1 2.1 1.0 1.3 1.3 1.5 1.2 1.9   serpin peptidase inhibitor, clade B (ovalbumin), member 1 (SERPINB1), mRNA. 
8021635 SERPINB2 1.1 41.3 2.2 51.3 0.7 41.2 0.7 25.2   serpin peptidase inhibitor, clade B (ovalbumin), member 2 (SERPINB2), transcript variant 1, mRNA. 
8081710 SIDT1 6.0 5.1 2.1 2.7 1.1 0.9 1.7 1.6   SID1 transmembrane family, member 1 (SIDT1), mRNA. 
8068810 SLC37A1 2.3 2.4 1.5 1.7 1.6 2.5 1.6 2.9   solute carrier family 37 (glycerol-3-phosphate transporter), member 1 (SLC37A1), mRNA. 
7984364 SMAD3 2.2 2.2 1.5 2.0 1.2 1.5 1.1 1.6   SMAD family member 3 (SMAD3), transcript variant 1, mRNA. 
8048926 SP140L 2.8 2.3 1.7 1.5 1.9 1.6 1.6 2.0   SP140 nuclear body protein-like (SP140L), mRNA. 
7914904 STK40 2.1 2.2 0.9 1.4 1.2 1.7 0.9 1.5   serine/threonine kinase 40 (STK40), mRNA. 
7916584 TACSTD2 2.0 11.1 1.8 7.7 0.8 6.3 0.8 6.1   tumor-associated calcium signal transducer 2 (TACSTD2), mRNA. 
7971813 THSD1 2.4 2.7 1.3 1.5 1.4 1.6 1.4 1.8   thrombospondin, type I, domain containing 1 (THSD1), transcript variant 1, mRNA. 
8032899 TICAM1 2.1 3.0 1.3 2.5 1.3 1.9 1.5 2.0   toll-like receptor adaptor molecule 1 (TICAM1), mRNA. 
7978208 TINF2 2.7 2.7 1.3 1.5 1.1 1.3 1.3 1.4   TERF1 (TRF1)-interacting nuclear factor 2 (TINF2), transcript variant 2, mRNA. 
8098611 TLR3 0.9 0.7 2.4 2.5 1.0 0.6 1.6 1.3   toll-like receptor 3 (TLR3), mRNA. 
7966448 TMEM116 2.6 2.1 1.7 2.0 0.9 0.9 1.0 1.1   transmembrane protein 116 (TMEM116), mRNA. 
8106170 TMEM171 3.5 2.3 1.3 1.2 0.9 0.9 1.8 2.3   transmembrane protein 171 (TMEM171), transcript variant 1, mRNA. 
7983157 TMEM62 2.2 2.1 1.9 2.1 1.1 1.0 1.5 1.6   transmembrane protein 62 (TMEM62), mRNA. 
8008289 TMEM92 2.6 3.9 1.3 3.6 1.1 2.1 1.0 1.9   transmembrane protein 92 (TMEM92), transcript variant 1, mRNA. 
8149762 TNFRSF10A 2.3 3.2 1.4 2.6 1.3 2.2 0.9 1.5   tumor necrosis factor receptor superfamily, member 10a (TNFRSF10A), mRNA. 
8163825 TRAF1 3.1 3.3 2.0 3.3 2.1 1.7 1.3 1.7   TNF receptor-associated factor 1 (TRAF1), mRNA. 
8086125 TRANK1 3.7 3.4 2.0 1.9 1.4 0.9 1.3 1.3   tetratricopeptide repeat and ankyrin repeat containing 1 (TRANK1), mRNA. 
8016847 TRIM25 2.3 2.1 1.4 1.5 1.8 2.0 1.6 2.2   tripartite motif-containing 25 (TRIM25), mRNA. 
8179638 TRIM26 2.9 2.8 1.5 1.6 1.4 1.6 1.8 2.0   tripartite motif-containing 26 (TRIM26), mRNA. 
8117321 TRIM38 3.1 3.8 2.1 2.1 1.6 1.1 2.3 1.7   tripartite motif-containing 38 (TRIM38), mRNA. 
8135064 TRIM56 3.0 2.8 1.5 1.5 2.1 1.7 1.4 1.5   tripartite motif-containing 56 (TRIM56), mRNA. 
7905428 TUFT1 2.5 2.4 1.3 1.8 1.3 1.3 0.7 0.9   tuftelin 1 (TUFT1), transcript variant 1, mRNA. 
8087485 UBA7 3.2 1.9 2.6 3.0 0.9 0.5 1.1 0.8   ubiquitin-like modifier activating enzyme 7 (UBA7), mRNA. 
7949904 UNC93B1 2.9 2.8 2.5 3.0 1.1 0.8 1.8 1.9   unc-93 homolog B1 (C. elegans) (UNC93B1), mRNA. 
7921738 USF1 2.9 3.2 1.4 1.8 1.6 1.5 1.8 2.0   upstream transcription factor 1 (USF1), transcript variant 1, mRNA. 
8131387 USP42 2.2 2.6 1.6 1.8 1.8 2.5 1.8 2.1   ubiquitin specific peptidase 42 (USP42), mRNA. 
8108631 VTRNA1-3 2.2 2.1 1.6 1.2 1.2 1.4 1.9 1.1   vault RNA 1-3 (VTRNA1-3), non-coding RNA. 
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8084232 YEATS2 2.1 2.0 1.5 1.5 1.4 1.2 1.4 1.6   YEATS domain containing 2 (YEATS2), mRNA. 
8067221 ZBP1 7.0 4.8 3.5 5.3 1.3 1.4 1.2 2.7   Z-DNA binding protein 1 (ZBP1), transcript variant 1, mRNA. 
7979757 ZFYVE26 2.5 2.3 1.3 1.3 1.2 1.0 1.5 1.2   zinc finger, FYVE domain containing 26 (ZFYVE26), mRNA. 
 > 2-fold induced in both donors IFN-alpha and in IFN-gamma
IFN-alpha IFN-gamma
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7922598 ANGPTL1 1.6 1.1 5.8 4.1 1.5 0.7 2.7 2.2   angiopoietin-like 1 (ANGPTL1), mRNA. 
8073081 APOBEC3F 5.3 4.2 2.0 2.7 1.4 1.2 2.5 3.3   apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F (APOBEC3F), transcript variant 1, mRNA. 
8073088 APOBEC3G 10.2 6.4 3.7 5.3 1.4 0.9 4.4 5.8   apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G), mRNA. 
8072735 APOL1 2.7 2.1 1.9 1.9 2.5 1.7 3.3 4.1   apolipoprotein L, 1 (APOL1), transcript variant 2, mRNA. 
8075720 APOL2 4.0 3.5 1.6 1.7 2.3 2.6 2.5 3.6   apolipoprotein L, 2 (APOL2), transcript variant alpha, mRNA. 
8075695 APOL3 6.4 4.3 2.9 2.9 5.8 3.8 9.4 8.3   apolipoprotein L, 3 (APOL3), transcript variant alpha/a, non-coding RNA. 
8075709 APOL4 2.6 4.9 1.2 2.1 6.2 3.2 20.9 22.5   apolipoprotein L, 4 (APOL4), transcript variant a, mRNA. 
8072108 ASPHD2 2.2 2.5 0.9 1.1 1.4 1.6 2.2 3.4   aspartate beta-hydroxylase domain containing 2 (ASPHD2), mRNA. 
7909610 ATF3 6.2 3.2 1.5 2.4 4.5 2.7 2.5 3.2   activating transcription factor 3 (ATF3), transcript variant 4, mRNA. 
7949340 BATF2 14.2 21.6 6.0 9.2 10.7 13.3 14.6 19.9   basic leucine zipper transcription factor, ATF-like 2 (BATF2), mRNA. 
7953993 BCL2L14 7.1 8.6 1.7 2.6 5.4 4.8 6.3 9.8   BCL2-like 14 (apoptosis facilitator) (BCL2L14), transcript variant 2, mRNA. 
8117435 BTN3A2 2.0 0.9 2.5 2.3 1.1 0.7 3.1 2.7   butyrophilin, subfamily 3, member A2 (BTN3A2), mRNA. 
8025551 C19orf66 3.5 2.7 2.5 3.1 1.2 1.3 2.2 2.3   chromosome 19 open reading frame 66 (C19orf66), mRNA. 
8094550 C4orf19 2.1 2.5 1.0 2.1 2.2 3.3 2.0 3.6   chromosome 4 open reading frame 19 (C4orf19), transcript variant 1, mRNA. 
8047403 CASP10 3.1 2.7 1.5 1.5 2.2 2.4 3.2 6.0   caspase 10, apoptosis-related cysteine peptidase (CASP10), transcript variant D, mRNA. 
8096808 CCDC109B 2.3 2.2 1.6 1.6 2.3 2.5 4.6 6.8   coiled-coil domain containing 109B (CCDC109B), mRNA. 
8006453 CCL8 33.6 1.9 18.4 1.0 20.1 3.9 34.0 42.4   chemokine (C-C motif) ligand 8 (CCL8), mRNA. 
8122334 CCRL1 3.0 3.0 4.3 8.0 3.9 4.0 58.3 65.3   chemokine (C-C motif) receptor-like 1 (CCRL1), transcript variant 1, mRNA. 
8154233 CD274 8.4 18.2 4.1 9.0 24.7 30.6 21.7 41.5   CD274 molecule (CD274), mRNA. 
8063156 CD40 2.2 2.5 1.6 2.3 1.9 2.2 3.7 6.2   CD40 molecule, TNF receptor superfamily member 5 (CD40), transcript variant 1, mRNA. 
8050102 CMPK2 14.7 12.5 10.3 11.1 7.4 5.0 9.4 10.2   cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial (CMPK2), nuclear gene encoding mitochondrial protein, mRNA. 
8062409 CTNNBL1 2.5 2.2 1.2 1.3 1.5 1.2 2.0 2.1   catenin, beta like 1 (CTNNBL1), mRNA. 
7996027 CX3CL1 7.9 9.9 2.5 3.6 10.3 12.5 8.1 13.7   chemokine (C-X3-C motif) ligand 1 (CX3CL1), mRNA. 
8101126 CXCL10 64.6 63.9 45.6 58.2 67.3 69.2 76.8 80.2   chemokine (C-X-C motif) ligand 10 (CXCL10), mRNA. 
8101131 CXCL11 29.7 24.4 35.0 35.6 49.1 35.8 75.1 69.3   chemokine (C-X-C motif) ligand 11 (CXCL11), mRNA. 
8101118 CXCL9 16.5 5.5 6.6 2.8 157.5 113.8 265.2 265.9   chemokine (C-X-C motif) ligand 9 (CXCL9), mRNA. 
7990391 CYP1A1 2.5 4.2 0.9 0.7 5.1 4.3 0.4 0.4   cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), mRNA. 
8157610 DAB2IP 2.7 3.3 1.3 2.1 1.6 2.5 2.0 2.6   DAB2 interacting protein (DAB2IP), transcript variant 1, mRNA. 
8160559 DDX58 3.8 4.1 6.6 6.4 5.1 3.0 3.3 5.1   DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 (DDX58), mRNA. 
8103563 DDX60 2.9 1.7 8.7 9.7 4.7 2.3 9.8 8.9   DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (DDX60), mRNA. 
8103601 DDX60L 3.6 3.3 4.6 7.3 4.1 3.0 3.4 5.4   DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like (DDX60L), mRNA. 
7946478 DENND5A 3.0 2.7 1.5 1.3 2.3 1.7 2.1 2.1   DENN/MADD domain containing 5A (DENND5A), mRNA. 
8015511 DHX58 8.2 5.1 6.6 6.0 2.6 1.3 3.6 3.4   DEXH (Asp-Glu-X-His) box polypeptide 58 (DHX58), mRNA. 
8051501 EIF2AK2 1.9 2.3 3.6 3.4 2.0 1.5 2.0 2.6   eukaryotic translation initiation factor 2-alpha kinase 2 (EIF2AK2), transcript variant 1, mRNA. 
7943293 ENDOD1 2.4 3.2 1.3 1.7 2.6 5.4 2.4 5.5   endonuclease domain containing 1 (ENDOD1), mRNA. 
7971296 EPSTI1 5.9 6.2 6.9 9.6 4.5 3.2 8.7 11.1   epithelial stromal interaction 1 (breast) (EPSTI1), transcript variant 1, mRNA. 
8107044 ERAP2 1.2 4.7 2.5 11.2 2.7 9.0 2.9 11.1   endoplasmic reticulum aminopeptidase 2 (ERAP2), transcript variant 1, mRNA. 
7953981 ETV6 2.8 3.0 1.3 1.0 2.1 2.0 2.3 2.0   ets variant 6 (ETV6), mRNA. 
8125993 ETV7 4.5 3.8 2.3 2.4 3.4 3.0 6.5 6.1   ets variant 7 (ETV7), mRNA. 
8169995 FAM122C 4.2 4.1 2.0 2.9 1.2 1.4 2.3 2.4   family with sequence similarity 122C (FAM122C), transcript variant 1, mRNA. 
8030339 FLT3LG 2.2 2.1 1.6 1.8 1.5 1.5 2.1 2.0   fms-related tyrosine kinase 3 ligand (FLT3LG), mRNA. 
8105302 FST 1.9 2.5 2.0 3.4 2.2 2.9 3.9 7.0   follistatin (FST), transcript variant FST317, mRNA. 
8041542 GALM 3.5 2.2 1.3 1.3 1.0 0.6 2.1 2.2   galactose mutarotase (aldose 1-epimerase) (GALM), mRNA. 
7917503 GBP3 1.1 1.1 2.7 3.1 2.1 2.0 3.4 4.4   guanylate binding protein 3 (GBP3), mRNA. 
7917561 GBP4 20.3 18.4 6.6 6.7 29.6 27.3 38.7 51.0   guanylate binding protein 4 (GBP4), mRNA. 
7917576 GBP5 12.7 4.0 4.3 1.9 50.6 9.8 225.5 153.9   guanylate binding protein 5 (GBP5), transcript variant 1, mRNA. 
8117034 GMPR 6.1 4.5 3.1 3.6 1.2 1.0 2.2 2.9   guanosine monophosphate reductase (GMPR), mRNA. 
8073039 GTPBP1 3.1 2.8 1.8 2.4 1.8 1.8 2.0 2.2   GTP binding protein 1 (GTPBP1), mRNA. 
8118111 HCP5 1.0 0.6 2.6 2.9 0.8 0.6 2.6 2.6   HLA complex P5 (HCP5), mRNA. 
8090193 HEG1 2.6 4.1 1.1 2.3 2.2 3.2 1.9 4.1   HEG homolog 1 (zebrafish) (HEG1), mRNA. 
8096335 HERC6 4.9 4.2 7.9 7.3 2.6 1.5 4.7 6.2   hect domain and RLD 6 (HERC6), transcript variant 1, mRNA. 
7948982 HRASLS2 11.5 5.4 14.2 14.4 1.4 1.0 5.8 4.5   HRAS-like suppressor 2 (HRASLS2), mRNA. 
8146092 IDO1 54.8 4.7 6.4 1.5 122.2 21.8 522.6 447.3   indoleamine 2,3-dioxygenase 1 (IDO1), mRNA. 
7906400 IFI16 1.6 1.0 3.6 2.4 3.2 1.8 3.5 3.1   interferon, gamma-inducible protein 16 (IFI16), mRNA. 
7976443 IFI27 3.3 1.8 12.5 11.7 1.4 0.8 4.4 5.1   interferon, alpha-inducible protein 27 (IFI27), transcript variant 1, mRNA. 
8007446 IFI35 6.1 4.4 7.7 9.4 3.1 3.3 6.7 10.4   interferon-induced protein 35 (IFI35), mRNA. 
7902553 IFI44 7.1 6.1 16.8 14.4 5.0 1.0 6.8 5.7   interferon-induced protein 44 (IFI44), mRNA. 
7902541 IFI44L 16.2 8.7 50.1 41.1 11.0 2.0 30.8 22.2   interferon-induced protein 44-like (IFI44L), mRNA. 
8056285 IFIH1 4.1 4.2 8.6 7.0 4.1 2.0 5.6 6.1   interferon induced with helicase C domain 1 (IFIH1), mRNA. 
7929065 IFIT1 40.6 40.0 42.7 36.0 3.9 0.6 7.2 9.4   interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), transcript variant 2, mRNA. 
7929047 IFIT2 17.9 21.4 20.7 21.2 18.9 11.8 21.7 23.5   interferon-induced protein with tetratricopeptide repeats 2 (IFIT2), mRNA. 
7929052 IFIT3 7.8 9.2 9.2 9.1 9.6 7.5 9.4 9.9   interferon-induced protein with tetratricopeptide repeats 3 (IFIT3), transcript variant 2, mRNA. 
7929072 IFIT5 1.2 1.6 3.2 3.1 2.7 2.8 2.5 3.4   interferon-induced protein with tetratricopeptide repeats 5 (IFIT5), mRNA. 
7937335 IFITM1 10.0 5.5 17.5 13.6 3.5 1.7 14.2 10.7   interferon induced transmembrane protein 1 (9-27) (IFITM1), mRNA. 
7931899 IL15RA 2.7 2.9 1.7 1.9 2.0 2.2 2.1 2.4   interleukin 15 receptor, alpha (IL15RA), transcript variant 1, mRNA. 
8044574 IL1RN 11.7 4.9 2.9 3.6 2.3 2.0 3.4 5.0   interleukin 1 receptor antagonist (IL1RN), transcript variant 1, mRNA. 
8114010 IRF1 6.4 5.7 2.3 2.1 11.3 12.3 11.7 12.5   interferon regulatory factor 1 (IRF1), mRNA. 
8103911 IRF2 2.7 2.8 1.6 1.7 1.8 2.0 2.5 2.3   interferon regulatory factor 2 (IRF2), mRNA. 
7896817 ISG15 7.2 4.0 7.5 7.9 2.2 1.1 2.4 3.4   ISG15 ubiquitin-like modifier (ISG15), mRNA. 
7985777 ISG20 4.5 3.9 3.4 3.8 3.5 2.3 4.0 3.8   interferon stimulated exonuclease gene 20kDa (ISG20), mRNA. 
8028908 ITPKC 2.2 2.5 1.2 1.7 4.5 6.5 2.2 5.1   inositol 1,4,5-trisphosphate 3-kinase C (ITPKC), mRNA. 
7922474 KIAA0040 4.4 6.7 1.7 2.0 2.8 3.9 2.7 4.5   KIAA0040 (KIAA0040), transcript variant 2, mRNA. 
8092348 LAMP3 19.7 19.5 23.1 29.1 7.0 3.2 15.7 19.4   lysosomal-associated membrane protein 3 (LAMP3), mRNA. 
8094259 LAP3 2.9 2.7 3.2 3.1 2.6 2.0 4.5 4.7   leucine aminopeptidase 3 (LAP3), mRNA. 
8028744 LGALS17A 4.4 2.3 1.3 1.5 10.5 4.4 53.8 57.8   lectin, galactoside-binding, soluble, 14-like (LOC400696), mRNA. 
8005809 LGALS9 3.2 1.8 5.6 4.6 0.9 0.6 2.6 2.8   lectin, galactoside-binding, soluble, 9 (LGALS9), transcript variant 1, mRNA. 
8013450 LGALS9B 3.5 2.1 5.4 5.3 1.1 0.8 3.0 3.2   lectin, galactoside-binding, soluble, 9B (LGALS9B), mRNA. 
8005458 LGALS9C 3.5 2.2 5.2 4.8 1.1 0.8 2.9 3.0   lectin, galactoside-binding, soluble, 9C (LGALS9C), mRNA. 
7975687 LIN52 3.9 3.1 1.7 1.8 2.2 2.3 3.4 4.7   lin-52 homolog (C. elegans) (LIN52), mRNA. 
8148572 LY6E 2.1 1.6 3.1 3.8 1.2 1.1 2.1 2.8   lymphocyte antigen 6 complex, locus E (LY6E), transcript variant 1, mRNA. 
8123606 MGC39372 2.8 2.0 1.3 1.8 1.0 1.1 2.5 2.8   hypothetical protein MGC39372, mRNA (cDNA clone IMAGE:5089466), complete cds. 
8002778 MLKL 3.7 4.1 2.7 3.0 3.0 3.1 3.9 5.3   mixed lineage kinase domain-like (MLKL), transcript variant 1, mRNA. 
8090180 MUC13 1.2 1.3 2.3 3.6 0.9 1.0 3.1 2.9   mucin 13, cell surface associated (MUC13), mRNA. 
8068713 MX1 5.9 4.7 4.9 4.9 3.1 1.7 3.7 4.1   myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) (MX1), transcript variant 2, mRNA. 
8068697 MX2 36.5 18.1 49.7 40.9 4.8 1.3 10.2 15.3   myxovirus (influenza virus) resistance 2 (mouse) (MX2), mRNA. 
8027377 NA 8.8 2.0 3.3 1.8 2.8 0.9 6.3 3.0   cDNA FLJ16183 fis, clone BRTHA2002702. 
8048976 NA 1.0 0.9 2.9 2.4 3.2 1.4 4.5 2.6  ncrna:misc_RNA chromosome:GRCh37:2:231371816:231372099:1 gene:ENSG00000222252 
7995926 NLRC5 4.8 4.8 2.4 2.8 3.0 3.0 3.8 3.5   NLR family, CARD domain containing 5 (NLRC5), mRNA. 
8055702 NMI 2.5 2.4 2.8 2.5 3.1 1.9 3.4 3.2   N-myc (and STAT) interactor (NMI), mRNA. 
7995539 NOD2 2.7 2.1 1.4 1.7 2.3 1.7 2.0 3.1   nucleotide-binding oligomerization domain containing 2 (NOD2), mRNA. 
7912520 NPPB 2.4 7.5 1.6 4.4 2.6 6.7 0.9 2.6   natriuretic peptide precursor B (NPPB), mRNA. 
8180396 NT5C3 2.4 3.8 4.1 3.9 2.3 1.5 2.7 3.2   5'-nucleotidase, cytosolic III (NT5C3), transcript variant 1, mRNA 
8180397 NT5C3 3.1 5.0 5.9 6.2 3.1 1.8 3.9 4.3   5'-nucleotidase, cytosolic III (NT5C3), transcript variant 3, mRNA 
7923753 NUAK2 2.3 5.4 1.4 2.9 2.8 3.9 1.2 2.5   NUAK family, SNF1-like kinase, 2 (NUAK2), mRNA. 
8137414 NUB1 2.7 2.6 2.2 1.9 1.9 2.0 2.4 2.8   negative regulator of ubiquitin-like proteins 1 (NUB1), mRNA. 
7958884 OAS1 6.1 4.4 6.6 6.2 1.9 1.1 4.1 4.1   2',5'-oligoadenylate synthetase 1, 40/46kDa (OAS1), transcript variant 1, mRNA. 
7958913 OAS2 6.1 4.9 7.0 7.5 2.9 1.7 5.0 6.0   2'-5'-oligoadenylate synthetase 2, 69/71kDa (OAS2), transcript variant 2, mRNA. 
7958895 OAS3 5.8 4.0 7.3 6.7 3.0 1.6 5.4 5.8   2'-5'-oligoadenylate synthetase 3, 100kDa (OAS3), mRNA. 
7967117 OASL 25.3 22.1 16.4 21.4 4.4 2.4 7.5 10.1   2'-5'-oligoadenylate synthetase-like (OASL), transcript variant 1, mRNA. 
8082100 PARP14 1.1 1.1 2.9 2.9 3.5 2.6 3.8 4.2   poly (ADP-ribose) polymerase family, member 14 (PARP14), mRNA. 
8154245 PDCD1LG2 2.3 2.6 3.7 4.3 4.0 3.8 12.3 9.2   programmed cell death 1 ligand 2 (PDCD1LG2), mRNA. 
8108080 PHF15 3.5 2.8 2.3 2.2 1.2 1.0 2.3 2.2   PHD finger protein 15 (PHF15), mRNA. 
8027398 PLEKHF1 2.2 2.5 1.1 1.6 2.3 2.2 2.0 2.1   pleckstrin homology domain containing, family F (with FYVE domain) member 1 (PLEKHF1), mRNA. 
8091327 PLSCR1 1.8 2.0 3.4 3.1 2.5 2.1 3.0 3.3   phospholipid scramblase 1 (PLSCR1), mRNA. 
7984779 PML 3.9 4.3 2.1 3.1 2.6 2.8 3.2 4.1   promyelocytic leukemia (PML), transcript variant 2, mRNA. 
8067680 PRIC285 5.1 4.6 3.1 3.8 2.6 2.0 2.2 2.9   peroxisomal proliferator-activated receptor A interacting complex 285 (PRIC285), transcript variant 1, mRNA. 
8062108 PROCR 2.0 3.9 2.0 4.9 1.7 2.5 3.8 6.1   protein C receptor, endothelial (EPCR) (PROCR), mRNA. 
8178211 PSMB9 3.2 3.0 3.4 4.5 2.5 2.3 5.2 6.1   proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2) (PSMB9), mRNA. 
7962884 RND1 6.2 2.5 1.1 2.1 2.6 2.4 1.3 2.1   Rho family GTPase 1 (RND1), mRNA. 
8063369 RNF114 2.3 2.4 1.6 1.5 1.9 2.0 2.2 2.4   ring finger protein 114 (RNF114), mRNA. 
8150186 RNF122 6.1 8.8 1.8 2.2 2.9 3.1 1.3 4.0   ring finger protein 122 (RNF122), mRNA. 
7914603 RNF19B 4.2 4.8 1.7 2.2 4.3 4.9 4.0 5.7   ring finger protein 19B (RNF19B), transcript variant 1, mRNA. 
8010426 RNF213 3.5 3.8 2.4 2.6 3.4 2.8 4.1 4.0   ring finger protein 213 (RNF213), transcript variant 1, mRNA. 
8064766 RNF24 3.0 2.3 1.1 1.3 2.2 2.2 2.3 2.6   ring finger protein 24 (RNF24), transcript variant 3, mRNA. 
8040080 RSAD2 104.5 119.5 88.3 114.3 30.4 13.8 29.7 57.6   radical S-adenosyl methionine domain containing 2 (RSAD2), mRNA. 
8079415 RTP3 3.7 3.3 1.5 1.2 2.0 2.1 0.7 0.7   receptor (chemosensory) transporter protein 3 (RTP3), mRNA. 
8084732 RTP4 12.8 11.9 10.6 9.8 5.8 4.8 6.6 6.8   receptor (chemosensory) transporter protein 4 (RTP4), mRNA. 
8140967 SAMD9 1.4 0.8 9.1 9.7 2.3 0.5 3.3 3.8   sterile alpha motif domain containing 9 (SAMD9), mRNA. 
8140971 SAMD9L 1.1 0.6 7.6 7.0 5.5 2.0 8.9 9.4   sterile alpha motif domain containing 9-like (SAMD9L), mRNA. 
8066117 SAMHD1 2.7 2.6 4.3 3.8 2.4 1.8 5.2 5.2   SAM domain and HD domain 1 (SAMHD1), mRNA. 
8019486 SECTM1 14.9 15.9 5.7 11.5 8.7 13.6 33.4 49.3   secreted and transmembrane 1 (SECTM1), mRNA. 
8123609 SERPINB9 3.2 2.2 1.0 0.8 2.4 2.0 1.0 0.9   serpin peptidase inhibitor, clade B (ovalbumin), member 9 (SERPINB9), mRNA. 
7948493 SLC15A3 4.3 2.7 5.6 6.0 2.3 1.1 4.1 3.7   solute carrier family 15, member 3 (SLC15A3), transcript variant 1, mRNA. 
7935639 SLC25A28 5.4 5.1 2.9 2.7 3.5 2.8 3.7 4.4   solute carrier family 25, member 28 (SLC25A28), mRNA. 
8006531 SLFN5 4.0 6.2 3.4 5.1 3.6 4.4 3.2 6.0   schlafen family member 5 (SLFN5), mRNA. 
7999423 SOCS1 4.8 6.0 1.5 2.1 4.4 4.9 8.1 10.8   suppressor of cytokine signaling 1 (SOCS1), mRNA. 
8059650 SP110 5.0 5.4 4.5 6.0 3.7 3.7 4.3 6.1   SP110 nuclear body protein (SP110), transcript variant c, mRNA. 
7990839 STARD5 6.0 5.3 2.5 3.2 1.9 2.1 3.4 5.9   StAR-related lipid transfer (START) domain containing 5 (STARD5), mRNA. 
8057744 STAT1 2.6 2.3 3.6 3.4 2.5 2.0 3.5 2.9   signal transducer and activator of transcription 1, 91kDa (STAT1), transcript variant alpha, mRNA. 
7964119 STAT2 5.6 4.7 3.6 4.0 2.8 2.2 5.2 5.8   signal transducer and activator of transcription 2, 113kDa (STAT2), transcript variant 1, mRNA. 
8140840 STEAP4 24.9 3.7 1.0 1.6 61.6 27.7 33.7 95.7   STEAP family member 4 (STEAP4), mRNA. 
8125512 TAP1 3.8 4.1 2.5 3.6 4.0 3.9 4.9 5.5   transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) (TAP1), mRNA. 
8180034 TAP2 3.1 3.1 2.6 3.8 2.6 2.9 4.6 5.8   transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) (TAP2), transcript variant 1, mRNA. 
8178841 TAP2 3.0 3.1 2.6 3.7 2.6 2.9 4.5 5.7   transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) (TAP2), transcript variant 2, mRNA. 
8156688 TDRD7 3.2 3.5 2.7 3.1 2.0 1.6 2.2 2.6   tudor domain containing 7 (TDRD7), mRNA. 
7915718 TESK2 4.1 3.5 1.3 1.6 5.8 4.0 4.5 6.7   testis-specific kinase 2 (TESK2), mRNA. 
8156060 TLE4 6.7 6.7 2.3 2.8 1.3 1.3 2.2 2.8   transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) (TLE4), mRNA. 
8019622 TMEM106A 4.0 10.6 1.4 6.1 1.3 5.1 2.2 6.6   transmembrane protein 106A (TMEM106A), mRNA. 
8088054 TMEM110 3.3 3.9 1.7 2.5 1.2 1.4 2.0 2.5   transmembrane protein 110 (TMEM110), mRNA. 
8136388 TMEM140 3.1 3.2 2.5 3.1 2.5 2.8 3.1 3.7   transmembrane protein 140 (TMEM140), mRNA. 
8070584 TMPRSS3 2.2 2.5 1.6 2.5 2.1 4.3 5.0 8.3   transmembrane protease, serine 3 (TMPRSS3), transcript variant A, mRNA. 
8122265 TNFAIP3 2.8 2.0 1.6 1.5 2.3 1.2 2.3 2.1   tumor necrosis factor, alpha-induced protein 3 (TNFAIP3), mRNA. 
8092169 TNFSF10 8.5 8.7 5.9 4.9 4.9 3.0 9.7 9.2   tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10), mRNA. 
7969986 TNFSF13B 3.9 3.9 3.3 4.9 2.1 0.9 9.1 8.3   tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B), transcript variant 1, mRNA. 
7958828 TRAFD1 5.3 5.1 2.0 1.9 4.4 5.0 5.1 6.6   TRAF-type zinc finger domain containing 1 (TRAFD1), transcript variant 1, mRNA. 
8177760 TRIM15 2.2 3.1 1.1 1.4 5.6 7.3 3.9 6.2   tripartite motif-containing 15 (TRIM15), mRNA. 
7945962 TRIM21 3.3 2.9 2.3 2.5 2.0 2.7 2.1 2.8   tripartite motif-containing 21 (TRIM21), mRNA. 
7938035 TRIM22 1.9 1.7 2.8 2.7 2.1 1.2 3.2 3.1   tripartite motif-containing 22 (TRIM22), mRNA. 
7904726 TXNIP 3.0 3.0 2.2 3.0 1.2 0.8 2.5 2.8   thioredoxin interacting protein (TXNIP), mRNA. 
8178295 UBD 2.3 2.2 1.3 1.3 3.2 4.6 6.3 8.2   ubiquitin D (UBD), mRNA. 
7948274 UBE2L6 2.4 2.1 2.3 2.6 1.8 1.2 3.2 2.9   ubiquitin-conjugating enzyme E2L 6 (UBE2L6), transcript variant 1, mRNA. 
8071155 USP18 18.3 11.6 9.9 10.5 2.9 2.1 3.9 6.2   ubiquitin specific peptidase 18 (USP18), mRNA. 
7981290 WARS 3.9 3.1 1.8 2.6 4.8 4.3 7.9 8.3   tryptophanyl-tRNA synthetase (WARS), transcript variant 1, mRNA. 
7976766 WDR25 2.4 2.1 0.9 1.5 1.7 1.9 2.2 2.4   WD repeat domain 25 (WDR25), transcript variant 1, mRNA. 
8004184 XAF1 0.8 0.5 4.1 3.4 2.5 1.4 3.7 3.7   XIAP associated factor 1 (XAF1), transcript variant 1, mRNA. 
8051322 XDH 2.5 2.2 1.0 2.1 1.1 1.4 2.6 4.3   xanthine dehydrogenase (XDH), mRNA. 
8143279 ZC3HAV1 2.2 2.7 1.8 1.8 2.2 2.3 1.7 1.9   zinc finger CCCH-type, antiviral 1 (ZC3HAV1), transcript variant 1, mRNA. 
8057418 ZNF385B 2.6 2.0 1.4 1.6 1.7 1.3 3.6 2.2   zinc finger protein 385B (ZNF385B), transcript variant 1, mRNA. 
8066905 ZNFX1 4.5 4.3 3.0 3.2 2.9 3.0 2.8 3.2   zinc finger, NFX1-type containing 1 (ZNFX1), mRNA. 
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8017039 SEPT4 1.1 1.0 0.9 0.9 1.1 1.2 3.2 3.1   septin 4 (SEPT4), transcript variant 2, mRNA. 
8122807 AKAP12 1.0 1.6 1.1 2.1 4.0 4.6 2.7 4.4   A kinase (PRKA) anchor protein 12 (AKAP12), transcript variant 1, mRNA. 
8096919 ALPK1 2.6 1.7 1.6 0.9 3.3 1.5 5.2 4.1   alpha-kinase 1 (ALPK1), transcript variant 1, mRNA. 
7957861 ANO4 1.1 1.0 0.9 1.1 1.1 1.0 2.8 9.6   anoctamin 4 (ANO4), mRNA. 
8073072 APOBEC3D 3.5 1.8 1.9 1.9 1.2 1.4 3.1 2.6   apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D (APOBEC3D), mRNA. 
8072710 APOL6 1.7 1.5 1.4 1.3 2.4 2.3 2.5 2.7   apolipoprotein L, 6 (APOL6), mRNA. 
8099760 ARAP2 1.0 0.6 1.4 1.6 3.2 1.6 2.7 2.9   ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 (ARAP2), mRNA. 
7927732 ARID5B 0.7 0.7 1.3 2.0 2.2 2.4 1.6 1.9   AT rich interactive domain 5B (MRF1-like) (ARID5B), mRNA. 
7954527 ARNTL2 0.9 1.1 0.9 0.9 2.4 1.6 2.1 2.1   aryl hydrocarbon receptor nuclear translocator-like 2 (ARNTL2), mRNA. 
8125017 BAT5 1.6 1.6 1.3 1.8 1.3 1.4 2.3 2.3   HLA-B associated transcript 5 (BAT5), transcript variant 1, mRNA. 
8081465 BBX 0.4 0.2 1.5 1.2 1.5 0.9 2.1 2.1   bobby sox homolog (Drosophila) (BBX), transcript variant 1, mRNA. 
8092691 BCL6 1.3 1.0 1.3 1.3 1.9 1.9 2.4 2.4   B-cell CLL/lymphoma 6 (BCL6), transcript variant 1, mRNA. 
8117458 BTN3A1 2.0 1.4 1.6 1.9 0.9 0.7 2.6 2.3   butyrophilin, subfamily 3, member A1 (BTN3A1), transcript variant 4, mRNA. 
8117476 BTN3A3 1.8 0.9 1.8 1.7 1.0 0.6 3.2 2.6   butyrophilin, subfamily 3, member A3 (BTN3A3), transcript variant 1, mRNA. 
8107934 C5orf56 2.0 1.5 1.5 1.3 2.0 1.4 2.3 2.0   full length insert cDNA clone ZA99C08. 
8147112 CA13 1.8 2.1 0.9 1.0 3.0 3.2 2.1 3.3   carbonic anhydrase XIII (CA13), mRNA. 
8142585 CADPS2 0.9 1.0 1.2 1.9 1.5 1.1 2.0 2.9   Ca++-dependent secretion activator 2 (CADPS2), transcript variant 1, mRNA. 
8077944 CAND2 1.2 1.3 1.1 0.9 1.2 1.0 3.0 5.3   cullin-associated and neddylation-dissociated 2 (putative) (CAND2), transcript variant 1, mRNA. 
7999319 CARHSP1 1.6 1.2 0.9 0.8 1.5 1.9 2.3 3.8   calcium regulated heat stable protein 1, 24kDa (CARHSP1), transcript variant 1, mRNA. 
8023401 CCDC68 0.6 0.5 1.0 1.2 2.7 3.0 1.9 3.6   coiled-coil domain containing 68 (CCDC68), transcript variant 1, mRNA. 
8006433 CCL2 2.0 1.3 1.2 0.5 2.4 2.3 1.8 2.2   chemokine (C-C motif) ligand 2 (CCL2), mRNA. 
8097461 CCRN4L 1.9 2.9 1.1 1.9 2.3 2.6 1.7 2.5   CCR4 carbon catabolite repression 4-like (S. cerevisiae) (CCRN4L), mRNA. 
8094240 CD38 7.2 0.5 4.5 0.7 3.3 0.4 18.2 6.2   CD38 molecule (CD38), mRNA. 
8089299 CD47 1.4 1.7 1.9 2.2 1.9 2.1 2.8 3.6   CD47 molecule (CD47), transcript variant 1, mRNA. 
8115147 CD74 1.5 0.5 1.7 0.9 1.4 0.5 5.3 3.6   CD74 molecule, major histocompatibility complex, class II invariant chain (CD74), transcript variant 1, mRNA. 
8026300 CD97 1.3 3.2 1.3 4.1 1.2 3.5 2.2 4.6   CD97 molecule (CD97), transcript variant 1, mRNA. 
8060675 CDC25B 1.4 1.2 1.0 0.7 1.0 0.9 3.2 2.7   cell division cycle 25 homolog B (S. pombe) (CDC25B), transcript variant 1, mRNA. 
8086517 CDCP1 1.3 10.6 1.5 9.4 1.4 9.2 2.6 9.7   CUB domain containing protein 1 (CDCP1), transcript variant 1, mRNA. 
8136187 CPA2 1.3 1.3 1.0 1.4 1.7 2.1 3.6 18.9   carboxypeptidase A2 (pancreatic) (CPA2), mRNA. 
8103389 CTSO 0.9 0.9 1.5 1.3 1.4 1.1 3.5 3.1   cathepsin O (CTSO), mRNA. 
7919800 CTSS 1.4 0.9 1.6 1.0 1.6 0.9 3.4 2.8   cathepsin S (CTSS), mRNA. 
8079993 CYB561D2 2.0 1.9 1.0 1.5 2.3 2.8 1.7 3.4   cytochrome b-561 domain containing 2 (CYB561D2), mRNA. 
8051583 CYP1B1 1.4 2.0 0.9 0.6 3.7 2.6 1.7 1.0   cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1), mRNA. 
7958425 DAO 2.1 0.7 0.9 0.5 1.6 1.8 5.6 8.0   D-amino-acid oxidase (DAO), mRNA. 
7988350 DUOX2 1.0 1.6 1.1 1.2 1.1 1.7 7.6 30.2   dual oxidase 2 (DUOX2), mRNA. 
7983405 DUOXA2 1.3 1.9 1.0 1.2 1.6 2.0 6.7 10.7   dual oxidase maturation factor 2 (DUOXA2), mRNA. 
7965335 DUSP6 1.2 0.9 1.2 1.6 2.8 2.0 3.4 4.6   dual specificity phosphatase 6 (DUSP6), transcript variant 1, mRNA. 
8066716 ELMO2 2.6 1.9 1.3 1.5 1.5 1.2 2.1 2.2   engulfment and cell motility 2 (ELMO2), transcript variant 1, mRNA. 
8112274 ELOVL7 1.3 3.3 1.2 7.5 2.6 4.4 2.8 7.8   ELOVL family member 7, elongation of long chain fatty acids (yeast) (ELOVL7), transcript variant 1, mRNA. 
8136954 FAM115C 1.8 2.2 0.9 0.8 3.8 3.7 3.2 4.1   family with sequence similarity 115, member C (FAM115C), transcript variant 3, mRNA. 
8047565 FAM117B 1.1 0.9 1.1 1.1 2.2 2.2 5.3 3.0   family with sequence similarity 117, member B (FAM117B), mRNA. 
8017867 FAM20A 1.1 0.5 0.8 0.4 1.5 0.6 4.8 2.2   family with sequence similarity 20, member A (FAM20A), transcript variant 1, mRNA. 
8152703 FBXO32 2.7 1.3 1.8 1.1 1.4 0.8 3.8 2.7   F-box protein 32 (FBXO32), transcript variant 1, mRNA. 
7897728 FBXO6 2.2 1.8 1.6 1.8 1.5 1.3 2.5 2.8   F-box protein 6 (FBXO6), mRNA. 
8161964 FRMD3 0.9 1.5 0.9 1.7 0.9 1.3 3.4 4.4   FERM domain containing 3 (FRMD3), mRNA. 
8088745 FRMD4B 0.9 1.2 1.6 1.5 2.5 2.6 2.8 3.8   FERM domain containing 4B (FRMD4B), mRNA. 
7953943 GABARAPL1 1.6 1.4 1.1 0.8 2.0 2.1 2.2 2.6   GABA(A) receptor-associated protein like 1 (GABARAPL1), mRNA. 
7917516 GBP1 1.8 1.8 1.8 1.7 2.7 2.5 3.0 3.1   guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA. 
7917532 GBP2 2.6 1.2 1.3 0.7 5.1 2.6 5.5 5.1   guanylate binding protein 2, interferon-inducible (GBP2), mRNA. 
7917548 GBP7 1.3 1.3 0.9 0.7 2.2 1.3 3.7 3.4   guanylate binding protein 7 (GBP7), mRNA. 
8151816 GEM 2.7 1.9 1.4 2.4 3.4 2.3 0.8 1.2   GTP binding protein overexpressed in skeletal muscle (GEM), transcript variant 1, mRNA. 
7948344 GLYAT 1.2 0.7 0.5 0.3 2.3 1.6 4.0 4.4   glycine-N-acyltransferase (GLYAT), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 
8045336 GPR39 2.0 1.9 1.2 1.8 1.6 1.9 2.0 2.9   G protein-coupled receptor 39 (GPR39), mRNA. 
7995362 GPT2 2.2 1.9 1.1 1.6 1.7 1.4 2.9 4.2   glutamic pyruvate transaminase (alanine aminotransferase) 2 (GPT2), transcript variant 1, mRNA. 
8081758 GRAMD1C 0.7 0.4 1.2 0.9 1.2 0.7 2.2 2.6   GRAM domain containing 1C (GRAMD1C), transcript variant 1, mRNA. 
8014903 GSDMB 1.6 1.2 1.6 1.8 1.5 1.0 2.1 2.0   gasdermin B (GSDMB), transcript variant 3, mRNA. 
7991224 HAPLN3 1.8 2.0 1.1 1.0 4.3 5.8 6.0 11.8   hyaluronan and proteoglycan link protein 3 (HAPLN3), mRNA. 
8125537 HLA-DMA 1.3 0.6 1.3 0.9 1.0 0.7 8.6 6.9   major histocompatibility complex, class II, DM alpha (HLA-DMA), mRNA. 
8125530 HLA-DMB 1.1 0.8 1.2 0.6 0.8 0.6 11.2 6.2   major histocompatibility complex, class II, DM beta (HLA-DMB), mRNA. 
8178833 HLA-DOB 1.8 1.4 1.0 1.5 1.7 1.7 4.5 8.5   major histocompatibility complex, class II, DO beta (HLA-DOB), mRNA. 
8125556 HLA-DPA1 2.5 0.5 1.9 0.7 1.8 0.6 11.9 7.8   major histocompatibility complex, class II, DP alpha 1 (HLA-DPA1), mRNA. 
8179519 HLA-DPB1 1.7 0.8 1.2 0.7 1.3 1.0 7.5 3.8   major histocompatibility complex, class II, DP beta 1 (HLA-DPB1), mRNA. 
8125447 HLA-DQB1 2.5 1.0 1.9 1.0 1.9 0.8 14.7 9.9   major histocompatibility complex, class II, DQ beta 1 (HLA-DQB1), mRNA. 
8178193 HLA-DRA 2.7 0.3 2.4 0.5 2.7 0.4 17.3 10.0   major histocompatibility complex, class II, DR alpha (HLA-DRA), mRNA. 
8125436 HLA-DRB5 1.9 0.4 2.0 0.5 1.5 0.6 7.6 5.4   major histocompatibility complex, class II, DR beta 5 (HLA-DRB5), mRNA. 
8179103 HLA-E 2.0 1.8 1.9 2.0 1.6 1.3 2.2 2.4   major histocompatibility complex, class I, E (HLA-E), mRNA. 
8025601 ICAM1 1.6 1.6 1.3 1.1 3.8 3.8 3.0 4.2   intercellular adhesion molecule 1 (ICAM1), mRNA. 
7942300 IL18BP 2.2 1.6 1.9 1.9 2.2 1.7 5.8 6.3   interleukin 18 binding protein (IL18BP), transcript variant A, mRNA. 
7997712 IRF8 1.5 1.0 1.3 0.9 3.9 3.0 3.4 4.1   interferon regulatory factor 8 (IRF8), mRNA. 
8154178 JAK2 1.2 1.1 1.6 1.5 5.6 3.0 8.1 6.3   Janus kinase 2 (JAK2), mRNA. 
8163002 KLF4 1.7 2.4 1.3 1.9 2.0 2.2 2.3 3.6   Kruppel-like factor 4 (gut) (KLF4), mRNA. 
8015387 KRT17 1.3 3.0 1.3 3.2 2.1 5.3 1.9 8.3   keratin 17 (KRT17), mRNA. 
7980958 LGMN 1.5 1.3 1.7 1.6 1.1 0.9 2.0 2.2   legumain (LGMN), transcript variant 1, mRNA. 
8112803 LHFPL2 0.6 0.8 1.1 0.5 2.3 2.1 1.6 1.3   lipoma HMGIC fusion partner-like 2 (LHFPL2), mRNA. 
8072461 LIMK2 2.0 1.8 1.1 1.3 3.4 2.2 2.9 2.7   LIM domain kinase 2 (LIMK2), transcript variant 2b, mRNA. 
7969438 LMO7 1.0 1.5 1.7 3.1 3.8 4.4 3.3 4.9   LIM domain 7 (LMO7), transcript variant 1, mRNA. 
8040340 LPIN1 1.4 1.1 1.2 1.5 1.6 1.4 2.0 2.0   lipin 1 (LPIN1), mRNA. 
8126102 MDGA1 1.5 2.8 1.2 2.6 1.4 3.0 2.4 6.8   MAM domain containing glycosylphosphatidylinositol anchor 1 (MDGA1), mRNA. 
8160521 MOBKL2B 0.9 1.5 0.8 2.0 1.8 3.5 2.7 5.4   MOB1, Mps One Binder kinase activator-like 2B (yeast) (MOBKL2B), mRNA. 
7912496 MTHFR 1.7 1.3 1.1 1.2 1.8 1.3 2.4 2.1   5,10-methylenetetrahydrofolate reductase (NADPH) (MTHFR), mRNA. 
7920642 MUC1 1.7 9.9 1.9 7.3 1.8 5.5 3.5 14.1   mucin 1, cell surface associated (MUC1), transcript variant 2, mRNA. 
8178826 NA 1.9 1.6 1.9 1.3 1.9 1.3 14.2 6.8   cDNA FLJ52646 complete cds, highly similar to HLA class II histocompatibility antigen, DQB1*0602 beta chain precursor. 
8178811 NA 2.0 0.5 1.8 0.5 1.3 0.6 6.4 4.6   cDNA FLJ75018 complete cds. 
8180003 NA 2.0 0.5 1.7 0.5 1.3 0.6 6.4 4.5   major histocompatibility complex, class II, DR beta 3 (HLA-DRB3), mRNA. 
7917530 NA 2.5 0.9 1.3 0.7 8.8 5.4 8.6 8.2   mRNA; cDNA DKFZp451C2311 (from clone DKFZp451C2311); complete cds. 
8117739 NA 1.6 1.4 1.2 0.8 2.5 2.6 4.6 5.4  cdna:pseudogene chromosome:GRCh37:HSCHR6_MHC_APD:29520735:29522057:1 gene:ENSG00000226896 
7917528 NA 1.2 1.0 0.9 0.6 7.3 5.5 9.4 10.3  cdna:pseudogene chromosome:GRCh37:1:89569968:89570450:-1 gene:ENSG00000234518 
8081818 NA 1.3 0.8 0.9 5.4 3.1 1.7 2.1 3.2  ncrna:misc_RNA chromosome:GRCh37:3:115556715:115557005:1 gene:ENSG00000222510 
8053944 NEURL3 2.0 1.7 1.3 1.1 2.3 2.0 2.0 2.1   neuralized homolog 3 (Drosophila) pseudogene (NEURL3), non-coding RNA. 
8152340 NUDCD1 1.3 1.8 1.5 2.1 3.2 2.7 2.1 2.6   NudC domain containing 1 (NUDCD1), transcript variant 2, mRNA. 
7959251 P2RX7 2.9 1.0 1.5 1.1 3.5 1.3 4.5 4.0   purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7), mRNA. 
8091255 PAQR9 0.9 0.7 0.9 0.9 1.6 1.3 2.9 3.5   progestin and adipoQ receptor family member IX (PAQR9), mRNA. 
8105191 PARP8 1.2 1.6 1.5 1.7 1.5 1.3 2.1 2.4   poly (ADP-ribose) polymerase family, member 8 (PARP8), transcript variant 1, mRNA. 
7920228 PGLYRP4 1.0 1.7 1.0 1.7 1.0 3.5 2.1 7.2   peptidoglycan recognition protein 4 (PGLYRP4), mRNA. 
8081890 PLA1A 2.7 1.4 3.0 1.9 1.2 0.8 5.3 4.6   phospholipase A1 member A (PLA1A), mRNA. 
7913216 PLA2G2A 6.3 0.8 2.2 0.5 2.4 0.6 18.0 11.6   phospholipase A2, group IIA (platelets, synovial fluid) (PLA2G2A), transcript variant 1, mRNA. 
8091306 PLSCR4 1.0 1.5 1.2 1.3 1.7 1.2 2.9 2.7   phospholipid scramblase 4 (PLSCR4), transcript variant 1, non-coding RNA. 
8021470 PMAIP1 1.1 4.2 1.5 5.1 3.3 6.4 2.5 9.1   phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1), mRNA. 
8166705 PRRG1 0.7 1.4 1.3 2.2 2.8 4.8 2.2 5.1   proline rich Gla (G-carboxyglutamic acid) 1 (PRRG1), transcript variant 1, mRNA. 
8002133 PSMB10 2.0 1.9 1.8 2.4 2.2 1.6 3.2 4.0   proteasome (prosome, macropain) subunit, beta type, 10 (PSMB10), mRNA. 
8180049 PSMB8 2.4 1.4 1.8 1.9 1.6 1.4 2.0 2.8   proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional peptidase 7) (PSMB8), transcript variant 1, mRNA. 
7978123 PSME2 2.1 1.5 2.0 1.8 1.5 1.2 2.2 2.4   proteasome (prosome, macropain) activator subunit 2 (PA28 beta) (PSME2), mRNA. 
8020110 RAB31 1.1 0.5 0.9 0.5 0.9 0.8 2.3 2.5   RAB31, member RAS oncogene family (RAB31), mRNA. 
7905938 RAG1AP1 1.7 1.5 1.1 1.8 1.3 1.6 2.0 2.8   recombination activating gene 1 activating protein 1 (RAG1AP1), transcript variant 1, mRNA. 
8091723 RARRES1 1.3 0.8 0.9 0.6 1.3 0.8 7.8 3.4   retinoic acid receptor responder (tazarotene induced) 1 (RARRES1), transcript variant 1, mRNA. 
7940775 RARRES3 3.5 1.6 3.1 1.7 3.0 2.8 7.2 8.2   retinoic acid receptor responder (tazarotene induced) 3 (RARRES3), mRNA. 
7909214 RASSF5 1.3 1.0 1.3 1.1 5.4 3.9 4.6 7.2   Ras association (RalGDS/AF-6) domain family member 5 (RASSF5), transcript variant 1, mRNA. 
8110327 RGS14 1.1 1.2 1.1 1.0 1.8 1.9 2.5 2.9   regulator of G-protein signaling 14 (RGS14), mRNA. 
8105596 RGS7BP 1.1 1.2 1.4 1.2 3.1 4.8 3.5 11.6   regulator of G-protein signaling 7 binding protein (RGS7BP), mRNA. 
8147206 RIPK2 1.5 2.0 1.5 1.5 2.7 2.7 2.7 3.1   receptor-interacting serine-threonine kinase 2 (RIPK2), mRNA. 
7899192 RPS6KA1 1.0 1.6 1.0 1.1 1.3 1.7 2.2 4.0   ribosomal protein S6 kinase, 90kDa, polypeptide 1 (RPS6KA1), transcript variant 1, mRNA. 
8174304 SERPINA7 1.1 0.3 1.0 0.3 1.8 0.6 14.0 5.2   serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7 (SERPINA7), mRNA. 
7931951 SFMBT2 1.2 1.0 1.0 0.7 1.9 2.2 3.5 5.6   Scm-like with four mbt domains 2 (SFMBT2), mRNA. 
7944049 SIDT2 1.4 1.1 1.0 1.0 1.0 1.0 2.2 2.6   SID1 transmembrane family, member 2 (SIDT2), mRNA. 
8129666 SLC2A12 1.5 1.5 1.9 1.8 1.7 1.7 4.9 4.9   solute carrier family 2 (facilitated glucose transporter), member 12 (SLC2A12), mRNA. 
8143367 SLC37A3 1.9 3.0 1.3 2.4 2.4 4.3 1.6 4.2   solute carrier family 37 (glycerol-3-phosphate transporter), member 3 (SLC37A3), transcript variant 1, mRNA. 
8018864 SOCS3 4.4 1.3 1.1 0.9 5.7 4.2 2.4 7.3   suppressor of cytokine signaling 3 (SOCS3), mRNA. 
8048940 SP100 0.7 0.7 2.1 2.1 2.0 1.4 2.5 2.3   SP100 nuclear antigen (SP100), transcript variant 1, mRNA. 
8180339 ST6GALNAC6 1.6 1.6 0.8 1.1 1.6 1.7 2.1 2.7   ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 (ST6GALNAC6), mRNA 
8164304 ST6GALNAC6 1.5 1.7 0.8 1.1 1.5 1.7 2.0 2.6   ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1, 3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 (ST6GALNAC6), mRNA. 
8168028 STARD8 1.3 1.6 1.2 1.8 2.2 2.2 1.9 2.5   StAR-related lipid transfer (START) domain containing 8 (STARD8), transcript variant 1, mRNA. 
8007212 STAT5A 1.9 1.7 1.4 1.3 1.6 1.3 2.5 3.0   signal transducer and activator of transcription 5A (STAT5A), mRNA. 
8165866 STS 0.9 0.7 1.1 0.9 1.6 0.9 3.3 2.8   steroid sulfatase (microsomal), isozyme S (STS), mRNA. 
8158059 STXBP1 0.7 1.7 0.9 1.9 0.7 1.8 2.1 4.0   syntaxin binding protein 1 (STXBP1), transcript variant 1, mRNA. 
7974920 SYNE2 0.7 0.6 1.0 1.3 2.0 1.0 2.4 4.1   spectrin repeat containing, nuclear envelope 2 (SYNE2), transcript variant 5, mRNA. 
7953150 TEAD4 1.7 2.6 1.2 1.4 2.7 3.4 2.3 3.3   TEA domain family member 4 (TEAD4), transcript variant 1, mRNA. 
8126086 TMEM217 1.7 2.2 1.0 1.4 2.8 2.8 1.5 3.3   transmembrane protein 217 (TMEM217), transcript variant 1, mRNA. 
8179617 TRIM31 1.6 1.0 1.2 0.9 2.8 1.1 18.3 2.0   tripartite motif-containing 31 (TRIM31), mRNA. 
8117840 TRIM40 1.4 2.1 1.0 1.3 9.3 20.5 17.6 34.0   tripartite motif-containing 40 (TRIM40), mRNA. 
8129637 VNN2 0.9 0.8 0.8 1.1 1.1 1.0 2.8 3.2   vanin 2 (VNN2), transcript variant 1, mRNA. 
8040430 VSNL1 1.1 0.4 1.2 0.9 2.5 1.7 7.4 7.5   visinin-like 1 (VSNL1), mRNA. 
8091141 XRN1 0.8 0.5 1.9 1.7 3.3 1.9 3.7 3.4   5'-3' exoribonuclease 1 (XRN1), transcript variant 1, mRNA. 
8028652 ZFP36 2.2 1.6 1.2 2.0 1.8 2.0 2.2 2.6   zinc finger protein 36, C3H type, homolog (mouse) (ZFP36), mRNA. 
8051814 ZFP36L2 0.9 1.0 1.2 1.6 1.5 1.6 2.2 3.2   zinc finger protein 36, C3H type-like 2 (ZFP36L2), mRNA. 
7995258 ZNF267 0.3 0.3 1.2 0.9 2.8 1.7 2.3 2.4   zinc finger protein 267 (ZNF267), transcript variant 498723, mRNA. 
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 > 2-fold reduced in both donors after IFN-gamma, but not in IFN-alpha
probeSetID Symbol D1 D2 D1 D2 D1 D2 D1 D2 GeneName
8112920 ACOT12 1.17 0.93 0.72 0.65 1.07 0.82 0.36 0.31   acyl-CoA thioesterase 12 (ACOT12), mRNA. 
8006214 ADAP2 0.90 0.39 0.87 0.33 0.41 0.41 0.85 0.39   ArfGAP with dual PH domains 2 (ADAP2), mRNA. 
8136336 AKR1B10 1.21 1.41 0.68 0.63 0.79 1.28 0.31 0.46   aldo-keto reductase family 1, member B10 (aldose reductase) (AKR1B10), mRNA. 
7925929 AKR1C3 0.81 0.65 0.66 0.41 0.75 0.49 0.47 0.27   aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) (AKR1C3), mRNA. 
8161618 APBA1 1.19 1.25 0.88 1.05 0.92 1.08 0.39 0.49   amyloid beta (A4) precursor protein-binding, family A, member 1 (APBA1), mRNA. 
7906458 APCS 1.46 1.03 0.85 0.81 1.04 0.87 0.39 0.34   amyloid P component, serum (APCS), mRNA. 
7960874 C3AR1 1.28 0.09 1.25 0.06 0.44 0.06 1.33 0.06   complement component 3a receptor 1 (C3AR1), mRNA. 
8115397 C5orf4 1.19 1.40 0.92 1.24 0.89 1.05 0.31 0.35   chromosome 5 open reading frame 4 (C5orf4), mRNA. 
7996264 CDH5 0.76 0.24 0.85 0.21 0.66 0.20 0.46 0.19   cadherin 5, type 2 (vascular endothelium) (CDH5), mRNA. 
7990391 CYP1A1 2.46 4.24 0.93 0.71 5.13 4.32 0.39 0.42   cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), mRNA. 
8141342 CYP3A7 2.05 0.10 0.88 0.13 0.93 0.11 0.43 0.12   cytochrome P450, family 3, subfamily A, polypeptide 7 (CYP3A7), mRNA. 
7929664 DHDPSL 1.80 0.64 0.66 0.43 1.26 0.49 0.35 0.36   dihydrodipicolinate synthase-like, mitochondrial (DHDPSL), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 
8041781 EPAS1 0.96 0.68 0.70 0.38 0.79 0.55 0.47 0.25   endothelial PAS domain protein 1 (EPAS1), mRNA. 
7921873 FCGR3A 1.05 0.05 1.49 0.03 0.40 0.05 0.83 0.04   Fc fragment of IgG, low affinity IIIa, receptor (CD16a) (FCGR3A), transcript variant 1, mRNA. 
8103326 FGG 1.31 0.65 0.85 0.44 1.09 0.31 0.43 0.16   fibrinogen gamma chain (FGG), transcript variant gamma-B, mRNA. 
8030866 FPR3 0.73 0.14 1.85 0.13 0.28 0.10 0.83 0.09   formyl peptide receptor 3 (FPR3), mRNA. 
7940135 GLYATL1 1.52 0.20 0.69 0.15 0.82 0.17 0.19 0.10   glycine-N-acyltransferase-like 1 (GLYATL1), mRNA. 
7904396 HAO2 0.87 0.24 0.72 0.26 0.57 0.21 0.43 0.09   hydroxyacid oxidase 2 (long chain) (HAO2), transcript variant 2, mRNA. 
8115464 HAVCR2 0.85 0.25 0.95 0.22 0.39 0.18 0.90 0.21   hepatitis A virus cellular receptor 2 (HAVCR2), mRNA. 
7959234 HNF1A 0.82 0.68 1.15 1.25 0.47 0.49 1.24 0.95   HNF1 homeobox A (HNF1A), mRNA. 
7956271 HSD17B6 1.14 0.86 0.56 0.43 0.80 0.56 0.32 0.25   hydroxysteroid (17-beta) dehydrogenase 6 homolog (mouse) (HSD17B6), mRNA. 
7951686 IL18 0.96 1.88 0.68 1.12 0.89 1.01 0.35 0.45   interleukin 18 (interferon-gamma-inducing factor) (IL18), mRNA. 
8082916 IL20RB 1.85 0.33 1.71 0.73 0.82 0.22 0.46 0.18   interleukin 20 receptor beta (IL20RB), mRNA. 
8139207 INHBA 1.02 0.46 1.81 2.35 0.80 0.68 0.29 0.37   inhibin, beta A (INHBA), mRNA. 
7956426 INHBE 0.86 0.30 1.05 0.59 0.58 0.33 0.39 0.16   inhibin, beta E (INHBE), mRNA. 
7955441 METTL7A 1.27 0.88 0.82 0.66 0.98 0.81 0.47 0.40   methyltransferase like 7A (METTL7A), mRNA. 
8136662 MGAM 1.02 0.48 0.86 0.38 0.94 0.39 0.36 0.31   maltase-glucoamylase (alpha-glucosidase) (MGAM), mRNA. 
7905329 MLLT11 0.91 1.32 0.92 1.36 0.79 1.30 0.41 0.50   myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11 (MLLT11), mRNA. 
7909877 MOSC1 1.08 0.79 0.72 0.61 0.78 0.71 0.43 0.31   MOCO sulphurase C-terminal domain containing 1 (MOSC1), nuclear gene encoding mitochondrial protein, mRNA. 
7948364 MPEG1 0.79 0.05 0.83 0.05 0.43 0.06 0.74 0.09   macrophage expressed 1 (MPEG1), mRNA. 
7940237 MS4A4A 0.78 0.06 1.11 0.06 0.30 0.06 0.66 0.05   membrane-spanning 4-domains, subfamily A, member 4 (MS4A4A), transcript variant 1, mRNA. 
7965884 PAH 0.84 0.54 0.80 0.46 0.79 0.67 0.47 0.28   phenylalanine hydroxylase (PAH), mRNA. 
8017599 PECAM1 0.88 0.11 0.93 0.11 0.41 0.09 0.46 0.09   platelet/endothelial cell adhesion molecule (PECAM1), mRNA. 
8173120 PFKFB1 2.02 0.64 0.63 0.43 1.41 0.72 0.43 0.17   6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 (PFKFB1), mRNA. 
8012896 PMP22 0.80 0.84 0.89 0.58 0.29 0.34 0.61 0.43   peripheral myelin protein 22 (PMP22), transcript variant 1, mRNA. 
8141052 PON1 1.15 0.39 0.56 0.30 0.81 0.40 0.40 0.19   paraoxonase 1 (PON1), mRNA. 
8102468 PRSS12 1.02 0.77 0.71 0.53 0.79 0.71 0.49 0.33   protease, serine, 12 (neurotrypsin, motopsin) (PRSS12), mRNA. 
8101304 RASGEF1B 1.04 0.33 1.56 1.19 0.43 0.15 0.59 0.30   RasGEF domain family, member 1B (RASGEF1B), mRNA. 
8064790 RASSF2 0.76 0.27 0.84 0.35 0.35 0.24 0.72 0.28   Ras association (RalGDS/AF-6) domain family member 2 (RASSF2), transcript variant 1, mRNA. 
7977615 RNASE1 0.74 0.29 1.35 0.46 0.34 0.24 0.51 0.24   ribonuclease, RNase A family, 1 (pancreatic) (RNASE1), transcript variant 3, mRNA. 
8146685 RRS1 0.74 0.61 0.92 0.82 0.73 0.68 0.46 0.37   RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) (RRS1), mRNA. 
8147461 SDC2 0.88 0.89 0.83 1.04 0.84 0.83 0.50 0.50   syndecan 2 (SDC2), mRNA. 
7979878 SLC10A1 1.90 0.39 0.52 0.12 1.23 0.35 0.25 0.08   solute carrier family 10 (sodium/bile acid cotransporter family), member 1 (SLC10A1), mRNA. 
8124351 SLC17A3 1.06 0.67 0.51 0.28 0.80 0.46 0.27 0.15   solute carrier family 17 (sodium phosphate), member 3 (SLC17A3), transcript variant 1, mRNA. 
7901316 SLC5A9 1.99 0.27 0.66 0.30 1.26 0.30 0.38 0.25   solute carrier family 5 (sodium/glucose cotransporter), member 9 (SLC5A9), transcript variant 1, mRNA. 
8060745 SMOX 1.37 0.94 0.91 1.01 0.81 0.74 0.38 0.37   spermine oxidase (SMOX), transcript variant 1, mRNA. 
8117165 SOX4 0.71 0.60 0.92 1.25 0.52 0.55 0.35 0.39   SRY (sex determining region Y)-box 4 (SOX4), mRNA. 
8051361 SRD5A2 1.20 0.99 0.59 0.59 0.75 1.26 0.32 0.43   steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) (SRD5A2), mRNA. 
8002556 TAT 1.15 0.16 1.20 0.30 0.47 0.13 1.48 0.19   tyrosine aminotransferase (TAT), nuclear gene encoding mitochondrial protein, mRNA. 
8136557 TBXAS1 0.91 0.29 0.56 0.21 0.49 0.26 0.50 0.25   thromboxane A synthase 1 (platelet) (TBXAS1), transcript variant 3, mRNA. 
8005475 TRIM16L 0.92 0.68 0.95 0.56 0.84 0.65 0.41 0.25   tripartite motif-containing 16-like (TRIM16L), mRNA. 
8100768 UGT2B11 0.96 0.77 0.75 0.74 0.86 0.81 0.44 0.46   UDP glucuronosyltransferase 2 family, polypeptide B10 (UGT2B10), transcript variant 1, mRNA. 
8100784 UGT2B4 0.89 0.82 0.65 0.80 0.69 0.93 0.21 0.29   UDP glucuronosyltransferase 2 family, polypeptide B4 (UGT2B4), mRNA. 
8100758 UGT2B7 0.98 0.69 0.72 0.69 1.06 0.84 0.34 0.31   UDP glucuronosyltransferase 2 family, polypeptide B7 (UGT2B7), mRNA. 
7952249 USP2 0.74 0.75 0.84 0.50 0.44 0.39 0.63 0.27   ubiquitin specific peptidase 2 (USP2), transcript variant 1, mRNA. 
8048319 VIL1 1.31 1.16 0.56 0.42 1.11 1.05 0.46 0.43   villin 1 (VIL1), mRNA. 
 > 2-fold reduced in both donors after IFN-alpha and IFN-gamma
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8114006 – 0.29 0.17 0.92 1.10 0.59 0.83 0.32 0.34   cDNA FLJ44796 fis, clone BRACE3040504. 
7906465 – 0.51 0.06 0.85 0.89 0.36 0.13 0.43 0.19  cdna:pseudogene chromosome:GRCh37:1:159568088:159568918:1 gene:ENSG00000158731 
7993754 – 0.39 0.26 0.56 0.34 0.39 0.22 2.21 0.39  cDNA FLJ34659 fis, clone KIDNE2018863 gene:ENSG00000226720 
8165680 – 0.31 0.41 0.85 0.99 0.23 0.38 0.92 1.14  gi|17981852|ref|NC_001807.4|:12139-12207; gene=TRNH; product=tRNA-His 
8165682 – 0.43 0.41 0.83 0.72 0.28 0.36 0.88 0.99  gi|17981852|ref|NC_001807.4|:12208-12266; gene=TRNS2; product=tRNA-Ser 
8043375 – 0.68 0.75 0.84 0.66 0.37 0.49 0.73 0.96  gi|17981852|ref|NC_001807.4|:8296-8365; gene=TRNK; product=tRNA-Lys 
7961710 ABCC9 0.35 0.24 0.67 0.91 0.72 0.76 0.47 0.51   ATP-binding cassette, sub-family C (CFTR/MRP), member 9 (ABCC9), transcript variant SUR2A, mRNA. 
7918533 ADORA3 0.17 0.07 1.02 0.09 0.09 0.05 0.40 0.06   adenosine A3 receptor (ADORA3), transcript variant 1, mRNA. 
8149885 ADRA1A 0.35 0.26 0.60 0.28 0.38 0.32 1.54 0.36   adrenergic, alpha-1A-, receptor (ADRA1A), transcript variant 1, mRNA. 
7968344 ALOX5AP 0.83 0.18 0.43 0.17 0.33 0.17 0.24 0.13   arachidonate 5-lipoxygenase-activating protein (ALOX5AP), mRNA. 
7901883 ANGPTL3 0.36 0.31 0.83 0.73 0.90 0.74 0.38 0.38   angiopoietin-like 3 (ANGPTL3), mRNA. 
7993815 ANKS4B 0.52 0.20 0.91 0.60 0.43 0.31 1.32 0.31   ankyrin repeat and sterile alpha motif domain containing 4B (ANKS4B), mRNA. 
7954398 C12orf39 0.19 0.28 1.62 1.10 0.53 0.46 0.32 0.24   chromosome 12 open reading frame 39 (C12orf39), mRNA. 
7903980 C1orf162 0.41 0.09 0.89 0.09 0.28 0.08 0.74 0.09   chromosome 1 open reading frame 162 (C1orf162), mRNA. 
8104758 C5orf23 0.29 0.14 1.22 0.84 0.48 0.32 0.43 0.16   chromosome 5 open reading frame 23, mRNA (cDNA clone MGC:22189 IMAGE:4702775), complete cds. 
7953200 CCND2 0.52 0.28 0.74 0.26 0.64 0.24 0.29 0.18   cyclin D2 (CCND2), mRNA. 
7960794 CD163 0.41 0.04 0.61 0.04 0.30 0.05 0.49 0.03   CD163 molecule (CD163), transcript variant 1, mRNA. 
8127563 COL12A1 0.46 0.68 0.77 0.63 1.09 0.84 0.46 0.34   collagen, type XII, alpha 1 (COL12A1), transcript variant long, mRNA. 
8024754 CREB3L3 0.62 0.22 0.98 0.23 0.42 0.16 4.07 1.27   cAMP responsive element binding protein 3-like 3 (CREB3L3), mRNA. 
8055465 CXCR4 0.59 0.33 0.84 0.35 0.38 0.26 0.53 0.33   chemokine (C-X-C motif) receptor 4 (CXCR4), transcript variant 1, mRNA. 
8141317 CYP3A4 1.62 0.10 0.39 0.10 1.21 0.09 0.36 0.07   cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4), mRNA. 
8014063 EVI2B 0.05 0.03 1.00 0.06 0.23 0.03 1.02 0.04   ecotropic viral integration site 2B (EVI2B), mRNA. 
8022283 FAM38B 0.36 0.32 0.57 0.60 0.52 0.45 0.42 0.28   family with sequence similarity 38, member B (FAM38B), mRNA. 
8089112 FILIP1L 0.35 0.23 1.14 1.40 0.49 0.48 0.45 0.41   filamin A interacting protein 1-like (FILIP1L), transcript variant 1, mRNA. 
8105121 GHR 0.44 0.19 0.87 0.46 0.66 0.39 0.35 0.30   growth hormone receptor (GHR), mRNA. 
7936322 GPAM 0.38 0.15 0.72 0.87 0.33 0.42 0.21 0.14   glycerol-3-phosphate acyltransferase, mitochondrial (GPAM), nuclear gene encoding mitochondrial protein, mRNA. 
8131844 GPNMB 0.58 0.05 0.76 0.06 0.42 0.05 0.58 0.05   glycoprotein (transmembrane) nmb (GPNMB), transcript variant 1, mRNA. 
8022338 GPR125 0.49 0.34 0.93 0.88 0.92 0.78 0.32 0.42   G protein-coupled receptor 125 (GPR125), mRNA. 
8127094 GSTA4 0.62 0.49 0.67 0.42 0.45 0.45 0.53 0.38   glutathione S-transferase alpha 4 (GSTA4), mRNA. 
7961673 GYS2 0.37 0.25 0.98 0.40 0.42 0.28 0.21 0.11   glycogen synthase 2 (liver) (GYS2), mRNA. 
8115455 HAVCR1 0.44 0.58 0.56 0.49 0.66 0.60 0.32 0.25   hepatitis A virus cellular receptor 1 (HAVCR1), transcript variant 1, mRNA. 
8084880 HES1 0.59 0.43 1.06 0.97 0.40 0.35 0.61 0.38   hairy and enhancer of split 1, (Drosophila) (HES1), mRNA. 
8103769 HPGD 0.43 0.41 0.75 1.06 0.81 0.64 0.43 0.52   hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD), transcript variant 1, mRNA. 
8040103 ID2 0.61 0.40 0.86 0.71 0.44 0.36 0.80 0.60   inhibitor of DNA binding 2, dominant negative helix-loop-helix protein (ID2), mRNA. 
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7910950 KMO 0.54 0.26 1.05 0.33 0.62 0.23 0.46 0.16   kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) (KMO), mRNA. 
8020551 LAMA3 0.62 0.58 0.79 0.98 0.68 0.60 0.28 0.41   laminin, alpha 3 (LAMA3), transcript variant 1, mRNA. 
8044391 MERTK 0.32 0.19 0.93 0.26 0.18 0.19 0.54 0.25   c-mer proto-oncogene tyrosine kinase (MERTK), mRNA. 
8083494 MME 0.24 0.15 0.80 0.32 0.59 0.25 0.50 0.25   membrane metallo-endopeptidase (MME), transcript variant 2a, mRNA. 
7926410 MRC1 0.10 0.05 0.34 0.05 0.43 0.06 0.14 0.04   mannose receptor, C type 1 (MRC1), mRNA. 
7948455 MS4A6A 0.55 0.30 1.75 0.36 0.50 0.26 1.23 0.33   membrane-spanning 4-domains, subfamily A, member 6A (MS4A6A), transcript variant 1, mRNA. 
7940259 MS4A7 0.46 0.20 1.30 0.19 0.44 0.19 1.14 0.19   membrane-spanning 4-domains, subfamily A, member 7 (MS4A7), transcript variant 1, mRNA. 
8152764 MTSS1 0.47 0.26 1.01 0.69 0.39 0.32 0.93 0.48   metastasis suppressor 1 (MTSS1), mRNA. 
7902495 NEXN 0.35 0.23 0.97 1.90 0.69 1.02 0.49 0.64   nexilin (F actin binding protein) (NEXN), transcript variant 1, mRNA. 
8104746 NPR3 0.60 0.24 1.24 0.71 0.57 0.38 0.37 0.17   natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C) (NPR3), mRNA. 
7957835 NR1H4 0.44 0.17 1.13 0.46 0.42 0.19 0.86 0.38   nuclear receptor subfamily 1, group H, member 4 (NR1H4), mRNA. 
7903227 PALMD 0.36 0.57 1.08 1.11 0.51 0.69 0.44 0.40   palmdelphin (PALMD), mRNA. 
8141094 PDK4 0.44 0.17 1.03 0.45 0.45 0.29 1.83 0.88   pyruvate dehydrogenase kinase, isozyme 4 (PDK4), mRNA. 
8126784 PLA2G7 0.35 0.03 1.14 0.05 0.44 0.03 1.03 0.05   phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) (PLA2G7), transcript variant 2, mRNA. 
8053602 PLGLB2 0.66 0.16 0.54 0.18 0.66 0.17 0.47 0.16   plasminogen-like B2 (PLGLB2), mRNA. 
8160297 PLIN2 0.43 0.51 1.05 0.77 0.33 0.47 1.13 0.74   perilipin 2 (PLIN2), mRNA. 
7926545 PLXDC2 0.34 0.14 0.58 0.21 0.32 0.17 0.63 0.14   plexin domain containing 2 (PLXDC2), mRNA. 
8099633 PPARGC1A 0.37 0.13 1.19 0.74 0.35 0.23 1.00 0.43   peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PPARGC1A), mRNA. 
8106660 RASGRF2 0.47 0.94 0.74 1.03 0.62 1.06 0.47 0.49   Ras protein-specific guanine nucleotide-releasing factor 2 (RASGRF2), mRNA. 
8165672 RFC1 0.53 0.43 0.71 0.60 0.14 0.39 0.68 1.18  Human replication factor C large subunit mRNA, complete cds. 
8038824 SIGLEC10 0.55 0.20 0.91 0.16 0.35 0.18 0.98 0.19   sialic acid binding Ig-like lectin 10 (SIGLEC10), transcript variant 1, mRNA. 
8121515 SLC16A10 0.22 0.15 0.47 0.14 0.30 0.17 0.22 0.17   solute carrier family 16, member 10 (aromatic amino acid transporter) (SLC16A10), mRNA. 
7934936 SLC16A12 0.51 0.37 0.71 0.81 0.80 0.72 0.47 0.42   solute carrier family 16, member 12 (monocarboxylic acid transporter 12) (SLC16A12), mRNA. 
7924342 SLC30A10 0.39 0.19 0.74 0.39 0.41 0.24 0.39 0.20   solute carrier family 30, member 10 (SLC30A10), mRNA. 
8057677 SLC40A1 0.35 0.27 1.01 0.59 0.57 0.33 0.43 0.19   solute carrier family 40 (iron-regulated transporter), member 1 (SLC40A1), mRNA. 
8085914 SLC4A7 0.45 0.42 0.67 0.83 0.76 0.72 0.50 0.37   solute carrier family 4, sodium bicarbonate cotransporter, member 7 (SLC4A7), mRNA. 
8068361 SLC5A3 0.13 0.10 0.68 0.56 0.41 0.45 0.82 0.64   solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 (SLC5A3), mRNA. 
7977933 SLC7A8 0.32 0.28 0.88 0.34 0.23 0.24 0.39 0.38   solute carrier family 7 (amino acid transporter, L-type), member 8 (SLC7A8), transcript variant 1, mRNA. 
7942569 SLCO2B1 0.55 0.34 0.90 0.29 0.45 0.35 1.20 1.10   solute carrier organic anion transporter family, member 2B1 (SLCO2B1), transcript variant 2, mRNA. 
8104035 SORBS2 0.39 0.38 0.93 1.23 0.47 0.46 0.51 0.58   sorbin and SH3 domain containing 2 (SORBS2), transcript variant 2, mRNA. 
8096301 SPP1 0.65 0.12 0.98 0.17 0.63 0.13 0.37 0.06   secreted phosphoprotein 1 (SPP1), transcript variant 1, mRNA. 
8146863 SULF1 0.53 0.37 0.82 0.59 0.78 0.49 0.49 0.23   sulfatase 1 (SULF1), transcript variant 1, mRNA. 
7970831 UBL3 0.32 0.48 0.95 0.77 0.56 0.68 0.46 0.39   ubiquitin-like 3 (UBL3), mRNA. 
8100746 UGT2B15 0.82 0.32 0.41 0.29 1.15 0.33 0.30 0.17   UDP glucuronosyltransferase 2 family, polypeptide B15 (UGT2B15), mRNA. 
8056860 WIPF1 0.66 0.30 1.29 0.27 0.41 0.19 0.83 0.26   WAS/WASL interacting protein family, member 1 (WIPF1), transcript variant 1, mRNA. 
 > 2-fold reduced in both donors after IFN-alpha, but not in IFN-gamma
IFN-alpha IFN-gamma
6h 24h 6h 24h
probeSetID Symbol D1 D2 D1 D2 D1 D2 D1 D2 GeneName
8045919 MARCH7 0.27 0.26 1.11 1.01 1.06 0.83 0.97 0.85   membrane-associated ring finger (C3HC4) 7 (MARCH7), mRNA. 
8132292 SEPT7 0.32 0.32 0.91 0.97 0.90 0.81 0.65 0.74   septin 7 (SEPT7), transcript variant 1, mRNA. 
8054467 SEPT10 0.30 0.48 1.11 0.97 0.92 1.06 0.96 1.10   septin 10 (SEPT10), transcript variant 1, mRNA. 
8095854 SEPT11 0.35 0.44 0.87 0.93 0.99 1.06 1.11 1.25   septin 11 (SEPT11), mRNA. 
7943552 AASDHPPT 0.33 0.37 1.13 0.95 0.72 0.78 0.87 0.67   aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (AASDHPPT), mRNA. 
8017964 ABCA6 0.36 0.15 1.02 0.69 1.01 0.40 0.91 0.48   ATP-binding cassette, sub-family A (ABC1), member 6 (ABCA6), mRNA. 
7903119 ABCD3 0.36 0.26 0.75 0.67 0.91 0.88 0.72 0.68   ATP-binding cassette, sub-family D (ALD), member 3 (ABCD3), transcript variant 1, mRNA. 
8097647 ABCE1 0.18 0.23 0.89 0.77 0.80 0.82 0.51 0.47   ATP-binding cassette, sub-family E (OABP), member 1 (ABCE1), transcript variant 1, mRNA. 
7902367 ACADM 0.25 0.29 0.90 0.71 0.96 0.76 0.90 0.72   acyl-CoA dehydrogenase, C-4 to C-12 straight chain (ACADM), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 
8092933 ACAP2 0.33 0.26 0.93 1.02 0.96 0.87 1.08 0.99   ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 (ACAP2), mRNA. 
7932703 ACBD5 0.38 0.44 1.22 1.08 0.98 0.93 1.43 1.32   acyl-CoA binding domain containing 5 (ACBD5), transcript variant 1, mRNA. 
8154733 ACO1 0.97 0.74 0.39 0.29 0.88 0.72 1.01 0.64   aconitase 1, soluble (ACO1), mRNA. 
8174474 ACSL4 0.35 0.44 0.91 1.56 0.88 1.74 1.04 1.25   acyl-CoA synthetase long-chain family member 4 (ACSL4), transcript variant 2, mRNA. 
7989224 ADAM10 0.32 0.31 1.03 1.06 0.80 0.86 0.95 0.92   ADAM metallopeptidase domain 10 (ADAM10), mRNA. 
8146000 ADAM9 0.35 0.38 0.93 1.25 0.94 1.38 0.89 1.28   ADAM metallopeptidase domain 9 (meltrin gamma) (ADAM9), transcript variant 1, mRNA. 
8067011 ADNP 0.41 0.49 0.97 0.94 0.72 0.70 0.88 0.74   activity-dependent neuroprotector homeobox (ADNP), transcript variant 1, mRNA. 
8106429 AGGF1 0.42 0.45 1.05 1.02 0.95 1.03 0.94 0.86   angiogenic factor with G patch and FHA domains 1 (AGGF1), mRNA. 
7903239 AGL 0.17 0.10 0.63 0.42 0.87 0.42 0.81 0.48   amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase (AGL), transcript variant 4, mRNA. 
8056220 AHCTF1 0.14 0.10 0.98 1.00 0.89 0.71 0.89 0.72   AT hook containing transcription factor 1 (AHCTF1), mRNA. 
8131614 AHR 0.27 0.48 1.08 1.47 0.76 0.97 0.74 0.78   aryl hydrocarbon receptor (AHR), mRNA. 
7968835 AKAP11 0.42 0.20 1.06 1.26 1.03 0.68 0.96 0.86   A kinase (PRKA) anchor protein 11 (AKAP11), mRNA. 
8134122 AKAP9 0.28 0.12 0.89 0.93 0.72 0.28 0.76 0.72   A kinase (PRKA) anchor protein (yotiao) 9 (AKAP9), transcript variant 2, mRNA. 
8081431 ALCAM 0.36 0.24 0.89 0.92 1.04 0.76 0.87 0.83   activated leukocyte cell adhesion molecule (ALCAM), mRNA. 
8162884 ALDOB 1.19 0.45 0.48 0.11 0.91 0.38 0.71 0.14   aldolase B, fructose-bisphosphate (ALDOB), mRNA. 
8094408 ANAPC4 0.32 0.44 0.97 0.81 0.83 0.77 0.98 0.85   anaphase promoting complex subunit 4 (ANAPC4), mRNA. 
8100902 ANKRD17 0.43 0.47 1.08 1.03 0.86 0.93 0.95 0.91   ankyrin repeat domain 17 (ANKRD17), transcript variant 1, mRNA. 
8085628 ANKRD28 0.39 0.20 1.10 0.93 0.78 0.52 0.87 0.55   ankyrin repeat domain 28 (ANKRD28), mRNA. 
8053801 ANKRD36B 0.35 0.21 0.99 1.11 0.97 0.50 0.97 0.78   ankyrin repeat domain 36 (ANKRD36), mRNA. 
8043697 ANKRD36B 0.45 0.28 1.08 1.26 1.11 0.57 1.08 0.86   ankyrin repeat domain 36B (ANKRD36B), mRNA. 
8152053 ANKRD46 0.49 0.49 0.96 1.08 0.62 0.80 0.88 0.78   ankyrin repeat domain 46 (ANKRD46), mRNA. 
8102720 ANKRD50 0.31 0.31 0.87 1.53 0.82 1.11 0.89 1.07   ankyrin repeat domain 50 (ANKRD50), transcript variant 1, mRNA. 
8050619 APOB 0.50 0.20 0.85 0.70 1.02 0.52 0.95 0.73   apolipoprotein B (including Ag(x) antigen) (APOB), mRNA. 
8017235 APPBP2 0.36 0.46 1.04 0.89 0.92 0.87 0.95 0.97   amyloid beta precursor protein (cytoplasmic tail) binding protein 2 (APPBP2), mRNA. 
8080645 APPL1 0.45 0.46 0.92 0.85 1.13 0.98 0.76 0.61   adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 (APPL1), mRNA. 
7987325 AQR 0.30 0.31 0.95 0.82 0.92 0.87 0.85 0.84   aquarius homolog (mouse) (AQR), mRNA. 
8151149 ARFGEF1 0.26 0.18 0.86 0.85 0.96 0.90 0.79 0.78   ADP-ribosylation factor guanine nucleotide-exchange factor 1(brefeldin A-inhibited) (ARFGEF1), mRNA. 
8063242 ARFGEF2 0.50 0.44 0.81 0.80 1.04 0.95 0.82 0.70   ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited) (ARFGEF2), mRNA. 
7932885 ARHGAP12 0.40 0.25 1.07 1.07 1.30 0.87 1.97 1.54   Rho GTPase activating protein 12 (ARHGAP12), mRNA. 
8129458 ARHGAP18 0.23 0.23 0.88 0.97 0.92 0.73 0.86 0.84   Rho GTPase activating protein 18 (ARHGAP18), mRNA. 
7932554 ARHGAP21 0.33 0.48 1.10 1.42 1.04 1.41 1.18 1.73   Rho GTPase activating protein 21 (ARHGAP21), mRNA. 
7917850 ARHGAP29 0.24 0.24 1.19 1.36 1.50 1.08 1.09 1.42   Rho GTPase activating protein 29 (ARHGAP29), mRNA. 
7943349 ARHGAP42 0.31 0.30 1.02 0.89 1.15 0.81 1.48 0.95   Rho GTPase activating protein 42 (ARHGAP42), mRNA. 
7973840 ARHGAP5 0.26 0.22 0.96 1.02 1.02 0.77 0.93 1.02   Rho GTPase activating protein 5 (ARHGAP5), transcript variant 1, mRNA. 
7944560 ARHGEF12 0.42 0.47 0.79 0.74 1.05 0.84 0.93 0.80   Rho guanine nucleotide exchange factor (GEF) 12 (ARHGEF12), mRNA. 
7955019 ARID2 0.19 0.22 1.03 0.97 0.89 0.78 1.03 0.70   AT rich interactive domain 2 (ARID, RFX-like) (ARID2), mRNA. 
7974621 ARID4A 0.27 0.22 1.08 1.21 0.86 0.63 0.92 0.83   AT rich interactive domain 4A (RBP1-like) (ARID4A), transcript variant 1, mRNA. 
8113073 ARRDC3 0.49 0.25 1.21 1.68 1.58 1.16 1.07 1.58   arrestin domain containing 3 (ARRDC3), mRNA. 
8149534 ASAH1 0.42 0.46 0.88 0.67 0.62 0.53 0.91 0.57   N-acylsphingosine amidohydrolase (acid ceramidase) 1 (ASAH1), transcript variant 2, mRNA. 
8128472 ASCC3 0.25 0.16 0.81 0.67 1.05 0.61 0.89 0.67   activating signal cointegrator 1 complex subunit 3 (ASCC3), transcript variant 1, mRNA. 
7920766 ASH1L 0.32 0.23 0.96 0.99 0.99 0.83 1.12 0.87   ash1 (absent, small, or homeotic)-like (Drosophila) (ASH1L), mRNA. 
8046997 ASNSD1 0.43 0.48 1.02 0.93 0.99 1.01 0.76 0.69   asparagine synthetase domain containing 1 (ASNSD1), mRNA. 
8050875 ASXL2 0.38 0.43 0.94 1.09 0.83 0.98 0.95 0.76   additional sex combs like 2 (Drosophila) (ASXL2), mRNA. 
8056909 ATF2 0.47 0.31 1.09 1.09 0.95 0.91 1.18 1.04   activating transcription factor 2 (ATF2), mRNA. 
7954104 ATF7IP 0.39 0.37 1.04 1.07 0.66 0.64 1.04 0.88   activating transcription factor 7 interacting protein (ATF7IP), mRNA. 
7981217 ATG2B 0.27 0.23 0.85 0.78 0.81 0.86 1.02 1.03   ATG2 autophagy related 2 homolog B (S. cerevisiae) (ATG2B), mRNA. 
7901895 ATG4C 0.25 0.26 1.02 0.80 0.60 0.62 0.82 0.62   ATG4 autophagy related 4 homolog C (S. cerevisiae) (ATG4C), transcript variant 7, mRNA. 
8128592 ATG5 0.45 0.46 0.98 0.76 0.85 0.78 0.98 0.71   ATG5 autophagy related 5 homolog (S. cerevisiae) (ATG5), mRNA. 
7943620 ATM 0.28 0.15 0.97 0.82 1.01 0.45 1.15 0.62   ataxia telangiectasia mutated (ATM), transcript variant 1, mRNA. 
8084173 ATP11B 0.29 0.37 0.92 1.03 0.88 0.81 0.89 0.89   ATPase, class VI, type 11B (ATP11B), mRNA. 
8175492 ATP11C 0.29 0.16 0.80 0.74 1.04 0.65 1.03 0.85   ATPase, class VI, type 11C (ATP11C), transcript variant 1, mRNA. 
8092849 ATP13A3 0.29 0.35 0.85 0.90 1.25 1.29 0.97 0.98   ATPase type 13A3 (ATP13A3), mRNA. 
7965359 ATP2B1 0.23 0.11 0.81 1.08 0.70 0.55 0.62 0.51   ATPase, Ca++ transporting, plasma membrane 1 (ATP2B1), transcript variant 1, mRNA. 
8168472 ATP7A 0.30 0.32 0.76 1.03 0.65 1.09 0.70 0.69   ATPase, Cu++ transporting, alpha polypeptide (ATP7A), mRNA. 
8091190 ATR 0.45 0.17 0.90 0.82 1.70 0.82 1.03 0.93   ataxia telangiectasia and Rad3 related (ATR), mRNA. 
8176276 ATRX 0.17 0.15 1.16 1.22 1.12 0.52 1.53 0.89   alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae) (ATRX), transcript variant 1, mRNA. 
7907310 BAT2L2 0.41 0.47 1.10 1.16 1.18 1.12 1.23 1.28   HLA-B associated transcript 2-like 2 (BAT2L2), mRNA. 
7978595 BAZ1A 0.37 0.32 1.26 1.24 1.39 1.24 1.49 1.70   bromodomain adjacent to zinc finger domain, 1A (BAZ1A), transcript variant 1, mRNA. 
8056060 BAZ2B 0.44 0.18 1.12 1.05 0.97 0.45 1.24 0.67   bromodomain adjacent to zinc finger domain, 2B (BAZ2B), mRNA. 
7965060 BBS10 0.29 0.29 1.25 1.16 0.62 0.75 0.78 0.60   Bardet-Biedl syndrome 10 (BBS10), mRNA. 
8081465 BBX 0.37 0.20 1.47 1.24 1.48 0.91 2.13 2.06   bobby sox homolog (Drosophila) (BBX), transcript variant 1, mRNA. 
8129773 BCLAF1 0.21 0.22 0.88 0.99 0.90 0.77 1.07 0.87   BCL2-associated transcription factor 1 (BCLAF1), transcript variant 1, mRNA. 
8177560 BDP1 0.31 0.14 1.30 1.25 1.07 0.47 0.93 0.75   B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB (BDP1), mRNA. 
7943413 BIRC3 0.47 0.30 1.58 1.59 1.31 0.92 1.61 1.62   baculoviral IAP repeat-containing 3 (BIRC3), transcript variant 1, mRNA. 
8041283 BIRC6 0.33 0.16 0.92 0.94 0.99 0.79 0.99 0.81   baculoviral IAP repeat-containing 6 (BIRC6), mRNA. 
7926609 BMI1 0.24 0.50 0.98 1.04 0.90 0.85 0.98 0.80   BMI1 polycomb ring finger oncogene (BMI1), mRNA. 
8096004 BMP2K 0.30 0.33 1.14 1.36 0.87 1.13 0.92 1.29   BMP2 inducible kinase (BMP2K), transcript variant 1, mRNA. 
7989323 BNIP2 0.34 0.40 1.07 1.13 1.21 1.03 1.06 1.10   BCL2/adenovirus E1B 19kDa interacting protein 2 (BNIP2), mRNA. 
8009382 BPTF 0.40 0.26 0.93 0.85 0.84 0.66 0.96 0.77   bromodomain PHD finger transcription factor (BPTF), transcript variant 2, mRNA. 
8171006 BRCC3 0.20 0.29 0.96 0.96 0.85 0.92 0.89 0.95   BRCA1/BRCA2-containing complex, subunit 3 (BRCC3), transcript variant 1, mRNA. 
8070341 BRWD1 0.39 0.24 0.90 0.92 1.02 0.54 0.87 0.60   bromodomain and WD repeat domain containing 1 (BRWD1), transcript variant 2, mRNA. 
8173766 BRWD3 0.36 0.28 0.82 1.02 0.97 0.74 0.85 0.74   bromodomain and WD repeat domain containing 3 (BRWD3), mRNA. 
7929201 BTAF1 0.45 0.38 1.11 1.10 1.35 1.24 1.02 1.11   BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae) (BTAF1), mRNA. 
7936419 C10orf118 0.21 0.13 0.93 1.15 1.02 0.43 0.90 0.76   chromosome 10 open reading frame 118 (C10orf118), mRNA. 
7929609 C10orf12 0.32 0.31 0.93 1.21 1.17 1.15 0.77 0.90   chromosome 10 open reading frame 12, mRNA (cDNA clone MGC:17862 IMAGE:3903728), complete cds. 
7925978 C10orf18 0.37 0.23 1.08 1.15 1.24 0.96 1.08 0.91   chromosome 10 open reading frame 18 (C10orf18), mRNA. 
7961964 C12orf11 0.31 0.29 0.89 0.80 0.99 0.77 0.97 0.80   chromosome 12 open reading frame 11 (C12orf11), mRNA. 
7954711 C12orf35 0.26 0.23 1.32 1.36 0.66 0.45 0.98 0.93   chromosome 12 open reading frame 35 (C12orf35), mRNA. 
7960411 C12orf4 0.21 0.24 1.02 0.97 1.17 1.16 1.08 1.20   chromosome 12 open reading frame 4 (C12orf4), mRNA. 
7953211 C12orf5 0.34 0.48 0.83 0.76 0.77 0.77 0.68 0.67   chromosome 12 open reading frame 5 (C12orf5), mRNA. 
7968883 C13orf31 0.30 0.18 0.96 1.02 0.81 0.70 0.77 0.89   chromosome 13 open reading frame 31 (C13orf31), transcript variant 2, mRNA. 
7976571 C14orf129 0.36 0.37 0.95 1.01 0.89 0.96 0.93 1.39   chromosome 14 open reading frame 129 (C14orf129), mRNA. 
7916506 C1orf168 0.40 0.16 1.07 0.68 1.19 0.56 1.77 2.28   chromosome 1 open reading frame 168 (C1orf168), mRNA. 
7908330 C1orf27 0.31 0.43 1.04 0.99 1.17 0.85 0.71 0.76   chromosome 1 open reading frame 27 (C1orf27), transcript variant 1, mRNA. 
7909931 C1orf58 0.35 0.45 1.04 0.98 1.12 1.00 1.05 1.13   chromosome 1 open reading frame 58 (C1orf58), mRNA. 
7907404 C1orf9 0.24 0.32 1.15 1.71 0.86 0.99 0.92 1.20   chromosome 1 open reading frame 9 (C1orf9), transcript variant 1, mRNA. 
8075542 C22orf30 0.39 0.28 1.17 1.15 1.07 0.95 1.14 0.92   chromosome 22 open reading frame 30 (C22orf30), mRNA. 
8079170 C3orf23 0.40 0.41 0.93 1.05 1.11 1.18 1.19 1.39   chromosome 3 open reading frame 23 (C3orf23), transcript variant 1, mRNA. 
8098512 C4orf41 0.36 0.49 0.92 0.72 0.92 0.83 0.95 0.77   chromosome 4 open reading frame 41 (C4orf41), transcript variant 1, mRNA. 
8163839 C5 0.32 0.06 0.84 0.38 0.64 0.22 0.52 0.25   complement component 5 (C5), mRNA. 
8108163 C5orf24 0.35 0.38 1.08 1.01 0.82 0.80 0.82 0.71   chromosome 5 open reading frame 24 (C5orf24), transcript variant 2, mRNA. 
8111552 C5orf33 0.39 0.47 0.87 0.78 0.84 0.62 0.72 0.45   chromosome 5 open reading frame 33 (C5orf33), transcript variant 1, mRNA. 
8110032 C5orf41 0.43 0.29 1.29 0.97 1.09 0.63 1.79 1.23   chromosome 5 open reading frame 41 (C5orf41), transcript variant 1, mRNA. 
8105104 C5orf51 0.22 0.35 0.98 1.17 0.93 1.17 1.00 1.08   chromosome 5 open reading frame 51 (C5orf51), mRNA. 
8127502 C6orf155 0.45 0.36 0.92 1.26 0.64 0.76 0.79 0.71   chromosome 6 open reading frame 155 (C6orf155), non-coding RNA. 
8122818 C6orf211 0.43 0.49 0.90 0.85 0.83 1.06 0.77 0.85   chromosome 6 open reading frame 211, mRNA (cDNA clone MGC:16862 IMAGE:4340090), complete cds. 
8156601 C9orf102 0.24 0.12 1.03 0.79 0.98 0.50 1.10 0.76   mRNA; cDNA DKFZp434O1521 (from clone DKFZp434O1521). 
8161829 C9orf41 0.30 0.38 1.00 0.88 0.83 0.89 0.68 0.57   chromosome 9 open reading frame 41, mRNA (cDNA clone MGC:24721 IMAGE:4278547), complete cds. 
8136347 CALD1 0.49 0.37 0.90 0.89 0.98 0.84 0.80 0.77   caldesmon 1 (CALD1), transcript variant 1, mRNA. 
7908614 CAMSAP1L1 0.17 0.18 1.00 1.27 0.91 1.00 0.82 0.98   calmodulin regulated spectrin-associated protein 1-like 1 (CAMSAP1L1), mRNA. 
7956910 CAND1 0.43 0.40 1.08 0.98 1.05 0.94 1.09 0.87   cullin-associated and neddylation-dissociated 1 (CAND1), mRNA. 
8078110 CAPN7 0.30 0.41 0.88 0.80 0.90 0.74 0.98 0.68   calpain 7 (CAPN7), mRNA. 
8134318 CASD1 0.24 0.33 0.92 1.03 0.64 0.81 0.65 0.50   CAS1 domain containing 1 (CASD1), mRNA. 
7927889 CCAR1 0.46 0.30 0.95 0.96 0.96 0.75 0.98 0.90   cell division cycle and apoptosis regulator 1 (CCAR1), mRNA. 
8090133 CCDC14 0.31 0.25 1.18 1.02 0.83 0.58 1.00 0.68   coiled-coil domain containing 14 (CCDC14), mRNA. 
8006112 CCDC55 0.22 0.15 1.08 1.15 0.94 0.73 0.90 1.00   coiled-coil domain containing 55 (CCDC55), transcript variant 1, mRNA. 
8052269 CCDC88A 0.17 0.12 0.99 0.77 0.72 0.33 0.82 0.50   coiled-coil domain containing 88A (CCDC88A), transcript variant 1, mRNA. 
7954613 CCDC91 0.44 0.27 1.09 0.80 0.94 0.82 0.99 0.87   coiled-coil domain containing 91 (CCDC91), mRNA. 
8109830 CCDC99 0.28 0.24 1.13 0.81 0.64 0.69 0.65 0.51   coiled-coil domain containing 99 (CCDC99), mRNA. 
8045381 CCNT2 0.43 0.35 1.17 1.16 0.97 1.00 1.19 1.12   cyclin T2 (CCNT2), transcript variant b, mRNA. 
8120102 CD2AP 0.37 0.35 1.28 1.57 1.75 1.82 1.91 2.72   CD2-associated protein (CD2AP), mRNA. 
7924773 CDC42BPA 0.22 0.19 0.71 0.98 0.94 0.99 0.89 0.83   CDC42 binding protein kinase alpha (DMPK-like) (CDC42BPA), transcript variant B, mRNA. 
8140955 CDK6 0.28 0.30 0.95 1.30 0.90 0.87 0.85 0.82   cyclin-dependent kinase 6 (CDK6), transcript variant 1, mRNA. 
8113733 CEP120 0.46 0.28 0.89 0.84 0.83 0.72 0.93 0.58   centrosomal protein 120kDa (CEP120), transcript variant 1, mRNA. 
7925525 CEP170 0.13 0.10 1.01 0.88 0.77 0.33 0.92 0.69   centrosomal protein 170kDa (CEP170), transcript variant alpha, mRNA. 
8180257 CEP170 0.21 0.13 1.13 1.04 0.92 0.56 1.16 0.83   centrosomal protein 170kDa (CEP170), transcript variant gamma, mRNA 
8020267 CEP192 0.47 0.42 1.03 0.98 1.13 0.69 1.76 1.15   centrosomal protein 192kDa (CEP192), mRNA. 
7907790 CEP350 0.25 0.15 0.95 0.90 1.09 0.45 1.06 0.78   centrosomal protein 350kDa (CEP350), mRNA. 
8081362 CEP97 0.26 0.34 1.09 1.45 0.93 1.10 0.76 1.08   centrosomal protein 97kDa (CEP97), mRNA. 
8113305 CHD1 0.40 0.20 1.20 1.38 1.33 0.77 1.10 0.97   chromodomain helicase DNA binding protein 1 (CHD1), mRNA. 
7995583 CHD9 0.21 0.10 0.89 1.08 0.90 0.42 1.02 0.83   chromodomain helicase DNA binding protein 9 (CHD9), mRNA. 
8173892 CHM 0.23 0.19 0.81 0.97 0.81 0.77 0.86 0.88   choroideremia (Rab escort protein 1) (CHM), transcript variant 1, mRNA. 
7925500 CHML 0.31 0.19 1.03 1.19 0.88 0.55 0.68 0.55   choroideremia-like (Rab escort protein 2) (CHML), mRNA. 
8022666 CHST9 0.31 0.37 0.88 0.87 0.55 0.57 0.58 0.58   carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9 (CHST9), mRNA. 
7935707 CHUK 0.31 0.48 1.11 1.00 1.18 1.07 0.91 0.85   conserved helix-loop-helix ubiquitous kinase (CHUK), mRNA. 
7969243 CKAP2 0.27 0.22 1.22 1.04 0.82 0.74 0.90 1.05   cytoskeleton associated protein 2 (CKAP2), transcript variant 1, mRNA. 
7947694 CKAP5 0.31 0.39 1.04 1.26 1.06 1.01 0.87 0.89   cytoskeleton associated protein 5 (CKAP5), transcript variant 1, mRNA. 
8098291 CLCN3 0.30 0.41 0.70 0.85 0.85 1.04 0.91 0.89   chloride channel 3 (CLCN3), transcript variant e, mRNA. 
7967255 CLIP1 0.36 0.25 1.10 1.08 1.03 0.98 0.98 0.94   CAP-GLY domain containing linker protein 1 (CLIP1), transcript variant 1, mRNA. 
8144279 CLN8 0.53 0.61 0.49 0.44 0.79 0.90 0.55 0.32   ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental retardation) (CLN8), mRNA. 
8100428 CLOCK 0.22 0.18 0.94 0.75 0.68 0.72 0.92 0.82   clock homolog (mouse) (CLOCK), mRNA. 
8008834 CLTC 0.39 0.46 0.87 0.98 1.05 1.11 0.99 0.96   clathrin, heavy chain (Hc) (CLTC), mRNA. 
8056343 COBLL1 0.29 0.34 0.83 1.27 0.94 1.19 1.14 1.63   COBL-like 1 (COBLL1), mRNA. 
7968711 COG6 0.26 0.26 0.96 1.29 0.95 1.08 0.95 1.14   component of oligomeric golgi complex 6 (COG6), transcript variant 1, mRNA. 
7946703 COPB1 0.28 0.38 0.87 1.01 0.97 1.02 0.91 0.94   coatomer protein complex, subunit beta 1 (COPB1), transcript variant 1, mRNA. 
7988605 COPS2 0.19 0.25 0.97 0.86 0.82 0.75 0.80 0.82   COP9 constitutive photomorphogenic homolog subunit 2 (Arabidopsis) (COPS2), transcript variant 1, mRNA. 
8006123 CPD 0.29 0.31 0.72 0.91 0.78 0.96 0.99 1.05   carboxypeptidase D (CPD), mRNA. 
8110055 CPEB4 0.37 0.27 0.94 1.22 0.57 0.70 0.83 0.67   cytoplasmic polyadenylation element binding protein 4 (CPEB4), mRNA. 
7962250 CPNE8 0.39 0.41 1.03 1.03 1.30 1.37 1.31 1.68   copine VIII (CPNE8), mRNA. 
7976243 CPSF2 0.36 0.38 1.00 0.77 0.87 0.88 0.98 0.71   cleavage and polyadenylation specific factor 2, 100kDa (CPSF2), mRNA. 
8081171 CRYBG3 0.23 0.09 0.95 0.91 1.07 0.61 1.06 0.89   beta-gamma crystallin domain containing 3 (CRYBG3), mRNA. 
8063283 CSE1L 0.21 0.32 0.97 0.81 0.87 0.83 0.76 0.68   CSE1 chromosome segregation 1-like (yeast) (CSE1L), mRNA. 
8107655 CSNK1G3 0.36 0.34 1.08 1.20 0.96 0.92 0.99 1.08   casein kinase 1, gamma 3 (CSNK1G3), transcript variant 1, mRNA. 
7938422 CTR9 0.30 0.32 1.00 0.97 1.00 0.95 0.97 0.88   Ctr9, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) (CTR9), mRNA. 
7933047 CUL2 0.37 0.36 1.12 0.88 1.11 0.99 1.40 1.23   cullin 2 (CUL2), mRNA. 
7943580 CUL5 0.31 0.28 0.94 0.85 0.93 0.77 0.80 0.89   cullin 5 (CUL5), mRNA. 
8057441 CWC22 0.29 0.26 1.32 1.03 1.09 0.81 1.02 1.02   CWC22 spliceosome-associated protein homolog (S. cerevisiae) (CWC22), mRNA. 
8067955 CXADR 0.35 0.45 0.92 1.38 0.74 1.06 0.79 0.89   coxsackie virus and adenovirus receptor (CXADR), mRNA. 
8120943 CYB5R4 0.42 0.45 0.91 0.75 0.90 0.85 1.08 0.87   cytochrome b5 reductase 4 (CYB5R4), mRNA. 
8166730 CYBB 0.49 0.09 0.62 0.07 1.07 0.10 1.86 0.12   cytochrome b-245, beta polypeptide (CYBB), mRNA. 
8028963 CYP2B6 1.94 0.17 0.36 0.05 1.18 0.16 0.55 0.08   cytochrome P450, family 2, subfamily B, polypeptide 6 (CYP2B6), mRNA. 
8028955 CYP2B7P1 1.64 0.25 0.34 0.10 1.32 0.23 0.56 0.12   cytochrome P450, family 2, subfamily B, polypeptide 7 pseudogene 1 (CYP2B7P1), non-coding RNA. 
7974697 DAAM1 0.38 0.30 1.03 1.19 0.91 1.03 0.92 1.01   dishevelled associated activator of morphogenesis 1 (DAAM1), mRNA. 
7918008 DBT 0.41 0.39 1.01 0.99 0.84 0.84 0.76 0.83   dihydrolipoamide branched chain transacylase E2 (DBT), nuclear gene encoding mitochondrial protein, mRNA. 
8107356 DCP2 0.50 0.32 0.80 0.69 1.05 0.83 0.80 0.68   DCP2 decapping enzyme homolog (S. cerevisiae) (DCP2), mRNA. 
8092321 DCUN1D1 0.30 0.21 1.21 1.01 0.82 0.72 1.11 0.82   DCN1, defective in cullin neddylation 1, domain containing 1 (S. cerevisiae) (DCUN1D1), mRNA. 
8095009 DCUN1D4 0.43 0.39 1.08 0.97 1.06 0.90 0.84 0.83   DCN1, defective in cullin neddylation 1, domain containing 4 (S. cerevisiae) (DCUN1D4), transcript variant 1, mRNA. 
7979223 DDHD1 0.36 0.43 1.00 1.05 0.90 0.91 1.01 0.80   DDHD domain containing 1 (DDHD1), transcript variant 3, mRNA. 
7943690 DDX10 0.38 0.38 1.03 0.90 0.84 0.69 0.71 0.41   DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 (DDX10), mRNA. 
8044745 DDX18 0.23 0.33 1.11 0.90 0.83 0.73 0.67 0.61   DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 (DDX18), mRNA. 
7927936 DDX21 0.33 0.27 1.26 1.21 1.52 1.82 0.78 1.05   DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 (DDX21), mRNA. 
8176624 DDX3Y 0.39 0.20 0.88 0.66 1.02 0.65 0.91 0.78   DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked (DDX3Y), transcript variant 1, mRNA. 
8108134 DDX46 0.37 0.32 0.91 0.75 1.24 1.15 0.78 0.77   DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 (DDX46), mRNA. 
8124144 DEK 0.43 0.29 1.30 0.95 1.33 0.84 0.96 1.02   DEK oncogene (DEK), transcript variant 1, mRNA. 
7923131 DENND1B 0.39 0.19 1.14 1.12 1.26 0.78 1.67 1.35   DENN/MADD domain containing 1B (DENND1B), transcript variant 1, mRNA. 
7989849 DENND4A 0.39 0.19 0.91 0.75 2.01 1.09 1.57 1.31   DENN/MADD domain containing 4A (DENND4A), transcript variant 1, mRNA. 
8154531 DENND4C 0.32 0.20 0.97 0.91 0.85 0.73 1.23 0.89   DENN/MADD domain containing 4C (DENND4C), mRNA. 
7962151 DENND5B 0.48 0.49 0.82 0.92 0.84 0.88 1.11 0.71   DENN/MADD domain containing 5B (DENND5B), mRNA. 
8112081 DHX29 0.29 0.17 1.03 0.97 0.91 0.88 0.86 0.74   DEAH (Asp-Glu-Ala-His) box polypeptide 29 (DHX29), mRNA. 
8091562 DHX36 0.37 0.28 1.01 1.05 1.60 1.02 1.25 1.04   DEAH (Asp-Glu-Ala-His) box polypeptide 36 (DHX36), transcript variant 1, mRNA. 
8051637 DHX57 0.43 0.49 1.27 0.97 0.87 0.95 1.00 0.92   DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 57 (DHX57), mRNA. 
8168691 DIAPH2 0.36 0.19 0.76 0.82 1.13 0.62 0.75 0.71   diaphanous homolog 2 (Drosophila) (DIAPH2), transcript variant 156, mRNA. 
7981111 DICER1 0.21 0.19 0.93 0.89 1.19 1.02 1.06 1.03   dicer 1, ribonuclease type III (DICER1), transcript variant 1, mRNA. 
7901565 DIO1 1.93 0.54 0.48 0.20 1.26 0.48 0.71 0.23   deiodinase, iodothyronine, type I (DIO1), transcript variant 1, mRNA. 
7971967 DIS3 0.24 0.24 1.15 1.03 0.95 0.93 1.03 1.03   DIS3 mitotic control homolog (S. cerevisiae) (DIS3), transcript variant 1, mRNA. 
8093191 DLG1 0.37 0.34 0.78 0.74 0.76 0.78 0.63 0.54   discs, large homolog 1 (Drosophila) (DLG1), transcript variant 1, mRNA. 
8133914 DMTF1 0.42 0.36 1.38 1.35 1.61 1.04 1.84 1.46   cyclin D binding myb-like transcription factor 1 (DMTF1), transcript variant 4, non-coding RNA. 
8107474 DMXL1 0.26 0.14 0.86 0.80 1.05 0.57 0.84 0.75   Dmx-like 1 (DMXL1), mRNA. 
7988789 DMXL2 0.23 0.09 0.99 0.68 0.84 0.43 1.15 0.65   Dmx-like 2 (DMXL2), transcript variant 1, mRNA. 
8101934 DNAJB14 0.38 0.40 1.15 1.27 1.34 0.83 1.05 0.90   DnaJ (Hsp40) homolog, subfamily B, member 14 (DNAJB14), transcript variant 1, mRNA. 
7902512 DNAJB4 0.29 0.37 1.30 1.31 0.97 1.06 0.79 0.82   DnaJ (Hsp40) homolog, subfamily B, member 4 (DNAJB4), mRNA. 
8046759 DNAJC10 0.23 0.35 0.90 1.06 0.92 0.97 0.87 1.13   DnaJ (Hsp40) homolog, subfamily C, member 10 (DNAJC10), mRNA. 
8082688 DNAJC13 0.20 0.11 0.75 0.60 0.97 0.66 0.87 0.66   DnaJ (Hsp40) homolog, subfamily C, member 13 (DNAJC13), mRNA. 
8141898 DNAJC2 0.46 0.34 1.10 0.99 1.07 0.87 0.92 0.83   DnaJ (Hsp40) homolog, subfamily C, member 2 (DNAJC2), transcript variant 1, mRNA. 
7969651 DNAJC3 0.41 0.49 0.70 0.97 1.11 1.07 0.83 1.17   DnaJ (Hsp40) homolog, subfamily C, member 3 (DNAJC3), mRNA. 
7954752 DNM1L 0.24 0.23 1.04 0.94 0.92 0.94 0.89 1.03   dynamin 1-like (DNM1L), transcript variant 1, mRNA. 
7917771 DNTTIP2 0.30 0.14 1.01 1.16 0.81 0.66 0.68 0.65   deoxynucleotidyltransferase, terminal, interacting protein 2 (DNTTIP2), mRNA. 
8142345 DOCK4 0.35 0.33 0.89 0.95 1.12 0.77 2.00 1.33   dedicator of cytokinesis 4 (DOCK4), mRNA. 
7916669 DOCK7 0.28 0.27 0.92 0.94 1.13 1.01 1.13 0.99   dedicator of cytokinesis 7 (DOCK7), mRNA. 
8147375 DPY19L4 0.47 0.43 1.11 1.09 0.93 0.93 0.84 0.85   dpy-19-like 4 (C. elegans) (DPY19L4), mRNA. 
7917912 DPYD 0.49 0.26 0.90 0.73 0.98 0.50 2.13 1.21   dihydropyrimidine dehydrogenase (DPYD), transcript variant 1, mRNA. 
8127234 DST 0.29 0.08 0.73 0.88 0.89 0.28 0.68 0.72   dystonin (DST), transcript variant 1eA, mRNA. 
8172035 DYNLT3 0.29 0.42 0.78 1.10 1.06 1.18 0.98 1.27   dynein, light chain, Tctex-type 3 (DYNLT3), mRNA. 
8129379 ECHDC1 0.37 0.33 0.72 0.58 1.07 0.79 0.92 0.89   enoyl CoA hydratase domain containing 1 (ECHDC1), transcript variant 1, mRNA. 
8083941 ECT2 0.34 0.37 1.07 1.35 1.17 1.25 1.13 1.78   epithelial cell transforming sequence 2 oncogene (ECT2), mRNA. 
7922823 EDEM3 0.18 0.12 0.97 0.94 0.75 0.68 0.91 0.80   ER degradation enhancer, mannosidase alpha-like 3 (EDEM3), mRNA. 
7965436 EEA1 0.15 0.08 0.99 0.98 0.98 0.47 0.83 0.79   early endosome antigen 1 (EEA1), mRNA. 
8148333 EFR3A 0.46 0.50 1.06 1.18 1.45 1.27 1.48 1.58   EFR3 homolog A (S. cerevisiae) (EFR3A), mRNA. 
8042223 EHBP1 0.38 0.31 1.18 1.13 1.17 1.03 1.40 1.38   EH domain binding protein 1 (EHBP1), transcript variant 1, mRNA. 
8092523 EHHADH 0.32 0.31 0.86 0.55 0.74 0.66 0.78 0.60   enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase (EHHADH), transcript variant 1, mRNA. 
7936614 EIF3A 0.38 0.32 0.91 0.95 0.96 1.11 0.84 0.90   eukaryotic translation initiation factor 3, subunit A (EIF3A), mRNA. 
8043861 EIF5B 0.26 0.09 1.05 1.16 0.97 0.68 0.82 0.95   eukaryotic translation initiation factor 5B (EIF5B), mRNA. 
7917182 ELTD1 0.28 0.18 0.89 0.26 1.70 0.28 2.33 0.35   EGF, latrophilin and seven transmembrane domain containing 1 (ELTD1), mRNA. 
8122099 ENPP1 0.42 0.46 0.87 0.53 0.92 0.55 0.78 0.39   ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), mRNA. 
8120061 ENPP4 0.45 0.44 1.17 1.02 1.09 0.99 1.15 1.02   ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) (ENPP4), mRNA. 
8045619 EPC2 0.35 0.31 1.05 1.07 0.98 0.80 1.06 0.86   enhancer of polycomb homolog 2 (Drosophila) (EPC2), mRNA. 
8086141 EPM2AIP1 0.32 0.49 1.05 0.98 0.95 0.91 0.99 0.66   EPM2A (laforin) interacting protein 1 (EPM2AIP1), mRNA. 
7924351 EPRS 0.21 0.20 0.81 0.81 0.97 0.89 0.91 0.94   glutamyl-prolyl-tRNA synthetase (EPRS), mRNA. 
8105681 ERBB2IP 0.20 0.19 1.04 0.90 0.92 0.76 0.98 0.95   erbb2 interacting protein (ERBB2IP), transcript variant 2, mRNA. 
7962013 ERGIC2 0.39 0.36 0.87 0.69 0.81 0.74 0.79 0.74   ERGIC and golgi 2 (ERGIC2), mRNA. 
7917707 EVI5 0.32 0.44 0.84 0.87 1.21 0.79 0.77 0.59   ecotropic viral integration site 5 (EVI5), mRNA. 
8095163 EXOC1 0.31 0.41 1.15 1.19 1.00 0.98 1.02 1.07   exocyst complex component 1 (EXOC1), transcript variant 3, mRNA. 
7979367 EXOC5 0.12 0.15 1.08 0.97 0.95 0.91 0.96 1.05   exocyst complex component 5 (EXOC5), mRNA. 
7929288 EXOC6 0.46 0.43 0.87 0.85 0.89 1.01 1.00 1.08   exocyst complex component 6 (EXOC6), transcript variant 1, mRNA. 
8170215 F9 0.29 0.09 0.48 0.18 0.88 0.25 0.54 0.20   coagulation factor IX (F9), mRNA. 
8180403 FAM115A 0.45 0.36 0.94 0.90 0.87 0.74 0.86 0.82   KIAA0738 gene product (KIAA0738), mRNA 
8138553 FAM126A 0.44 0.42 0.78 0.73 1.12 0.94 0.89 1.16   family with sequence similarity 126, member A (FAM126A), mRNA. 
8114326 FAM13B 0.40 0.35 1.10 0.99 1.08 0.99 1.14 0.98   family with sequence similarity 13, member B (FAM13B), transcript variant 1, mRNA. 
8113083 FAM172A 0.42 0.50 0.68 0.82 0.87 1.04 0.59 0.58   family with sequence similarity 172, member A (FAM172A), transcript variant 1, mRNA. 
7931216 FAM175B 0.45 0.49 1.14 0.96 0.98 1.12 0.97 1.10   family with sequence similarity 175, member B (FAM175B), mRNA. 
7928800 FAM190B 0.31 0.31 0.88 0.94 1.19 1.09 1.10 1.20   family with sequence similarity 190, member B (FAM190B), mRNA. 
7927267 FAM35A 0.29 0.28 0.82 0.72 0.83 0.80 0.82 0.75   family with sequence similarity 35, member B (FAM35B), non-coding RNA. 
7927288 FAM35A 0.38 0.31 0.83 0.77 0.91 0.79 0.85 0.73   family with sequence similarity 35, member B2 (FAM35B2), non-coding RNA. 
7928909 FAM35A 0.42 0.38 0.88 0.82 0.94 1.07 0.83 0.81   family with sequence similarity 35, member A (FAM35A), mRNA. 
7917728 FAM69A 0.32 0.46 1.02 1.23 0.69 0.77 0.67 0.68   family with sequence similarity 69, member A (FAM69A), mRNA. 
7902476 FAM73A 0.44 0.43 0.84 1.15 1.29 1.19 0.82 0.85   mRNA; cDNA DKFZp686M07166 (from clone DKFZp686M07166); complete cds. 
8148208 FAM91A1 0.39 0.35 1.03 0.96 1.01 1.09 1.11 0.86   family with sequence similarity 91, member A1 (FAM91A1), mRNA. 
8047815 FASTKD2 0.44 0.36 1.00 0.72 1.05 0.88 0.78 0.59   FAST kinase domains 2 (FASTKD2), transcript variant 1, mRNA. 
8104079 FAT1 0.37 0.38 0.69 0.86 0.70 0.80 0.63 0.52   FAT tumor suppressor homolog 1 (Drosophila) (FAT1), mRNA. 
7909992 FBXO28 0.38 0.48 1.00 1.07 1.02 1.13 0.77 0.76   F-box protein 28 (FBXO28), transcript variant 1, mRNA. 
8130032 FBXO30 0.40 0.29 1.18 0.85 1.18 0.85 0.80 0.62   F-box protein 30 (FBXO30), mRNA. 
8106141 FCHO2 0.25 0.20 1.16 0.99 0.67 0.56 1.26 1.03   FCH domain only 2 (FCHO2), transcript variant 1, mRNA. 
7954729 FGD4 0.44 0.40 1.06 1.49 0.71 0.71 0.66 0.68   FYVE, RhoGEF and PH domain containing 4 (FGD4), mRNA. 
8097256 FGF2 0.47 0.39 1.05 0.69 0.86 0.70 0.75 0.48   fibroblast growth factor 2 (basic) (FGF2), mRNA. 
8056323 FIGN 0.36 0.30 1.09 1.30 0.62 0.63 0.90 0.71   fidgetin (FIGN), mRNA. 
8144228 FLJ36840 0.29 0.19 0.89 0.47 1.80 0.41 1.68 0.35   cDNA FLJ36840 fis, clone ASTRO2011461. 
8065071 FLRT3 0.39 0.41 1.10 1.04 0.61 0.77 0.59 0.67   fibronectin leucine rich transmembrane protein 3 (FLRT3), transcript variant 2, mRNA. 
8045736 FMNL2 0.31 0.29 0.99 0.87 0.73 0.70 1.01 1.05   formin-like 2 (FMNL2), mRNA. 
7903092 FNBP1L 0.20 0.20 1.03 1.16 0.76 0.94 0.68 0.82   formin binding protein 1-like (FNBP1L), transcript variant 1, mRNA. 
7969060 FNDC3A 0.31 0.25 1.17 1.31 0.93 0.84 1.03 0.91   fibronectin type III domain containing 3A (FNDC3A), transcript variant 1, mRNA. 
8113914 FNIP1 0.26 0.23 1.12 1.08 1.09 1.01 1.15 0.90   folliculin interacting protein 1 (FNIP1), transcript variant 1, mRNA. 
8129071 FRK 0.25 0.23 0.86 1.03 0.76 0.69 1.01 0.69   fyn-related kinase (FRK), mRNA. 
7957043 FRS2 0.38 0.45 1.34 1.32 1.01 1.07 1.13 1.25   fibroblast growth factor receptor substrate 2 (FRS2), transcript variant 1, mRNA. 
8100292 FRYL 0.52 0.36 1.01 0.96 1.33 0.89 1.30 1.14   FRY-like (FRYL), mRNA. 
8084146 FXR1 0.33 0.40 1.02 0.94 1.03 0.88 0.90 0.82   fragile X mental retardation, autosomal homolog 1 (FXR1), transcript variant 3, mRNA. 
8133030 GABPA 0.29 0.20 1.02 1.02 0.73 0.82 0.73 0.98   GA binding protein transcription factor, alpha subunit 60kDa (GABPA), mRNA. 
8020903 GALNT1 0.22 0.36 0.80 1.03 0.88 1.15 0.75 0.84   UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) (GALNT1), mRNA. 
8044236 GCC2 0.18 0.06 1.30 1.25 0.84 0.32 1.04 0.92   GRIP and coiled-coil domain containing 2 (GCC2), transcript variant 1, mRNA. 
8040440 GEN1 0.29 0.22 0.97 0.92 1.29 1.01 1.07 0.87   Gen homolog 1, endonuclease (Drosophila) (GEN1), transcript variant 1, mRNA. 
7984517 GLCE 0.33 0.45 0.88 0.91 0.85 0.76 0.97 0.68   glucuronic acid epimerase (GLCE), mRNA. 
8180344 GNAQ 0.36 0.48 0.93 1.12 0.98 1.19 0.84 0.99   guanine nucleotide binding protein (G protein), q polypeptide (GNAQ), mRNA 
8161906 GNAQ 0.34 0.47 1.00 1.11 1.03 1.10 0.96 0.98   guanine nucleotide binding protein (G protein), q polypeptide (GNAQ), mRNA. 
8080419 GNL3 0.42 0.50 1.20 1.18 0.99 1.13 0.63 0.78   guanine nucleotide binding protein-like 3 (nucleolar) (GNL3), transcript variant 2, mRNA. 
7965812 GNPTAB 0.33 0.32 0.72 0.75 0.78 0.88 0.81 0.69   N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits (GNPTAB), mRNA. 
8078569 GOLGA4 0.21 0.07 0.76 0.74 0.77 0.31 0.78 0.71   golgin A4 (GOLGA4), transcript variant 2, mRNA. 
8089930 GOLGB1 0.25 0.15 0.78 0.83 1.03 0.24 1.02 0.80   golgin B1 (GOLGB1), mRNA. 
8091954 GOLIM4 0.31 0.23 0.86 0.82 0.83 0.75 0.93 0.72   golgi integral membrane protein 4 (GOLIM4), mRNA. 
8129181 GOPC 0.45 0.44 1.02 1.47 0.95 1.03 0.96 1.06   golgi-associated PDZ and coiled-coil motif containing (GOPC), transcript variant 1, mRNA. 
8122365 GPR126 0.28 0.27 1.01 1.11 0.83 0.80 0.81 0.72   G protein-coupled receptor 126 (GPR126), transcript variant a1, mRNA. 
7980523 GTF2A1 0.37 0.40 0.90 1.01 1.02 1.17 1.07 0.97   general transcription factor IIA, 1, 19/37kDa (GTF2A1), transcript variant 1, mRNA. 
8094876 GUF1 0.36 0.38 1.01 0.68 0.97 0.84 0.77 0.63   GUF1 GTPase homolog (S. cerevisiae) (GUF1), mRNA. 
7962349 GXYLT1 0.43 0.34 0.85 0.81 0.84 0.66 0.67 0.53   glucoside xylosyltransferase 1 (GXYLT1), transcript variant 1, mRNA. 
8132843 HAUS6 0.22 0.20 0.73 0.96 1.06 0.77 0.82 0.55   HAUS augmin-like complex, subunit 6 (HAUS6), mRNA. 
7925364 HEATR1 0.25 0.28 0.90 0.72 0.90 0.94 0.60 0.55   HEAT repeat containing 1 (HEATR1), mRNA. 
7978492 HEATR5A 0.26 0.28 0.84 0.78 0.86 0.98 0.87 0.79   HEAT repeat containing 5A (HEATR5A), mRNA. 
8051464 HEATR5B 0.47 0.43 0.93 0.99 1.03 1.00 1.03 0.87   HEAT repeat containing 5B (HEATR5B), mRNA. 
7978449 HECTD1 0.32 0.21 0.83 0.83 0.88 0.89 0.73 0.61   HECT domain containing 1 (HECTD1), mRNA. 
8017776 HELZ 0.38 0.34 1.12 1.06 0.88 0.88 1.05 0.97   helicase with zinc finger (HELZ), mRNA. 
7974851 HIF1A 0.37 0.35 1.03 0.94 1.00 0.99 1.05 1.27   hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) (HIF1A), transcript variant 1, mRNA. 
7939197 HIPK3 0.34 0.47 1.02 1.15 1.32 1.38 1.14 1.64   homeodomain interacting protein kinase 3 (HIPK3), transcript variant 1, mRNA. 
8116910 HIVEP1 0.46 0.44 1.05 1.32 1.26 0.93 1.07 1.07   human immunodeficiency virus type I enhancer binding protein 1 (HIVEP1), mRNA. 
8091354 HLTF 0.23 0.12 0.76 0.60 0.93 0.40 0.57 0.43   helicase-like transcription factor (HLTF), transcript variant 1, mRNA. 
7919055 HMGCS2 0.73 0.92 0.45 0.26 0.58 0.67 3.02 0.54   3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) (HMGCS2), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 
8045499 HNMT 0.45 0.48 0.96 0.97 1.23 0.87 1.72 1.43   histamine N-methyltransferase (HNMT), transcript variant 1, mRNA. 
8146243 HOOK3 0.27 0.27 0.74 1.02 0.88 1.01 0.83 0.93   hook homolog 3 (Drosophila) (HOOK3), mRNA. 
7902789 HS2ST1 0.40 0.44 0.82 0.99 0.91 0.99 0.73 0.76   heparan sulfate 2-O-sulfotransferase 1 (HS2ST1), transcript variant 1, mRNA. 
8157233 HSDL2 0.33 0.41 0.81 0.54 0.71 0.68 0.89 0.78   hydroxysteroid dehydrogenase like 2 (HSDL2), mRNA. 
7981335 HSP90AA1 0.43 0.37 1.04 0.82 0.93 0.90 0.98 1.02   heat shock protein 90kDa alpha (cytosolic), class A member 1 (HSP90AA1), transcript variant 1, mRNA. 
7947245 HSP90AA2 0.46 0.49 0.88 0.77 0.89 0.97 1.02 1.40  Human heat shock protein 86 mRNA, 5'end. 
7958130 HSP90B1 0.50 0.43 0.85 0.94 0.95 0.80 0.84 0.89   heat shock protein 90kDa beta (Grp94), member 1 (HSP90B1), mRNA. 
8069532 HSPA13 0.37 0.35 1.00 1.13 1.16 0.94 0.98 1.12   heat shock protein 70kDa family, member 13 (HSPA13), mRNA. 
8097335 HSPA4L 0.14 0.08 0.86 0.45 0.75 0.39 0.62 0.35   heat shock 70kDa protein 4-like (HSPA4L), mRNA. 
7970864 HSPH1 0.36 0.29 1.13 0.96 1.05 0.87 0.84 0.74   heat shock 105kDa/110kDa protein 1 (HSPH1), mRNA. 
8127787 IBTK 0.42 0.19 0.86 1.00 1.38 1.05 0.88 0.96   inhibitor of Bruton agammaglobulinemia tyrosine kinase (IBTK), mRNA. 
8127109 ICK 0.47 0.43 1.13 1.07 0.80 0.78 0.87 0.77   intestinal cell (MAK-like) kinase (ICK), transcript variant 2, mRNA. 
7935027 IDE 0.29 0.24 0.76 0.77 1.01 1.02 0.79 0.95   insulin-degrading enzyme (IDE), transcript variant 1, mRNA. 
8154670 IFT74 0.41 0.41 1.52 1.55 1.17 0.93 0.99 1.33   intraflagellar transport 74 homolog (Chlamydomonas) (IFT74), transcript variant 1, mRNA. 
8091737 IFT80 0.22 0.15 1.00 1.17 0.84 0.57 0.92 0.82   intraflagellar transport 80 homolog (Chlamydomonas) (IFT80), mRNA. 
7965873 IGF1 0.42 0.49 0.95 0.93 0.85 0.97 0.55 0.95   insulin-like growth factor 1 (somatomedin C) (IGF1), transcript variant 1, mRNA. 
7936826 IKZF5 0.43 0.47 1.52 1.43 0.97 1.10 1.13 1.18   IKAROS family zinc finger 5 (Pegasus) (IKZF5), mRNA. 
8112139 IL6ST 0.33 0.16 1.02 0.86 1.06 0.63 1.07 1.00   interleukin 6 signal transducer (gp130, oncostatin M receptor) (IL6ST), transcript variant 1, mRNA. 
8150906 IMPAD1 0.25 0.39 0.77 0.48 0.58 0.82 0.58 0.66   inositol monophosphatase domain containing 1 (IMPAD1), mRNA. 
8058415 INO80D 0.37 0.40 1.12 1.46 1.26 1.04 1.50 1.17   INO80 complex subunit D (INO80D), mRNA. 
8017283 INTS2 0.47 0.36 1.15 1.15 1.19 0.95 1.01 0.93   integrator complex subunit 2 (INTS2), transcript variant 2, transcribed RNA. 
7933723 IPMK 0.42 0.27 0.97 0.98 0.93 0.96 0.88 0.80   inositol polyphosphate multikinase (IPMK), mRNA. 
8105545 IPO11 0.25 0.33 0.84 0.69 0.88 0.87 0.86 0.78   importin 11 (IPO11), transcript variant 2, mRNA. 
7938313 IPO7 0.19 0.26 0.89 0.83 0.95 0.83 0.83 0.77   importin 7 (IPO7), mRNA. 
7962085 IPO8 0.32 0.46 0.83 0.79 1.17 0.93 0.84 0.84   importin 8 (IPO8), mRNA. 
7986010 IQGAP1 0.26 0.40 1.01 1.27 1.09 1.19 1.16 1.27   IQ motif containing GTPase activating protein 1 (IQGAP1), mRNA. 
8106354 IQGAP2 0.22 0.09 0.90 0.50 0.84 0.44 1.25 0.57   IQ motif containing GTPase activating protein 2 (IQGAP2), mRNA. 
7985166 IREB2 0.33 0.28 1.04 1.01 1.04 0.99 0.92 0.86   iron-responsive element binding protein 2 (IREB2), mRNA. 
8046861 ITGAV 0.31 0.27 0.81 0.90 0.97 0.94 0.73 0.88   integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) (ITGAV), transcript variant 1, mRNA. 
8056184 ITGB6 0.29 0.20 0.75 0.56 0.81 0.68 0.78 0.69   integrin, beta 6 (ITGB6), mRNA. 
7961900 ITPR2 0.29 0.12 0.56 0.38 1.23 0.48 0.77 0.57   inositol 1,4,5-triphosphate receptor, type 2 (ITPR2), mRNA. 
8050719 ITSN2 0.37 0.34 0.94 1.08 1.15 0.93 1.03 0.82   intersectin 2 (ITSN2), transcript variant 1, mRNA. 
7933877 JMJD1C 0.39 0.11 1.17 1.06 1.05 0.45 1.08 0.86   jumonji domain containing 1C (JMJD1C), transcript variant 2, mRNA. 
8106516 JMY 0.32 0.23 1.00 0.87 0.84 0.63 1.11 0.68   junction mediating and regulatory protein, p53 cofactor (JMY), mRNA. 
7970844 KATNAL1 0.39 0.35 0.71 0.83 0.92 0.86 0.69 0.51   katanin p60 subunit A-like 1 (KATNAL1), transcript variant 2, mRNA. 
7909745 KCTD3 0.42 0.46 1.00 0.83 0.91 0.84 0.77 0.69   potassium channel tetramerisation domain containing 3 (KCTD3), mRNA. 
8159854 KIAA0020 0.39 0.43 0.97 1.10 1.30 0.82 0.58 0.80   KIAA0020 (KIAA0020), mRNA. 
8093961 KIAA0232 0.49 0.45 0.93 1.11 0.94 1.09 1.18 1.00   KIAA0232 (KIAA0232), transcript variant 1, mRNA. 
7961767 KIAA0528 0.33 0.30 1.07 0.86 0.85 0.61 1.25 0.69   cDNA FLJ60272 complete cds. 
7974653 KIAA0586 0.27 0.24 1.07 0.93 0.74 0.66 0.93 0.67   KIAA0586 (KIAA0586), mRNA. 
8121161 KIAA0776 0.21 0.13 1.06 0.89 0.83 0.79 0.95 0.84   KIAA0776 (KIAA0776), mRNA. 
8104350 KIAA0947 0.36 0.19 1.19 0.98 1.22 1.22 1.21 1.09   KIAA0947 (KIAA0947), mRNA. 
8022767 KIAA1012 0.23 0.18 0.79 0.89 0.87 0.88 0.82 0.78   KIAA1012 (KIAA1012), mRNA. 
7958216 KIAA1033 0.35 0.22 1.10 0.96 1.34 0.74 1.28 1.03   KIAA1033 (KIAA1033), mRNA. 
8097148 KIAA1109 0.24 0.09 0.68 0.61 0.93 0.34 0.89 0.62   KIAA1109 (KIAA1109), mRNA. 
7988970 KIAA1370 0.31 0.16 0.98 1.04 0.83 0.81 1.06 0.94   KIAA1370 (KIAA1370), mRNA. 
8151842 KIAA1429 0.30 0.34 0.89 0.78 0.93 0.96 0.90 0.89   KIAA1429 (KIAA1429), transcript variant 1, mRNA. 
8103979 KIAA1430 0.35 0.27 0.84 0.84 0.85 0.76 0.80 0.72   KIAA1430 (KIAA1430), mRNA. 
8021496 KIAA1468 0.45 0.44 1.07 1.02 1.14 1.03 1.30 1.09   KIAA1468 (KIAA1468), mRNA. 
8056943 KIAA1715 0.35 0.35 0.68 0.76 0.93 1.00 0.68 0.68   KIAA1715 (KIAA1715), mRNA. 
8089647 KIAA2018 0.24 0.18 1.01 1.15 0.82 0.90 1.18 1.05   KIAA2018 (KIAA2018), mRNA. 
8160011 KIAA2026 0.15 0.11 0.99 1.13 0.98 0.66 1.16 0.82   KIAA2026 (KIAA2026), mRNA. 
8050128 KIDINS220 0.31 0.25 0.89 0.99 0.94 1.02 1.00 0.99   kinase D-interacting substrate, 220kDa (KIDINS220), mRNA. 
7962274 KIF21A 0.30 0.14 0.95 1.33 0.95 0.93 0.72 0.77   kinesin family member 21A (KIF21A), transcript variant 1, mRNA. 
8105523 KIF2A 0.33 0.36 1.05 1.14 1.40 1.51 1.51 1.72   kinesin heavy chain member 2A (KIF2A), transcript variant 1, mRNA. 
7932911 KIF5B 0.22 0.17 0.92 0.98 1.04 0.95 0.94 0.97   kinesin family member 5B (KIF5B), mRNA. 
8084219 KLHL24 0.39 0.29 0.92 0.74 0.74 0.57 0.98 0.72   kelch-like 24 (Drosophila) (KLHL24), mRNA. 
7978760 KLHL28 0.49 0.44 1.10 1.45 1.23 1.14 1.28 0.86   kelch-like 28 (Drosophila) (KLHL28), mRNA. 
7971620 KPNA3 0.31 0.36 0.86 0.90 0.93 0.90 0.89 0.91   karyopherin alpha 3 (importin alpha 4) (KPNA3), mRNA. 
8140878 KRIT1 0.39 0.41 1.06 1.10 0.97 0.80 1.08 0.85   KRIT1, ankyrin repeat containing (KRIT1), transcript variant 4, mRNA. 
7974483 KTN1 0.32 0.11 1.05 1.01 1.19 0.54 0.95 1.08   kinectin 1 (kinesin receptor) (KTN1), transcript variant 1, mRNA. 
7955361 LARP4 0.37 0.27 1.12 1.03 1.28 1.20 1.33 1.37   La ribonucleoprotein domain family, member 4 (LARP4), transcript variant 1, mRNA. 
8114861 LARS 0.33 0.49 0.84 0.74 0.83 0.69 0.69 0.48   leucyl-tRNA synthetase (LARS), mRNA. 
7929596 LCOR 0.27 0.34 1.09 1.35 1.05 1.04 1.01 1.14   ligand dependent nuclear receptor corepressor (LCOR), transcript variant 1, mRNA. 
7988838 LEO1 0.46 0.28 1.39 1.11 0.95 0.96 1.07 1.18   Leo1, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) (LEO1), mRNA. 
7972737 LIG4 0.33 0.19 0.95 1.38 1.25 0.88 1.10 1.21   ligase IV, DNA, ATP-dependent (LIG4), transcript variant 1, mRNA. 
7965156 LIN7A 0.48 0.38 0.80 0.86 0.73 0.61 0.70 0.58   lin-7 homolog A (C. elegans) (LIN7A), mRNA. 
7947221 LIN7C 0.32 0.28 0.94 0.88 0.98 0.91 0.88 0.75   lin-7 homolog C (C. elegans) (LIN7C), mRNA. 
8023561 LMAN1 0.41 0.38 0.84 0.85 0.94 0.89 0.91 1.13   lectin, mannose-binding, 1 (LMAN1), mRNA. 
8111533 LMBRD2 0.30 0.23 0.86 0.72 0.81 0.72 0.70 0.71   LMBR1 domain containing 2 (LMBRD2), mRNA. 
8085033 LMLN 0.27 0.37 0.90 0.80 0.74 0.76 1.00 0.85   leishmanolysin-like (metallopeptidase M8 family) (LMLN), transcript variant 1, mRNA. 
7995697 LPCAT2 0.39 0.27 0.86 0.37 0.69 0.56 1.46 0.51   lysophosphatidylcholine acyltransferase 2 (LPCAT2), mRNA. 
7902565 LPHN2 0.23 0.25 0.85 0.71 0.62 0.66 0.63 0.52   latrophilin 2 (LPHN2), mRNA. 
8084742 LPP 0.47 0.34 0.74 0.65 1.22 0.83 1.19 0.79   LIM domain containing preferred translocation partner in lipoma (LPP), transcript variant 1, mRNA. 
7961339 LRP6 0.44 0.33 0.79 1.14 0.75 0.83 0.76 0.68   low density lipoprotein receptor-related protein 6 (LRP6), mRNA. 
8051882 LRPPRC 0.20 0.21 0.87 0.79 0.86 0.93 0.58 0.66   leucine-rich PPR-motif containing (LRPPRC), mRNA. 
7916910 LRRC40 0.26 0.23 0.99 0.78 1.03 0.72 0.81 0.61   leucine rich repeat containing 40 (LRRC40), mRNA. 
8089830 LRRC58 0.21 0.22 1.02 0.96 0.73 0.84 0.80 0.55   leucine rich repeat containing 58 (LRRC58), mRNA. 
8122440 LTV1 0.33 0.40 1.07 0.92 1.01 0.91 0.69 0.58   LTV1 homolog (S. cerevisiae) (LTV1), mRNA. 
8113064 LYSMD3 0.18 0.21 0.92 1.16 1.02 1.13 0.90 0.96   LysM, putative peptidoglycan-binding, domain containing 3 (LYSMD3), mRNA. 
7925257 LYST 0.24 0.20 1.14 1.12 0.78 0.51 0.86 0.70   lysosomal trafficking regulator (LYST), mRNA. 
7904340 MAN1A2 0.38 0.33 0.85 1.16 1.11 1.25 0.79 0.80   mannosidase, alpha, class 1A, member 2 (MAN1A2), mRNA. 
8107234 MAN2A1 0.31 0.35 0.83 1.01 1.10 1.06 1.01 0.99   mannosidase, alpha, class 2A, member 1 (MAN2A1), mRNA. 
8121144 MANEA 0.23 0.17 0.96 0.95 0.85 0.66 1.10 0.86   mannosidase, endo-alpha (MANEA), mRNA. 
8106098 MAP1B 0.29 0.45 0.83 1.84 0.78 1.63 0.75 1.12   microtubule-associated protein 1B (MAP1B), mRNA. 
8105436 MAP3K1 0.30 0.48 1.32 1.73 0.79 1.21 1.00 1.09   mitogen-activated protein kinase kinase kinase 1 (MAP3K1), mRNA. 
8054997 MAP3K2 0.17 0.20 1.04 1.02 0.82 0.82 1.02 0.81   mitogen-activated protein kinase kinase kinase 2 (MAP3K2), mRNA. 
8051707 MAP4K3 0.40 0.35 1.16 1.49 0.66 0.82 1.02 0.97   mitogen-activated protein kinase kinase kinase kinase 3 (MAP4K3), mRNA. 
7978997 MAP4K5 0.33 0.47 1.06 1.42 1.11 1.38 1.00 1.15   mitogen-activated protein kinase kinase kinase kinase 5 (MAP4K5), transcript variant 2, mRNA. 
8175369 MAP7D3 0.28 0.30 0.97 0.82 0.79 0.90 0.67 0.60   MAP7 domain containing 3 (MAP7D3), transcript variant 1, mRNA. 
7983763 MAPK6 0.21 0.26 0.89 0.71 0.90 0.80 1.04 0.80   mitogen-activated protein kinase 6 (MAPK6), mRNA. 
8108403 MATR3 0.40 0.31 1.09 0.95 1.06 0.79 0.89 0.88   matrin 3 (MATR3), transcript variant 1, mRNA. 
8083429 MBNL1 0.34 0.27 0.94 1.01 0.99 0.73 0.86 0.61   muscleblind-like (Drosophila) (MBNL1), transcript variant 1, mRNA. 
7969677 MBNL2 0.34 0.18 1.06 0.94 0.75 0.59 0.82 0.71   muscleblind-like 2 (Drosophila) (MBNL2), transcript variant 1, mRNA. 
8175177 MBNL3 0.50 0.23 0.63 0.40 0.81 0.49 0.83 0.88   muscleblind-like 3 (Drosophila) (MBNL3), transcript variant 1, mRNA. 
8060813 MCM8 0.26 0.35 0.91 0.69 0.79 0.71 0.74 0.52   minichromosome maintenance complex component 8 (MCM8), transcript variant 1, mRNA. 
7956989 MDM2 0.39 0.37 1.05 0.76 0.86 0.64 1.06 0.72   Mdm2 p53 binding protein homolog (mouse) (MDM2), transcript variant MDM2, mRNA. 
8017312 MED13 0.40 0.40 1.22 1.41 1.31 1.12 1.24 1.18   mediator complex subunit 13 (MED13), mRNA. 
8129522 MED23 0.36 0.46 1.08 1.05 0.99 0.96 1.08 1.02   mediator complex subunit 23 (MED23), transcript variant 1, mRNA. 
8097066 METTL14 0.39 0.32 1.54 1.23 1.02 0.94 1.19 0.88   methyltransferase like 14 (METTL14), mRNA. 
8109403 MFAP3 0.28 0.37 0.92 0.87 0.79 0.94 0.83 0.82   microfibrillar-associated protein 3 (MFAP3), transcript variant 3, non-coding RNA. 
8103695 MFAP3L 0.49 0.45 0.95 0.94 0.93 0.92 0.66 0.71   microfibrillar-associated protein 3-like (MFAP3L), transcript variant 1, mRNA. 
7982957 MGA 0.35 0.26 1.24 1.08 1.08 0.77 1.17 0.85   MAX gene associated (MGA), transcript variant 1, mRNA. 
8054135 MGAT4A 0.23 0.27 0.94 0.77 0.74 0.75 1.17 1.32   mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A (MGAT4A), transcript variant 1, mRNA. 
7909898 MIA3 0.43 0.41 1.14 1.41 0.95 0.89 1.20 1.45   melanoma inhibitory activity family, member 3 (MIA3), mRNA. 
8020423 MIB1 0.39 0.35 0.73 0.77 1.06 0.84 0.60 0.58   mindbomb homolog 1 (Drosophila) (MIB1), mRNA. 
7902166 MIER1 0.46 0.48 1.38 1.58 1.69 1.13 1.65 1.65   mesoderm induction early response 1 homolog (Xenopus laevis) (MIER1), transcript variant 1, mRNA. 
8112182 MIER3 0.40 0.31 1.39 1.49 1.19 1.13 1.39 1.31   mesoderm induction early response 1, family member 3 (MIER3), mRNA. 
8131479 MIOS 0.21 0.29 0.91 0.60 0.67 0.53 0.61 0.34   missing oocyte, meiosis regulator, homolog (Drosophila) (MIOS), mRNA. 
7993310 MKL2 0.37 0.42 1.02 1.11 0.86 1.08 1.05 1.17   MKL/myocardin-like 2 (MKL2), mRNA. 
7980246 MLH3 0.42 0.30 1.10 0.98 1.04 0.59 1.20 0.85   mutL homolog 3 (E. coli) (MLH3), transcript variant 1, mRNA. 
8143988 MLL3 0.34 0.32 0.94 1.11 0.97 0.88 1.02 0.95   myeloid/lymphoid or mixed-lineage leukemia 3 (MLL3), mRNA. 
8135277 MLL5 0.25 0.22 1.24 1.22 0.97 0.91 1.12 1.04   myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax homolog, Drosophila) (MLL5), transcript variant 1, mRNA. 
8095566 MOBKL1A 0.47 0.26 0.87 0.90 1.25 0.77 1.08 0.71   MOB1, Mps One Binder kinase activator-like 1A (yeast) (MOBKL1A), mRNA. 
8047228 MOBKL3 0.24 0.42 1.07 1.07 0.90 1.07 0.91 1.09   MOB1, Mps One Binder kinase activator-like 3 (yeast) (MOBKL3), transcript variant 2, mRNA. 
7956697 MON2 0.37 0.39 0.91 0.98 1.15 0.95 1.08 0.87   MON2 homolog (S. cerevisiae) (MON2), mRNA. 
8166140 MOSPD2 0.24 0.19 1.05 1.09 1.14 0.93 1.19 1.19   motile sperm domain containing 2 (MOSPD2), transcript variant 1, mRNA. 
8160088 MPDZ 0.26 0.15 0.85 0.62 0.81 0.46 0.84 0.49   multiple PDZ domain protein (MPDZ), mRNA. 
8042588 MPHOSPH10 0.37 0.45 1.08 0.97 0.82 0.84 0.63 0.77   M-phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein) (MPHOSPH10), mRNA. 
7967386 MPHOSPH9 0.29 0.18 1.13 0.95 0.84 0.67 1.10 0.78   M-phase phosphoprotein 9 (MPHOSPH9), mRNA. 
7975203 MPP5 0.42 0.43 0.91 0.94 1.21 1.27 0.93 0.93   membrane protein, palmitoylated 5 (MAGUK p55 subfamily member 5) (MPP5), mRNA. 
8106633 MSH3 0.48 0.38 0.95 0.99 1.08 0.98 0.97 0.86   mutS homolog 3 (E. coli) (MSH3), mRNA. 
8149448 MSR1 0.47 0.06 1.04 0.06 0.63 0.07 1.20 0.06   macrophage scavenger receptor 1 (MSR1), transcript variant SR-AII, mRNA. 
8169949 MST4 0.38 0.49 0.86 0.91 0.85 0.94 0.66 0.66   serine/threonine protein kinase MST4 (MST4), transcript variant 1, mRNA. 
8052250 MTIF2 0.42 0.36 0.92 0.75 1.09 0.84 0.83 0.66   mitochondrial translational initiation factor 2 (MTIF2), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 
8170428 MTM1 0.35 0.41 0.90 1.10 0.83 0.98 1.14 0.88   myotubularin 1 (MTM1), mRNA. 
7970655 MTMR6 0.33 0.32 0.91 0.99 0.96 0.86 0.81 0.74   myotubularin related protein 6 (MTMR6), mRNA. 
7974566 MUDENG 0.43 0.45 1.02 0.96 0.82 0.84 1.09 0.96   MU-2/AP1M2 domain containing, death-inducing (MUDENG), transcript variant 1, mRNA. 
8126860 MUT 0.45 0.46 0.83 0.79 1.18 1.01 0.94 0.91   methylmalonyl Coenzyme A mutase (MUT), nuclear gene encoding mitochondrial protein, mRNA. 
7972069 MYCBP2 0.36 0.21 0.90 0.73 1.35 0.75 1.19 0.94   MYC binding protein 2 (MYCBP2), mRNA. 
7988921 MYO5A 0.37 0.28 0.74 0.50 1.04 0.84 0.82 0.56   myosin VA (heavy chain 12, myoxin) (MYO5A), transcript variant 1, mRNA. 
8120783 MYO6 0.39 0.40 0.90 1.05 1.28 1.14 1.34 1.13   myosin VI (MYO6), mRNA. 
7916592 MYSM1 0.22 0.12 1.14 0.81 0.85 0.51 0.96 0.52   Myb-like, SWIRM and MPN domains 1 (MYSM1), mRNA. 
8150491 MYST3 0.36 0.39 1.24 1.17 1.04 0.95 1.10 0.92   MYST histone acetyltransferase (monocytic leukemia) 3 (MYST3), transcript variant 1, mRNA. 
7928491 MYST4 0.41 0.31 0.99 0.99 0.77 0.68 1.17 0.89   MYST histone acetyltransferase (monocytic leukemia) 4 (MYST4), mRNA. 
7970907 N4BP2L2 0.44 0.31 0.97 0.87 1.06 0.55 1.11 0.55   NEDD4 binding protein 2-like 2 (N4BP2L2), transcript variant 2, mRNA. 
8161556 – 0.30 0.15 0.50 0.14 0.53 0.18 1.09 0.14  cdna:pseudogene chromosome:GRCh37:2:95403082:95403994:1 gene:ENSG00000213355 
8176253 – 0.25 0.14 0.61 0.61 0.59 0.31 0.75 0.60   cDNA FLJ40916 fis, clone UTERU2005533. 
8083445 – 0.14 0.13 1.14 0.92 0.68 0.26 1.18 0.37  ncrna:misc_RNA chromosome:GRCh37:3:152167061:152167173:1 gene:ENSG00000201217 
7957549 – 0.33 0.23 0.47 0.56 0.71 0.79 0.52 0.51   cDNA FLJ37555 fis, clone BRCAN2028460. 
8171024 – 0.22 0.13 0.63 0.63 0.73 0.30 0.97 0.75   cDNA FLJ45551 fis, clone BRTHA2037247. 
8092081 – 0.19 0.10 0.79 0.69 0.78 0.48 0.76 0.69  ncrna:snRNA chromosome:GRCh37:3:170712659:170712822:-1 gene:ENSG00000199488 
8063444 – 0.45 0.27 1.03 0.59 0.79 0.48 1.14 0.67  Teashirt homolog 2 gene:ENSG00000182463 
8054557 – 0.24 0.18 0.90 0.91 0.84 0.66 0.82 0.78   RANBP2-like and GRIP domain containing 5 (RGPD5), transcript variant 2, mRNA. 
8054532 – 0.23 0.17 0.88 0.98 0.87 0.64 0.82 0.82   RANBP2-like and GRIP domain containing 5 (RGPD5), transcript variant 1, mRNA. 
7927799 – 0.45 0.43 0.94 0.99 0.97 1.05 1.04 0.99   receptor accessory protein 3 (REEP3), mRNA. 
8041170 – 0.43 0.22 0.81 0.68 0.98 0.46 0.79 0.38  ncrna:snoRNA chromosome:GRCh37:2:29150849:29150926:1 gene:ENSG00000212326 
7933593 – 0.31 0.40 0.81 0.99 1.07 0.64 1.32 0.59  ncrna:snoRNA chromosome:GRCh37:10:51383526:51383726:1 gene:ENSG00000223182 
7947989 – 0.35 0.34 0.89 0.89 1.07 0.76 1.47 0.71  ncrna:misc_RNA chromosome:GRCh37:11:47748446:47748544:-1 gene:ENSG00000200090 
8149248 – 0.43 0.24 0.54 0.35 1.34 0.23 1.18 0.22   liver-related low express protein 1 (LRLE1) mRNA, complete cds. 
8145766 – 0.25 0.14 1.06 0.33 2.22 0.61 1.44 1.07  MSTP131 gene:ENSG00000227478 
7939374 – 0.41 0.29 0.88 0.90 2.60 0.55 2.32 0.43   PNAS-17 mRNA, complete cds. 
8126093 – 0.35 0.45 0.75 1.14 2.68 1.48 2.30 1.96  ncrna:snoRNA chromosome:GRCh37:6:37218980:37219082:-1 gene:ENSG00000238375 
8097480 NAA15 0.21 0.20 0.80 0.91 1.12 1.14 0.79 0.89   N(alpha)-acetyltransferase 15, NatA auxiliary subunit (NAA15), mRNA. 
7966462 NAA25 0.37 0.35 1.19 1.14 1.39 1.34 1.07 0.98   N(alpha)-acetyltransferase 25, NatB auxiliary subunit (NAA25), mRNA. 
8112478 NAIP 0.37 0.27 1.21 0.69 1.08 0.45 1.25 0.46   NLR family, apoptosis inhibitory protein (NAIP), transcript variant 1, mRNA. 
8141872 NAPEPLD 0.46 0.41 1.18 1.23 1.11 0.98 2.83 1.71   N-acyl phosphatidylethanolamine phospholipase D (NAPEPLD), transcript variant 1, mRNA. 
7989347 NARG2 0.23 0.20 1.03 1.02 1.01 0.95 0.97 0.82   NMDA receptor regulated 2 (NARG2), transcript variant 1, mRNA. 
8047606 NBEAL1 0.23 0.07 0.67 0.83 0.99 0.41 0.86 0.76   neurobeachin-like 1 (NBEAL1), mRNA. 
8151711 NBN 0.27 0.29 1.25 1.27 1.32 0.97 1.27 1.26   nibrin (NBN), mRNA. 
8082911 NCK1 0.42 0.44 1.34 1.23 0.81 0.80 1.02 1.03   NCK adaptor protein 1 (NCK1), mRNA. 
8057517 NCKAP1 0.30 0.37 0.84 0.86 1.01 0.95 0.89 1.01   NCK-associated protein 1 (NCKAP1), transcript variant 1, mRNA. 
8040552 NCOA1 0.47 0.46 1.00 0.82 0.91 0.88 1.02 0.85   nuclear receptor coactivator 1 (NCOA1), transcript variant 2, mRNA. 
8151254 NCOA2 0.49 0.36 1.24 1.18 0.99 0.86 1.29 1.01   nuclear receptor coactivator 2 (NCOA2), mRNA. 
8012961 NCOR1 0.44 0.50 1.11 1.12 0.99 0.94 1.25 1.06   nuclear receptor co-repressor 1 (NCOR1), mRNA. 
7957715 NEDD1 0.39 0.48 1.10 1.43 1.61 1.13 1.25 1.11   neural precursor cell expressed, developmentally down-regulated 1 (NEDD1), transcript variant 1, mRNA. 
7989094 NEDD4 0.22 0.24 0.87 1.00 0.75 0.87 0.76 0.79   neural precursor cell expressed, developmentally down-regulated 4 (NEDD4), transcript variant 1, mRNA. 
7908543 NEK7 0.39 0.50 1.03 1.49 1.22 1.31 1.01 1.23   NIMA (never in mitosis gene a)-related kinase 7 (NEK7), mRNA. 
8006239 NF1 0.29 0.27 0.92 0.87 0.97 0.87 0.97 0.76   neurofibromin 1 (NF1), transcript variant 1, mRNA. 
7996954 NFAT5 0.35 0.33 1.10 1.17 1.35 0.96 1.24 1.04   nuclear factor of activated T-cells 5, tonicity-responsive (NFAT5), transcript variant 1, mRNA. 
8056977 NFE2L2 0.35 0.42 1.20 1.42 1.16 1.35 1.07 1.45   nuclear factor (erythroid-derived 2)-like 2 (NFE2L2), transcript variant 1, mRNA. 
7901788 NFIA 0.41 0.25 0.85 0.77 0.55 0.53 0.82 0.57   nuclear factor I/A (NFIA), transcript variant 1, mRNA. 
8160138 NFIB 0.42 0.44 0.93 1.06 0.73 0.78 0.84 0.67   nuclear factor I/B (NFIB), mRNA. 
8100179 NFXL1 0.36 0.44 1.04 1.18 1.05 0.83 0.89 0.66   nuclear transcription factor, X-box binding-like 1 (NFXL1), mRNA. 
7930614 NHLRC2 0.29 0.29 1.01 1.04 0.93 0.93 0.84 0.72   NHL repeat containing 2 (NHLRC2), mRNA. 
8104944 NIPBL 0.26 0.18 1.08 1.18 1.01 0.55 1.06 0.89   Nipped-B homolog (Drosophila) (NIPBL), transcript variant B, mRNA. 
8079079 NKTR 0.42 0.18 1.06 0.91 1.22 0.69 1.15 0.77   natural killer-tumor recognition sequence (NKTR), mRNA. 
8083757 NMD3 0.23 0.21 1.04 1.03 0.72 0.81 0.60 0.67   NMD3 homolog (S. cerevisiae) (NMD3), mRNA. 
7935146 NOC3L 0.29 0.24 1.35 1.14 1.04 0.93 0.71 0.82   nucleolar complex associated 3 homolog (S. cerevisiae) (NOC3L), mRNA. 
8162352 NOL8 0.22 0.17 1.21 1.15 0.82 0.64 0.94 0.84   nucleolar protein 8 (NOL8), transcript variant 2, non-coding RNA. 
8047518 NOP58 0.27 0.33 1.04 1.05 0.91 0.97 0.81 0.71   NOP58 ribonucleoprotein homolog (yeast) (NOP58), mRNA. 
7951497 NPAT 0.28 0.19 1.21 1.08 0.83 0.43 1.20 0.68   nuclear protein, ataxia-telangiectasia locus (NPAT), mRNA. 
8078272 NR1D2 0.43 0.46 1.23 1.19 1.16 1.08 1.22 1.08   nuclear receptor subfamily 1, group D, member 2 (NR1D2), transcript variant 1, mRNA. 
8069553 NRIP1 0.28 0.15 1.32 0.85 1.29 0.78 1.32 0.77   nuclear receptor interacting protein 1 (NRIP1), mRNA. 
7938687 NUCB2 0.44 0.37 1.05 1.44 1.10 1.10 1.22 1.87   nucleobindin 2 (NUCB2), mRNA. 
8113413 NUDT12 0.40 0.37 0.97 0.88 0.72 0.78 0.77 0.93   nudix (nucleoside diphosphate linked moiety X)-type motif 12 (NUDT12), mRNA. 
8013908 NUFIP2 0.29 0.33 1.02 1.17 1.08 0.99 0.89 0.90   nuclear fragile X mental retardation protein interacting protein 2 (NUFIP2), mRNA. 
8046804 NUP35 0.48 0.45 1.15 0.80 1.08 0.76 0.76 0.53   nucleoporin 35kDa (NUP35), mRNA. 
7916570 OMA1 0.38 0.37 0.83 0.46 0.72 0.44 0.72 0.42   OMA1 homolog, zinc metallopeptidase (S. cerevisiae) (OMA1), mRNA. 
8084844 OPA1 0.30 0.21 0.80 0.81 1.01 0.84 0.66 0.69   optic atrophy 1 (autosomal dominant) (OPA1), nuclear gene encoding mitochondrial protein, transcript variant 8, mRNA. 
8121043 ORC3L 0.35 0.35 1.15 1.12 1.02 0.94 1.01 0.94   origin recognition complex, subunit 3-like (yeast) (ORC3L), transcript variant 1, mRNA. 
8055645 ORC4L 0.42 0.47 1.12 1.04 1.08 0.85 0.91 1.00   origin recognition complex, subunit 4-like (yeast) (ORC4L), transcript variant 2, mRNA. 
8090277 OSBPL11 0.29 0.42 0.98 0.79 0.80 0.82 1.22 0.94   oxysterol binding protein-like 11 (OSBPL11), mRNA. 
7965064 OSBPL8 0.14 0.14 0.79 0.89 0.88 0.68 0.78 0.78   oxysterol binding protein-like 8 (OSBPL8), transcript variant 1, mRNA. 
7901385 OSBPL9 0.35 0.38 1.06 1.00 0.83 0.86 0.89 0.83   oxysterol binding protein-like 9 (OSBPL9), transcript variant 6, mRNA. 
8147262 OTUD6B 0.25 0.21 1.12 1.44 0.75 0.61 0.90 0.73   OTU domain containing 6B (OTUD6B), mRNA. 
8116848 PAK1IP1 0.39 0.43 1.16 1.05 0.86 0.91 0.62 0.56   PAK1 interacting protein 1 (PAK1IP1), mRNA. 
8000329 PALB2 0.44 0.41 1.19 1.08 0.90 0.88 1.21 0.90   partner and localizer of BRCA2 (PALB2), mRNA. 
7976598 PAPOLA 0.25 0.29 0.86 0.77 0.84 0.92 0.95 0.95   poly(A) polymerase alpha (PAPOLA), mRNA. 
8087951 PBRM1 0.37 0.32 0.91 1.02 1.25 1.14 1.12 1.05   polybromo 1 (PBRM1), transcript variant 1, mRNA. 
7942839 PCF11 0.44 0.35 0.97 0.95 1.12 0.83 0.98 0.91   PCF11, cleavage and polyadenylation factor subunit, homolog (S. cerevisiae) (PCF11), mRNA. 
8144812 PCM1 0.22 0.10 0.90 0.71 0.95 0.47 1.03 1.03   pericentriolar material 1 (PCM1), mRNA. 
8150714 PCMTD1 0.25 0.39 1.03 1.08 0.74 0.82 1.03 1.01   protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 (PCMTD1), mRNA. 
8099926 PDS5A 0.28 0.23 1.01 0.89 0.97 0.82 0.92 0.80   PDS5, regulator of cohesion maintenance, homolog A (S. cerevisiae) (PDS5A), transcript variant 1, mRNA. 
7936559 PDZD8 0.39 0.41 0.91 0.94 0.85 0.99 0.77 0.74   PDZ domain containing 8 (PDZD8), mRNA. 
8140915 PEX1 0.33 0.40 0.82 0.78 0.77 0.77 0.90 0.79   peroxisomal biogenesis factor 1 (PEX1), mRNA. 
8148358 PHF20L1 0.32 0.32 0.90 1.08 0.96 0.99 0.91 0.83   PHD finger protein 20-like 1 (PHF20L1), transcript variant 1, mRNA. 
8120441 PHF3 0.20 0.07 0.99 0.86 0.80 0.43 1.03 0.68   PHD finger protein 3 (PHF3), mRNA. 
8169969 PHF6 0.36 0.25 0.98 1.05 0.79 0.74 0.86 0.82   PHD finger protein 6 (PHF6), transcript variant 2, mRNA. 
8127698 PHIP 0.27 0.15 0.91 0.82 1.11 0.47 0.93 0.52   pleckstrin homology domain interacting protein (PHIP), mRNA. 
7995382 PHKB 0.31 0.47 0.76 0.63 0.83 0.73 0.96 0.71   phosphorylase kinase, beta (PHKB), transcript variant 2, mRNA. 
8081590 PHLDB2 0.50 0.31 1.05 1.24 1.36 0.97 1.03 0.99   pleckstrin homology-like domain, family B, member 2 (PHLDB2), transcript variant 2, mRNA. 
8023133 PIAS2 0.44 0.48 0.90 0.84 0.90 0.83 1.07 0.86   protein inhibitor of activated STAT, 2 (PIAS2), transcript variant beta, mRNA. 
7946815 PIK3C2A 0.13 0.07 0.92 0.97 0.85 0.49 1.01 0.90   phosphoinositide-3-kinase, class 2, alpha polypeptide (PIK3C2A), mRNA. 
7954208 PIK3C2G 0.40 0.18 0.90 0.90 0.88 0.38 1.26 0.84   phosphoinositide-3-kinase, class 2, gamma polypeptide (PIK3C2G), mRNA. 
8084016 PIK3CA 0.20 0.17 1.03 1.11 1.13 0.91 1.04 1.04   phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA), mRNA. 
8105778 PIK3R1 0.20 0.16 1.12 1.04 0.66 0.78 1.10 1.01   phosphoinositide-3-kinase, regulatory subunit 1 (alpha) (PIK3R1), transcript variant 1, mRNA. 
8113469 PJA2 0.25 0.21 0.98 1.21 0.99 1.01 0.95 1.04   praja ring finger 2 (PJA2), mRNA. 
7902822 PKN2 0.25 0.22 1.08 1.09 0.99 0.80 1.16 0.92   protein kinase N2 (PKN2), mRNA. 
8092134 PLD1 0.44 0.49 1.03 1.31 0.72 0.73 0.60 0.50   phospholipase D1, phosphatidylcholine-specific (PLD1), transcript variant 1, mRNA. 
7983502 PLDN 0.29 0.44 0.83 0.78 1.18 0.99 0.68 0.73   pallidin homolog (mouse) (PLDN), mRNA. 
7954245 PLEKHA5 0.36 0.40 0.83 1.32 0.96 0.89 0.92 0.92   pleckstrin homology domain containing, family A member 5 (PLEKHA5), transcript variant 1, mRNA. 
8083146 PLS1 0.24 0.24 0.91 0.91 1.16 0.93 0.79 0.86   plastin 1 (PLS1), transcript variant 3, mRNA. 
8169473 PLS3 0.44 0.47 0.95 0.85 1.16 0.95 1.06 1.26   plastin 3 (PLS3), transcript variant 1, mRNA. 
7957570 PLXNC1 0.36 0.44 0.88 1.52 0.47 0.69 1.13 1.14   plexin C1 (PLXNC1), mRNA. 
8047038 PMS1 0.48 0.38 1.04 0.88 0.78 0.61 0.78 0.62   PMS1 postmeiotic segregation increased 1 (S. cerevisiae) (PMS1), transcript variant 1, mRNA. 
7974066 PNN 0.41 0.32 1.07 0.93 0.88 0.74 0.80 0.68   pinin, desmosome associated protein (PNN), mRNA. 
8142307 PNPLA8 0.28 0.30 0.96 1.15 1.22 1.08 0.90 1.05   patatin-like phospholipase domain containing 8 (PNPLA8), mRNA. 
8021275 POLI 0.37 0.27 0.86 0.78 0.97 0.71 0.94 0.72   polymerase (DNA directed) iota (POLI), mRNA. 
8106303 POLK 0.16 0.10 1.20 1.09 1.04 0.48 0.97 1.01   polymerase (DNA directed) kappa (POLK), mRNA. 
8100495 PPAT 0.40 0.27 1.27 0.99 1.01 0.80 0.76 0.67   phosphoribosyl pyrophosphate amidotransferase (PPAT), mRNA. 
8130087 PPIL4 0.45 0.43 1.15 0.89 1.18 1.00 0.92 0.96   peptidylprolyl isomerase (cyclophilin)-like 4 (PPIL4), mRNA. 
8107164 PPIP5K2 0.17 0.14 0.94 0.71 0.84 0.68 1.07 0.78   diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2), mRNA. 
7965123 PPP1R12A 0.25 0.24 0.99 1.05 1.10 0.99 1.35 1.26   protein phosphatase 1, regulatory (inhibitor) subunit 12A (PPP1R12A), transcript variant 2, mRNA. 
8082869 PPP2R3A 0.41 0.48 0.83 1.42 1.31 1.77 0.71 0.87   protein phosphatase 2 (formerly 2A), regulatory subunit B'', alpha (PPP2R3A), transcript variant 1, mRNA. 
8101971 PPP3CA 0.34 0.50 0.78 0.73 0.92 0.80 0.68 0.65   protein phosphatase 3, catalytic subunit, alpha isozyme (PPP3CA), transcript variant 1, mRNA. 
8080973 PPP4R2 0.47 0.28 0.95 1.06 1.25 1.07 0.91 1.01   protein phosphatase 4, regulatory subunit 2 (PPP4R2), mRNA. 
8105633 PPWD1 0.32 0.31 0.90 0.95 1.07 0.66 1.11 0.64   peptidylprolyl isomerase domain and WD repeat containing 1 (PPWD1), mRNA. 
8051928 PREPL 0.25 0.29 0.71 0.62 0.71 0.78 0.76 0.68   prolyl endopeptidase-like (PREPL), transcript variant 1, mRNA. 
8111796 PRKAA1 0.43 0.38 1.07 0.98 0.84 0.94 0.86 0.87   protein kinase, AMP-activated, alpha 1 catalytic subunit (PRKAA1), transcript variant 2, mRNA. 
7902594 PRKACB 0.38 0.36 0.89 0.79 1.42 0.86 1.18 0.87   protein kinase, cAMP-dependent, catalytic, beta (PRKACB), transcript variant 1, mRNA. 
8150599 PRKDC 0.29 0.38 0.56 0.59 1.00 0.86 0.64 0.55   protein kinase, DNA-activated, catalytic polypeptide (PRKDC), transcript variant 1, mRNA. 
7924817 PRO2012 0.29 0.26 0.87 1.15 0.96 0.33 2.07 0.77   hypothetical protein PRO2012, mRNA (cDNA clone IMAGE:4995736). 
7909681 PROX1 0.39 0.29 1.16 1.08 0.73 0.69 1.21 1.16   prospero homeobox 1 (PROX1), mRNA. 
7903519 PRPF38B 0.46 0.42 0.91 1.00 0.92 1.08 0.81 0.69   PRP38 pre-mRNA processing factor 38 (yeast) domain containing B (PRPF38B), mRNA. 
8055913 PRPF40A 0.24 0.24 1.14 1.14 1.08 0.96 0.96 0.94   PRP40 pre-mRNA processing factor 40 homolog A (S. cerevisiae) (PRPF40A), mRNA. 
8116664 PRPF4B 0.41 0.24 1.34 1.24 1.11 0.95 1.12 1.10   PRP4 pre-mRNA processing factor 4 homolog B (yeast) (PRPF4B), mRNA. 
8149551 PSD3 0.19 0.12 0.57 0.76 0.70 0.75 0.57 0.55   pleckstrin and Sec7 domain containing 3 (PSD3), transcript variant 1, mRNA. 
8161632 PTAR1 0.27 0.34 1.10 1.23 0.99 0.99 1.10 0.92   protein prenyltransferase alpha subunit repeat containing 1 (PTAR1), mRNA. 
7903188 PTBP2 0.48 0.36 0.91 0.73 1.43 0.55 1.11 0.44   polypyrimidine tract binding protein 2 (PTBP2), mRNA. 
7926356 PTER 0.35 0.34 0.84 0.74 1.18 0.86 1.13 1.29   phosphotriesterase related (PTER), transcript variant 1, mRNA. 
7958846 PTPN11 0.37 0.40 0.62 0.54 0.90 0.88 0.58 0.54   protein tyrosine phosphatase, non-receptor type 11 (PTPN11), mRNA. 
8133788 PTPN12 0.40 0.43 1.04 1.04 0.81 0.87 0.91 1.01   protein tyrosine phosphatase, non-receptor type 12 (PTPN12), transcript variant 1, mRNA. 
8160040 PTPRD 0.46 0.26 0.75 0.46 0.70 0.42 0.94 0.44   protein tyrosine phosphatase, receptor type, D (PTPRD), transcript variant 1, mRNA. 
8050565 PUM2 0.36 0.41 1.16 1.00 0.96 0.97 1.03 0.88   pumilio homolog 2 (Drosophila) (PUM2), mRNA. 
8052418 PUS10 0.29 0.33 1.21 1.44 0.52 0.75 1.20 0.86   pseudouridylate synthase 10 (PUS10), mRNA. 
8081548 PVRL3 0.41 0.39 0.86 0.88 0.82 0.74 0.79 0.72   poliovirus receptor-related 3 (PVRL3), mRNA. 
7954382 PYROXD1 0.30 0.31 0.84 1.17 0.94 1.04 0.69 0.95   pyridine nucleotide-disulphide oxidoreductase domain 1 (PYROXD1), mRNA. 
7939158 QSER1 0.20 0.22 0.80 0.81 1.06 0.79 0.97 0.74   glutamine and serine rich 1 (QSER1), mRNA. 
7936567 RAB11FIP2 0.25 0.21 1.18 1.28 1.01 0.88 0.92 0.55   RAB11 family interacting protein 2 (class I) (RAB11FIP2), mRNA. 
7950743 RAB30 0.38 0.47 0.99 1.42 0.51 0.67 0.86 0.86   RAB30, member RAS oncogene family (RAB30), mRNA. 
7924405 RAB3GAP2 0.38 0.34 1.05 1.04 1.01 1.05 0.96 1.11   RAB3 GTPase activating protein subunit 2 (non-catalytic) (RAB3GAP2), mRNA. 
8004111 RABEP1 0.29 0.28 0.94 0.81 1.01 0.81 0.88 0.68   rabaptin, RAB GTPase binding effector protein 1 (RABEP1), transcript variant 1, mRNA. 
8177478 RAD17 0.29 0.39 1.22 1.19 0.71 0.87 0.84 0.96   RAD17 homolog (S. pombe) (RAD17), transcript variant 1, mRNA. 
8085145 RAD18 0.41 0.45 0.86 0.92 1.02 0.94 0.94 0.73   RAD18 homolog (S. cerevisiae) (RAD18), mRNA. 
8152477 RAD21 0.40 0.37 1.15 1.07 1.14 1.04 1.06 1.10   RAD21 homolog (S. pombe) (RAD21), mRNA. 
8107942 RAD50 0.20 0.09 1.11 0.95 1.03 0.53 0.97 0.72   RAD50 homolog (S. cerevisiae) (RAD50), mRNA. 
8104788 RAI14 0.40 0.46 1.11 1.40 1.09 1.09 0.76 0.77   retinoic acid induced 14 (RAI14), transcript variant 6, mRNA. 
8180364 RALGAPA1 0.27 0.18 1.03 0.91 0.91 0.64 1.04 0.67   GTPase activating Rap/RanGAP domain-like 1 (GARNL1), transcript variant 1, mRNA 
8180365 RALGAPA1 0.27 0.18 1.03 0.91 0.91 0.64 1.04 0.67   GTPase activating Rap/RanGAP domain-like 1 (GARNL1), transcript variant 2, mRNA 
7978653 RALGAPA1 0.46 0.33 1.26 0.86 1.03 0.78 1.70 0.92   Ral GTPase activating protein, alpha subunit 1 (catalytic) (RALGAPA1), transcript variant 1, mRNA. 
7907657 RALGPS2 0.39 0.43 0.90 0.97 0.93 1.19 1.24 1.29   Ral GEF with PH domain and SH3 binding motif 2 (RALGPS2), mRNA. 
8044263 RANBP2 0.27 0.13 0.96 0.84 0.80 0.43 0.87 0.69   RAN binding protein 2 (RANBP2), mRNA. 
8160016 RANBP6 0.23 0.23 1.10 1.10 1.36 1.19 0.73 0.82   RAN binding protein 6 (RANBP6), transcript variant 1, mRNA. 
7969693 RAP2A 0.29 0.46 0.68 0.82 1.10 0.99 0.84 0.94   RAP2A, member of RAS oncogene family (RAP2A), mRNA. 
8106784 RASA1 0.30 0.34 0.94 1.10 0.92 0.87 0.80 0.77   RAS p21 protein activator (GTPase activating protein) 1 (RASA1), transcript variant 1, mRNA. 
7969017 RB1 0.22 0.21 0.98 0.92 0.99 0.90 1.16 1.21   retinoblastoma 1 (RB1), mRNA. 
8150757 RB1CC1 0.30 0.12 0.78 0.62 0.86 0.38 0.86 0.63   RB1-inducible coiled-coil 1 (RB1CC1), transcript variant 1, mRNA. 
8020468 RBBP8 0.35 0.26 1.11 0.94 1.01 0.78 1.32 0.98   retinoblastoma binding protein 8 (RBBP8), transcript variant 1, mRNA. 
7972190 RBM26 0.46 0.37 1.31 1.12 1.04 0.92 0.97 0.94   RNA binding motif protein 26 (RBM26), mRNA. 
8108927 RBM27 0.29 0.38 1.18 1.24 0.98 1.00 1.13 1.08   RNA binding motif protein 27 (RBM27), mRNA. 
8094460 RBPJ 0.19 0.27 1.10 0.97 0.90 0.95 0.95 0.93   recombination signal binding protein for immunoglobulin kappa J region (RBPJ), transcript variant 1, mRNA. 
7922432 RC3H1 0.32 0.43 1.13 1.40 1.10 1.34 1.14 1.11   ring finger and CCCH-type zinc finger domains 1 (RC3H1), mRNA. 
7909529 RCOR3 0.39 0.40 1.10 1.00 0.72 0.68 1.10 0.87   REST corepressor 3 (RCOR3), transcript variant 1, mRNA. 
7951554 RDX 0.28 0.25 0.88 0.76 1.07 1.00 0.97 1.18   radixin (RDX), mRNA. 
7961654 RECQL 0.48 0.34 1.28 1.40 1.34 0.88 1.18 1.21   RecQ protein-like (DNA helicase Q1-like) (RECQL), transcript variant 1, mRNA. 
8095262 REST 0.40 0.29 1.03 1.33 1.05 1.15 1.03 0.98   RE1-silencing transcription factor (REST), mRNA. 
8128894 REV3L 0.26 0.20 1.03 0.97 1.02 0.52 1.15 0.77   REV3-like, catalytic subunit of DNA polymerase zeta (yeast) (REV3L), mRNA. 
8099860 RFC1 0.23 0.22 1.15 1.13 1.02 0.88 1.32 1.23   replication factor C (activator 1) 1, 145kDa (RFC1), mRNA. 
7989132 RFX7 0.32 0.29 1.08 0.96 0.78 0.70 1.24 0.93   regulatory factor X, 7 (RFX7), mRNA. 
8081343 RG9MTD1 0.36 0.41 1.13 1.18 0.99 1.17 0.82 0.88   RNA (guanine-9-) methyltransferase domain containing 1 (RG9MTD1), nuclear gene encoding mitochondrial protein, mRNA. 
8053622 RGPD1 0.26 0.19 0.87 0.90 0.82 0.67 0.78 0.75   RANBP2-like and GRIP domain containing 1 (RGPD1), mRNA. 
8054414 RGPD3 0.21 0.16 0.86 0.89 0.83 0.61 0.79 0.76   RANBP2-like and GRIP domain containing 3 (RGPD3), mRNA. 
8044161 RGPD4 0.21 0.16 0.87 0.91 0.85 0.62 0.80 0.77   RANBP2-like and GRIP domain containing 4 (RGPD4), mRNA. 
8044304 RGPD6 0.23 0.17 0.89 0.98 0.88 0.67 0.83 0.82   RANBP2-like and GRIP domain containing 6 (RGPD6), transcript variant 1, mRNA. 
8106986 RHOBTB3 0.34 0.44 0.90 0.76 0.64 0.80 0.88 0.67   Rho-related BTB domain containing 3 (RHOBTB3), mRNA. 
8006345 RHOT1 0.39 0.49 0.83 0.80 0.78 0.75 0.86 0.79   ras homolog gene family, member T1 (RHOT1), transcript variant 1, mRNA. 
8045697 RIF1 0.25 0.19 1.33 1.32 1.22 0.50 1.00 0.83   RAP1 interacting factor homolog (yeast) (RIF1), transcript variant 1, mRNA. 
8113286 RIOK2 0.24 0.28 1.21 1.11 0.96 0.90 0.96 0.76   RIO kinase 2 (yeast) (RIOK2), transcript variant 1, mRNA. 
7900395 RLF 0.38 0.20 1.36 1.32 1.25 0.93 1.07 1.13   rearranged L-myc fusion (RLF), mRNA. 
8069711 RNF160 0.18 0.14 0.98 0.92 1.05 0.65 0.90 0.72   ring finger protein 160 (RNF160), mRNA. 
8022441 ROCK1 0.20 0.13 0.97 0.97 0.98 0.63 0.85 0.88   Rho-associated, coiled-coil containing protein kinase 1 (ROCK1), mRNA. 
8050302 ROCK2 0.33 0.16 1.25 1.31 1.56 0.90 1.27 1.25   Rho-associated, coiled-coil containing protein kinase 2 (ROCK2), mRNA. 
7902992 RPAP2 0.32 0.28 0.92 0.86 0.73 0.67 0.89 0.74   RNA polymerase II associated protein 2 (RPAP2), mRNA. 
8022914 RPRD1A 0.38 0.49 0.97 1.01 1.04 1.15 0.89 0.77   regulation of nuclear pre-mRNA domain containing 1A (RPRD1A), mRNA. 
8171762 RPS6KA3 0.35 0.45 0.90 0.88 1.10 1.02 1.10 1.23   ribosomal protein S6 kinase, 90kDa, polypeptide 3 (RPS6KA3), mRNA. 
8152133 RRM2B 0.14 0.13 1.12 0.70 0.86 0.69 1.50 1.15   ribonucleotide reductase M2 B (TP53 inducible) (RRM2B), transcript variant 1, mRNA. 
7994565 RRN3 0.64 0.50 1.20 0.69 0.85 0.60 0.84 0.57   RRN3 RNA polymerase I transcription factor homolog (S. cerevisiae) (RRN3), mRNA. 
7950606 RSF1 0.43 0.26 1.41 1.45 1.48 0.66 1.42 1.12   remodeling and spacing factor 1 (RSF1), mRNA. 
8083605 RSRC1 0.36 0.40 0.84 0.75 1.00 0.79 0.86 0.66   arginine/serine-rich coiled-coil 1 (RSRC1), mRNA. 
7933999 RUFY2 0.29 0.32 1.19 1.19 1.03 1.04 0.94 0.98   RUN and FYVE domain containing 2 (RUFY2), transcript variant 1, mRNA. 
8079346 SACM1L 0.22 0.33 0.96 0.98 0.90 0.91 0.78 0.85   SAC1 suppressor of actin mutations 1-like (yeast) (SACM1L), mRNA. 
7970569 SACS 0.29 0.25 0.84 1.10 1.27 0.55 0.67 0.57   spastic ataxia of Charlevoix-Saguenay (sacsin) (SACS), mRNA. 
7967420 SBNO1 0.29 0.15 0.69 0.72 0.92 0.82 0.70 0.61   strawberry notch homolog 1 (Drosophila) (SBNO1), transcript variant 1, mRNA. 
8106479 SCAMP1 0.34 0.38 1.22 1.07 0.86 0.87 0.79 0.89   secretory carrier membrane protein 1 (SCAMP1), mRNA. 
7920875 SCARNA4 1.50 0.43 0.49 0.26 1.26 0.09 1.15 0.13   small Cajal body-specific RNA 4 (SCARNA4), guide RNA. 
7973770 SCFD1 0.32 0.28 0.88 0.95 0.92 0.83 0.88 0.90   sec1 family domain containing 1 (SCFD1), transcript variant 1, mRNA. 
8056491 SCN9A 0.36 0.42 0.69 1.00 1.49 1.53 1.17 1.72   sodium channel, voltage-gated, type IX, alpha subunit (SCN9A), mRNA. 
8097521 SCOC 0.42 0.44 0.82 0.76 0.88 0.96 0.62 0.70   short coiled-coil protein (SCOC), transcript variant 4, mRNA. 
8046502 SCRN3 0.30 0.34 0.78 0.66 0.59 0.70 0.71 0.68   secernin 3 (SCRN3), mRNA. 
7957806 SCYL2 0.18 0.25 0.98 0.94 0.99 1.05 1.04 1.19   SCY1-like 2 (S. cerevisiae) (SCYL2), mRNA. 
8101099 SDAD1 0.35 0.32 1.10 1.19 1.56 1.17 1.27 1.29   SDA1 domain containing 1 (SDAD1), mRNA. 
7978866 SDCCAG1 0.25 0.15 0.96 0.97 0.80 0.48 0.82 0.79   serologically defined colon cancer antigen 1 (SDCCAG1), mRNA. 
8083826 SEC62 0.23 0.18 0.97 0.97 0.87 0.81 0.65 0.73   SEC62 homolog (S. cerevisiae) (SEC62), mRNA. 
8128650 SEC63 0.34 0.34 0.87 0.95 1.05 0.93 0.85 1.03   SEC63 homolog (S. cerevisiae) (SEC63), mRNA. 
7988581 SECISBP2L 0.35 0.29 1.12 1.34 1.10 1.18 1.20 1.23   SECIS binding protein 2-like (SECISBP2L), mRNA. 
7980547 SEL1L 0.40 0.25 0.78 0.79 0.89 0.80 0.79 0.86   sel-1 suppressor of lin-12-like (C. elegans) (SEL1L), mRNA. 
8120758 SENP6 0.36 0.20 1.10 0.92 1.14 0.87 0.90 0.83   SUMO1/sentrin specific peptidase 6 (SENP6), transcript variant 1, mRNA. 
8099696 SEPSECS 0.40 0.31 1.09 1.14 0.80 0.65 1.24 0.81   Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase (SEPSECS), mRNA. 
8128698 SESN1 0.30 0.33 0.95 0.52 0.65 0.37 0.87 0.51   sestrin 1 (SESN1), mRNA. 
8086706 SETD2 0.34 0.23 1.16 1.03 0.96 0.84 1.18 0.85   SET domain containing 2 (SETD2), mRNA. 
8164701 SETX 0.41 0.26 1.19 1.27 1.55 0.91 1.44 1.58   senataxin (SETX), mRNA. 
8058024 SF3B1 0.30 0.33 0.96 0.92 0.92 0.80 1.03 0.85   splicing factor 3b, subunit 1, 155kDa (SF3B1), transcript variant 1, mRNA. 
8112337 SFRS12IP1 0.19 0.25 0.92 1.33 0.89 1.04 0.84 0.70   SFRS12-interacting protein 1 (SFRS12IP1), mRNA. 
8128394 SFRS18 0.45 0.26 1.00 1.00 0.80 0.67 1.00 0.78   splicing factor, arginine/serine-rich 18 (SFRS18), transcript variant 1, mRNA. 
8146717 SGK3 0.39 0.36 0.91 0.69 1.15 0.76 1.35 0.71   serum/glucocorticoid regulated kinase family, member 3 (SGK3), transcript variant 1, mRNA. 
8168557 SH3BGRL 0.45 0.32 1.22 0.95 0.77 0.60 1.08 0.92   SH3 domain binding glutamic acid-rich protein like (SH3BGRL), mRNA. 
7930470 SHOC2 0.20 0.24 0.94 1.09 0.89 0.74 1.02 1.00   soc-2 suppressor of clear homolog (C. elegans) (SHOC2), mRNA. 
7918847 SIKE1 0.49 0.47 1.08 1.08 0.92 0.93 0.86 0.82   suppressor of IKBKE 1 (SIKE1), transcript variant 1, mRNA. 
8105353 SKIV2L2 0.24 0.13 0.83 0.65 0.95 0.63 0.73 0.47   superkiller viralicidic activity 2-like 2 (S. cerevisiae) (SKIV2L2), mRNA. 
7956658 SLC16A7 0.37 0.23 0.64 0.73 1.13 0.77 0.72 0.61   solute carrier family 16, member 7 (monocarboxylic acid transporter 2) (SLC16A7), mRNA. 
8104930 SLC1A3 0.38 0.12 1.00 0.15 0.60 0.13 1.29 0.17   solute carrier family 1 (glial high affinity glutamate transporter), member 3 (SLC1A3), transcript variant 1, mRNA. 
8140814 SLC25A40 0.38 0.45 0.85 0.69 0.62 0.69 0.78 0.73   solute carrier family 25, member 40 (SLC25A40), nuclear gene encoding mitochondrial protein, mRNA. 
8092083 SLC2A2 0.38 0.35 0.87 0.75 0.73 0.63 0.79 0.84   solute carrier family 2 (facilitated glucose transporter), member 2 (SLC2A2), mRNA. 
8094848 SLC30A9 0.34 0.46 0.95 0.74 1.17 1.07 0.88 0.84   solute carrier family 30 (zinc transporter), member 9 (SLC30A9), mRNA. 
7903281 SLC35A3 0.24 0.26 0.87 0.79 0.83 0.99 0.59 0.61   solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member A3 (SLC35A3), mRNA. 
7962559 SLC38A4 0.40 0.18 1.35 1.23 0.67 0.38 2.75 1.69   solute carrier family 38, member 4 (SLC38A4), transcript variant 1, mRNA. 
8047174 SLC39A10 0.30 0.48 0.82 1.49 1.32 1.35 1.01 1.09   solute carrier family 39 (zinc transporter), member 10 (SLC39A10), transcript variant 1, mRNA. 
8095585 SLC4A4 0.34 0.36 0.74 0.75 1.03 1.12 0.73 0.66   solute carrier family 4, sodium bicarbonate cotransporter, member 4 (SLC4A4), transcript variant 1, mRNA. 
7954356 SLCO1B1 0.38 0.12 0.71 0.21 1.14 0.36 0.70 0.20   solute carrier organic anion transporter family, member 1B1 (SLCO1B1), mRNA. 
7930276 SLK 0.31 0.12 0.97 1.18 1.28 0.96 1.10 1.24   STE20-like kinase (yeast) (SLK), mRNA. 
8080685 SLMAP 0.35 0.46 1.12 1.26 1.15 1.25 1.11 1.32   sarcolemma associated protein (SLMAP), mRNA. 
7989253 SLTM 0.31 0.22 0.99 0.82 0.89 0.76 0.76 0.74   SAFB-like, transcription modulator (SLTM), transcript variant 1, mRNA. 
8115606 SLU7 0.41 0.47 1.29 1.19 1.05 1.17 1.19 1.20   SLU7 splicing factor homolog (S. cerevisiae) (SLU7), mRNA. 
8023191 SMAD2 0.21 0.31 0.52 0.74 1.23 1.01 0.85 0.61   SMAD family member 2 (SMAD2), transcript variant 1, mRNA. 
8096463 SMARCAD1 0.23 0.14 1.17 1.08 0.96 0.76 0.99 0.85   SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1 (SMARCAD1), transcript variant 1, mRNA. 
7930422 SMC3 0.15 0.09 1.10 0.93 0.89 0.43 1.01 0.83   structural maintenance of chromosomes 3 (SMC3), mRNA. 
8083709 SMC4 0.19 0.12 1.18 1.34 0.76 0.55 0.85 0.91   structural maintenance of chromosomes 4 (SMC4), transcript variant 1, mRNA. 
8155770 SMC5 0.49 0.16 1.08 0.84 1.32 0.71 0.92 0.66   structural maintenance of chromosomes 5 (SMC5), mRNA. 
8050443 SMC6 0.26 0.16 0.95 0.86 1.18 0.62 0.93 0.85   structural maintenance of chromosomes 6 (SMC6), transcript variant 1, mRNA. 
8019885 SMCHD1 0.39 0.18 1.82 1.45 1.33 0.78 1.60 1.36   structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1), mRNA. 
8052307 SMEK2 0.30 0.28 0.81 0.79 0.92 0.84 0.93 0.77   SMEK homolog 2, suppressor of mek1 (Dictyostelium) (SMEK2), transcript variant 1, mRNA. 
8131957 SNX10 0.40 0.24 1.07 0.60 1.19 0.69 1.62 0.92   sorting nexin 10 (SNX10), mRNA. 
8138401 SNX13 0.37 0.29 0.88 0.89 0.97 0.78 0.90 0.90   sorting nexin 13 (SNX13), mRNA. 
8107613 SNX2 0.41 0.47 1.11 0.63 0.79 0.67 1.03 0.82   sorting nexin 2 (SNX2), mRNA. 
7907702 SOAT1 0.42 0.49 0.98 0.58 0.75 0.56 1.05 0.60   sterol O-acyltransferase 1 (SOAT1), transcript variant 688113, mRNA. 
7974447 SOCS4 0.34 0.30 0.96 1.10 0.91 0.86 0.82 0.81   suppressor of cytokine signaling 4 (SOCS4), transcript variant 1, mRNA. 
8051670 SOS1 0.30 0.44 1.05 1.06 1.00 1.18 1.44 1.31   son of sevenless homolog 1 (Drosophila) (SOS1), mRNA. 
7978932 SOS2 0.19 0.18 1.12 1.17 0.77 0.85 1.13 0.87   son of sevenless homolog 2 (Drosophila) (SOS2), mRNA. 
8041236 SPAST 0.41 0.29 0.96 0.91 0.88 0.82 0.78 0.69   spastin (SPAST), transcript variant 1, mRNA. 
7988286 SPG11 0.42 0.33 0.96 0.72 1.01 0.73 1.14 0.76   spastic paraplegia 11 (autosomal recessive) (SPG11), transcript variant 1, mRNA. 
7970999 SPG20 0.28 0.16 0.93 0.32 0.78 0.25 0.85 0.27   spastic paraplegia 20 (Troyer syndrome) (SPG20), transcript variant 1, mRNA. 
8045514 SPOPL 0.30 0.38 1.07 1.00 0.83 0.86 1.06 0.97   speckle-type POZ protein-like (SPOPL), mRNA. 
8083183 SR140 0.31 0.18 1.20 1.14 1.11 0.93 1.12 1.01   U2-associated SR140 protein (SR140), mRNA. 
8107578 SRFBP1 0.40 0.27 1.26 1.02 1.74 1.21 1.09 1.29   serum response factor binding protein 1 (SRFBP1), mRNA. 
8095230 SRP72 0.42 0.49 0.94 0.83 0.99 1.00 0.85 0.97   signal recognition particle 72kDa (SRP72), mRNA. 
7962499 SRSF2IP 0.26 0.18 1.07 1.09 0.94 0.70 1.03 0.96   splicing factor, arginine/serine-rich 2, interacting protein (SFRS2IP), mRNA. 
8046201 SSB 0.50 0.43 1.07 0.93 1.19 0.92 0.88 0.84   Sjogren syndrome antigen B (autoantigen La) (SSB), mRNA. 
7917255 SSX2IP 0.31 0.29 0.84 0.67 0.87 0.80 1.04 1.48   synovial sarcoma, X breakpoint 2 interacting protein (SSX2IP), transcript variant 5, mRNA. 
8169750 STAG2 0.23 0.10 1.06 0.96 0.83 0.59 1.15 1.16   stromal antigen 2 (STAG2), transcript variant 2, mRNA. 
8051443 STRN 0.37 0.43 0.88 1.03 1.18 1.07 1.13 1.12   striatin, calmodulin binding protein (STRN), mRNA. 
7903541 STXBP3 0.29 0.26 1.16 1.09 1.12 0.86 1.02 0.93   syntaxin binding protein 3 (STXBP3), mRNA. 
7974387 STYX 0.30 0.37 0.97 0.94 0.99 1.01 0.95 0.91   serine/threonine/tyrosine interacting protein (STYX), transcript variant 1, mRNA. 
7971541 SUCLA2 0.24 0.37 0.74 0.87 0.76 0.79 0.81 0.89   succinate-CoA ligase, ADP-forming, beta subunit (SUCLA2), nuclear gene encoding mitochondrial protein, mRNA. 
8100798 SULT1B1 0.28 0.17 0.90 0.76 0.55 0.45 1.20 0.89   sulfotransferase family, cytosolic, 1B, member 1 (SULT1B1), mRNA. 
8006325 SUZ12 0.27 0.22 1.11 0.97 0.88 0.75 1.16 0.79   suppressor of zeste 12 homolog (Drosophila) (SUZ12), mRNA. 
8152553 TAF2 0.26 0.28 1.04 0.88 0.93 0.93 0.90 0.76   TAF2 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 150kDa (TAF2), mRNA. 
8173732 TAF9B 0.33 0.42 0.84 0.87 1.03 1.08 0.82 0.84   TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31kDa (TAF9B), mRNA. 
8006030 TAOK1 0.33 0.26 0.86 1.03 0.98 0.81 0.90 0.84   TAO kinase 1 (TAOK1), mRNA. 
8131975 TAX1BP1 0.33 0.42 0.96 1.06 1.11 0.95 1.04 0.98   Tax1 (human T-cell leukemia virus type I) binding protein 1 (TAX1BP1), transcript variant 1, mRNA. 
8081256 TBC1D23 0.22 0.23 1.08 1.00 0.98 0.87 0.82 0.74   TBC1 domain family, member 23 (TBC1D23), mRNA. 
8102171 TBCK 0.30 0.38 1.05 0.93 0.95 0.96 1.41 1.46   TBC1 domain containing kinase (TBCK), transcript variant 1, mRNA. 
7956795 TBK1 0.30 0.34 1.27 1.10 1.23 0.90 1.10 0.82   TANK-binding kinase 1 (TBK1), mRNA. 
8092201 TBL1XR1 0.24 0.17 0.88 0.74 0.77 0.60 0.97 0.74   transducin (beta)-like 1 X-linked receptor 1 (TBL1XR1), mRNA. 
7983843 TCF12 0.34 0.30 1.11 1.00 0.88 0.80 0.93 0.87   transcription factor 12 (TCF12), transcript variant 1, mRNA. 
8023415 TCF4 0.45 0.17 1.03 0.21 0.54 0.19 0.80 0.22   transcription factor 4 (TCF4), transcript variant 1, mRNA. 
7938544 TEAD1 0.35 0.41 0.98 1.16 0.84 1.02 0.92 0.96   TEA domain family member 1 (SV40 transcriptional enhancer factor) (TEAD1), mRNA. 
8096675 TET2 0.27 0.27 1.36 1.29 0.81 0.54 1.57 0.95   tet oncogene family member 2 (TET2), transcript variant 1, mRNA. 
8057599 TFPI 0.34 0.45 0.94 1.18 0.99 1.06 0.91 1.05   tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) (TFPI), transcript variant 1, mRNA. 
8093053 TFRC 0.49 0.37 0.79 0.69 1.00 0.92 0.56 0.47   transferrin receptor (p90, CD71) (TFRC), mRNA. 
8180324 THAP5 0.33 0.36 1.18 1.34 0.75 1.25 0.98 1.45   THAP domain containing 5 (THAP5), mRNA 
8021924 THOC1 0.28 0.35 1.07 0.71 0.91 0.68 0.96 0.58   THO complex 1 (THOC1), mRNA. 
8174893 THOC2 0.26 0.09 1.26 1.14 1.06 0.52 1.15 0.88   THO complex 2 (THOC2), mRNA. 
8000003 THUMPD1 0.37 0.34 1.09 0.94 0.97 0.93 1.17 1.02   THUMP domain containing 1 (THUMPD1), mRNA. 
8157524 TLR4 0.23 0.19 1.09 0.56 0.62 0.49 1.04 0.48   toll-like receptor 4 (TLR4), transcript variant 3, non-coding RNA. 
8131539 TMEM106B 0.33 0.33 0.97 0.90 0.64 0.70 0.87 0.78   transmembrane protein 106B (TMEM106B), transcript variant 1, mRNA. 
7943369 TMEM133 0.41 0.15 1.00 0.98 0.97 0.93 1.23 1.04   transmembrane protein 133 (TMEM133), mRNA. 
7942964 TMEM135 0.48 0.37 0.90 1.20 1.23 0.98 1.44 1.10   transmembrane protein 135 (TMEM135), transcript variant 1, mRNA. 
8113023 TMEM161B 0.43 0.49 1.14 1.18 0.91 0.82 0.90 0.92   transmembrane protein 161B (TMEM161B), mRNA. 
8112967 TMEM167A 0.37 0.45 0.90 0.94 0.78 0.90 0.65 0.86   transmembrane protein 167A (TMEM167A), mRNA. 
8123062 TMEM181 0.41 0.43 0.78 0.83 0.82 0.89 0.86 0.86   transmembrane protein 181 (TMEM181), mRNA. 
8127637 TMEM30A 0.41 0.50 1.02 0.92 1.00 0.99 1.01 0.93   transmembrane protein 30A (TMEM30A), transcript variant 1, mRNA. 
8172022 TMEM47 0.46 0.43 0.99 1.14 0.83 0.94 0.83 0.79   transmembrane protein 47 (TMEM47), mRNA. 
7903162 TMEM56 0.41 0.47 0.76 0.81 1.01 0.95 0.71 0.59   transmembrane protein 56 (TMEM56), mRNA. 
8088700 TMF1 0.25 0.18 1.00 1.26 1.00 0.75 0.90 0.85   TATA element modulatory factor 1 (TMF1), mRNA. 
7983744 TMOD3 0.41 0.42 0.97 1.15 1.00 1.35 0.94 1.06   tropomodulin 3 (ubiquitous) (TMOD3), mRNA. 
7957478 TMTC3 0.20 0.16 0.91 0.96 0.82 0.65 0.79 0.72   transmembrane and tetratricopeptide repeat containing 3 (TMTC3), mRNA. 
8106122 TNPO1 0.26 0.37 1.01 1.02 0.98 1.04 0.88 0.97   transportin 1 (TNPO1), transcript variant 1, mRNA. 
8008547 TOM1L1 0.46 0.47 0.86 0.82 0.88 0.88 0.72 0.78   target of myb1 (chicken)-like 1 (TOM1L1), mRNA. 
8085815 TOP2B 0.24 0.14 0.80 0.56 1.07 0.65 0.74 0.51   topoisomerase (DNA) II beta 180kDa (TOP2B), mRNA. 
8090772 TOPBP1 0.27 0.17 0.90 0.79 0.95 0.76 0.73 0.64   topoisomerase (DNA) II binding protein 1 (TOPBP1), mRNA. 
8160581 TOPORS 0.43 0.33 1.17 1.30 1.01 0.99 0.94 0.89   topoisomerase I binding, arginine/serine-rich (TOPORS), mRNA. 
7969881 TPP2 0.26 0.33 0.95 1.03 0.92 0.90 0.96 0.81   tripeptidyl peptidase II (TPP2), mRNA. 
7922912 TPR 0.25 0.11 1.05 0.99 0.91 0.38 1.05 0.92   translocated promoter region (to activated MET oncogene) (TPR), mRNA. 
8097841 TRIM2 0.31 0.43 0.81 1.13 0.93 1.02 0.80 0.85   tripartite motif-containing 2 (TRIM2), transcript variant 1, mRNA. 
8136473 TRIM24 0.44 0.45 1.05 1.10 0.71 0.80 1.35 1.17   tripartite motif-containing 24 (TRIM24), transcript variant 1, mRNA. 
7918725 TRIM33 0.35 0.42 1.12 1.03 0.95 0.95 1.08 1.00   tripartite motif-containing 33 (TRIM33), transcript variant a, mRNA. 
7980923 TRIP11 0.16 0.11 0.83 0.83 0.84 0.40 0.88 0.84   thyroid hormone receptor interactor 11 (TRIP11), mRNA. 
7908421 TROVE2 0.21 0.18 1.02 0.94 0.95 0.72 0.88 0.74   TROVE domain family, member 2 (TROVE2), transcript variant 2, mRNA. 
7988713 TRPM7 0.25 0.11 0.94 0.71 0.92 0.58 0.82 0.65   transient receptor potential cation channel, subfamily M, member 7 (TRPM7), mRNA. 
8152453 TRPS1 0.20 0.14 0.80 0.14 0.79 0.15 1.12 0.13   trichorhinophalangeal syndrome I (TRPS1), mRNA. 
8068522 TTC3 0.14 0.10 0.54 0.55 0.80 0.62 0.61 0.46   tetratricopeptide repeat domain 3 (TTC3), transcript variant 1, mRNA. 
8113157 TTC37 0.19 0.08 1.00 0.98 0.95 0.59 0.90 0.87   tetratricopeptide repeat domain 37 (TTC37), mRNA. 
7917199 TTLL7 0.40 0.15 0.78 0.36 1.58 0.51 1.15 0.74   tubulin tyrosine ligase-like family, member 7 (TTLL7), mRNA. 
8072407 TUG1 0.33 0.47 0.99 0.94 0.87 0.98 0.83 0.86   taurine upregulated 1 (non-protein coding) (TUG1), non-coding RNA. 
8013906 TWF1 0.23 0.33 0.91 0.88 1.11 0.95 1.08 0.98   twinfilin, actin-binding protein, homolog 1 (Drosophila) (TWF1), mRNA. 
8166230 TXLNG 0.30 0.31 1.05 0.91 0.93 0.80 0.74 0.72   taxilin gamma (TXLNG), transcript variant 1, mRNA. 
7990054 UACA 0.42 0.30 1.16 2.24 1.45 1.10 2.56 1.82   uveal autoantigen with coiled-coil domains and ankyrin repeats (UACA), transcript variant 1, mRNA. 
8100615 UBA6 0.49 0.33 1.47 1.50 1.49 1.01 1.73 1.96   ubiquitin-like modifier activating enzyme 6 (UBA6), mRNA. 
7986769 UBE3A 0.37 0.41 1.00 0.92 1.05 1.07 0.95 0.84   ubiquitin protein ligase E3A (UBE3A), transcript variant 3, mRNA. 
8109597 UBLCP1 0.15 0.21 1.03 0.97 0.80 0.77 1.01 0.86   ubiquitin-like domain containing CTD phosphatase 1 (UBLCP1), mRNA. 
7987981 UBR1 0.32 0.35 0.91 0.92 1.20 1.43 1.24 1.40   ubiquitin protein ligase E3 component n-recognin 1 (UBR1), mRNA. 
8046213 UBR3 0.32 0.22 0.77 0.82 1.14 0.94 0.94 0.68   ubiquitin protein ligase E3 component n-recognin 3 (putative) (UBR3), mRNA. 
8152148 UBR5 0.40 0.34 0.83 0.84 1.07 0.86 0.98 0.77   ubiquitin protein ligase E3 component n-recognin 5 (UBR5), mRNA. 
8146544 UBXN2B 0.46 0.24 0.88 0.62 0.85 0.59 0.63 0.72   UBX domain protein 2B (UBXN2B), mRNA. 
8045455 UBXN4 0.35 0.33 1.03 1.09 1.19 1.17 1.24 1.17   UBX domain protein 4 (UBXN4), mRNA. 
7947027 UEVLD 0.34 0.35 0.87 0.95 1.03 0.97 1.11 0.98   UEV and lactate/malate dehyrogenase domains (UEVLD), transcript variant 1, mRNA. 
8095402 UGT2A3 0.38 0.15 0.76 0.73 0.54 0.32 0.87 0.53   UDP glucuronosyltransferase 2 family, polypeptide A3 (UGT2A3), mRNA. 
7965723 UHRF1BP1L 0.29 0.23 0.94 0.79 0.84 0.80 0.91 0.78   UHRF1 binding protein 1-like (UHRF1BP1L), transcript variant 1, mRNA. 
7932041 UPF2 0.46 0.21 1.42 1.19 1.18 0.90 1.21 1.23   UPF2 regulator of nonsense transcripts homolog (yeast) (UPF2), transcript variant 1, mRNA. 
8095773 USO1 0.23 0.24 0.77 0.97 1.12 0.82 1.06 0.96   USO1 vesicle docking protein homolog (yeast) (USO1), mRNA. 
8180323 USP12 0.49 0.43 1.00 0.86 1.29 1.13 1.28 1.09   ubiquitin specific peptidase 12 (USP12), mRNA 
7956670 USP15 0.38 0.31 1.48 1.32 1.54 0.90 1.70 1.65   ubiquitin specific peptidase 15 (USP15), mRNA. 
8068062 USP16 0.28 0.22 1.00 1.01 1.04 0.93 0.90 0.89   ubiquitin specific peptidase 16 (USP16), transcript variant 1, mRNA. 
7916443 USP24 0.31 0.27 0.75 0.62 1.04 0.83 0.83 0.64   ubiquitin specific peptidase 24 (USP24), mRNA. 
8052443 USP34 0.27 0.14 0.75 0.79 0.99 0.62 0.82 0.58   ubiquitin specific peptidase 34 (USP34), mRNA. 
8097570 USP38 0.41 0.41 1.02 1.00 0.98 0.85 0.97 0.75   ubiquitin specific peptidase 38 (USP38), mRNA. 
7938448 USP47 0.30 0.18 1.11 1.17 1.19 0.91 0.89 0.84   ubiquitin specific peptidase 47 (USP47), mRNA. 
8097098 USP53 0.46 0.15 1.18 1.50 1.32 0.73 0.72 0.68   ubiquitin specific peptidase 53 (USP53), mRNA. 
7983663 USP8 0.18 0.19 0.79 0.87 0.88 0.70 0.90 0.77   ubiquitin specific peptidase 8 (USP8), transcript variant 1, mRNA. 
8166826 USP9X 0.33 0.23 0.76 0.79 0.95 0.97 0.95 0.93   ubiquitin specific peptidase 9, X-linked (USP9X), transcript variant 3, mRNA. 
7968333 USPL1 0.42 0.36 1.15 1.10 1.03 0.86 1.00 0.80   ubiquitin specific peptidase like 1 (USPL1), mRNA. 
7957890 UTP20 0.26 0.18 0.90 0.78 1.05 0.98 0.60 0.54   UTP20, small subunit (SSU) processome component, homolog (yeast) (UTP20), mRNA. 
8122464 UTRN 0.32 0.18 0.72 0.95 1.33 0.88 1.86 2.08   utrophin (UTRN), mRNA. 
8151118 VCPIP1 0.46 0.45 1.10 1.16 1.32 1.18 1.24 1.25   valosin containing protein (p97)/p47 complex interacting protein 1 (VCPIP1), mRNA. 
8165658 VIPR2 0.46 0.76 1.05 1.44 0.30 0.53 1.00 2.07  gi|17981852|ref|NC_001807.4|:5513-5580; gene=TRNW; product=tRNA-Trp 
8155946 VPS13A 0.31 0.16 0.75 0.62 0.93 0.28 0.83 0.53   vacuolar protein sorting 13 homolog A (S. cerevisiae) (VPS13A), transcript variant A, mRNA. 
8147580 VPS13B 0.41 0.25 0.86 0.87 1.16 0.70 1.25 0.83   vacuolar protein sorting 13 homolog B (yeast) (VPS13B), transcript variant 5, mRNA. 
7989387 VPS13C 0.25 0.10 0.81 0.67 1.45 0.43 1.52 1.05   vacuolar protein sorting 13 homolog C (S. cerevisiae) (VPS13C), transcript variant 2A, mRNA. 
7927972 VPS26A 0.37 0.47 1.00 1.00 0.94 0.93 0.91 0.97   vacuolar protein sorting 26 homolog A (S. pombe) (VPS26A), transcript variant 1, mRNA. 
8139165 VPS41 0.42 0.48 0.70 0.69 1.21 0.69 0.93 0.68   vacuolar protein sorting 41 homolog (S. cerevisiae) (VPS41), transcript variant 1, mRNA. 
7934812 WAPAL 0.41 0.45 1.02 1.15 1.05 1.09 0.88 0.86   wings apart-like homolog (Drosophila) (WAPAL), mRNA. 
8101511 WDFY3 0.32 0.39 0.81 0.84 0.91 0.73 0.79 0.59   WD repeat and FYVE domain containing 3 (WDFY3), transcript variant 1, mRNA. 
8107282 WDR36 0.34 0.35 1.16 0.87 1.12 0.96 0.82 0.89   WD repeat domain 36 (WDR36), mRNA. 
7979565 WDR89 0.45 0.37 1.31 1.17 1.09 0.98 0.79 0.69   WD repeat domain 89 (WDR89), transcript variant 2, mRNA. 
7952986 WNK1 0.44 0.49 0.87 0.82 0.90 0.68 1.34 0.72   hereditary sensory neuropathy, type II (HSN2), mRNA. 
8147156 WWP1 0.32 0.32 0.93 0.89 0.78 0.81 0.91 0.73   WW domain containing E3 ubiquitin protein ligase 1 (WWP1), mRNA. 
8052526 XPO1 0.25 0.21 1.15 1.10 0.76 0.66 0.93 0.91   exportin 1 (CRM1 homolog, yeast) (XPO1), mRNA. 
7970473 XPO4 0.32 0.38 0.90 0.83 0.89 0.94 0.69 0.56   exportin 4 (XPO4), mRNA. 
8021984 YES1 0.38 0.27 0.95 0.82 1.09 0.91 1.00 0.91   v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 (YES1), mRNA. 
8107375 YTHDC2 0.29 0.20 0.96 0.89 1.12 1.01 1.04 1.14   YTH domain containing 2 (YTHDC2), mRNA. 
8146637 YTHDF3 0.29 0.38 0.88 0.92 0.86 0.91 0.87 0.86   YTH domain family, member 3 (YTHDF3), mRNA. 
7975068 ZBTB1 0.37 0.38 1.25 1.10 1.16 0.87 1.00 0.99   zinc finger and BTB domain containing 1 (ZBTB1), transcript variant 1, mRNA. 
8089234 ZBTB11 0.39 0.30 1.11 1.17 1.08 1.12 1.00 0.98   zinc finger and BTB domain containing 11 (ZBTB11), mRNA. 
8169683 ZBTB33 0.30 0.28 1.19 0.97 0.80 0.75 1.02 0.78   zinc finger and BTB domain containing 33 (ZBTB33), mRNA. 
8083092 ZBTB38 0.20 0.12 0.98 0.90 0.69 0.64 1.14 0.74   zinc finger and BTB domain containing 38 (ZBTB38), mRNA. 
7923119 ZBTB41 0.13 0.15 1.14 1.24 1.13 0.91 1.28 1.13   zinc finger and BTB domain containing 41 (ZBTB41), mRNA. 
8180263 ZC3H11A 0.42 0.38 1.11 1.01 1.01 0.93 1.00 1.02   zinc finger CCCH-type containing 11A (ZC3H11A), mRNA 
7908978 ZC3H11A 0.38 0.31 0.97 0.69 1.27 0.80 0.79 0.88   zinc finger CCCH-type containing 11A (ZC3H11A), mRNA. 
7971422 ZC3H13 0.49 0.31 1.10 1.05 1.02 0.69 1.03 0.95   zinc finger CCCH-type containing 13 (ZC3H13), mRNA. 
8046848 ZC3H15 0.30 0.38 1.05 0.91 0.98 0.79 0.76 0.84   zinc finger CCCH-type containing 15 (ZC3H15), mRNA. 
7916185 ZCCHC11 0.36 0.24 1.12 0.91 0.79 0.64 0.95 0.59   zinc finger, CCHC domain containing 11 (ZCCHC11), transcript variant 1, mRNA. 
8162147 ZCCHC6 0.37 0.14 1.01 0.93 0.79 0.71 0.90 0.67   zinc finger, CCHC domain containing 6 (ZCCHC6), mRNA. 
7957277 ZDHHC17 0.44 0.44 0.96 1.39 1.18 0.97 0.98 0.71   zinc finger, DHHC-type containing 17 (ZDHHC17), mRNA. 
8160151 ZDHHC21 0.35 0.32 1.02 1.01 1.01 0.96 0.91 0.87   zinc finger, DHHC-type containing 21 (ZDHHC21), mRNA. 
7926916 ZEB1 0.30 0.18 1.24 1.04 1.63 0.63 1.77 1.45   zinc finger E-box binding homeobox 1 (ZEB1), transcript variant 2, mRNA. 
7964937 ZFC3H1 0.41 0.23 1.07 1.12 1.22 0.85 0.84 0.97   zinc finger, C3H1-type containing (ZFC3H1), mRNA. 
8166500 ZFX 0.43 0.42 1.06 1.09 1.26 0.87 1.37 0.89   zinc finger protein, X-linked (ZFX), mRNA. 
8106602 ZFYVE16 0.28 0.16 0.97 0.93 1.19 0.57 1.13 0.84   zinc finger, FYVE domain containing 16 (ZFYVE16), transcript variant 1, mRNA. 
8152656 ZHX1 0.19 0.21 0.99 0.96 0.72 0.62 1.08 0.87   zinc fingers and homeoboxes 1 (ZHX1), transcript variant 1, mRNA. 
8092230 ZMAT3 0.41 0.31 0.81 0.63 1.01 0.93 0.83 0.78   zinc finger, matrin type 3 (ZMAT3), transcript variant 1, mRNA. 
7967900 ZMYM2 0.39 0.21 1.11 1.14 0.87 0.81 0.97 0.98   zinc finger, MYM-type 2 (ZMYM2), mRNA. 
7899957 ZMYM4 0.36 0.32 1.01 0.95 0.96 1.01 1.08 1.04   zinc finger, MYM-type 4 (ZMYM4), mRNA. 
8033789 ZNF121 0.29 0.32 1.09 1.40 0.86 1.05 0.84 0.93   zinc finger protein 121 (ZNF121), mRNA. 
8105136 ZNF131 0.42 0.38 1.07 1.11 0.83 1.00 0.81 0.88   zinc finger protein 131 (ZNF131), mRNA. 
8028186 ZNF146 0.18 0.13 1.28 1.05 0.92 0.75 0.62 0.60   zinc finger protein 146 (ZNF146), transcript variant 1, mRNA. 
8090237 ZNF148 0.28 0.16 1.08 0.94 0.91 0.70 1.07 0.91   zinc finger protein 148 (ZNF148), mRNA. 
8156935 ZNF189 0.29 0.37 1.01 0.94 0.77 0.75 1.13 0.81   zinc finger protein 189 (ZNF189), transcript variant 1, mRNA. 
8117646 ZNF192 0.34 0.28 1.10 0.93 0.98 0.68 0.94 0.61   zinc finger protein 192 (ZNF192), mRNA. 
7945864 ZNF195 0.35 0.30 1.07 1.12 0.80 0.70 0.84 0.58   zinc finger protein 195 (ZNF195), transcript variant 1, mRNA. 
8022882 ZNF24 0.38 0.39 1.15 1.07 1.12 1.41 1.15 1.44   zinc finger protein 24 (ZNF24), mRNA. 
8036324 ZNF260 0.16 0.16 1.37 1.61 0.66 0.83 0.77 0.91   zinc finger protein 260 (ZNF260), transcript variant 1, mRNA. 
7995258 ZNF267 0.33 0.29 1.17 0.92 2.83 1.66 2.26 2.40   zinc finger protein 267 (ZNF267), transcript variant 498723, mRNA. 
8020898 ZNF271 0.40 0.46 0.70 0.77 0.80 0.83 0.69 0.82   zinc finger protein 271 (ZNF271), transcript variant 1, non-coding RNA. 
8135497 ZNF277 0.49 0.46 1.12 1.11 1.06 1.06 1.23 1.33   zinc finger protein 277 (ZNF277), mRNA. 
8175076 ZNF280C 0.29 0.29 1.47 1.07 1.37 1.18 1.39 1.06   zinc finger protein 280C (ZNF280C), mRNA. 
7989159 ZNF280D 0.45 0.39 0.99 0.95 0.81 0.67 0.94 0.70   zinc finger protein 280D (ZNF280D), transcript variant 1, mRNA. 
8120992 ZNF292 0.37 0.15 1.35 1.47 0.94 0.50 1.36 1.05   zinc finger protein 292 (ZNF292), mRNA. 
8028194 ZNF382 0.24 0.33 1.16 0.97 0.70 0.82 0.89 0.86   zinc finger protein 382 (ZNF382), mRNA. 
8030908 ZNF480 0.38 0.46 1.19 1.01 0.66 0.73 0.82 0.79   zinc finger protein 480 (ZNF480), mRNA. 
8027439 ZNF507 0.32 0.23 1.11 0.94 0.83 0.72 0.99 0.75   zinc finger protein 507 (ZNF507), transcript variant 1, mRNA. 
7929562 ZNF518A 0.25 0.20 1.17 1.18 1.11 0.60 1.53 0.93   zinc finger protein 518A (ZNF518A), mRNA. 
8030980 ZNF525 0.26 0.46 1.13 0.96 0.76 0.81 0.71 0.93   zinc finger protein 525 (ZNF525), non-coding RNA. 
8042601 ZNF638 0.32 0.21 0.91 0.87 0.91 0.46 1.12 0.77   zinc finger protein 638 (ZNF638), transcript variant 1, mRNA. 
7917604 ZNF644 0.26 0.12 1.06 1.00 1.11 0.58 0.99 0.73   zinc finger protein 644 (ZNF644), transcript variant 1, mRNA. 
8081069 ZNF654 0.16 0.20 1.19 1.42 1.20 0.97 1.13 1.33   zinc finger protein 654 (ZNF654), mRNA. 
8098758 ZNF721 0.23 0.12 1.16 0.99 1.00 0.48 1.22 0.67   zinc finger protein 721 (ZNF721), mRNA. 
8035793 ZNF737 0.27 0.40 1.04 2.16 0.55 0.71 0.69 0.81   zinc finger protein 737 (ZNF737), mRNA. 
7987361 ZNF770 0.26 0.17 0.84 0.83 0.93 0.67 0.69 0.43   zinc finger protein 770 (ZNF770), mRNA. 
8142730 ZNF800 0.49 0.43 1.03 1.03 0.93 0.96 1.09 0.99   zinc finger protein 800 (ZNF800), mRNA. 
7960143 ZNF84 0.45 0.40 1.19 1.27 0.94 0.86 1.05 1.00   zinc finger protein 84 (ZNF84), transcript variant 1, mRNA. 
8035842 ZNF91 0.16 0.08 0.92 0.77 0.69 0.41 0.93 0.55   zinc finger protein 91 (ZNF91), mRNA. 
7917359 ZNHIT6 0.35 0.38 1.14 1.11 1.36 1.41 0.78 0.69   zinc finger, HIT type 6 (ZNHIT6), transcript variant 1, mRNA. 
7916969 ZRANB2 0.29 0.24 1.19 1.10 0.88 0.64 0.82 0.80   zinc finger, RAN-binding domain containing 2 (ZRANB2), transcript variant 2, mRNA. 
7901479 ZYG11B 0.32 0.35 0.90 0.83 0.91 1.00 1.01 0.81   zyg-11 homolog B (C. elegans) (ZYG11B), mRNA. 
7917103 ZZZ3 0.34 0.20 1.11 1.03 1.02 0.84 1.01 0.88   zinc finger, ZZ-type containing 3 (ZZZ3), mRNA. 
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Genes preferentially induced by IFN gamma (IFN gamma signature)
6h 24h 6h 24h
8075695 APOL3 6.6 3.6 5.9 11.1 apolipoprotein L, 3
7954527 ARNTL2 0.9 0.8 1.9 2.1 aryl hydrocarbon receptor nuclear translocator-like 2
7953993 BCL2L14 7.1 1.9 4.6 7.1 BCL2-like 14 (apoptosis facilitator)
8023401 CCDC68 0.5 0.9 2.5 2.4 coiled-coil domain containing 68
8060675 CDC25B 1.5 1.0 1.1 3.4 cell division cycle 25 homolog B (S. pombe)
8103389 CTSO 1.2 1.8 1.6 4.3 cathepsin O
8101131 CXCL11 42.0 55.0 65.3 112.5 chemokine (C-X-C motif) ligand 11
7958425 DAO 1.6 0.9 2.2 8.5 D-amino-acid oxidase
7983405 DUOXA2 1.5 1.1 1.8 8.3 dual oxidase maturation factor 2
7965335 DUSP6 1.0 1.4 2.3 3.9 dual specificity phosphatase 6
8125993 ETV7 4.8 2.7 3.8 7.4 ets variant 7
8136940 FAM115C 1.9 0.8 3.6 3.4 family with sequence similarity 115, member C
8047565 FAM117B 1.0 1.1 2.2 4.0 family with sequence similarity 117, member B
7917561 GBP4 34.1 11.8 50.2 78.4 guanylate binding protein 4
7917576 GBP5 7.5 3.0 23.3 195.0 guanylate binding protein 5
7917548 GBP7 1.8 1.1 2.4 4.9 guanylate binding protein 7
7984001 GCNT3 1.0 0.9 1.9 2.1 glucosaminyl (N-acetyl) transferase 3, mucin type
8180086 HLA-DMA 1.1 1.2 1.0 9.5 major histocompatibility complex, class II, DM alpha
8125530 HLA-DMB 1.4 1.2 1.0 12.2 major histocompatibility complex, class II, DM beta
8125447 HLA-DQB1 1.9 1.7 1.5 15.0 major histocompatibility complex, class II, DQ beta 1
8025601 ICAM1 1.7 1.3 4.1 3.8 intercellular adhesion molecule 1
7942300 IL18BP 2.1 2.1 2.1 6.6 interleukin 18 binding protein
8114010 IRF1 6.7 2.5 13.2 13.5 interferon regulatory factor 1
8154178 JAK2 1.1 1.5 4.0 7.1 Janus kinase 2
8028744 LGALS17A 3.0 1.3 6.4 52.7 lectin, galactoside-binding, soluble, 14 pseudogene
8112803 LHFPL2 0.9 1.0 2.9 1.8 lipoma HMGIC fusion partner-like 2
8072461 LIMK2 1.7 1.1 2.5 2.6 LIM domain kinase 2
8141872 NAPEPLD 0.4 1.2 1.0 2.2 N-acyl phosphatidylethanolamine phospholipase D
8091255 PAQR9 1.0 1.1 1.8 3.8 progestin and adipoQ receptor family member IX
8091306 PLSCR4 1.2 1.2 1.4 2.7 phospholipid scramblase 4
8115997 RAB24 1.4 1.1 1.7 2.3 RAB24, member RAS oncogene family
7909214 RASSF5 1.0 1.1 4.1 5.2 Ras association (RalGDS/AF-6) domain family member 5
8110327 RGS14 1.3 1.1 2.1 3.0 regulator of G-protein signaling 14
8064766 RNF24 2.2 1.0 1.9 2.1 ring finger protein 24
8017039 SEPT4 1.2 1.0 1.2 3.5 septin 4
7998637 SEPX1 1.5 0.8 1.7 2.0 selenoprotein X, 1
7931951 SFMBT2 1.2 1.0 2.2 4.9 Scm-like with four mbt domains 2
8129666 SLC2A12 1.5 1.8 1.7 4.9 solute carrier family 2 (facilitated glucose transporter), member 12
7999423 SOCS1 5.1 1.7 4.5 9.0 suppressor of cytokine signaling 1
8060997 SPTLC3 0.7 0.9 1.6 2.4 serine palmitoyltransferase, long chain base subunit 3
8180339 ST6GALNAC6 1.4 0.9 1.4 2.1 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6
8007212 STAT5A 1.8 1.3 1.4 2.7 signal transducer and activator of transcription 5A
8165866 STS 0.9 1.2 1.5 3.7 steroid sulfatase (microsomal), isozyme S
7938812 TMEM86A 1.2 1.0 1.1 2.4 transmembrane protein 86A
7977046 TNFAIP2 1.6 1.0 2.2 2.3 tumor necrosis factor, alpha-induced protein 2
8117840 TRIM40 1.6 1.0 12.6 22.2 tripartite motif-containing 40
8178295 UBD 2.4 1.4 4.2 7.8 ubiquitin D
8129637 VNN2 0.9 1.0 1.2 3.4 vanin 2
8040430 VSNL1 1.1 1.6 3.2 11.8 visinin-like 1
Genes preferentially induced by IFN alpha (IFN alpha signature)
6h 24h 6h 24h
8073062 APOBEC3B 4.6 1.8 1.3 1.1 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B
8073081 APOBEC3F 4.9 2.4 1.4 3.0 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F
8073088 APOBEC3G 9.5 5.2 1.3 5.9 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G
8035304 BST2 2.5 3.9 1.2 2.5 bone marrow stromal cell antigen 2
7996403 C16orf70 2.4 1.6 1.1 1.6 chromosome 16 open reading frame 70
8126371 CCND3 2.2 1.8 1.1 1.6 cyclin D3
8007188 CNP 3.8 2.3 1.3 2.1 2',3'-cyclic nucleotide 3' phosphodiesterase
8169995 FAM122C 3.9 2.3 1.2 2.2 family with sequence similarity 122C
8152812 FAM84B 2.3 1.3 1.0 1.0 family with sequence similarity 84, member B
8117034 GMPR 5.6 3.5 1.2 2.7 guanosine monophosphate reductase
7976443 IFI27 3.3 16.7 1.4 6.5 interferon, alpha-inducible protein 27
7902553 IFI44 11.9 28.4 4.1 11.4 interferon-induced protein 44
7929065 IFIT1 85.6 83.3 3.3 17.5 interferon-induced protein with tetratricopeptide repeats 1
8078729 MYD88 2.9 1.9 1.3 1.6 myeloid differentiation primary response gene (88)
8108080 PHF15 3.5 2.5 1.2 2.5 PHD finger protein 15
8038225 PLEKHA4 4.9 2.3 1.5 1.7 pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 4
8037794 PRKD2 4.5 2.3 1.3 1.2 protein kinase D2
8132031 PRR15 3.0 1.1 1.1 1.6 proline rich 15
7941865 RAD9A 2.6 1.3 1.0 1.4 RAD9 homolog A (S. pombe)
7927120 RET 4.8 3.4 1.1 1.5 ret proto-oncogene
8084732 RTP4 11.4 9.4 4.9 6.2 receptor (chemosensory) transporter protein 4
8140967 SAMD9 1.4 12.4 1.4 4.7 sterile alpha motif domain containing 9
8081710 SIDT1 5.5 2.4 1.0 1.7 SID1 transmembrane family, member 1
7916403 SSBP3 2.2 1.4 0.9 1.4 single stranded DNA binding protein 3
7990839 STARD5 5.7 2.9 2.1 4.6 StAR-related lipid transfer (START) domain containing 5
7964119 STAT2 6.1 4.5 3.0 6.6 signal transducer and activator of transcription 2, 113kDa
8156060 TLE4 6.8 2.6 1.3 2.5 transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila)
8088054 TMEM110 3.1 1.8 1.1 1.9 transmembrane protein 110
8087485 UBA7 3.6 4.2 1.0 1.4 ubiquitin-like modifier activating enzyme 7
8071155 USP18 14.3 10.0 2.4 4.8 ubiquitin specific peptidase 18
7979757 ZFYVE26 2.4 1.3 1.1 1.3 zinc finger, FYVE domain containing 26
alpha gamma
ID Symbol Genename
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Supplementary Table V. 
PHH-derived gene sets used for 
GSEA. The table shows genes that 
are preferentially induced by IFN 
alpha or IFN gamma in PHH (at 
least at one time point the fold 
difference of expression induced by 
the two cytokines is higher than 2, 
with the corresponding p-value 
below 0.05). 
Patient 1 pSTAT1 CD3 CD8 CD20 CD56 CD123
1 4 9 10 0 0 0
2 8 25 10 1 1 0
3 32 53 25 2 4 3
4 3 11 14 0 0 0
5 1 11 11 0 0 0
Mean 9.6 21.8 14 0.6 1 0.6
Patient 2 pSTAT1 CD3 CD8 CD20 CD56 CD123
1 32 47 65 1 - -
2 38 53 55 2 - -
3 44 43 45 3 - -
4 30 59 39 1 - -
5 38 40 60 2 - -
Mean 36.4 48.4 52.8 1.8 - -
Patient 3 pSTAT1 CD3 CD8 CD20 CD56 CD123
1 62 33 148 1 0 0
2 11 30 32 0 0 1
3 5 23 35 0 0 1
4 16 34 37 1 0 1
5 0 22 18 1 1 0
Mean 18.8 28.4 30.5 0.6 0.2 0.6
Patient 4 pSTAT1 CD3 CD8 CD20 CD56 CD123
1 46 47 33 11 0 2
2 15 20 27 0 0 1
3 10 10 19 1 0 0
4 15 18 19 2 0 0
5 10 16 8 1 0 1
Mean 19.2 22.2 21.2 3 0 0.8
Patient 5 pSTAT1 CD3 CD8 CD20 CD56 CD123
1 36 39 31 1 0 -
2 47 49 60 1 0 -
3 24 26 39 0 0 -
4 31 24 29 1 0 -
5 23 28 35 0 0 -
Mean 32.2 33.2 38.8 0.6 0 -
Patient 6 pSTAT1 CD3 CD8 CD20 CD56 CD123
1 12 49 41 1 0 0
2 11 41 34 0 0 1
3 16 31 29 2 0 0
4 3 29 34 0 0 0
5 12 34 42 1 0 0
Mean 10.8 36.8 36 0.8 0 0.2
Amount of positive cells per high power field in AHC liver biopsies.
Supplementary Table VI.
Supplementary Table VII.   
Primer sequences used for real-time RT-PCR analysis 
   
Gene Forward primer sequence Reverse primer sequence 
GAPDH 5' GCTCCTCCTGTTCGACAGTCA 3' 5' ACCTTCCCCATGGTGTCTGA 3' 
IFNγ 5' GAAATATTTTAATGCAGGTCATTCAG 3' 5' TCTTTTGGATGCTCTGGTCA 3' 
USP18 5' CTCAGTCCCGACGTGGAACT 3' 5' ATCTCTCAAGCGCCATGCA 3' 
IFI27 5' GGCAGCCTTGTGGCTACTCT 3' 5' CCCAGGATGAACTTGGTCAATC 3' 
IFIT1 5' CCCTGCAGAACGGCTGCCTA 3' 5' TCAGGGCTTCCTCATTCTGGCCT 3' 
GBP5 5' CGCAAAGGTTGGCGGCGATT 3' 5' AGCTGTGCAGCCTGTTCCTGC 3' 
HLA-DMB 5' ACCAACAGGACACGGCCACCA 3' 5' TGCGCACTGCTGTGAGGCAT 3' 
IFNα 5' GACCTGGAAGCCTGTGTGA 3' 5' GACAACCTCCCAGGCACAA 3' 
IFNβ 5' TGCTCTGGCACAACAGGTAG 3' 5' GCTGCAGCTGCTTAATCTCC 3' 
 
 
Supplementary Table VIII.   
Primary antibodies used for immunohistochemistry or Western Blot  
       
Antibody Dilution IHC Dilution WB Catalogue No. Company 
PY701-STAT1 1:300 1:1000 #9171 Cell Signalling 
USP18 1:50 1:1000 #4813 Cell Signalling 
CD3 1:600 - #A0452 DAKO 
CD8 1:1000 - #M7103 DAKO 
CD20 1:500 - #M0755 DAKO 
CD56 1:200 - NCL-CD56-1B6 Novocastra 
CD123 1:50 - #554527 BD Biosciences 
STAT1 - 1:1000 #610186 BD Biosciences 
MAVS - 1:500 ALX-804-847 Enzo Life Sciences 
β-Actin - 1:2000 A5441 Sigma 
Supplementary Figure 1. Association of IL28B SNPs with hepatic mRNA expression of (A) IL28A, (B) IL29 (IFN1), (C) IL28RA, and (D) IL10R.
Expression levels were determined by quantitative reverse-transcription polymerase chain reaction and normalized relative to GAPDH mRNA. Shown
are the mean values (SEM) after log10 transformation. The only statistical significant differences (Student t test) were found for IL28RA between the
rs12979860 CC and CT groups and the rs8099917 TT and TG groups.
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Supplementary Figure 2. Hepatic ISG expression according to IL28B genotypes (SNP  rs8099917). (A) Expression of 4 ISGs (IFI44L, RSAD2,
ISG15, IFI27) in the liver according to the IL28B genotype (rs8099917) in 109 patients with CHC. (B) Hepatic expression of 4 ISGs (IFI44L, RSAD2,
ISG15, IFI27) in 35 patients with rs8099917 TT genotype, stratified according to treatment response (SVR vs non-SVR). (C) Hepatic expression of
4 ISGs (IFI44L, RSAD2, ISG15, IFI27) in 38 patients with rs8099917 TG genotype, stratified according to treatment response (SVR vs non-SVR).
Shown are mean values (SEM) after log transformation. P values were obtained with Student t test. The number of patients in each group is shown
below the plots.
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Supplementary Figure 3. Hepatic ISG expression according to IL28B genotypes (SNP  rs8099917) in patients infected with HCV genotype 1
or 4. (A) Expression of 4 ISGs (IFI44L, RSAD2, ISG15, IFI27) in the liver according to the IL28B genotype (rs8099917) in 75 patients with CHC infected
with HCV genotype 1 or 4. (B) Hepatic expression of 4 ISGs (IFI44L, RSAD2, ISG15, IFI27) in 19 patients with rs8099917 TT genotype, stratified
according to treatment response (SVR vs non-SVR). (C) Hepatic expression of 4 ISGs (IFI44L, RSAD2, ISG15, IFI27) in 26 patients with rs8099917
TG genotype, stratified according to treatment response (SVR vs non-SVR). Shown are mean values (SEM) after log transformation. P values were
obtained with Student t test. The number of patients in each group is shown below the plots.
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Supplementary Figure 4. (A) Expression of 4 ISGs (IFI44L, RSAD2, ISG15, IFI27) in the liver according to the IL28B genotype (rs12979860) in the
subset of 73 patients with CHC who have undergone treatment with pegIFN- and ribavirin. (B) Hepatic expression of 4 ISGs (IFI44L, RSAD2, ISG15,
IFI27) in 7 patients with the rs12979860 TT genotype, stratified according to treatment response (SVR vs non-SVR). Due to the small number of
patients, the difference is not significant. Shown are mean values (SEM) after log transformation. P values were obtained with Student t test. The
number of patients in each group is shown below the plots.
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Supplementary Figure 5. (A) Expression of 2 ISGs (LAMP3, OAS3) in the liver according to the IL28B genotype (rs12979860) in all 109 patients
with CHC and in patients with either CC, CT, or TT IL28B genotype stratified according to treatment response (SVR vs non-SVR). (B) Expression of
2 ISGs (LAMP3, OAS3) in the liver according to the IL28B genotype (rs12979860) in all 75 patients infected with HCV genotype 1 or 4 and in patients
with either CC or CT IL28B genotype stratified according to treatment response (SVR vs non-SVR). Shown are mean values (SEM) after log
transformation. P values were obtained with Student t test. The number of patients in each group is shown below the plots.
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Supplementary Table 1. Patient Characteristics and SNP Genotypes
No. Sex Age (y) HCV genotype Viral load (IU/mL) METAVIR score Treatment rs12979860 rs8099917
1 M 37 3a 247,290 A2/F2 SVR TT TG
2 M 37 3a 78,684 A1/F2 SVR CT TT
3 M 38 1a 9,638,894 A2/F1 SVR CC TT
4 F 63 2a/c 3,306,636 A2/F3 SVR CT TT
5 F 53 2a/c 1,196,303 A2/F3 SVR CT TG
6 M 61 4f 14,552,681 A3/F4 SVR CT TG
7 M 47 2b 4,663,883 A3/F4 SVR CT TG
8 M 33 3a 1,683,442 A2/F1 SVR CC TT
9 M 49 3a 12,381,160 A2/F2 SVR CC TT
10 F 38 1b 8,002,763 A2/F3 SVR CC TT
11 M 40 3a 2,531,993 A3/F3 SVR CT TT
12 M 41 3a 15,538,256 A1/F1 SVR CC TT
13 M 44 1b 67,587 A2/F4 SVR CT TG
14 F 24 1b 440 A2/F2 SVR CC TT
15 F 50 1b 16,639,113 A1/F2 SVR CC TT
16 F 24 3a 805,551 A2/F3 SVR CC TT
17 M 38 4 12,000 A2/F2 SVR CC TT
18 F 54 3a 75,644 A2/F4 SVR CC TT
19 M 49 4 165,330 A3/F4 SVR CT TT
20 M 34 4 173,000 A2/F2 SVR CT TG
21 M 45 4 1,331,047 A2/F2 SVR CC TT
22 F 47 3a 7850 A3/F4 SVR CT TT
23 F 48 3a 13,790 A1/F1 SVR CT TT
24 M 44 3 419,083 A2/F2 SVR TT TG
25 F 20 2a 87,375 A1/F2 SVR TT TG
26 M 29 1b 384,525 A2/F2 SVR CT TG
27 F 48 3a 28,368 A2/F3 SVR CC TT
28 F 42 3a 234,210 A3/F4 SVR CC TG
29 M 34 3a 3,145,764 A3/F2 SVR CC TT
30 F 44 3a 319,000 A2/F3 SVR CT TG
31 M 35 4 4,491,065 A2/F3 SVR CC TT
32 F 31 3a 249,240 A1/F1 SVR CT TG
33 M 27 1b 3102 A3/F4 SVR CC TT
34 M 36 3a 1,480,000 A1/F1 PNR CT TG
35 M 67 1b 2,137,002 A1/F2 No EoTR CT TG
36 F 47 1a 1,444,062 A2/F2 PNR CT TG
37 M 48 1b 713,046 A3/F4 PNR CT TG
38 F 52 1a 4,458,717 A2/F2 PNR CT TG
39 F 38 2 5,780,000 A2/F3 No EoTR TT TT
40 M 41 1 12,328,724 A2/F3 PNR CT TT
41 M 59 1b 191,299 A3/F3 PNR CT TG
42 M 63 1 1,752,158 A3/F4 No EoTR CT TG
43 M 56 1b 7,790,643 A2/F3 PNR CT TG
44 M 48 1b 2,949,376 A2/F4 PNR CT TT
45 M 48 1a 36,108,528 A1/F2 PNR CT TT
46 F 58 2 5,262,008 A2/F4 No EoTR CT TG
47 F 37 1a 953,556 A3/F3 PNR CT TG
48 M 61 1a 5,545,733 A2/F4 PNR TT TG
49 M 62 1a 5,624,281 A3/F4 PNR TT TG
50 M 54 1 222,053 A3/F4 No EoTR CC TT
51 M 45 4 321,000 A2/F2 PNR CT TG
52 F 41 1a 321,000 A2/F2 PNR CT TG
53 F 36 1a 717,000 A2/F2 PNR CT TG
54 M 51 1b 851,138 A3/F4 PNR CT TG
55 M 49 4c 371,535 A1/F2 No EoTR CT TG
56 F 50 3 1,123,718 A3/F4 PNR CT TG
57 F 48 1a 2,834,081 A3/F2 PNR CT TT
58 M 50 1 6,216,555 A3/F2 PNR CT TT
59 F 38 1 362,282 A1/F2 PNR CT TG
60 M 48 1b 245,062 A2/F4 PNR CT TG
61 M 48 4b 3,201,553 A2/F4 No-EoTR TT TT
62 M 42 1a 4,291,956 A2/F3 No EoTR CT TG
63 M 60 1b 4,326,723 A3/F3 PNR CT TG
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Supplementary Table 1. Continued
No. Sex Age (y) HCV genotype Viral load (IU/mL) METAVIR score Treatment rs12979860 rs8099917
64 M 55 1a 1,710,592 A3/F4 PNR CT TT
65 M 45 1b 2,910,319 A1/F4 EoTR, relapse CT TG
66 F 52 2a/c 72,157 A2/F4 EoTR, relapse CC TT
67 F 48 3a 13,538,256 A2/F3 EoTR, relapse CT TT
68 M 42 3 2,085,698 A1/F2 EoTR, relapse CT TG
69 M 40 1a 15,900,000 A3/F4 EoTR, relapse CC TT
70 M 44 1a 3,884,688 A2/F3 EoTR, relapse CT TG
71 M 53 1b 770,000 A2/F4 EoTR, relapse CT TT
72 M 55 3 578,305 A2/F2 EoTR, relapse CT TT
73 F 34 1b 36,000 A1/F2 EoTR, relapse CT TG
74 M 35 1b 1,578,381 A1/F2 EoTR CT TT
75 F 56 3a 712,846 A2/F2 EoTR CT TT
76 M 37 3a 828,467 A2/F3 EoTR CC TT
77 M 36 3a 1,140,000 A2/F3 EoTR CT TG
78 M 51 1b 241,223 A1/F2 EoTR CT TG
79 M 43 1b 1,089,515 A2/F2 EoTR CT TG
80 M 49 1a 1,484,271 A2/F2 EoTR CC TT
81 M 35 1b 17,594 A1/F2 EoTR CC TT
82 M 58 1b 57,791 A2/F2 Ongoing TT GG
83 M 37 3a 6,420,826 A2/F2 Ongoing CT TT
84 F 47 1 7,500,000 A3/F3 Ongoing CC TT
85 M 48 4 45,523 A1/F4 Ongoing TT GG
86 M 45 1 5,632,925 A2/F3 Ongoing CC TT
87 F 48 1a 3,107,291 A3/F4 Ongoing CC TT
88 M 46 1b 69,000,000 A1/F2 Interrupted CC TT
89 M 55 1a 788,024 A1/F1 Interrupted CC TT
90 M 46 1a 1,218,968 A1/F1 Interrupted TT GG
91 M 39 1a 3,427,262 A1/F2 Interrupted CC TT
92 M 42 1a 3,556,921 A1/F1 No treatment CT TG
93 M 43 1a 792,776 A1/F1 No treatment CT TG
94 F 41 1a 4,519,497 A2/F1 No treatment CC TT
95 F 48 4 88,216 A1/F1 No treatment TT GG
96 M 51 4e 864,372 A3/F4 No treatment CT TG
97 M 57 1 10,327,448 A1/F1 No treatment CT TG
98 F 53 1  A3/F4 No treatment CT TG
99 F 69 1b 1,686,605 A1/F2 No treatment CT TG
100 F 67 3a 265,382 A3/F4 No treatment CT TG
101 M 35 1a 3,378,710 A1/F1 No treatment CT TT
102 M 50 1b 2,230,542 A1/F1 No treatment CC TT
103 M 54 1a 4,625,025 A2/F2 No treatment CC TT
104 F 53 3a 228,439 A2/F4 No treatment CT TG
105 F 44 1 90,124 A1/F1 No treatment CT TG
106 M 45 1 135,556 A3/F2 No treatment CC TT
107 F 47 1b 10,527,018 A3/F3 No treatment CT TT
108 F 45 1a 551,185 A1/F1 No treatment CT TG
109 M 46 1a 3,380,665 A2/F2 No treatment CC TT
M, male; F, female; PNR, primary non-response: 2 log 10 reduction of viral load after 12 weeks of treatment; EoTR, end of treatment response:
negative viral load at the end of treatment; SVR, sustained virological response: negative viral load 6 months after end of treatment.
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Supplementary Table 2. Primer Sequences Used for Real-Time Reverse-Transcription Polymerase Chain Reaction Analysis
Gene Forward primer sequence Reverse primer sequence
GAPDH 5= GCTCCTCCTGTTCGACAGTCA 3= 5= ACCTTCCCCATGGTGTCTGA 3=
IFI44L 5= GCTGCGGGCTGCAGAT 3= 5= CTCTCTCAATTGCACCAGTTTCC 3=
RSAD2 5= CTTTGTGCTGCCCCTTGAG 3= 5= TCCATACCAGCTTCCTTAAGCAA 3=
ISG15 5= TCCTGCTGGTGGTGGACAA 3= 5= TTGTTATTCCTCACCAGGATGCT 3=
IFI27 5= GGCAGCCTTGTGGCTACTCT 3= 5= CCCAGGATGAACTTGGTCAATC 3=
LAMP3 5= GCGGCCGCGCTCTT 3= 5= TTTGACTGCCATCGTGCAA 3=
OAS3 5= TCTCCCATCAAAGTGATCAAGGT 3= 5= CCACGAGGTCGGCATCTG 3=
LGALS3BP 5= GGCTGGCTGAAGAGCAACTG 3= 5= GTGGGTGCTCCTGGTTTCAT 3=
HTATIP2 5= GGGCGGAGGGATTTGTTC 3= 5= TGCCAGCTCTGCAGACTTCA 3=
IL28A 5= GACCCAGCCCTGGTGGAC 3= 5= CTGGATACAGGCCCGGAA 3=
IL28B 5= GGCCTTTAAGAGGGCCAAAG 3= 5= GGCGGGAGCGGCACT 3=
IL29 5= CACAGGAGCTAGCGAGCTTCA 3= 5= TTTTCAGCTTGAGTGACTCTTCCA 3=
IL28RA 5= TGACCTATTTTGTGGCCTATCAGA 3= 5= GTTCCCGCACACTCTTCCA 3=
IL10RB 5= GCAAACAACCCATGACGAAA 3= 5= CCGAGGCCATGAGGATGAC 3=
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Supplementary Table 3. Gene Expression Relative to GAPDH (log10 transformed)
No. IFI44L RSAD2 ISG15 IFI27 LAMP3 OAS3 LGALS3BP HTATIP2 IL28A IL28B IL29 IL28RA IL10RB
1 1.2312 1.6843 0.6969 0.3176 3.8908 1.5518 0.3281 1.3983 5.1276 4.8029 Undetected 2.2788 1.8950
2 1.5217 1.8890 1.3817 0.9663 4.4823 1.9733 0.8640 1.2192 3.9896 6.1944 Undetected 2.2457 1.7746
3 1.8905 2.2472 1.4374 1.1364 4.5335 2.1102 0.8323 1.4675 5.1412 4.2750 5.5028 2.3510 1.8589
4 1.4675 2.0485 1.5006 0.8098 4.5847 1.7746 0.7511 1.4254 4.9727 4.5275 5.1476 2.4700 1.9973
5 1.7475 2.2502 1.4389 1.0340 4.1045 1.8513 0.8474 1.4826 4.3454 4.5586 5.8881 2.4865 2.0666
6 1.8844 2.3902 1.3426 1.2884 4.3469 2.1208 0.6653 1.3245 4.5877 4.5060 Undetected 2.3149 1.8002
7 1.6948 2.0621 1.4630 0.7360 4.1723 1.7625 0.5720 1.4720 5.2883 5.6367 5.8114 2.4504 2.0982
8 2.0455 2.3721 1.9130 0.9964 4.7262 2.3390 0.9693 1.4796 5.3076 Undetected Undetected 2.5572 2.1614
9 1.2177 1.7204 1.1259 0.1039 3.9796 1.5563 0.4004 1.4811 4.3604 5.9748 4.5817 2.4429 2.0816
10 1.7415 2.2457 1.5292 1.2523 4.8240 2.3525 1.0672 1.1800 Undetected Undetected 5.4336 2.2306 1.7941
11 1.4449 1.9311 1.2222 0.4094 4.3574 1.6858 0.4305 1.1409 4.6802 Undetected Undetected 2.2698 1.8860
12 1.4495 1.9371 1.6000 1.0521 4.6494 1.9898 0.8128 1.4043 Undetected 4.4011 Undetected 2.6355 1.9356
13 1.5127 2.1283 1.7068 0.7435 3.8667 1.9206 0.5990 1.4464 Undetected Undetected 4.5320 2.2713 1.8107
14 1.5473 2.0846 1.7053 0.8128 3.8306 1.8483 0.6261 1.4284 Undetected 4.6961 5.9092 2.3405 1.8664
15 2.0470 2.4052 1.4991 1.7821 4.5862 2.1659 1.0822 1.2523 Undetected 4.2460 Undetected 2.2306 1.8905
16 1.8257 2.1930 1.2523 0.9934 3.9134 1.8528 0.7089 1.2688 4.2174 4.6855 Undetected 2.2517 1.5834
17 2.2231 2.6024 2.1238 1.4570 5.1401 2.5467 1.1499 1.5669 5.3265 Undetected Undetected 2.6235 2.0997
18 0.7947 1.3622 0.5689 0.0602 3.4016 1.1981 0.1656 1.2688 4.2927 4.7066 4.4778 2.0380 1.6120
19 1.1695 1.5112 0.8489 0.0060 3.7839 1.3637 0.2920 1.4359 4.5591 4.4869 4.8105 2.4203 2.0922
20 0.9121 1.5924 0.7767 0.2724 3.7569 1.4781 0.7014 1.3712 4.3032 5.0633 4.6991 2.5211 1.9748
21 1.0672 1.4645 1.1123 0.5494 4.8391 1.5036 0.6021 1.3381 4.3695 Undetected 5.0137 2.0816 1.8047
22 1.4163 1.9763 1.4495 0.5765 3.9962 1.7294 0.5449 1.3983 4.7533 4.8406 Undetected 2.3510 1.7520
23 1.0145 1.5533 0.8895 0.0166 3.9013 1.5036 0.7450 1.1800 5.3050 Undetected Undetected 2.1584 1.8092
24 1.9281 2.2005 1.4374 0.4034 4.4342 2.0831 0.7119 1.3622 5.4476 5.4216 5.8144 2.4022 2.0244
25 1.4826 1.8694 1.1018 0.4109 4.1151 1.8408 0.6954 1.4269 4.7849 5.5751 5.2936 2.4323 1.9386
26 1.1981 1.5262 0.5118 0.2785 3.6214 1.3456 0.5388 1.4645 Undetected 5.0874 5.6037 2.1253 1.7234
27 1.0717 1.5879 0.9151 0.1279 3.8938 1.5217 0.5464 1.4645 4.4720 4.7317 5.0754 2.3014 2.0741
28 1.4314 1.8333 1.1168 0.4666 3.9600 1.6918 0.2619 1.4359 3.6590 5.4104 6.1651 2.4820 1.9657
29 1.1138 1.7384 1.0446 0.7782 3.9209 1.7746 0.7345 1.1590 Undetected Undetected 4.7442 1.9597 1.5684
30 0.8143 1.2357 0.2378 0.1430 3.4016 1.0130 0.4832 1.5051 Undetected 4.6976 5.3418 1.9973 1.6060
31 1.5157 2.0365 1.5473 0.9844 4.4041 1.9025 0.6999 1.3260 5.2205 Undetected 5.8746 2.4594 1.8814
32 1.7309 1.9281 1.4028 0.2845 4.3409 1.9236 0.6412 1.2839 4.9809 5.0918 Undetected 2.2382 1.6888
33 1.4841 1.8694 1.2297 0.7872 3.8306 1.7971 0.6939 1.2974 4.3970 4.3657 4.8225 2.4895 1.8679
34 1.1861 1.6903 1.2448 0.0271 4.1783 1.7144 0.8113 1.5337 4.0323 4.2129 Undetected 2.5226 1.9657
35 1.0792 1.2538 0.7977 0.0075 3.4950 1.3531 0.4741 1.3531 4.5372 5.5555 5.2138 2.4293 2.0094
36 0.2438 0.7466 0.0978 0.3883 3.0223 0.8384 0.0015 1.2177 4.3348 5.6232 4.8270 1.7911 1.7099
37 1.1830 1.3802 0.5705 0.0211 3.3324 1.4103 0.2920 1.3938 Undetected Undetected 5.1566 2.4022 1.9928
38 0.8941 1.3260 0.5388 0.3658 3.4664 1.2282 0.2213 1.1575 4.7081 5.2523 5.4562 2.1539 1.9040
39 1.3832 1.7866 0.5464 0.2890 3.8502 1.6933 0.4395 1.2673 Undetected 5.0395 Undetected 2.4158 1.9371
40 0.2529 0.7315 0.1008 0.5358 3.0088 0.8730 0.1054 0.9528 3.9164 5.2261 4.5275 1.8122 1.6406
41 0.6472 1.2568 0.4591 0.1626 3.4257 1.3592 0.2393 1.2553 5.3493 4.9027 4.6374 2.2637 2.0515
42 0.6999 1.2086 0.6382 0.1731 3.3219 1.1966 0.1325 1.3020 Undetected 5.1633 4.8827 2.2382 1.9115
43 0.8038 1.3847 0.5178 0.3131 3.4889 1.3682 0.1144 1.3471 4.2838 5.4493 4.9881 1.9447 1.7309
44 0.7541 1.3381 0.7661 0.0045 3.9811 1.5337 0.4079 1.2839 Undetected 4.9233 5.1807 2.4218 1.9447
45 0.7526 1.2658 0.2860 0.3658 3.5973 1.3050 0.5750 1.2538 4.5425 5.1024 5.3884 2.1945 1.9266
46 0.4726 0.9768 1.0295 0.0421 4.6870 1.4058 0.3221 1.3306 Undetected 4.4929 4.2325 2.3902 1.9130
47 0.5509 0.8835 0.1505 0.4470 3.6741 1.0295 0.2815 1.3004 4.0940 4.9158 5.2003 2.0997 1.9191
48 1.6210 2.1162 1.2764 0.1264 4.8225 2.0274 1.0973 1.4118 4.5440 5.1551 Undetected 2.3315 2.0711
49 0.9136 1.3637 0.7134 0.1340 3.5461 1.6195 0.4184 1.3531 4.6122 5.8415 4.8074 2.2833 1.9657
50 0.8956 1.3080 0.7195 0.0692 3.9435 1.4540 0.5539 1.4480 4.5804 Undetected 4.5576 2.2412 1.8935
51 0.7797 1.1981 0.1595 0.5178 3.4814 1.2794 0.1550 1.2026 4.5757 5.8294 4.5320 2.1238 1.9040
52 1.1228 1.4043 0.5087 0.1656 3.9706 1.4766 0.4425 1.1620 4.6044 Undetected 5.2259 2.3691 2.0034
53 0.4862 0.9212 0.3356 0.2724 3.3414 1.0145 0.0512 1.2026 4.7217 5.7753 5.1536 2.2231 1.6993
54 0.6141 1.0416 0.3943 0.1460 3.2075 1.0235 0.0467 1.2598 4.5675 4.6690 4.9444 2.2246 1.9025
55 0.8579 1.3787 0.6021 0.2860 3.5296 1.2929 0.1942 1.3998 4.6178 5.4818 5.5495 2.3465 2.0651
56 0.6969 1.2899 0.4832 0.1912 3.7418 1.2794 0.3898 1.1319 4.4989 5.3922 5.5073 2.3119 1.9221
57 0.8263 1.1996 0.2453 0.2167 3.3956 1.1364 0.2649 1.4269 4.1647 4.4430 4.8481 2.1840 2.0034
58 0.9016 1.4856 0.8188 0.0873 4.0037 1.5232 0.5268 1.3441 4.4702 Undetected 4.8707 2.3104 1.9477
59 1.3607 1.8047 1.0942 0.0978 4.3619 1.8950 0.4862 1.3170 5.4772 4.3803 Undetected 2.4293 2.0485
60 0.8910 1.3426 0.7962 0.0722 3.7298 1.3516 0.2980 1.4224 4.6569 5.1920 5.6759 2.2472 2.0380
61 1.2387 1.8709 1.0039 0.0888 3.8848 1.6858 0.5930 1.4314 5.0327 5.0113 Undetected 2.3525 1.9040
62 1.1575 1.6963 0.7812 0.2589 3.9676 1.5247 0.5975 1.2884 4.5140 5.1126 5.0558 2.3661 1.8528
63 0.8929 1.3592 0.8615 0.1045 4.4876 1.6600 0.3537 1.3501 5.1759 5.0059 5.5329 2.6129 2.0034
64 1.0021 1.6174 0.9839 0.1801 4.6302 1.7397 0.4440 1.1459 4.9280 4.7759 5.1792 2.3556 1.9221
65 0.8173 1.3983 0.3582 0.1671 3.1443 1.1635 0.2318 1.0717 Undetected 5.4486 Undetected 2.0259 1.8829
66 1.0747 1.4028 0.9046 0.0813 3.8637 1.5036 0.3382 1.1634 4.5297 5.1227 4.4688 2.3029 1.8965
67 1.8920 2.3375 1.7294 0.8098 4.3815 2.1162 0.6871 1.4392 5.4532 5.8249 Undetected 2.4188 2.0711
68 1.3456 1.5804 0.7887 0.1701 3.9631 1.3381 0.3628 1.3604 Undetected Undetected 6.0296 2.2216 1.8739
69 1.2267 1.5307 0.7526 0.0060 3.7102 1.3230 0.4199 1.2252 4.3051 4.4011 4.1693 2.2713 1.8062
70 1.0100 1.2974 0.3447 0.0467 3.7298 1.2839 0.5569 1.1575 4.5707 4.7623 Undetected 2.2728 1.7008
71 0.6337 1.0506 0.4666 0.3507 3.5928 1.2643 0.4275 1.2824 4.0792 Undetected 4.0218 2.2954 2.0304
72 0.6322 0.9332 0.4079 0.1565 3.2842 1.0867 0.3928 1.3501 4.5313 4.0731 5.2936 2.4323 1.8303
73 1.1093 1.7971 0.9513 0.0181 3.8728 1.5834 0.7706 1.5819 5.0318 4.9252 5.6142 2.2984 1.8754
74 0.7661 1.0912 0.5012 0.0105 3.7794 1.2177 0.6246 1.5337 Undetected Undetected 4.8150 2.1915 2.0018
75 1.2402 1.6226 0.8098 0.0346 3.9585 1.6873 0.2507 1.1191 5.1209 4.5659 Undetected 2.2020 1.8694
76 1.8167 2.3194 1.7309 1.0717 4.4086 2.2367 0.8425 1.3869 4.9046 4.3665 Undetected 2.5618 2.1223
77 1.2342 1.7776 1.1003 0.1460 4.1151 1.6948 0.7119 1.2779 4.8150 5.1100 5.5495 2.3435 1.9913
78 0.6578 1.1394 0.2785 0.5659 3.1969 1.0882 0.2950 1.2312 4.6121 Undetected 4.7232 2.0952 1.7670
79 1.3712 1.8604 1.1153 0.0542 4.1918 1.8137 0.8053 1.2478 4.4837 4.9773 Undetected 2.2923 1.7866
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No. IFI44L RSAD2 ISG15 IFI27 LAMP3 OAS3 LGALS3BP HTATIP2 IL28A IL28B IL29 IL28RA IL10RB
80 1.9537 2.3586 1.6557 0.9994 4.4251 2.0094 0.6833 1.3622 4.8661 4.2784 Undetected 2.4308 1.7264
81 2.2653 2.6596 1.9070 1.3050 4.6539 2.5076 0.9937 1.3968 5.3689 4.9498 Undetected 2.3074 1.9567
82 0.8775 1.4540 0.6292 0.2423 3.2030 1.2854 0.2576 1.3595 4.9324 5.4757 5.2635 2.4218 2.0395
83 1.1710 1.6797 0.7721 0.1942 3.9871 1.5021 0.6705 1.2210 4.7601 5.0100 5.8912 2.4910 1.9717
84 1.6993 2.1599 1.4284 1.0912 4.2867 1.8513 0.5665 1.2672 4.6105 4.1547 5.2725 2.4955 1.9326
85 1.3456 1.8875 0.7827 0.2544 3.8487 1.5789 Not measured Not measured 4.9338 4.9866 4.6148 2.4504 1.8739
86 0.9814 1.4510 1.1243 0.5223 4.2972 1.8047 0.6517 1.3576 Undetected 4.9881 5.1025 2.3992 1.8378
87 1.6903 2.1584 1.6978 0.8158 4.8767 1.9672 0.5780 1.3351 5.5253 4.8691 5.5390 2.4097 1.8558
88 2.0726 2.5542 1.9130 1.5398 4.2536 2.2938 Not measured Not measured 5.2673 5.1642 Undetected 2.4835 2.0214
89 1.0235 1.4194 0.8775 0.2318 4.0308 1.5940 Not measured Not measured 4.1895 5.5224 4.5922 2.3255 1.9025
90 0.8293 1.2177 0.5464 0.4109 3.1608 1.1710 Not measured Not measured 4.1193 5.8129 4.9805 2.1057 1.9266
91 1.9115 2.2637 1.6632 1.2764 4.1632 2.1253 Not measured Not measured 5.4894 4.4823 5.4938 2.3586 1.7701
92 1.3245 1.8604 0.9482 0.3507 3.7629 1.6436 Not measured Not measured 4.7404 4.9625 5.1040 2.2472 1.6331
93 0.4410 0.7405 0.0241 0.4531 3.1473 0.8339 Not measured Not measured 3.8622 4.9956 5.0001 2.1403 1.9281
94 1.6030 2.0952 1.5789 1.2508 3.7569 1.9266 Not measured Not measured 4.6341 4.6001 Undetected 2.4233 1.8453
95 0.2965 0.8068 0.0391 0.3838 3.2556 1.0386 Not measured Not measured 4.0955 4.2446 5.7015 1.9973 1.8694
96 0.2935 0.7932 0.0376 0.4726 2.9832 0.9091 Not measured Not measured 3.9013 4.7578 4.9414 2.1268 1.8769
97 0.8534 1.3110 0.5434 0.2769 3.7885 1.3682 Not measured Not measured 4.4944 4.3667 5.6850 2.4037 1.9717
98 1.0566 1.4901 0.5945 0.2739 3.6093 1.4329 Not measured Not measured 4.1392 5.6636 5.3568 2.3014 1.8980
99 0.6021 1.0897 0.2423 0.3296 3.5326 1.1981 Not measured Not measured 4.1346 Undetected 5.5314 2.1283 1.9326
100 1.7580 2.0771 1.0807 0.5629 3.9209 1.7670 Not measured Not measured 5.3553 4.7141 5.9589 2.4308 2.0681
101 0.8083 1.2207 0.5975 0.1791 3.3956 1.2132 Not measured Not measured 4.6514 4.6584 5.1085 2.1494 1.9808
102 1.7640 2.0891 1.4525 0.3808 3.8908 1.8062 Not measured Not measured 3.7975 5.3780 Undetected 2.4700 1.8468
103 1.9793 2.3556 1.7369 0.7134 4.4342 2.2984 Not measured Not measured 5.4285 4.2433 5.3493 2.3525 1.9687
104 1.4480 2.0365 1.3140 0.2363 3.7915 1.8152 Not measured Not measured 5.6959 5.3703 Undetected 2.1373 1.6587
105 0.4937 0.9166 0.0798 0.4892 3.4664 1.1003 Not measured Not measured 4.4314 5.2498 4.7352 1.8799 1.7430
106 1.5684 2.2126 1.6692 1.1349 3.7343 2.0500 Not measured Not measured 4.3306 4.4488 5.4246 2.4067 1.9431
107 1.2643 1.7746 1.1484 0.4410 3.7448 1.7806 Not measured Not measured 4.0708 5.0373 4.6750 2.3134 1.8167
108 0.4395 0.8053 0.2845 0.0256 3.3685 1.2402 Not measured Not measured 4.7310 4.8335 5.1627 2.1463 1.9070
109 1.7068 2.1870 1.6948 1.1695 4.2114 2.1509 0.8921 1.5543 4.2516 4.3741 Undetected 2.2833 1.8724
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